0000105770-24-00008110-Q WEST PHARMACEUTICAL SERVICES INC 20241024202410241621381621391621390 0000105770-24-000081 10-Q 90 20240930 20241024 20241024 WEST PHARMACEUTICAL SERVICES INC 0000105770 3841 231210010 PA 1231 10-Q 34 001-08036 241392930 530 HERMAN O. WEST DRIVE EXTON PA 19341 6105942900 530 HERMAN O. WEST DRIVE EXTON PA 19341 WEST CO INC 19990405 10-Q 1 wst-20240930.htm 10-Q wst-20240930000001057702--12-312024Q3falsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:SGDiso4217:EURiso4217:JPYutr:bbliso4217:USDwst:bblwst:facilitywst:segment00001001-012024-09-30000010577022024-10-22000010577022024-07-012024-09-30000010577022023-07-012023-09-30000010577022023-01-012023-09-30000010577022024-09-30000010577022023-12-31000010577022022-12-31000010577022023-09-30000010577wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:HighValueComponentsMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:HighValueComponentsMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:HighValueComponentsMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:HighValueComponentsMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:StandardPackagingMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:StandardPackagingMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:StandardPackagingMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:StandardPackagingMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-30000010577srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-30000010577srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-30000010577srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-30000010577020220102-280000105770srt:AffiliatedEntityMember2024-09-300000105770srt:AffiliatedEntityMember2023-12-310000105770srt:AffiliatedEntityMember2024-07-012024-09-300000105770srt:AffiliatedEntityMember2023-07-012023-09-300000105770srt:AffiliatedEntityMember2024-01-012024-09-300000105770srt:AffiliatedEntityMember2023-01-012023-09-300000105770wst:TermLoanDue2027Member2024-09-300000105770wst:TermLoanDue2027Member2023-12-310000105770wst:TermLoanDue2024Member2024-09-300000105770wst:TermLoanDue2024Member2023-12-310000105770wst:SeniorBNotesDue2024Member2024-09-300000105770wst:SeniorBNotesDue2024Member2023-12-310000105770wst:SeniorCNotesDue2027Member2024-09-300000105770wst:SeniorCNotesDue2027Member2023-12-310000105770wst:TermLoanDue2027Member2024-07-020000105770wst:TermLoanDue2024Member2024-07-022024-07-020000105770wst:SeniorBNotesDue2024Member2024-07-022024-07-020000105770wst:SeniorBNotesDue2024Member2012-07-050000105770us-gaap:RevolvingCreditFacilityMemberwst:Revolvingcreditfacilitydue2024Member2024-09-300000105770us-gaap:LetterOfCreditMemberwst:Revolvingcreditfacilitydue2024Member2024-09-300000105770wst:TermLoansMember2024-09-300000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:SGD2024-09-300000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:USD2024-09-300000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:SGD2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:USD2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:EUR2024-09-300000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:USD2024-09-300000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:EUR2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:SGD2023-12-310000105770us-gaap:ForeignExchangeForwardMember2024-01-012024-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2024-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2024-09-300000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2024-07-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:JPY2024-09-300000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2024-09-300000105770us-gaap:OptionMember2017-11-012024-09-300000105770us-gaap:OptionMember2024-01-012024-09-300000105770us-gaap:OptionMember2024-09-300000105770wst:OtherExpenseIncomeMember2024-07-012024-09-300000105770wst:OtherExpenseIncomeMember2023-07-012023-09-300000105770wst:OtherExpenseIncomeMember2024-01-012024-09-300000105770wst:OtherExpenseIncomeMember2023-01-012023-09-300000105770us-gaap:FairValueHedgingMember2024-07-012024-09-300000105770us-gaap:FairValueHedgingMember2024-01-012024-09-300000105770us-gaap:FairValueHedgingMember2023-07-012023-09-300000105770us-gaap:FairValueHedgingMember2023-01-012023-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2024-07-012024-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2023-07-012023-09-300000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2024-07-012024-09-300000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2023-07-012023-09-300000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2024-07-012024-09-300000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-07-012023-09-300000105770us-gaap:TreasuryLockMember2024-07-012024-09-300000105770us-gaap:TreasuryLockMember2023-07-012023-09-300000105770us-gaap:CurrencySwapMember2024-07-012024-09-300000105770us-gaap:CurrencySwapMember2023-07-012023-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2024-01-012024-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2023-01-012023-09-300000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2024-01-012024-09-300000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-09-300000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2024-01-012024-09-300000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-09-300000105770us-gaap:TreasuryLockMember2024-01-012024-09-300000105770us-gaap:TreasuryLockMember2023-01-012023-09-300000105770us-gaap:CurrencySwapMember2024-01-012024-09-300000105770us-gaap:CurrencySwapMember2023-01-012023-09-300000105770wst:NetSalesMember2024-07-012024-09-300000105770wst:NetSalesMember2023-07-012023-09-300000105770wst:NetSalesMember2024-01-012024-09-300000105770wst:NetSalesMember2023-01-012023-09-300000105770us-gaap:CostOfSalesMember2024-07-012024-09-300000105770us-gaap:CostOfSalesMember2023-07-012023-09-300000105770us-gaap:CostOfSalesMember2024-01-012024-09-300000105770us-gaap:CostOfSalesMember2023-01-012023-09-300000105770us-gaap:InterestExpenseMember2024-07-012024-09-300000105770us-gaap:InterestExpenseMember2023-07-012023-09-300000105770us-gaap:InterestExpenseMember2024-01-012024-09-300000105770us-gaap:InterestExpenseMember2023-01-012023-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2024-07-012024-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2023-07-012023-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2024-01-012024-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2023-01-012023-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2024-07-012024-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2023-07-012023-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2024-01-012024-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember2023-01-012023-09-300000105770us-gaap:NondesignatedMember2024-07-012024-09-300000105770us-gaap:NondesignatedMember2023-07-012023-09-300000105770us-gaap:NondesignatedMember2024-01-012024-09-300000105770us-gaap:NondesignatedMember2023-01-012023-09-300000105770us-gaap:FairValueInputsLevel1Member2024-09-300000105770us-gaap:FairValueInputsLevel2Member2024-09-300000105770us-gaap:FairValueInputsLevel3Member2024-09-300000105770us-gaap:MoneyMarketFundsMember2024-09-300000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-09-300000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-09-300000105770us-gaap:BankTimeDepositsMember2024-09-300000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member2024-09-300000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member2024-09-300000105770us-gaap:CurrencySwapMember2024-09-300000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember2024-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2024-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2024-09-300000105770us-gaap:CommodityMember2024-09-300000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember2024-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember2024-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember2024-09-300000105770us-gaap:FairValueInputsLevel1Member2023-12-

310000105770us-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:MoneyMarketFundsMember2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:BankTimeDepositsMember2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300000105770us-gaap:AociEquityMethodInvestmentParentMember2024-01-012024-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000105770us-gaap:AociEquityMethodInvestmentParentMember2024-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300000105770us-gaap:AociEquityMethodInvestmentParentMember2023-01-012023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000105770us-gaap:AociEquityMethodInvestmentParentMember2023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:CommonStockMember2023-12-310000105770us-gaap:AdditionalPaidInCapitalMember2023-12-310000105770us-gaap:TreasuryStockCommonMember2023-12-310000105770us-gaap:RetainedEarningsMember2023-12-310000105770us-gaap:RetainedEarningsMember2024-01-012024-03-310000105770us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000105770us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000105770us-gaap:CommonStockMember2024-03-310000105770us-gaap:AdditionalPaidInCapitalMember2024-03-310000105770us-gaap:TreasuryStockCommonMember2024-03-310000105770us-gaap:RetainedEarningsMember2024-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000105770us-gaap:RetainedEarningsMember2024-04-012024-06-300000105770us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000105770us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000105770us-gaap:CommonStockMember2024-06-300000105770us-gaap:AdditionalPaidInCapitalMember2024-06-300000105770us-gaap:TreasuryStockCommonMember2024-06-300000105770us-gaap:RetainedEarningsMember2024-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000105770us-gaap:RetainedEarningsMember2024-07-012024-09-300000105770us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000105770us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000105770us-gaap:CommonStockMember2024-09-300000105770us-gaap:AdditionalPaidInCapitalMember2024-09-300000105770us-gaap:TreasuryStockCommonMember2024-09-300000105770us-gaap:RetainedEarningsMember2024-09-300000105770us-gaap:CommonStockMember2022-12-310000105770us-gaap:AdditionalPaidInCapitalMember2022-12-310000105770us-gaap:TreasuryStockCommonMember2022-12-310000105770us-gaap:RetainedEarningsMember2022-12-310000105770us-gaap:RetainedEarningsMember2023-01-012023-03-310000105770us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000105770us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000105770us-gaap:CommonStockMember2023-03-310000105770us-gaap:AdditionalPaidInCapitalMember2023-03-310000105770us-gaap:TreasuryStockCommonMember2023-03-310000105770us-gaap:RetainedEarningsMember2023-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100001057702023-03-310000105770us-gaap:RetainedEarningsMember2023-04-012023-06-3000001057702023-04-012023-06-300000105770us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000105770us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000105770us-gaap:CommonStockMember2023-06-300000105770us-gaap:AdditionalPaidInCapitalMember2023-06-300000105770us-gaap:TreasuryStockCommonMember2023-06-300000105770us-gaap:RetainedEarningsMember2023-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000001057702023-06-300000105770us-gaap:RetainedEarningsMember2023-07-012023-09-300000105770us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000105770us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:CommonStockMember2023-09-300000105770us-gaap:AdditionalPaidInCapitalMember2023-09-300000105770us-gaap:TreasuryStockCommonMember2023-09-300000105770us-gaap:RetainedEarningsMember2023-09-300000105770us-gaap:PerformanceSharesMember2024-01-012024-09-300000105770us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-09-300000105770us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-09-300000105770us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-3000001057702022-12-012022-12-310000105770srt:MinimumMember2022-12-012022-12-310000105770srt:MaximumMember2022-12-012022-12-310000105770us-gaap:EmployeeSeveranceMember2023-12-310000105770wst:AssetRelatedChargesMember2023-12-310000105770us-gaap:EmployeeSeveranceMember2024-01-012024-09-300000105770wst:AssetRelatedChargesMember2024-01-012024-09-300000105770us-gaap:EmployeeSeveranceMember2024-09-300000105770wst:AssetRelatedChargesMember2024-09-300000105770wst:ProprietaryProductsMember2024-07-012024-09-300000105770wst:ProprietaryProductsMember2023-07-012023-09-300000105770wst:ProprietaryProductsMember2024-01-012024-09-300000105770wst:ProprietaryProductsMember2023-01-012023-09-300000105770wst:ContractManufacturedProductsMember2024-07-012024-09-300000105770wst:ContractManufacturedProductsMember2023-07-012023-09-300000105770wst:ContractManufacturedProductsMember2024-01-012024-09-300000105770wst:ContractManufacturedProductsMember2023-01-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2024-07-012024-09-300000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2023-07-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2024-01-012024-09-300000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2023-01-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2024-07-012024-09-300000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2023-07-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2024-01-012024-09-300000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2023-01-012023-09-300000105770us-gaap:OperatingSegmentsMember2024-07-012024-09-300000105770us-gaap:OperatingSegmentsMember2023-07-012023-09-300000105770us-gaap:OperatingSegmentsMember2024-01-012024-09-300000105770us-gaap:OperatingSegmentsMember2023-01-012023-09-300000105770us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000105770us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000105770us-gaap:CorporateNonSegmentMember2024-01-012024-09-300000105770us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000105770wst:A2022RestructuringPlanMemberwst:OtherIncomeExpenseMemberus-gaap:CorporateNonSegmentMember2024-01-012024-09-300000105770wst:A2022RestructuringPlanMemberwst:OtherIncomeExpenseMemberus-gaap:CorporateNonSegmentMember2024-07-012024-09-300000105770wst:A2022RestructuringPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CorporateNonSegmentMember2024-01-012024-09-300000105770wst:A2022RestructuringPlanMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CorporateNonSegmentMember2024-07-012024-09-300000105770wst:A2022RestructuringPlanMemberus-gaap:CostOfSalesMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000105770wst:A2022RestructuringPlanMemberwst:OtherIncomeExpenseMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-30UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.Â Â 20549FORM 10-Q (Mark One)â˜‘QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended SeptemberÂ 30, 2024 orâ˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromÂ toCommission File Number 1-8036WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter)Pennsylvania23-1210010Â (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)530 Herman O. West Drive, Exton, PA19341-1147(Address of principal executive offices)(Zip Code)Registrantâ€™s telephone number, including area code: 610-594-2900 Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registeredCommon Stock, par value $0.25 per shareWSTNew York Stock ExchangeIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Â Â Â Â Â Â Â Â Yes â˜’ NoÂ â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Â YesÂ â˜’ NoÂ â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.Â See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerâ˜’Â Â Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

companies164.5Â 187.0Â 420.6Â 529.8Â Income tax expense32.4Â 29.4Â 70.7Â 87.8Â Equity in net income of affiliated companies(3.9)(3.7)(12.7)(14.4)Net income$136.0Â $161.3Â $362.6Â $456.4Â Net income per share:Â Â Â Basic$1.87Â $2.17Â $4.96Â $6.13Â Diluted$1.85Â $2.14Â $4.91Â $6.05Â Weighted average shares outstanding:Â Â Â Â Basic72.8Â 74.3Â 73.1Â 74.4Â Diluted73.4Â 75.3Â 73.8Â 75.5Â See accompanying notes to condensed consolidated financial statements.3Table of ContentsCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)West Pharmaceutical Services, Inc. and Subsidiaries(in millions)Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Â 20242023Net income$136.0Â $161.3Â $362.6Â $456.4Â Other comprehensive income (loss), net of tax:Â Â Â Foreign currency translation adjustments, net of tax of $(2.5), $0.4, $(0.8) and $1.9, respectively74.7Â (40.9)6.7Â (36.9)Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2), $0.0, $(0.3), and $(0.5), respectively(0.8)0.2Â (1.2)(1.2)Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively0.2Â â€”Â (0.1)Net gain (loss) on derivatives, net of tax of $1.1, $0.8, $0.7 and $(0.3), respectively6.5Â 1.2Â 2.0Â (1.8)Other comprehensive income (loss), net of tax80.6Â (39.5)7.5Â (40.0)Comprehensive income$216.6Â $121.8Â $370.1Â $416.4Â See accompanying notes to condensed consolidated financial statements.4Table of ContentsCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)West Pharmaceutical Services, Inc. and Subsidiaries(in millions, except per share data)September 30,2024December 31,2023ASSETSÂ Â Current assets:Â Â Cash and cash equivalents$490.9Â $853.9Â Accounts receivable, net524.3Â 512.0Â Inventories401.2Â 434.7Â Other current assets134.2Â 135.8Â Total current assets1,550.6Â 1,936.4Â Property, plant and equipment2,990.7Â 2,738.0Â Less: accumulated depreciation and amortization1,419.7Â 1,324.7Â Property, plant and equipment, net1,571.0Â 1,413.3Â Operating lease right-of-use assets108.0Â 99.2Â Investments in affiliated companies217.5Â 210.0Â Goodwill108.8Â 108.5Â Intangible assets, net12.3Â 15.1Â Deferred income taxes37.6Â 25.7Â Other noncurrent assets69.3Â 21.3Â Total Assets$3,675.1Â $3,829.5Â LIABILITIES AND EQUITYÂ Â Current liabilities:Â Â Notes payable and other current debt$â€”Â $134.0Â Accounts payable224.3Â 242.4Â Accrued salaries, wages and benefits79.6Â 105.9Â Income taxes payable33.4Â 16.6Â Operating lease liabilities19.9Â 17.7Â Other current liabilities159.3Â 155.2Â Total current liabilities516.5Â 671.8Â Long-term debt202.6Â 72.8Â Deferred income taxes9.4Â 12.7Â Pension and other postretirement benefits30.2Â 29.6Â Operating lease liabilities82.3Â 84.5Â Deferred compensation benefits15.2Â 18.6Â Other long-term liabilities66.8Â 58.5Â Total Liabilities923.0Â 948.5Â Commitments and contingencies (Note 16)Equity:Preferred stock, 3.0Â million shares authorized; 0 shares issued and outstandingâ€”Â â€”Â Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: SeptemberÂ 30, 2024 - 75.3Â million, DecemberÂ 31, 2023 - 75.3 million; shares outstanding: SeptemberÂ 30, 2024 - 72.5Â million, DecemberÂ 31, 2023 - 73.5 million18.8Â 18.8Â Capital in excess of par value23.3Â 120.2Â Retained earnings3,856.9Â 3,523.4Â Accumulated other comprehensive loss(136.3)(143.8)Treasury stock, at cost (SeptemberÂ 30, 2024 - 2.8Â million, DecemberÂ 31, 2023 - 1.8 million)(1,010.6)(637.6)Total Equity2,752.1Â 2,881.0Â Total Liabilities and Equity$3,675.1Â $3,829.5Â See accompanying notes to condensed consolidated financial statements.5Table of ContentsCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)West Pharmaceutical Services, Inc. and Subsidiaries(in millions)Â Nine Months EndedSeptember 30,Â 20242023Cash flows from operating activities:Â Â Net income$362.6Â $456.4Â Adjustments to reconcile net income to net cash provided by operating activities:Depreciation112.0Â 99.1Â Amortization2.7Â 2.3Â Stock-based compensation14.4Â 21.9Â Loss on disposal of plantâ€”Â 11.6Â Asset impairments1.9Â 6.9Â Other non-cash items, net(9.7)(13.5)Changes in assets and liabilities(20.6)(47.3)Net cash provided by operating activities463.3Â 537.4Â Cash flows from investing activities:Â Â Capital expenditures(272.1) (253.3)Other, net(1.8)(6.6)Net cash used in investing activities(273.9)(259.9)Cash flows from financing activities:Â Â Borrowings of long-term debt164.7Â â€”Â Repayments of long-term debt(169.0)(1.7)Principal repayments on finance leases(23.2)â€”Â Dividend payments(43.8)(42.2)Proceeds from stock-based compensation awards24.0Â 42.6Â Employee stock purchase plan contributions5.6Â 5.3Â Shares purchased under share repurchase programs(506.5)(261.3)Shares repurchased for employee tax withholdings(5.5)(12.8)Net cash used in financing activities(553.7)(270.1)Effect of exchange rates on cash1.3Â (3.1)Net (decrease) increase in cash and cash equivalents(363.0)4.3Â Cash, including cash equivalents at beginning of period853.9Â 894.3Â Cash, including cash equivalents at end of period$490.9Â $898.6Â See accompanying notes to condensed consolidated financial statements.6Table of ContentsNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)Note 1:Â Â Basis of PresentationBasis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (â€œU.S.â€) generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial reporting and U.S. Securities and Exchange Commission (â€œSECâ€) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended SeptemberÂ 30, 2024, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as â€œWestâ€, the â€œCompanyâ€, â€œweâ€, â€œusâ€ or â€œourâ€) appearing in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œ2023 Annual Reportâ€). The results of operations for any interim period are not necessarily indicative of results for the full year.Note 2:Â Â New Accounting StandardsStandards Issued Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company does not expect the adoption to have a material impact on the consolidated financial statements and disclosures.In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.7Table of ContentsNote 3:Â Â RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (â€œASCâ€) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.The following table presents the approximate percentage of our net sales by market group:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Biologics40 %40 %38 %37 %GenericsÂ 18 %19 %17 %20 %Pharma23 %22 %25 %24 %Contract-Manufactured Products19 %19 %20 %19 %100 %100 %100 %100 %The following table presents the approximate percentage of our net sales by product category: Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232High-Value Product ("HVP") Components45 %50 %46 %50 %High-Value Product ("HVP") Delivery Devices16 %11 %12 %10 %Standard Packaging20 %20 %22 %21 %Contract-Manufactured Products19 %19 %20 %19 %100 %100 %100 %100 %Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from HVP Components to HVP Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. The following table presents the approximate percentage of our net sales by geographic location: Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Americas48 %46 %44 %45 %Europe, Middle East, Africa44 %46 %47 %46 %Asia Pacific8 %8 %9 %9 %100 %100 %100 %100 %8Table of ContentsContract Assets and LiabilitiesThe following table summarizes our contract assets and liabilities:($ in millions)Contract assets, DecemberÂ 31, 2023$21.5Â Contract assets, SeptemberÂ 30, 202442.3Â Change in contract assets - increase (decrease)$20.8Â Deferred income, DecemberÂ 31, 2023$(53.9)Deferred income, SeptemberÂ 30, 2024(53.8)Change in deferred income - decrease (increase)$0.1Â Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended SeptemberÂ 30, 2024, $32.8Â million of revenue was recognized that was included in deferred income at the beginning of the year. The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year are not material as of SeptemberÂ 30, 2024.Note 4:Â Â Net Income Per ShareThe following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232Net income$136.0Â $161.3Â $362.6Â $456.4Â Weighted average common shares outstanding72.8Â 74.3Â 73.1Â 74.4Â Dilutive effect of equity awards, based on the treasury stock method0.6Â 1.0Â 0.7Â 1.1Â Weighted average shares assuming dilution73.4Â 75.3Â 73.8Â 75.5Â During the three months ended SeptemberÂ 30, 2024 and 2023, there were 0.3 million and less than 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.3 million and 0.1 million antidilutive shares excluded during the nine months ended SeptemberÂ 30, 2024 and 2023, respectively.9Table of ContentsIn February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0Â billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The below table summarizes the details of the Company's repurchases of common stock under this program: Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Shares repurchased170,771Â 77,329Â 1,409,786Â 753,399Â Total cost of repurchases ($ in millions)$52.4Â $27.8Â $506.5Â $261.3Â Average price per repurchased share$306.34Â $360.25Â $359.24Â $346.86Â Note 5:Â Â InventoriesInventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:($ in millions)September 30,2024December 31,2023Raw materials$170.3Â $172.3Â Work in process80.0Â 87.3Â Finished goods150.9Â 175.1Â Â $401.2Â $434.7Â Note 6:Â Â LeasesA lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise. The components of lease expense were as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232Operating lease cost$6.4Â $4.3Â $18.1Â $15.0Â Finance lease - amortization of right-of-use (ROU) assets0.3Â â€”Â 0.6Â â€”Â Finance lease - interest on lease liabilities0.1Â â€”Â 0.1Â â€”Â Short-term lease cost0.8Â 1.9Â 1.9Â 4.4Â Variable lease cost2.5Â 1.4Â 6.3Â 4.4Â Total lease cost$10.1Â $7.6Â $27.0Â $23.8Â 10Table of ContentsAs of DecemberÂ 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of SeptemberÂ 30, 2024:September 30,($ in millions)Balance Sheet Classification2024ROU assets, netOther noncurrent assets$31.9Â Lease liabilities (current)Other current liabilities$0.9Â Lease liabilities (noncurrent)Other long-term liabilities$2.2Â Supplemental cash flow information related to leases were as follows:Nine Months EndedSeptember 30,($ in millions)20242023Cash paid for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases$26.3Â $14.4Â Financing cash flows from finance leases$23.2Â $â€”Â Right-of-use assets obtained in exchange for new lease liabilities:Operating leases$36.8Â $6.6Â Finance leases$24.3Â $â€”Â As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the weighted average remaining lease term for operating leases was 8.5 years and 9.8 years, respectively. As of SeptemberÂ 30, 2024, the weighted average remaining lease term for finance leases was 7.0 years. As of DecemberÂ 31, 2023, finance leases were not material.As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the weighted average discount rate for operating leases was 3.84% and 3.55%, respectively. As of SeptemberÂ 30, 2024, the weighted average discount rate for finance leases was 4.92%. As of DecemberÂ 31, 2023, finance leases were not material.Maturities of the Company's lease liabilities as of SeptemberÂ 30, 2024 were as follows:($ in millions)YearOperating LeasesFinance Leases2024 (remaining period as of SeptemberÂ 30, 2024)$6.2Â $0.2Â 202523.2Â 0.9Â 202620.2Â 0.9Â 202715.5Â 0.8Â 202814.1Â 0.5Â Thereafter37.2Â 0.1Â 116.4Â 3.4Â Less: imputed lease interest(14.2)(0.3)Total lease liabilities$102.2Â $3.1Â 11Table of ContentsNote 7:Â Â Affiliated CompaniesThe following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:September 30,December 31,($ in millions)20242023Aggregate carrying value of investments in affiliated companies:Â Â Â Equity method affiliates$210.3Â $203.2Â Â Â Â Non-equity method affiliates7.2Â 6.8Â Total investments in affiliated companies$217.5Â $210.0Â We have elected to record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:September 30,December 31,($ in millions)20242023Payables due to affiliates$24.8Â $25.9Â Receivables due from affiliates$2.7Â $1.6Â The following table summarizes the Company's affiliate transactions: Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232Purchases from (and payments to) affiliates$30.1Â $34.4Â $83.6Â $118.5Â Sales to affiliates$3.5Â $2.5Â $10.7Â $8.5Â The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products. 12Table of ContentsNote 8:Â Â DebtThe following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.($ in millions)September 30,2024December 31,2023Term Loan, due July 2, 2027 (6.67%)$130.0Â $â€”Â Term Loan, due December 31, 2024 (6.32%)â€”Â 81.0Â Series B notes, due July 5, 2024 (3.82%)â€”Â 53.0Â Series C notes, due July 5, 2027 (4.02%) 73.0Â 73.0Â 203.0Â 207.0Â Less: unamortized debt issuance costs0.4Â 0.2Â Total debt202.6Â 206.8Â Less: current portion of long-term debtâ€”Â 134.0Â Long-term debt, net$202.6Â $72.8Â Credit Facility On July 2, 2024, the Company entered into the Third Amendment to the Credit Facility Agreement, which amended the Existing Credit Facility Agreement. Among other changes to the existing credit agreement, the Third Amendment established an incremental term loan in the stated principal amount of $130.0Â million (the â€œNew Term Loanâ€), which was fully drawn at closing and matures on July 2, 2027. The entire stated principal amount of the New Term Loan is due at maturity and there is no scheduled amortization prior to such date. Together with cash on hand, proceeds from the New Term Loan were used to repay an outstanding term loan under the Existing Credit Facility Agreement in the principal amount of $79.9Â million prior to its December 31, 2024 maturity date and to repay an aggregate principal amount of $53.0Â million of the Companyâ€™s 3.82% Series B Senior Notes due July 5, 2024 issued under that certain Note Purchase Agreement dated as of July 5, 2012.At SeptemberÂ 30, 2024, the borrowing capacity available under our $500.0Â million multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million.Term LoanAt SeptemberÂ 30, 2024, we had $130.0 million in borrowings under the New Term Loan which were classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the New Term Loan.Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At SeptemberÂ 30, 2024, we were in compliance with all of our debt covenants.Note 9:Â Â Derivative Financial InstrumentsOur ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.13Table of ContentsForeign Exchange Rate RiskWe have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of SeptemberÂ 30, 2024 the notional amount of these forward exchange contracts was Singapore Dollar (â€œSGDâ€) 421.9 million and

$13.4 million. As of DecemberÂ 31, 2023 the notional amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of SeptemberÂ 30, 2024, the total notional amounts of these forward exchange contracts were Euro ("EUR") 143.9 million and $47.1 million. As of December 31, 2023, the total notional amounts of these forward exchange contracts were EUR 278.6 million and SGD 94.0 million.In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of SeptemberÂ 30, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:(in millions)SellCurrencyPurchaseUSDEuroSGDEUR24.1Â 26.5Â â€”Â â€”Â Yen6,102.9Â 28.7Â 11.4Â 1.7Â SGD43.4Â 19.0Â 12.5Â â€”Â In December 2019, we entered into a cross-currency swap for $90Â million, which we designated as a hedge of our net investment in Daikyo. The cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130Â million, which we designated as a hedge of our net investment in Daikyo. As of SeptemberÂ 30, 2024, the notional amount of the cross-currency swap is Â¥17.0Â billion ($130.0Â million) and the swap termination date is July 2, 2027. Under the cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments. Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.Commodity Price RiskMany of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.From November 2017 through September 2024, we purchased several series of call options for a total of 1,106,908 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of SeptemberÂ 30, 2024, we had outstanding contracts to purchase 187,861 barrels of crude oil from September 2024 to March 2026, at a weighted-average strike price of $85.66 per barrel.14Table of ContentsEffects of Derivative Instruments on Financial Position and Results of OperationsPlease refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023.The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for theThree Months EndedSeptember 30,Nine Months EndedSeptember 30,Location on Statement of Income($ in millions)20242023202420232024Fair Value Hedges:Hedged item (intercompany loan)(16.6)(1.2)(6.2)8.7Â Other expense (income)Derivative designated as hedging instrument 16.6Â 0.7Â 6.2Â (10.0)Other expense (income)Amount excluded from effectiveness testing(1.8)(1.5)(5.3)(0.4)Other expense (income)Total(1.8)(2.0)(5.3)(1.7)We recognize in earnings the initial value of forward point components for hedges of intercompany loans on a straight-line basis over the life of the fair value hedge. The value of forward point components for hedges of intercompany demand notes is recognized currently in earnings using a market approach. The expense recognized in earnings, pre-tax, for forward point components for the three and nine months ended SeptemberÂ 30, 2024 was $1.8 million and $5.3 million, respectively. The income recognized in earnings, pre-tax, for forward point components for the three and nine months ended SeptemberÂ 30, 2023 was $0.2 million and $1.6 million, respectively.15Table of ContentsThe following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (â€œOCIâ€) and earnings, net of tax:Â Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into IncomeThree Months EndedSeptember 30,Three Months EndedSeptember 30,($ in millions)20242023202420232024 Fair Value Hedges:Foreign currency hedge contracts$0.5Â (0.3)â€”Â $2.3Â Other expense (income)Total$0.5Â (0.3)â€”Â $2.3Â Cash Flow Hedges:Â Â Â Â Â Â Foreign currency hedge contracts$0.2Â $0.5Â $â€”Â $0.1Â Net salesForeign currency hedge contracts5.3Â (2.5)0.5Â 1.1Â Cost of goods and services soldForward treasury locksâ€”Â â€”Â â€”Â â€”Â Interest expenseTotal$5.5Â (2.0)0.5Â $1.2Â Â Net Investment Hedges:Â Â Â Â Â Â Cross-currency swap(8.1)2.9Â $â€”Â $â€”Â Other expense (income)Total(8.1)2.9Â $â€”Â $â€”Â Â Â Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into IncomeNine Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232024Â Fair Value Hedges:Foreign currency hedge contracts$0.7Â (2.3)(0.7)$4.2Â Other expense (income)Total$0.7Â (2.3)(0.7)$4.2Â Cash Flow Hedges:Â Â Â Â Â Â Foreign currency hedge contracts$0.3Â (0.4)(0.2)$1.2Â Net salesForeign currency hedge contracts(1.3)(6.1)3.1Â 1.5Â Cost of goods and services soldForward treasury locksâ€”Â â€”Â 0.1Â 0.1Â Interest expenseTotal(1.0)(6.5)$3.0Â $2.8Â Â Net Investment Hedges:Â Â Â Â Â Â Cross-currency swap$0.3Â $10.1Â $â€”Â $â€”Â Other expense (income)Total$0.3Â $10.1Â $â€”Â $â€”Â Â 16Table of ContentsRefer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Net salesâ€”Â $0.1Â (0.2)1.2Â Cost of goods and services sold0.5Â 1.1Â 3.1Â 1.5Â Interest expenseâ€”Â â€”Â 0.1Â 0.1Â The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Location on Statement of Income($ in millions)20242023202420232023Commodity call options(0.5)0.5Â (0.6)(0.5)Other expense (income)Currency Forwards(3.2)â€”Â (2.7)(0.2)Other expense (income)Total(3.7)0.5Â (3.3)(0.7)For the three and nine months ended SeptemberÂ 30, 2024 and 2023, there was no material ineffectiveness related to our hedges.Note 10:Â Â Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:â€¢Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.â€¢Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.â€¢Level 3: Unobservable inputs that reflect the reporting entityâ€™s own assumptions.17Table of ContentsThe following tables present the assets and liabilities recorded at fair value on a recurring basis:Â Balance atBasis of Fair Value Measurements($ in millions)September 30,2024Level 1Level 2Level 3Assets:Â Â Â Â Deferred compensation assets$11.3Â $11.3Â $â€”Â $â€”Â Money market funds128.5Â 128.5Â â€”Â â€”Â Time deposits73.5Â â€”Â 73.5Â â€”Â Foreign currency contracts19.7Â â€”Â 19.7Â â€”Â Cross-currency swap15.1Â â€”Â 15.1Â â€”Â Commodity call options0.2Â â€”Â 0.2Â â€”Â Â $248.3Â $139.8Â $108.5Â $â€”Â Liabilities:Â Â Â Â Contingent consideration$3.7Â $â€”Â $â€”Â $3.7Â Deferred compensation liabilities11.4Â 11.4Â â€”Â â€”Â Foreign currency contracts9.9Â â€”Â 9.9Â â€”Â Â $25.0Â $11.4Â $9.9Â $3.7Â Â Balance atBasis of Fair Value Measurements($ in millions)December 31,2023Level 1Level 2Level 3Assets:Â Â Â Â Deferred compensation assets$10.2Â $10.2Â $â€”Â $â€”Â Money market funds404.4Â 404.4Â â€”Â â€”Â Time deposits47.9Â â€”Â 47.9Â â€”Â Foreign currency contracts5.0Â â€”Â 5.0Â â€”Â Cross-currency swap18.4Â â€”Â 18.4Â â€”Â Commodity call options0.6Â â€”Â 0.6Â â€”Â Â Â $486.5Â $414.6Â $71.9Â $â€”Â Liabilities:Â Â Â Â Contingent consideration$3.6Â $â€”Â $â€”Â $3.6Â Deferred compensation liabilities10.4Â 10.4Â â€”Â â€”Â Foreign currency contracts2.2Â â€”Â 2.2Â â€”Â Â Â $16.2Â $10.4Â $2.2Â $3.6Â 18Table of ContentsDeferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDoseÂ® technology platform (the â€œSmartDoseÂ® contingent considerationâ€) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employeesâ€™ investment selections and is included within other long-term liabilities.Other Financial InstrumentsWe believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At SeptemberÂ 30, 2024, the estimated fair value of long-term debt was $201.6Â million compared to a carrying amount of $202.6Â million. At DecemberÂ 31, 2023, the estimated fair value of short-term and long-term debt was $204.4 million and the carrying amount was $206.8 million. As of SeptemberÂ 30, 2024, all debt is long-term.Note 11:Â Â Accumulated Other Comprehensive LossThe following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended SeptemberÂ 30, 2024:($ in millions)DerivativesChange in equity affiliate investment AOCIDefined benefitpension and other postretirement plansForeign currency translationTotalBalance, December 31, 2023$â€”Â $2.3Â (10.1)(136.0)$(143.8)Other comprehensive income (loss) before reclassifications(0.3)â€”Â (0.6)6.7Â 5.8Â Amounts reclassified out from accumulated other comprehensive income (loss)2.3Â â€”Â (0.6)â€”Â 1.7Â Other comprehensive income (loss), net of tax2.0Â â€”Â (1.2)6.7Â 7.5Â Balance, September 30, 2024$2.0Â $2.3Â (11.3)(129.3)$(136.3)19Table of ContentsThe following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended SeptemberÂ 30, 2023:($ in millions)DerivativesChange in equity affiliate investment AOCIDefined benefitpension and other postretirement plansForeign currency translationTotalBalance, DecemberÂ 31, 2022$0.2Â $1.6Â (9.4)(175.4)$(183.0)Other comprehensive (loss) income before reclassifications(8.8)(0.1)(0.1)(36.9)(45.9)Amounts reclassified out from accumulated other comprehensive (loss) income7.0Â â€”Â (1.1)â€”Â 5.9Â Other comprehensive (loss) income, net of tax(1.8)(0.1)(1.2)(36.9)(40.0)Balance, SeptemberÂ 30, 2023(1.6)1.5Â (10.6)(212.3)$(223.0)A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table: ($ in millions)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Location on Statement of IncomeDetail of components20242023202420232023Gains (losses) on derivatives:Foreign currency contracts$â€”Â (0.2)0.2Â $(1.5)Net salesForeign currency contracts(0.7)(1.4)(4.1)(2.0)Cost of goods and services soldForeign currency contractsâ€”Â (3.4)1.0Â (6.2)Other expense (income)Forward treasury locksâ€”Â (0.1)(0.1)(0.2)Interest expenseTotal before tax(0.7)(5.1)(3.0)(9.9)Tax benefit0.2Â 1.6Â 0.7Â 2.9Â Net of tax(0.5)(3.5)(2.3)(7.0)Amortization of defined benefit pension and other postretirement plans:Actuarial gains$0.3Â $0.3Â $0.8Â $1.1Â (a)Otherâ€”Â â€”Â â€”Â 0.4Â Total before tax0.3Â 0.3Â 0.8Â 1.5Â Tax expense(0.1)(0.1)(0.2)(0.4)Net of tax$0.2Â $0.2Â $0.6Â $1.1Â Total reclassifications for the period, net of tax(0.3)(3.3)(1.7)(5.9)(a) This component is included in the computation of net periodic benefit cost.20Table of ContentsNote 12: Shareholdersâ€™ EquityThe following table presents the changes in shareholdersâ€™ equity for the nine months ended SeptemberÂ 30, 2024:Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal(in millions)Balance, December 31, 202375.3Â $18.8Â $120.2Â 1.8Â (637.6)3,523.4Â (143.8)2,881.0Â Net incomeâ€”Â â€”Â â€”Â â€”Â 115.3Â â€”Â 115.3Â Activity related to stock-based compensationâ€”Â â€”Â (65.0)(0.2)79.4Â â€”Â â€”Â 14.4Â Shares purchased under share repurchase programâ€”Â â€”Â â€”Â 0.7Â (267.0)â€”Â â€”Â (267.0)Dividends declared ($0.20 per share)â€”Â â€”Â â€”Â â€”Â â€”Â (14.6)â€”Â (14.6)Other comprehensive loss, net of taxâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (48.5)(48.5)Balance, March 31, 202475.3Â $18.8Â $55.2Â 2.3Â (825.2)3,624.1Â (192.3)2,680.6Â Net incomeâ€”Â â€”Â â€”Â â€”Â 111.3Â â€”Â 111.3Â Activity related to stock-based compensationâ€”Â â€”Â (21.7)(0.1)32.8Â â€”Â â€”Â 11.1Â Shares purchased under share repurchase programâ€”Â â€”Â â€”Â 0.5Â (187.1)â€”Â â€”Â (187.1)Dividends declared ($0.20 per share)â€”Â â€”Â â€”Â â€”Â â€”Â (14.5)â€”Â (14.5)Other comprehensive loss, net of taxâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (24.6)(24.6)Balance, June 30, 202475.3Â $18.8Â $33.5Â 2.7Â (979.5)3,720.9Â (216.9)2,576.8Â Net incomeâ€”Â â€”Â â€”Â â€”Â 136.0Â â€”Â 136.0Â Activity related to stock-based compensationâ€”Â â€”Â (10.2)(0.1)21.3Â â€”Â â€”Â 11.1Â Shares purchased under share repurchase programâ€”Â â€”Â â€”Â 0.2Â (52.4)â€”Â â€”Â (52.4)Other comprehensive income, net of taxâ€”Â â€”Â â€”Â â€”Â â€”Â 80.6Â 80.6Â Balance, September 30, 202475.3Â $18.8Â $23.3Â 2.8Â $(1,010.6)$3,856.9Â (136.3)2,752.1Â 21Table of ContentsThe following table presents the changes in shareholdersâ€™ equity for the nine months ended SeptemberÂ 30, 2023:Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal(in millions)Balance, December 31, 202275.3Â $18.8Â $232.2Â 1.2Â (370.9)2,987.8Â (183.0)2,684.9Â Net incomeâ€”Â â€”Â â€”Â â€”Â 140.0Â â€”Â 140.0Â Activity related to stock-based compensationâ€”Â â€”Â (50.8)(0.3)61.8Â â€”Â â€”Â 11.0Â Shares purchased under share repurchase programâ€”Â â€”Â â€”Â 0.2Â (60.1)â€”Â â€”Â (60.1)Dividends declared ($0.19 per share)â€”Â â€”Â â€”Â â€”Â â€”Â (14.2)â€”Â (14.2)Other comprehensive income, net of taxâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â 14.6Â 14.6Â Balance, March 31, 202375.3Â $18.8Â $181.4Â 1.1Â (369.2)3,113.6Â (168.4)2,776.2Â Net incomeâ€”Â â€”Â â€”Â â€”Â 155.1Â â€”Â 155.1Â Activity related to stock-based compensationâ€”Â â€”Â (23.2)(0.2)41.2Â â€”Â â€”Â 18.0Â Shares purchased under share repurchase programâ€”Â â€”Â â€”Â 0.5Â (173.4)â€”Â â€”Â (173.4)Dividends declared ($0.19 per share)â€”Â â€”Â â€”Â â€”Â â€”Â (14.1)â€”Â (14.1)Other comprehensive loss, net of taxâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (15.1)(15.1)Balance, June 30, 202375.3Â $18.8Â $158.2Â 1.4Â (501.4)3,254.6Â (183.5)2,746.7Â Net incomeâ€”Â â€”Â â€”Â â€”Â 161.3Â â€”Â 161.3Â Activity related to stock-based compensationâ€”Â â€”Â (35.6)(0.2)63.1Â â€”Â â€”Â 27.5Â Shares purchased under share repurchase programâ€”Â â€”Â â€”Â 0.1Â (27.8)â€”Â â€”Â (27.8)Other comprehensive loss, net of taxâ€”Â â€”Â â€”Â â€”Â â€”Â (39.5)(39.5)Balance, September 30, 202375.3Â $18.8Â $122.6Â 1.3Â (466.1)3,415.9Â (223.0)2,868.2Â 22Table of ContentsNote 13:Â Â Stock-Based CompensationThe West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the â€œ2016 Planâ€) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At SeptemberÂ 30, 2024, there were 1,338,673 shares remaining in the 2016 Plan for future grants.During the nine months ended SeptemberÂ 30, 2024, we granted 88,588 stock options at a weighted average exercise price of $348.50 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $134.33 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.3%; expected life of 6.0 years based on prior experience; stock volatility of 32.0% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.During the nine months ended SeptemberÂ 30, 2024, we granted 34,188 stock-settled performance share unit (â€œPSUâ€) awards at a weighted average grant-date fair value of $348.46 per share to eligible employees. These awards are earned based on the Companyâ€™s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employeeâ€™s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.During the nine months ended SeptemberÂ 30, 2024, we granted 8,302 stock-settled restricted share unit (â€œRSUâ€) awards at a weighted average grant-date fair value of $342.74 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. Stock-based compensation expense was $5.1 million and $14.4 million for the three and nine months ended

SeptemberÂ 30, 2024, respectively. For the three and nine months ended SeptemberÂ 30, 2023, stock-based compensation expense was $5.9 million and $21.9 million, respectively. Note 14:Â Â Other Expense (Income) Other expense (income) consists of:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232Foreign exchange transaction losses$4.1Â $1.8Â $7.3Â $3.0Â Contingent consideration1.2Â 0.7Â 3.2Â 1.5Â Asset impairments1.0Â 3.5Â 1.9Â 6.9Â Restructuring and related charges(2.5)â€”Â (2.5)(0.8)Loss on disposal of plantâ€”Â â€”Â â€”Â 11.6Â Other items0.6Â (0.4)0.9Â 0.3Â Total other expense (income)$4.4Â $5.6Â $10.8Â $22.5Â 23Table of ContentsContingent ConsiderationContingent consideration represents changes in the fair value of the SmartDoseÂ® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.Restructuring and Related ChargesIn December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were implemented over a period of approximately twenty-four months from the date of approval. The plan is expected to have annualized savings in the range of $17Â million to $19Â million. As of SeptemberÂ 30, 2024, the Company does not expect additional expenses or payments associated with our 2022 restructuring plan. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:($ in millions)Severanceand benefitsOther chargesTotalBalance, December 31, 2023$3.0Â $â€”Â $3.0Â (Credits) Charges(2.5)â€”Â (2.5)Cash payments(0.5)â€”Â (0.5)Balance, September 30, 2024$â€”Â $â€”Â $â€”Â Loss on Disposal of PlantDuring the nine months ended SeptemberÂ 30, 2023, the Company recorded expense of $11.6Â million, within other expense (income), as a result of the sale of one of the Companyâ€™s manufacturing facilities within the Proprietary Products segment during the second quarter of 2023.Note 15:Â Â Income TaxesThe tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.The provision for income taxes was $32.4 million and $29.4 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and the effective tax rate was 19.7% and 15.7%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the three months ended SeptemberÂ 30, 2024 as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.The provision for income taxes was $70.7 million and $87.8 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively, and the effective tax rate was 16.8% and 16.6%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.The Company continues to address the change in tax laws enacted pursuant to the Organization for Economic Cooperation and Development (OECD)â€™s 15% global minimum tax initiative (Pillar 2). The 2024 forecasted impact of Pillar 2 is not expected to be material to the Company.24Table of ContentsNote 16:Â Â Commitments and ContingenciesFrom time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.There have been no significant changes to commitments and contingencies since DecemberÂ 31, 2023.Note 17:Â Â Segment InformationOur business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.The following table presents information about our reportable segments, reconciled to consolidated totals:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232Net sales:Â Â Â Â Proprietary Products$601.4Â $602.5Â $1,720.6Â $1,803.6Â Contract-Manufactured Products145.5Â 144.9Â 423.8Â 414.2Â Consolidated net sales$746.9Â $747.4Â $2,144.4Â $2,217.8Â 25Table of ContentsThe following table provides summarized financial information for our segments:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)20242023202420232Operating profit (loss):Proprietary Products$158.2Â $181.6Â $415.5Â $546.5Â Contract-Manufactured Products21.8Â 21.0Â 56.1Â 53.3Â Total business segment operating profit$180.0Â $202.6Â $471.6Â $599.8Â Corporate and UnallocatedStock-based compensation expense(5.1)(5.9)(14.4)(21.9)Corporate general costs (1)(14.3)(15.9)(47.2)(47.2)Unallocated Items:Loss on disposal of plant (2)â€”Â â€”Â â€”Â (11.6)Cost investment impairment (3)â€”Â (3.3)â€”Â (3.3)Restructuring and other charges (4)0.9Â â€”Â 0.9Â (0.1)Amortization of acquisition-related intangible assets (5)(0.2)(0.2)(0.6)(0.6)Total Corporate and Unallocated(18.7)(25.3)(61.3)(84.7)Total consolidated operating profit$161.3Â $177.3Â $410.3Â $515.1Â Interest (income) expense and other nonoperating expense (income), net(3.2)(9.7)(10.3)(14.7)Income before income taxes and equity in net income of affiliated companies$164.5Â $187.0Â $420.6Â $529.8Â (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.(2) During the nine months ended SeptemberÂ 30, 2023, the Company recorded expense of $11.6Â million within other expense (income), as a result of the sale of one of the Companyâ€™s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.(3) During the three and nine months ended SeptemberÂ 30, 2023, the Company recorded expense of $3.3Â million within other expense (income), as a result of an impairment of one of the Company's cost investments.(4) Restructuring and other charges were a benefit of $0.9Â million in the three and nine months ended SeptemberÂ 30, 2024. The net benefit represents the impact of two items, the first of which is a $2.5Â million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6Â million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. Restructuring and other charges of $0.1Â million for the nine months ended SeptemberÂ 30, 2023 represent the net impact of an inventory write down of $0.9Â million within cost of goods and services sold and a $0.8Â million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan.(5) During the three and nine months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023, the Company recorded $0.2Â million and $0.6Â million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.Please refer to Note 14, Other Expense (Income), for further discussion of these items.26Table of ContentsITEM 2.Â Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSOVERVIEWThe following discussion is intended to further the readerâ€™s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (â€œForm 10-Qâ€) as well as Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2023 Annual Report. Our historical financial statements may not be indicative of our future performance. This Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2023 Annual Report and in Part II, Item 1A of this Form 10-Q.Throughout this section, references to â€œNotesâ€ refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.Non-U.S. GAAP Financial MeasuresFor the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.Our OperationsWe are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.Our business operations are organized into two global segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.27Table of ContentsMacroeconomic FactorsWe have operations based in Israel that conduct research and development activities and manufacture certain components for our devices. Our Israel-based facilities continue to substantially operate as they had prior to the conflict in Israel and surrounding area. We continue to monitor the impact of the conflict in Israel and surrounding areas on our operations and those of our suppliers, the possible expansion of such conflict and potential geopolitical consequences, if any, on our business and operations.Financial Performance SummaryThe following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended SeptemberÂ 30, 2024:($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPSThree months ended SeptemberÂ 30, 2024 GAAP$161.3Â $32.4Â $136.0Â $1.85Â Unallocated items:Restructuring and other charges (1)(0.9)(0.3)(0.6)(0.01)Amortization of acquisition-related intangible assets (2)0.2Â 0.1Â 0.7Â 0.01Â Three months ended SeptemberÂ 30, 2024 adjusted amounts (non-U.S. GAAP)$160.6Â $32.2Â $136.1Â $1.85Â ($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPSNine months ended SeptemberÂ 30, 2024 GAAP$410.3Â $70.7Â $362.6Â $4.91Â Unallocated items:Restructuring and other charges (1)(0.9)(0.3)(0.6)(0.01)Amortization of acquisition-related intangible assets (2)0.6Â 0.1Â 2.1Â 0.03Â Nine months ended SeptemberÂ 30, 2024 adjusted amounts (non-U.S. GAAP)$410.0Â $70.5Â $364.1Â $4.93Â During the three and nine months ended SeptemberÂ 30, 2024, we recorded a tax benefit of $2.7Â million and $19.3Â million, respectively, associated with stock-based compensation.The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended SeptemberÂ 30, 2023:($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPSThree months ended SeptemberÂ 30, 2023 GAAP$177.3Â $29.4Â $161.3Â $2.14Â Unallocated items:Amortization of acquisition-related intangible assets (2)0.2Â 0.1Â 0.7Â 0.01Â Legal settlement (3)â€”Â (0.9)(2.9)(0.04)Cost investment impairment (4)3.3Â â€”Â 3.3Â 0.05Â Three months ended SeptemberÂ 30, 2023 adjusted amounts (non-U.S. GAAP)$180.8Â $28.6Â $162.4Â $2.16Â 28Table of Contents($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPSNine months ended SeptemberÂ 30, 2023 GAAP$515.1Â $87.8Â $456.4Â $6.05Â Unallocated items:Restructuring and other charges (1)0.1Â (0.3)0.4Â â€”Â Amortization of acquisition-related intangible assets (2)0.6Â 0.1Â 2.1Â 0.03Â Legal settlement (3)â€”Â (0.9)(2.9)(0.04)Cost investment impairment (4)3.3Â â€”Â 3.3Â 0.05Â Loss on disposal of plant (5)11.6Â (0.7)12.3Â 0.16Â Nine months ended SeptemberÂ 30, 2023 adjusted amounts (non-U.S. GAAP)$530.7Â $86.0Â $471.6Â $6.25Â During the three and nine months ended SeptemberÂ 30, 2023, we recorded a tax benefit of $12.0Â million and $31.3Â million, respectively, associated with stock-based compensation.(1)Restructuring and other charges were a benefit of $0.9Â million in the three and nine months ended SeptemberÂ 30, 2024. The net benefit represents the impact of two items, the first of which is a $2.5Â million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6Â million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. Restructuring and other charges of $0.1Â million for the nine months ended SeptemberÂ 30, 2023 represent the net impact of an inventory write down of $0.9Â million within cost of goods and services sold and a $0.8Â million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan.(2)During the three and nine months ended SeptemberÂ 30, 2024 and 2023, the Company recorded $0.2Â million and $0.6Â million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended SeptemberÂ 30, 2024 and 2023, the Company recorded $0.6Â million and $1.6Â million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.(3)During the three and nine months ended SeptemberÂ 30, 2023, the Company recorded a benefit of $3.8Â million within other nonoperating expense (income) as a result of a favorable legal settlement related to a matter not included in our normal operations.(4)During the three and nine months ended SeptemberÂ 30, 2023, the Company recorded expense of $3.3Â million within other expense (income), as a result of an impairment of one of the Company's cost investments.(5)During the nine months ended SeptemberÂ 30, 2023, the Company recorded expense of $11.6Â million within other expense (income), as a result of the sale of one of the Companyâ€™s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. 29Table of ContentsRESULTS OF OPERATIONSWe evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.Net SalesThe following table presents net sales, consolidated and by reportable segment, for the three months ended SeptemberÂ 30, 2024 and 2023:Three Months EndedSeptember 30,Percentage Change($ in millions)20242023As-ReportedOrganicProprietary Products$601.4Â $602.5Â (0.2)%(0.5)%Contract-Manufactured Products145.5Â 144.9Â 0.4Â %(0.1)%Consolidated net sales$746.9Â $747.4Â (0.1)%(0.5)%Consolidated net sales decreased by $0.5 million, or 0.1%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $2.9 million. Excluding foreign currency translation effects, consolidated net sales for the three months ended SeptemberÂ 30, 2024 decreased by $3.4 million, or 0.5%, as compared to the same period in 2023.Proprietary Products â€“ Proprietary Products net sales decreased by $1.1 million, or 0.2%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $2.2 million. Excluding foreign currency translation effects, net sales for the three months ended SeptemberÂ 30, 2024 decreased by $3.3 million, or 0.5%, as compared to the same period in 2023, due to a decline in sales of certain high-value product offerings due to customer inventory management, primarily FluroTecÂ® products, NovaBrand products, WestarÂ® components and DaikyoÂ® components. These reductions were partially offset by an increase in sales of self-injection device platforms, approximately $19Â million in customer incentives in connection with volumes achieved during the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, and increased sales prices.Contract-Manufactured Products â€“ Contract-Manufactured Products net sales increased by $0.6 million, or 0.4%, for the three months ended SeptemberÂ 30, 2024, as

compared to the same period in 2023, including a favorable foreign currency translation impact of $0.7 million. Excluding foreign currency translation effects, net sales for the three months ended SeptemberÂ 30, 2024 decreased by $0.1 million, or 0.1%, as compared to the same period in 2023, due primarily to a decrease in sales of healthcare diagnostic devices, offset by growth in self-injection devices for obesity and diabetes.The following table presents net sales, consolidated and by reportable segment, for the nine months ended SeptemberÂ 30, 2024 and 2023:30Table of ContentsNine Months EndedSeptember 30,Percentage Change($ in millions)20242023As-ReportedOrganicProprietary Products$1,720.6Â $1,803.6Â (4.6)%(4.4)%Contract-Manufactured Products423.8Â 414.2Â 2.3Â %2.2Â %Consolidated net sales$2,144.4Â $2,217.8Â (3.3)%(3.1)%Consolidated net sales decreased by $73.4 million, or 3.3%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.2 million. Excluding foreign currency translation effects and removal of the 2023 sales impact related to one of our plants that was disposed of in the second quarter of 2023 of $4.3 million, consolidated net sales for the nine months ended SeptemberÂ 30, 2024 decreased by $69.3 million, or 3.1%, as compared to the same period in 2023.Proprietary Products â€“ Proprietary Products net sales decreased by $83.0 million, or 4.6%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including an unfavorable foreign currency translation impact of $0.4 million. Excluding foreign currency translation effects and removal of the 2023 sales impact related to one of our plants that was disposed of in the second quarter of 2023 of $4.3 million, net sales for the nine months ended SeptemberÂ 30, 2024 decreased by $78.3 million, or 4.4%, as compared to the same period in 2023, due to a decline in sales of certain high-value product offerings due to customer inventory management, primarily WestarÂ® components, FluroTecÂ® products and DaikyoÂ® components. These reductions were partially offset by an increase in sales of self-injection device platforms and NovaBrand products, as well as increased sales prices.Contract-Manufactured Products â€“ Contract-Manufactured Products net sales increased by $9.6 million, or 2.3%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.6 million. Excluding foreign currency translation effects, net sales for the nine months ended SeptemberÂ 30, 2024 increased by $9.0 million, or 2.2%, as compared to the same period in 2023, primarily due to an increase in sales of components associated with injection-related devices and sales price increases. Gross ProfitThe following table presents gross profit and related gross profit margins, consolidated and by reportable segment:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Proprietary Products:Â Â Gross profit$235.7Â $261.4Â $649.8Â $780.6Â Gross profit margin39.2Â %43.4Â %37.8Â %43.3Â %Contract-Manufactured Products:Â Â Â Gross profit$29.0Â $26.9Â $75.1Â $71.3Â Gross profit margin19.9Â %18.6Â %17.7Â %17.2Â %Unallocated items$â€”Â $â€”Â $â€”Â $(0.9)Consolidated gross profit$264.7Â $288.3Â $724.9Â $851.0Â Consolidated gross profit margin35.4Â %38.6Â %33.8Â %38.4Â %31Table of ContentsConsolidated gross profit decreased by $23.6 million, or 8.2%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $1.0 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023. Consolidated gross profit margin decreased by 3.2 margin points for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Consolidated gross profit decreased by $126.1 million, or 14.8% for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.1 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023. Consolidated gross profit margin decreased by 4.6 margin points for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Proprietary Products - Proprietary Products gross profit decreased by $25.7 million, or 9.8%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.9 million. Proprietary Products gross profit margin decreased by 4.2 margin points for the three months ended SeptemberÂ 30, 2024, as compared to the same periods in 2023, primarily due to a shift in sales mix from HVP Components to HVP Delivery Devices, which have lower profitability. Profit was additionally impacted by lower plant absorption at our HVP Component plants from reduced customer demand. These headwinds were partially offset by approximately $19Â million in customer incentives in connection with volumes achieved during the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, and increased sales prices.Proprietary Products gross profit decreased by $130.8 million, or 16.8%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023. Proprietary Products gross profit margin decreased by 5.5 margin points for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to lower plant absorption from reduced customer demand and an unfavorable shift in mix of products sold from HVP Components to HVP Delivery Devices. These headwinds were partially offset by increased sales prices and approximately $22Â million in customer incentives in connection with volumes achieved during the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Contract-Manufactured Products - Contract-Manufactured Products gross profit increased by $2.1 million, or 7.8%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.1 million. Contract-Manufactured Products gross profit margin increased by 1.3 margin points for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to production efficiencies.Contract-Manufactured Products gross profit increased by $3.8 million, or 5.3%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023. Contract-Manufactured Products gross profit margin increased by 0.5 margin points for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to increased sales prices.Research and Development (â€œR&Dâ€) CostsThe following table presents consolidated R&D costs:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Consolidated R&D costs$15.5Â $16.4Â $50.6Â $50.0Â 32Table of ContentsConsolidated R&D costs decreased by $0.9 million, or 5.5%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023. Consolidated R&D costs increased $0.6 million, or 1.2%, for the nine months ended SeptemberÂ 30, 2024 as compared to the same period of 2023. Efforts remain focused on the continued investment in elastomeric packaging components, formulation development, drug containment systems, self-injection systems and drug administration consumable.All of the R&D costs incurred in the three and nine months ended SeptemberÂ 30, 2024 and 2023 related to Proprietary Products.Selling, General and Administrative (â€œSG&Aâ€) CostsThe following table presents SG&A costs, consolidated and by reportable segment and corporate and unallocated items:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Proprietary Products$56.6Â $61.4Â $173.4Â $176.8Â Contract-Manufactured Products6.7Â 6.0Â 19.1Â 18.1Â Corporate and unallocated items20.2Â 21.6Â 60.7Â 68.5Â Consolidated SG&A costs$83.5Â $89.0Â $253.2Â $263.4Â SG&A as a % of net sales11.2Â %11.9Â %11.8Â %11.9Â %Consolidated SG&A costs decreased by $5.5 million, or 6.2%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due primarily to lower annual incentive compensation and decreased costs related to professional services, offset by increased salary and wages.Consolidated SG&A costs decreased by $10.2 million, or 3.9%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.2 million, due primarily to a decrease in expense related to stock-based compensation and lower annual incentive compensation, offset by increased salary and wages.Proprietary Products - Proprietary Products SG&A costs decreased by $4.8 million, or 7.8%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023. Proprietary Products SG&A costs decreased primarily due to lower annual incentive compensation and decreased costs related to professional services.Proprietary Products SG&A costs decreased by $3.4 million, or 1.9%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.2 million. Proprietary Products SG&A costs decreased primarily due to lower annual incentive compensation.Contract-Manufactured Products - Contract-Manufactured Products SG&A costs increased by $0.7 million, or 11.7%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, and increased by $1.0 million, or 5.5%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due primarily to increased salary and wages.Corporate and unallocated items - Corporate SG&A costs decreased by $1.4 million, or 6.5%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to lower annual incentive compensation and a decrease in expense related to stock-based compensation, offset by increased salary and wages.Corporate SG&A costs decreased by $7.8 million, or 11.4%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to a decrease in expense related to stock-based compensation and lower annual incentive compensation, offset by increased salary and wages.33Table of ContentsOther Expense (Income)The following table presents other income and expense items, consolidated and by reportable segment, corporate and unallocated items:Expense (Income) Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Proprietary Products$5.4Â $2.0Â $10.3Â $7.3Â Contract-Manufactured Products0.5Â (0.1)(0.1)(0.1)Corporate and unallocated(1.5)3.7Â 0.6Â 15.3Â Consolidated other expense (income)$4.4Â $5.6Â $10.8Â $22.5Â Other expense and income items consist of a loss on disposal of plant, asset impairments, foreign exchange transaction gains and losses, contingent consideration and miscellaneous income and charges.Consolidated other expense (income) changed by $1.2 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023 and changed by $11.7 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due to the factors described below.Proprietary Products - Proprietary Products other expense (income) changed by $3.4 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to increased losses on foreign exchange transactions, increased asset impairments and increased contingent consideration expense being recorded in the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Proprietary Products other expense (income) changed by $3.0 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to increased losses on foreign exchange transactions and increased contingent consideration expense, offset by a decrease in asset impairments being recorded in the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Contract-Manufactured Products - Contract-Manufactured Products other expense (income) changed by $0.6 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023 and remained consistent for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Corporate and unallocated items - Corporate and unallocated items changed by $5.2 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to the Company recording expense related to impairment of one of the Company's cost investments of $3.3Â million in the three months ended SeptemberÂ 30, 2023 that did not occur in the same period in 2024. Additionally, the Company recorded a benefit of $2.5Â million related to revised severance estimates in connection with the Company's 2022 restructuring plan in the three months ended SeptemberÂ 30, 2024 that did not occur in the same period in 2023.Corporate and unallocated items changed by $14.7 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to the Company recording expense of $11.6Â million as a result of the sale of one of the Companyâ€™s manufacturing facilities within the Proprietary Products segment and the Company recording expense related to impairment of one of the Company's cost investments of $3.3Â million in the nine months ended SeptemberÂ 30, 2023. Neither of these items occurred in the same period in 2024. Additionally, the Company recorded a benefit of $2.5Â million related to revised severance estimates in connection with the Company's 2022 restructuring plan in the nine months ended SeptemberÂ 30, 2024, as compared to a benefit of $0.8Â million recorded in the same period in 2023.34Table of ContentsOperating ProfitThe following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Proprietary Products$158.2Â $181.6Â $415.5Â $546.5Â Contract-Manufactured Products21.8Â 21.0Â 56.1Â 53.3Â Corporate and unallocated items(18.7)(25.3)(61.3)(84.7)Consolidated operating profit$161.3Â $177.3Â $410.3Â $515.1Â Consolidated operating profit margin21.6Â %23.7Â %19.1Â %23.2Â %Unallocated items(0.7)3.5Â (0.3)15.6Â Adjusted consolidated operating profit$160.6Â $180.8Â $410.0Â $530.7Â Adjusted consolidated operating profit margin21.5Â %24.2Â %19.1Â %23.9Â %Consolidated operating profit decreased by $16.0 million, or 9.0%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.9 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Consolidated operating profit decreased by $104.8 million, or 20.3%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.3 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Proprietary Products - Proprietary Products operating profit decreased by $23.4 million, or 12.9%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.8 million, due to the factors described above, most notably lower gross profit driven by lower sales volume and an unfavorable mix of products sold.Proprietary Products operating profit decreased by $131.0 million, or 24.0%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.2 million, due to the factors described above, most notably lower gross profit driven by lower sales volume and an unfavorable mix of products sold.Contract-Manufactured Products - Contract-Manufactured Products operating profit increased by $0.8 million, or 3.8%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.1 million, due to the factors described above, most notably the increased sales prices.Contract-Manufactured Products operating profit increased by $2.8 million, or 5.3%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, including a favorable foreign currency translation impact of $0.1 million, due to the factors described above, most notably the increased sales prices.Corporate and unallocated - Excluding the unallocated items, Corporate costs decreased by $2.4 million, or 11.0%, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due to the factors described above, most notably the lower annual incentive compensation and the decrease in expense related to stock-based compensation.Excluding the unallocated items, Corporate costs decreased by $7.5 million, or 10.9%, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due to the factors described above, most notably the decrease in expense related to stock-based compensation and lower annual incentive compensation.35Table of ContentsFor unallocated items, please refer to the Financial Performance Summary section above for detail.Interest Expense, Net and Interest IncomeThe following table presents interest expense, net, by significant component:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,($ in millions)2024202320242023Interest expense$5.0Â $4.4Â $12.2Â $11.7Â Capitalized interest(4.3)(1.5)(8.4)(3.9)Interest expense, net$0.7Â $2.9Â $3.8Â $7.8Â Interest income$(4.6)(8.8)(14.8)$(18.6) Interest expense, net, decreased by $2.2 million, for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, and decreased by $4.0 million, for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due to an increase in capitalized interest.Interest income decreased by $4.2 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, and decreased by $3.8 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due primarily to the Company having a lower average cash balance during 2024, as compared to the same periods in 2023. Income Tax ExpenseThe provision for income taxes was $32.4 million and $29.4 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and the effective tax rate was 19.7% and 15.7%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the three months ended SeptemberÂ 30, 2024 as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.The provision for income taxes was $70.7 million and $87.8 million for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively, and the effective tax rate was 16.8% and 16.6%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.Equity in Net Income of Affiliated CompaniesEquity in net income of affiliated companies increased by $0.2 million for the three months ended SeptemberÂ 30, 2024, as compared to the same period in 2023.Equity in net income of affiliated companies decreased by $1.7 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due to less favorable operating results at Daikyo.36Table of ContentsFINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCESCash FlowsThe following table presents cash flow data for the nine months ended SeptemberÂ 30:($ in millions)20242023Net cash provided by operating activities$463.3Â $537.4Â Net cash used in investing activities(273.9)(259.9)Net cash used in financing activities(553.7)(270.1)Net Cash Provided by Operating Activities â€“ Net cash provided by operating activities decreased by $74.1 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to a decline in operating results, offset by favorable working capital management.Net Cash Used in Investing Activities â€“ Net cash used in investing activities increased by $14.0 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, due to an increase in capital expenditures for additional manufacturing capacity to meet future customer demand.Net Cash Used in Financing Activities â€“ Net cash used in financing activities increased by $283.6 million for the nine months ended SeptemberÂ 30, 2024, as compared to the same period in 2023, primarily due to an increase in purchases under our share repurchase program in 2024, as compared to 2023.Liquidity and Capital ResourcesThe table below presents selected liquidity and capital measures:($ in millions)September 30,2024December 31,2023Cash and cash equivalents$490.9Â $853.9Â Accounts receivable, net$524.3Â $512.0Â Inventories$401.2Â $434.7Â Accounts payable$224.3Â $242.4Â Debt$202.6Â $206.8Â Equity$2,752.1Â $2,881.0Â Working capital$1,034.1Â $1,264.6Â Cash and cash

equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities. Cash and cash equivalents â€“ Our cash and cash equivalents balance at SeptemberÂ 30, 2024 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at SeptemberÂ 30, 2024 included $80.3Â million of cash held by subsidiaries within the U.S., and $410.6Â million of cash held by subsidiaries outside of the U.S. During the nine months ended SeptemberÂ 30, 2024, we purchased 1,409,786 shares of our common stock under the share repurchase program at a cost of $506.5 million, or an average price of $359.24 per share.Working capital â€“ Working capital at SeptemberÂ 30, 2024 decreased by $230.5 million, or 18.2%, as compared to DecemberÂ 31, 2023, which includes a favorable foreign currency translation impact of $6.2Â million. Excluding the impact of currency exchange rates, cash and cash equivalents, total current liabilities and inventories decreased by $365.0Â million, $158.0Â million and $34.0Â million, respectively, while accounts receivable increased by $12.5Â million.37Table of ContentsThe decrease in cash and cash equivalents was due to capital expenditures and share repurchases, offset by cash from operations during the nine months ended SeptemberÂ 30, 2024. The decrease in total current liabilities was primarily due to the Company amending its Credit Facility Agreement during the nine months ended SeptemberÂ 30, 2024. As part of this amendment, all current notes payable and debt amounts were repaid. Please refer to Note 8, Debt, for further discussion. Additionally, a decline in accounts payable and the payout of the 2023 annual incentive plan accrual during the nine months ended SeptemberÂ 30, 2024 contributed to the decrease in total current liabilities. The decrease in inventories and the increase in accounts receivable were both due to increased net sales leading up to the SeptemberÂ 30, 2024 balance sheet date as compared to the DecemberÂ 31, 2023 balance sheet date.Debt and credit facilities â€“ The $4.2 million decrease in total debt at SeptemberÂ 30, 2024, as compared to DecemberÂ 31, 2023, is due to the net activity of debt repayments and borrowings as mentioned in Note 8, Debt.Our sources of liquidity include our multi-currency revolving credit facility. At SeptemberÂ 30, 2024, we had no outstanding borrowings under the multi-currency revolving credit facility. At SeptemberÂ 30, 2024, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million. We do not expect any significant limitations on our ability to access this source of funds.Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and not to exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At SeptemberÂ 30, 2024, we were in compliance with all of our debt covenants.We believe that cash on hand and cash generated from operations, together with availability under our multi-currency revolving credit facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.Commitments and Contractual ObligationsA summary of future material cash payments resulting from commitments and contractual obligations was provided in our 2023 Annual Report. During the three months ended SeptemberÂ 30, 2024, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.OFF-BALANCE SHEET ARRANGEMENTSAt SeptemberÂ 30, 2024, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2023 Annual Report.CRITICAL ACCOUNTING POLICIES AND ESTIMATESThere have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2023 Annual Report.NEW ACCOUNTING STANDARDSThere were no new accounting standards adopted during the three months ended SeptemberÂ 30, 2024, see Note 2, New Accounting Standards.38Table of ContentsCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on managementâ€™s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as â€œplan,â€ â€œexpect,â€ â€œbelieve,â€ â€œintend,â€ â€œwill,â€ â€œestimate,â€ â€œcontinueâ€ and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on managementâ€™s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements: â€¢sales demand and our ability to meet that demand;â€¢competition from other providers in our businesses, including customersâ€™ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;â€¢customersâ€™ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;â€¢interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or unauthorized access to our or our customersâ€™ information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;â€¢the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;â€¢whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;â€¢the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customersâ€™ products in Crystal Zenith prefilled syringes;â€¢profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;â€¢maintaining or improving production efficiencies and overhead absorption;â€¢dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;â€¢the loss of key personnel or highly-skilled employees;39Table of Contentsâ€¢the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;â€¢the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;â€¢the cost and progress of development, regulatory approval and marketing of new products;â€¢our ability to obtain and maintain licenses in any jurisdiction in which we do business;â€¢the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; andâ€¢the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2023 Annual Report as well as Part II, section 1A of this quarterly report. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.ITEM 3.Â Â QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKThere have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2023 Annual Report.ITEM 4.Â Â CONTROLS AND PROCEDURESDisclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer (â€œCEOâ€) and Chief Financial Officer (â€œCFOâ€), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.Evaluation of Disclosure Controls and ProceduresAn evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our CEO and CFO have concluded that, as of SeptemberÂ 30, 2024, our disclosure controls and procedures are effective.Changes in Internal ControlsDuring the quarter ended SeptemberÂ 30, 2024, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.40Table of ContentsPART II.Â Â OTHER INFORMATIONITEM 1.Â Â LEGAL PROCEEDINGSNone.ITEM 1A.Â Â RISK FACTORSThere are no material changes to the risk factors disclosed in Part I, Item 1A of our 2023 Annual Report.ITEM 2.Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSThe following table shows information with respect to purchases of our common stock made during the three months ended SeptemberÂ 30, 2024 by us or any of our â€œaffiliated purchasersâ€ as defined in Rule 10b-18(a)(3) under the Exchange Act: PeriodTotal number of shares purchased (1)Average price paid per share (1)Total number of shares purchased as part of publicly announced plans or programs (1)Approximate dollar value of shares that may yet be purchased under the plans or programs (1)July 1 - 31, 202455,907Â $316.00Â 55,907Â $89,800,000Â August 1 - 31, 202459,383Â 298.76Â 59,383Â 72,100,000Â September 1 - 30, 202455,481Â 304.71Â 55,481Â 55,200,000Â Total170,771Â $306.34Â 170,771Â $55,200,000Â (1)In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0Â billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.ITEM 5.Â Â OTHER INFORMATIONRule 10b5-1 Trading PlansDuring the three months ended SeptemberÂ 30, 2024, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the period covered by this Report.41Table of ContentsITEM 6.Â Â EXHIBITSExhibit NumberDescription3.1Our Amended and Restated Articles of Incorporation, effective April 24, 2024 (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q report for the quarter ended June 30, 2024, filed July 25, 2024).3.2Our Amended and Restated Bylaws, effective October 23, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Form 10-Q report for the quarter ended September 30, 2023, filed October 26, 2023).4.1Form of stock certificate for common stock (incorporated by reference to Exhibit 4 to the Company's 1998 Form 10-K, filed May 6, 1999).4.2Articles 5, 7, 8 and 9 of our Amended and Restated Articles of Incorporation, effective April 24, 2024 (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q report for the quarter ended June 30, 2024, filed July 25, 2024).4.3Articles I and IV of our Bylaws, as amended through October 23, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Form 10-Q report for the quarter ended September 30, 2023, filed October 26, 2023).4.4 (1)Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.10.1Third Amendment and Incremental Facility Amendment, dated as of July 2, 2024, among the Company, as borrower's representative, each of the lenders party thereto and Bank of America, N.A., as the administrative agent (incorporated by reference from our Form 8-k, filed July 8, 2024).31.1Certification by the Chief Executive Officer Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002.31.2Certification by the Chief Financial Officer Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002.32.1*Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2*Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.101.SCHInline XBRL Taxonomy Extension Schema Document101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document101.LABInline XBRL Taxonomy Extension Label Linkbase Document101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.* Furnished, not filed.42Table of ContentsSIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.WEST PHARMACEUTICAL SERVICES, INC.(Registrant)By: /s/ Bernard J. BirkettBernard J. BirkettSenior Vice President, Chief Financial OfficerOctoberÂ 24, 2024 43 EX-31.1 2 ex311q32024.htm EX-31.1 DocumentEXHIBIT 31.1CERTIFICATIONI, Eric M. Green, certify that:1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting./s/ Eric M. GreenEric M. GreenPresident and Chief Executive Officer, Chair of the Board of DirectorsDate: OctoberÂ 24, 2024 EX-31.2 3 ex312q32024.htm EX-31.2 DocumentEXHIBIT 31.2CERTIFICATIONI, Bernard J. Birkett, certify that:1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report

our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting./s/ Bernard J. BirkettBernard J. BirkettSenior Vice President, Chief Financial OfficerDate: OctoberÂ 24, 2024 EX-32.1 4 ex321q32024.htm EX-32.1 DocumentEXHIBIT 32.1CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TO SECTION 906 OFTHE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the â€œCompanyâ€) for the period ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Eric M. GreenEric M. GreenPresident and Chief Executive Officer, Chair of the Board of DirectorsDate: OctoberÂ 24, 2024 EX-32.2 5 ex322q32024.htm EX-32.2 DocumentEXHIBIT 32.2CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TO SECTION 906 OFTHE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the â€œCompanyâ€) for the period ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Bernard J. Birkett, Senior Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Bernard J. BirkettBernard J. BirkettSenior Vice President, Chief Financial OfficerDate: OctoberÂ 24, 2024 EX-101.SCH 6 wst-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Other Expense (Income) link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Affiliated Companies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Other Expense (Income) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Revenue - Contracts and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Net Income Per Share - Schedule of Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Net Income Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Net Income Per Share - Schedule of Repurchase of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Assets And Liabilities, Lessee (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Lease Weighted Average (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Affiliated Companies (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Shareholder's Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Other Expense (Income) - Schedule of Other Expense (Income) (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Other Expense (Income) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Other Expense (Income) - Schedule of Restructuring Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Segment Information - Sales by Product Group (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Segment Information - Segment Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 wst-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 wst-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 wst-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Lease Cost Lease, Cost [Table Text Block] Cover [Abstract] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other current liabilities Payables due to affiliates Other Liabilities, Current Derivative gain (loss) on hedged item, fair value hedges Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Intercompany Demand Notes Intercompany Demand Notes [Member] Intercompany Demand Notes Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair Value Hedges: Fair Value Hedging [Member] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Reconciliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Yen Japan, Yen Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Position [Axis] Position [Axis] Equity method affiliates Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Target award percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage Derivative [Table] Derivative [Table] Cross-currency swap Currency Swap [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from stock-based compensation awards Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Net Investment Hedges: Net Investment Hedging [Member] Other Performance Measure, Amount Other Performance Measure, Amount Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Shares available for issuance under the 2016 Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities Operating Lease, Liability, Noncurrent Finance lease - interest on lease liabilities Finance Lease, Interest Expense Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Series C notes, due July 5, 2027 (4.02%) Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Share purchased (in shares) Shares purchased under share repurchase program (in shares) Treasury Stock, Shares, Acquired Money market funds Money Market Funds [Member] Operating Segments Operating Segments [Member] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock Treasury Stock, Common [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Equity Components [Axis] Equity Components [Axis] Finance leases liabilities payments due Finance Lease, Liability, to be Paid Other current assets Receivables due from affiliates Other Assets, Current Net gain (loss) on derivatives, net of tax of $1.1, $0.8, $0.7 and $(0.3), respectively Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Award Timing Method Award Timing Method [Text Block] Derivative, forward point components, (loss) gain, recognized in earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Fair value hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted average remaining lease term (years) Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Europe, Middle East, Africa EMEA [Member] Schedule Of Assets And Liabilities, Lessee Schedule Of Assets And Liabilities, Lessee [Table Text Block] Schedule Of Assets And Liabilities, Lessee Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Generics Generics Customers [Member] Generics Customers [Member] Less: imputed lease interest Finance Lease, Liability, Undiscounted Excess Amount Cash payments Payments for Restructuring Credit Facility [Domain] Credit Facility [Domain] Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Shares repurchased for employee tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Inventories Inventory Disclosure [Text Block] Treasury stock, at cost (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Change in unrealized gain (loss) on fair value hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Short-term lease cost Short-Term Lease, Cost Foreign Exchange Forward Foreign Exchange Forward [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income taxes payable Accrued Income Taxes, Current Weighted average discount rate Finance Lease, Weighted Average Discount Rate, Percent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name 2025 Finance

Lease, Liability, to be Paid, Year One Award Type [Axis] Award Type [Axis] Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Work in process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, Plant and Equipment, Net Total Liabilities Liabilities Foreign currency contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk, percentage Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment Property, Plant and Equipment, Gross Cash flow hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Options Held Options Held [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total Equity Beginning balance Ending balance Equity, Attributable to Parent Interest expense Interest Expense, Nonoperating Hedging Designation [Domain] Hedging Designation [Domain] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Interest income Investment Income, Net Selling, general and administrative expenses Selling, General and Administrative Expense Other comprehensive income (loss), net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Cost of goods and services sold Cost of Sales [Member] Asset impairments Asset Impairment Charges Total debt Carrying amount Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Dilutive effect of equity awards, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Term Loan, due July 2, 2027 (6.67%) Term Loan, Due 2027 [Member] Term Loan, Due 2027 Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Dividend yield (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Document Type Document Type Derivative Contract Type [Domain] Derivative Contract [Domain] Actuarial gains Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Gain (loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Average price per repurchased share (in dollars per share) Shares Acquired, Average Cost Per Share Investments in affiliated companies Total investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures 2027 Finance Lease, Liability, to be Paid, Year Three Fair value hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Deferred compensation assets Deferred Compensation Plan Assets High-Value Product ("HVP") Delivery Devices Standard Packaging [Member] Standard Packaging [Member] Schedule of Change in Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Risk-free interest rate (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Amortization of acquisition-related intangible assets Amortization of Intangible Assets Deferred income, DecemberÂ 31, 2023 Deferred income, SeptemberÂ 30, 2024 Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease cost Lease, Cost Restructuring and related activities, period of implementation Restructuring and Related Activities, Period of Implementation Restructuring and Related Activities, Period of Implementation Statistical Measurement [Axis] Statistical Measurement [Axis] Term Loans Term Loans [Member] Term Loans PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes and equity in net income of affiliated companies Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Activity related to stock -based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Variable lease cost Variable Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Pension and other postretirement benefits Liability, Defined Benefit Plan, Noncurrent Deferred income taxes Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Other Income (Expense) Other Income (Expense) [Member] Other Income (Expense) Capital in Excess of Par Value Additional Paid-in Capital [Member] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Hedging Relationship [Axis] Hedging Relationship [Axis] Lease liabilities (noncurrent) Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Change in contract assets - increase (decrease) Increase (Decrease) in Contract with Customer, Asset Dividend payments Payments of Ordinary Dividends, Common Stock Class of Stock [Line Items] Class of Stock [Line Items] SGD Singapore, Dollars Standards Issued Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted 2028 Finance Lease, Liability, to be Paid, Year Four Revenue Revenue from Contract with Customer [Policy Text Block] Name Measure Name Number of loss on disposal manufacturing facility Number of Manufacturing Facilities Sold Number of Manufacturing Facilities Sold Contract-Manufactured Products Contract Manufactured Products [Member] Contract Manufactured Products [Member] Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Change in deferred income - decrease (increase) Increase (Decrease) in Contract with Customer, Liability Contract-Manufactured Products Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Foreign exchange transaction losses Gain (Loss), Foreign Currency Transaction, before Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Notes payable and other current debt Notes Payable and Other Debt, Current Notes Payable and Other Debt, Current Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Severance and benefits Employee Severance [Member] Statement of Financial Position [Abstract] Stock-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Defined benefit pension and other postretirement plans Amortization of defined benefit pension and other postretirement plans: Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income tax expense Tax benefit (expense) Provision for income taxes Income Tax Expense (Benefit) Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative, notional amount Derivative, Notional Amount Corporate and Unallocated Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Commodity call options Derivative Asset Defined benefit pension and other postretirement plan adjustments, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively OCI, Equity Method Investment, after Tax, Parent Net sales Sales to affiliates Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings Derivative Instruments, Gain (Loss) [Table Text Block] Interest (income) expense and other nonoperating expense (income), net Nonoperating Income (Expense) Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating profit Operating Income (Loss) Interest expense, net Interest Expense, Operating and Nonoperating Commodity call options Commodity [Member] Number of reportable segments Number of Reportable Segments 2024 (remaining period as of SeptemberÂ 30, 2024) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total Liabilities and Equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Capital in excess of par value Additional Paid in Capital Hedging Designation [Axis] Hedging Designation [Axis] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Restructuring and related charges Restructuring and other charges Restructuring and other charges Restructuring Charges Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] 2026 Finance Lease, Liability, to be Paid, Year Two Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative, average price risk option strike price Derivative, Average Price Risk Option Strike Price Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Total Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Derivatives Gains (losses) on derivatives: Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories Total inventories Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Net gain (loss) on equity affiliate accumulated other comprehensive income, tax OCI, Equity Method Investment, Tax, Parent Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Schedule of Other Expense (Income) Schedule Of Other Income And Expense, By Component [Table Text Block] Schedule Of Other Income And Expense, By Component Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Derivative contract term Derivative, Term of Contract Asia Pacific Asia Pacific [Member] Minimum Minimum [Member] Schedule of Repurchase of Common Stock Schedule Of Common Stock Repurchases [Table Text Block] Schedule Of Common Stock Repurchases Restatement Determination Date Restatement Determination Date Other charges Asset-Related Charges [Member] Asset-Related Charges [Member] Less: unamortized debt issuance costs Unamortized Debt Issuance Expense Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Derivative, nonmonetary notional amount, volume Derivative, Nonmonetary Notional Amount, Volume Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Currency [Axis] Currency [Axis] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Thereafter Finance Lease, Liability, To Be Paid, After Year Four Finance Lease, Liability, To Be Paid, After Year Four Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Long-Term Debt, Gross Exercise Price Award Exercise Price Net Income Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Leases Lessee, Finance Leases [Text Block] Grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Segment [Domain] Segments [Domain] Schedule of Lessee, Finance Lease, Liability, Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Total lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] Term Loan, due December 31, 2024 (6.32%) Term Loan Due 2024 [Member] Term Loan Due 2024 PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Estimated fair value Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Other nonoperating expense (income) Other Nonoperating Income (Expense) Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Net investment hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Treasury stock, at cost (SeptemberÂ 30, 2024 - 2.8Â million, DecemberÂ 31, 2023 - 1.8 million) Treasury Stock, Common, Value Equity in net income of affiliated companies Income (Loss) from Equity Method Investments High-Value Product ("HVP") Components High-Value Components [Member] High-Value Components [Member] Income before income taxes and equity in net income of affiliated companies Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Derivative gain (loss) recognized in income, fair value hedges Gain (Loss) on Fair Value Hedges Recognized in Earnings Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Pharma Pharma Customers [Member] Pharma Customers [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party, Type [Domain] Related and Nonrelated Parties [Domain] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Intercompany Loans Intercompany Loans [Member] Intercompany Loans Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Stock repurchase program, shares authorized (in shares) Share Repurchase Program, Authorized, Number of Shares Liability Class [Axis] Liability Class [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Deferred income taxes Deferred Income Tax Liabilities, Net Deferred compensation liabilities Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Americas Americas [Member] Stock volatility (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Interest expense Interest Expense [Member] Foreign currency translation adjustments, tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Contract With Customer, Asset [Roll Forward] Contract

With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Stock options, granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Entity Emerging Growth Company Entity Emerging Growth Company Effect on future earnings, amount Effect on Future Earnings, Amount Deferred compensation benefits Deferred Compensation Liability, Classified, Noncurrent Total liabilities at fair value Liabilities, Fair Value Disclosure Commodity call options Commodity Option [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Sell Short [Member] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Net sales Net Sales [Member] Net sales member Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount USD United States of America, Dollars ROU assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Shareholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Less: current portion of long-term debt Long-Term Debt, Current Maturities Segment Information Segment Reporting Disclosure [Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Activity related to stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Revolving credit facility, Due 2024 Revolving credit facility, due 2024 [Member] Revolving credit facility, due 2024 [Member] 2022 Restructuring Plan 2022 Restructuring Plan [Member] 2022 Restructuring Plan Title Trading Arrangement, Individual Title Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Schedule of Investments in Affiliated Companies Investments in and Advances to Affiliates [Table Text Block] Basis of Presentation Significant Accounting Policies [Text Block] Geographic Concentration Risk Geographic Concentration Risk [Member] Consolidation Items [Domain] Consolidation Items [Domain] Position [Domain] Position [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Schedule of Derivative Instruments Not Designated as Hedges Derivatives Not Designated as Hedging Instruments [Table Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Right-of-use assets obtained in exchange for new lease liabilities: Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities [Abstract] Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities Line of credit facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Shares purchased under share repurchase programs Payments for Repurchase of Common Stock Accrued salaries, wages and benefits Accrued Salaries, Wages, and Benefits, Current Accrued Salaries, Wages, and Benefits, Current Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Changes in assets and liabilities Increase (Decrease) in Operating Capital Long-term debt Long-term debt, net Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Stock options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-equity method affiliates Equity Securities without Readily Determinable Fair Value, Amount Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Time deposits Bank Time Deposits [Member] EUR Euro Member Countries, Euro Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Sales by Significant Product Group Revenue from External Customers by Products and Services [Table Text Block] Equity: Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Retained earnings Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Schedule of Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Purchase Long [Member] Standard Packaging Delivery Devices [Member] Delivery Devices [Member] Revenue Benchmark Revenue from Contract with Customer Benchmark [Member] Corporate general costs General and Administrative Expense Schedule of Long-term Debt Obligations, Net of Current Maturities Schedule of Debt [Table Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Other expense (income) (Note 14) Other expense (income) Total other expense (income) Other Income (Expense) The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. Total lease liabilities Operating Lease, Liability Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Performance Share Unit (PSUs) Performance Shares [Member] Credit Facility [Axis] Credit Facility [Axis] Dividends declared Dividends, Common Stock, Cash Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Loss on disposal of plant Loss on disposal of plant Gain (Loss) on Disposition of Property Plant Equipment Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Gross profit Gross Profit Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Foreign currency translation adjustments, net of tax of $(2.5), $0.4, $(0.8) and $1.9, respectively Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Finance lease - amortization of right-of-use (ROU) assets Finance Lease, Right-of-Use Asset, Amortization Customer Concentration Risk Customer Concentration Risk [Member] Affiliated Entity Affiliated Entity [Member] Other Expense (Income) Other Income and Other Expense Disclosure [Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Debt Debt Disclosure [Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Cost investment impairment Cost Investment Impairment Cost Investment Impairment Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Principal amount Debt Instrument, Face Amount Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of each class Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: SeptemberÂ 30, 2024 - 75.3Â million, DecemberÂ 31, 2023 - 75.3 million; shares outstanding: SeptemberÂ 30, 2024 - 72.5Â million, DecemberÂ 31, 2023 - 73.5 million Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other, net Payments for (Proceeds from) Other Investing Activities Net gain (loss) on derivatives, tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] All Currencies [Domain] All Currencies [Domain] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, 3.0Â million shares authorized; 0 shares issued and outstanding Preferred Stock, Value, Issued Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Currency Forwards Forward Contracts [Member] Basic (in dollars per share) Earnings Per Share, Basic Operating cash flows from operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Principal repayments on finance leases Financing cash flows from finance leases Finance Lease, Principal Payments Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Amortization Amortization Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Series B notes, due July 5, 2024 (3.82%) Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Total Assets Assets Cost of goods and services sold Cost of goods and services sold Cost of Goods and Services Sold Long-term line of credit Long-Term Line of Credit Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Capital expenditures Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 16) Commitments and Contingencies Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Entity Address, City or Town Entity Address, City or Town Borrowings of long-term debt Proceeds from Issuance of Long-Term Debt Proprietary Products Proprietary Products [Member] Proprietary Products Other items Other Operating Income (Expense), Net Stock-based compensation expense Share-Based Payment Arrangement, Expense Net income Net income Total reclassifications for the period, net of tax Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Stock options, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Product Concentration Risk Product Concentration Risk [Member] Total cost of repurchases ($ in millions) Shares purchased under share repurchase program Treasury Stock, Value, Acquired, Cost Method Weighted average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Restructuring Plan [Domain] Restructuring Plan [Domain] Total assets at fair value Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name 2024 (remaining period as of SeptemberÂ 30, 2024) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Lease liabilities (current) Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Other non-cash items, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Operating leases liabilities payments due Lessee, Operating Lease, Liability, to be Paid Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Insider Trading Arrangements [Line Items] Contract assets, DecemberÂ 31, 2023 Contract assets, SeptemberÂ 30, 2024 Contract with Customer, Asset, after Allowance for Credit Loss Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Purchases from (and payments to) affiliates Related Party Transaction, Purchases from Related Party Other Defined Benefit Plan, Other Cost (Credit) Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Foreign currency hedge contracts Foreign currency contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2), $0.0, $(0.3), and $(0.5), respectively Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related Party, Type [Axis] Related and Nonrelated Parties [Axis] Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Biologics Biologics Customers [Member] Biologics Customers [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Other expense (income) Other Expense (Income) [Member] Other Expense (Income) Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Forward treasury locks Treasury Lock [Member] Repayments of long-term debt Repayments of long-term debt Repayments of Other Long-Term Debt Entity Filer Category Entity Filer Category Balance, December 31, 2023 Balance, September 30, 2024 Restructuring Reserve Amounts reclassified out from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Amount excluded from effectiveness testing, fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name Change in equity affiliate investment AOCI AOCI, Equity Method Investment, Parent [Member] EX-101.PRE 10 wst-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 wst-20240930_g1.jpg GRAPHIC begin 644 wst-20240930_g1.jpg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

Z#\)M4N$'IAFNTS[_+^ M-?8O_!%#]HWX;?L??M12>#=,^,^H^--!^*#1::+*?P#<:'!;:DI_T:Y\Z6]F MVAE+PL/+!8M%T"YK))S[A_ K*E1P,)>TI:W<)+F_FNVK>:[6L?G>1Y[C?[4=
M7&U(\E32RDO=?2R_ ,_;N,AAD'.:=GFJDMPT,;$L%"Y+$]%QU.:\G\'?MS_#+ MQ[KNEV>D^*&N(-Q^HSK4X64VE<]CHIB.2[=QGBGU!H>'_M:?\%"OA9^Q!=^'X/B1X@DT M-
_%"W#Z>%M)) _.$'EB0G8#C'FIU]:\C'_!?/]E_.?^$^GYZ?\2FY_P#B*^)O M^#I;5?/^,'P7L0ZYM]'U6X*C[P\R>V4$^W[OCZ&ORR()7[S'\:_6>'.!,#C\
MOIXNM.2E*^UK;^C/R;B+CO&8#,*F$I1BXQMO?L5^8 \%]/V7Q_S(UQS_P!0 MJY_^(KZ* 9O_&G?@;4)-5\.WT\MO!)RC."N "4A+_P"'"7WPDC8DM?Z6^J$=/^/B:2;'_ (^*
M\OC+A+!Y3A(5L/*3E*5M:;6;/3X/XLQF:XB=*O%)15]/4^C?BE\3]&^#7P\U MGQ3XBO$T_0M LY+Z^N7&1##&,LV.IXZ =Z^4X_\ @OK^R^R!O^$]N5R,\Z3< M@_\ H%>:?
\'(G[1Q^%_[%FF>"K6*VX1X)P^98-XK$RDKMVM;9>J[F/%O&M?+<8L+AHIV2;OY_ ,HF/ M_!?/]E_&?^$]G/\ W";G_P"(KVW]DS]N;XH_#G69=:L?#UW'8WTK MVLD
CE>,2*HW@9^0@\=,$R;B+CO&8#,*F$I1BXQMO?L5^8 \%]/V7Q_S(UQS_P!0 MJY_^(KZ* 9O_&G?@;4)-5\.WT\MO!)RC."N "4A+_P"'"7WPDC8DM?Z6^J$=/^/B:2;'_ (^*
M\OC+A+!Y3A(5L/*3E*5M:;6;/3X/XLQF:XB=*O%)15]/4^C?BE\3]&^#7P\U MGQ3XBO$T_0M LY+Z^N7&1##&,LV.IXZ =Z^4X_\ @OK^R^R!O^$]N5R,\Z3< M@_\ H%>:?
\'(G[1Q^%_[%FF>"K6*VX1X)P^98-XK$RDKMVM;9>J[F/%O&M?+<8L+AHIV2;OY_ ,HF/ M_!?/]E_&?^$]G/\ W";G_P"(KVW]DS]N;XH_#G69=:L?#UW'8WTK MVLD
CE>,2*HW@9^0@\=,$R;BM=C_^ M^?MC_P &NOAZ2Q_90^).IN"U3QK MA#S@^586L9[>M:\5\%8'+,O>+H2DY)I:M=?D9\)<:8S-,>L-6C%1LWHGT^9^ MG7IMPZ!XW*-A@F",J>1P
M:]=_:\^/@_9C_8_^(/C=95BO-'T:?[$2VW-S(OEPX/'.]@>/2OY23[DY)KS>"^$]6;0JU<2VHQ:2M;?KO\ (]'C+BRIE,Z=/#1.4KMW M[=(U/Z)_ ^'^G[,&?^1^G_P#!3<__!%=%\'O^"S'[/\
\?/BCHO@WPKXMN]5 M\0^(;@6MC:II=POF/M+./CMX MR^+>I1,=/\%6BZ'I#%]G_ /E>78&IB^> M;:6FJU;VZ=SPL@XWS+,L=3PBA&S>NCT77J?MC!)YOMBIJ9%$(R<=Z?7Y%<_6
MTPHHHIC"BBB@ HHHH ***** "BBB@ JKJNJPZ1:R37,L4$$*&22:5@B1J.2Q) MX [DU9(JZ^4_P#@M?\ %@?"_ @FC\4;P.B7&L:?'H5OD_>>[F6 C_OEF_*N MG!89XG$0P\=Y+[V]+^T%X%9?\
D<_"?/\ U%[?_P"+ MI?\ AH'P*/\ F=/"G_@WM_\ XNOY-QI%JJ ?9XN#@?(!0VD6HZP0_P#? KJ7 M_P"(60Z8A\ \@/\ P3\F_P"(I3O_ +NO_ O^ ?UJ>'OB_P"%?%FK1V.F>)= MU&\ERT=O;:C#+*X
R<*K$G Z_2NFK*?^#8GX)P>)?VS/&'C*2SB\KP?X:^R MV\FP?)/=S*,@]B(H!]&K)UJ_/.(LGAEF->$A/FLEK:V_0_1N',VJ9E@EBYP MY;MZ7N%%%%>$>Z%03W #%,9..*)I2<,!SU/0U^:?
_!;C_@L4W[-]E>?"/X7 MWT4GQ%OX0NN:O&X<>%X'7/EIV-W(I& >(U.X_;5%>AE668C,,1'#897;^Y+J MV>=F>:8? 8>6(Q#LE^+Z)>;-K_@LO^V_\4=&TB{^$?P.\%^-6UW48Q#X@\1
MZ7IEQ)'ID+K_,>]LZK@SN#\S@_NQG^(_+^1FD_\$WOC]=K'': !;XCA#\][MM$FC5>,XY'':O.-+^*WB[02/L7BSQ1:D;CF+5;A"2QRQR&[G)/O6O;?M6_$S M3@HB^)_CN$(%\0W0"@=!C?TK][R?
A_$95AU0PCAKNVG=0[_N/P3., H9K7 M=;%]=ELDUI^!ZCI?_1)K]I/5P#%\&_%Z#;G]J) D.1]&8?E6#= _\ !/+]H+P1 M*P"!5GR?X@'1 ?_ !S%?@IC=T(K M^B/_ ((-Z.-
"_P""6GPX.W:U\VH7;#&-V^]FP?RQ7QGB9/ERB$>\U^3/LO#* M%\RG)[_JCPS_@YS_:/A3]G+P1\/;68I<^,]6>_O$5\'[+:*#S[&25/Q6OQ M/0 XQQD_E7VC_P %)OC^OQO_."BVOZ7;R^9IOP\LX?
#L(!ROG#]]<$>^^0* M1_TSZ\U\7$;5STP*]G@G ?5%[F#R=:O+3^V=9XP?MMU^^D! M_P!P%(Q[1CI7X5_\$H_V85_:W_;R\"^&;FW^T:)I]S_;NL KE/LMJ1)M;V>3 MRT_X$:_H4_:J_:[\!?
L7_"V7QA\0=S^&FE:?\ #70 Q$,\H34=6G7LSNP\ MJ(G^ZBMCIN/6OC3XA?MA_%KXM7)G\2_$_P ?:M(6+8DUN=$7)SA51E 'L*\7 M+_ #,;:T>:O*-_3=_AI^]..\25Z=\'/"B_QU^ 5Y#+X9^*G
MC&&*'_EUO;]K^U?ZQS;@?YUVUO"[$J-Z5=-^C7ZLXZ7BCA7*U2A)+U3_ $1_M4/%-Y@SC']=O%?G- P21_X+=)^VIXH3X<_$6PT_PY\0S 9=,O;,E;'Q$$&9 M%"'F&<
%MF2K+DJ1C;7Z*&01D<@#.!S7YYF>6XG 8AX;%1Y9+[FNZ9^@Y;F> M^Q]!8C"RO%_>O)^9+YB^M,EG"8P-VXX^M?/_.WM_P %%_A]_P $^/*:SXQ
MO)KK5=25QH^A6.'O]6=1SM4)&"0&D?"C<.I(! "]O_@X,^/?QWNKB#PU> MV'POTIV*QVVCXN+P(>F^ZD7);&.41[5Z^1\)YAFBYZ$;0_F>B^7?YDYUQ9 M@,L]RM*_P"5; /L?
T&?:'X_=F@W#C_EF37\HWC']HWXC?$:_>[UWXA>.=7G M?EGN=_:%_M9_OX9-%^)WB#4+6#'^@ZW+_:=]RC^$K+E@#_ ++ ^]?L5_P2@_X+#:3 ,%$ M([SPOKNEVWA7XE:+9_;9[&&(Y*
[E.Y@"ZL]X#SWA%;_P#P7V_X*.?$;]CGQ-\- M?#?PS\1KX?U'6(+W4M4F6WAN'DA4QQPH5D4A1N,ASWVXK\C?VG?VP/B+^V7X MFTO5_B/XA/B'4-$M'L;.4VL4'E1,^]AB-
0#EL)5?N<$<)8B=6AFLVO9IMI= M=+I:>OF>'QKQ9AJ=&MED$_/2_36WZ'FL;?NU)QD\T$Y!]:55V_C01N&!R17 M[OTQWCUK^8 M_P"'G_!5;X\?LQ "BQ\(>"?
& _P#8OAS1EE:VM%TRWD*EV,C99E+$EB>I[U_0 M[^Q3J?BG7?V2_AQJ'C?49-6\7:IX>L[[5KIX4A9[B:)96!10 ,;]O]VOY_X MYR7$X?%RQV(E&U23LDW?3Y=C^@^!LZPV(PD<%0B[TX][=K7^\]3+
&D9QM/T MICR+$,L< U\>?\%._P#@J7X+_8XTZ7P7#XUL]!^).N67FV,6=F)+$Y)))S6 MG?\ P7^!WC7Q1>ZKXA :NUC4=6UFZDO+^^E^%6HO-=3R-N:5V>[.22223^%= MSX._8R_9.UR-!?\ [8=
[9NPY\$P=:&; $=?O.^ >W]: :\HP.5Y;AE3G"I*37 MO24*BN_E;1'XSFN.S3,L6YPG345*%D0-^Q1\'90LADRI\,F_#'FVC< _I]*T?# MG['[$=U*!=?MB7G6MZ5?U9=#!YXY>[6H)?Z(#G_ 71
M^"\&D/YK?L:^ [":;85+V2Z;D\], 8UX_SBO4M*_X.2O@_'HMUID_[UVSTZ_C M-M=6]NU@T4T3+M9'4!0PP2-IZBMCPC_P1_85U95%O\ &"TUQF0$>5\0K$[L M=6 =GI7J'A+_ ((4?LCW];
[&*YUQ!B;/ "6M,NT_=^XWW3V-?$7K>%8 M^7ZL]ZAN)MO:TO "5_H?DE\4/VQO!NH^,J47P?\"/@YI?AU+V1]&>XTB^7 M4+>WW9A$C1WH42I\IW+C!48 [?NY_P $L?VVX_V\OV0?
#WB^[%K!XIT__B3^ M);6 XC@U"$*'=%.2J2J4E0')"R8R2I)^ ?\ @K;_,$G_P!G/]F+P3X/\2V? MBO7?A/I=Y=RZ5)_9^@3^)QJUP4,R[OWZ>2P5'P2<-Z9%<'_P1C_:.^&/[&?[
M6;Z!!'QAU[Q3H'Q,,&CSV5YX"?1[<7BL?LMS]H:_D\LC=)&P,1W>8.@ -=F> M4<#FV4JO@(3YX7M=2>BW5W=>>C.;)<1C,JS1T,?.'+/M9:O9V5GY'[H @=Z6 MJ]N[,S \D5+GV%?DEGT/U=RMN?
SX_P#!Q%]@U'_@IUK,8*DV?AO2KE?7W_!>35#]7_!4[XB EV%I;Z9;J&Y Q91MQ_P!JU\@DU_3O M"\.7*K?$_5MCJIZV%D4FQ)C(]LF/\ /17] MYT_\$+O! P#PF?\ P4Z^'H.=NDI=ZB?^V<# ?
JU;'_!?/]HMOCM_P4+UK289 MO,TKX=6D?AVU4'&J]1?%5ERK[M?PN?%I8G;@ $UZ+\:?@VOPF^%/PJO9U*ZIXXT2Y\ M1S$\%;=[MX;8$>Z0,W_;2N4^&GPUU+XT?$?
0/"&D*S:GXGU"#2[8CJCS.$W? M1023]*^N?^"].B6'@+]MG2?!6DH(M*\!^"M(T2T3 &V-$8K^F/QS7U>)QKCF M%'!QWDI2?HEI^+_ ^7PF O@*V+ELG&*]7_P$?%A8(H89QW_SZU_1Y_P39\4: M?
^S]_P $A/AKXDU5A#IGAWP/ ;EZ78S,!RL M+L,?[I-?MI_P4Z^*R_LW_P#!![X>^$K5EBO_ !WH^B>&8T7J(3;+*>$P.6)!EGD:1@,]@6P!V [5GNN3C.#G&:3!)R2*ZE'-OIMEN>5ESU\R9L8'4QJ*
M_.']O3]MWQ-^W \ M#7WC?Q#YUKIT1>V\/:0TF^/0[(MD1KT'F/M5I' !9@. MRJ!^@?\ P7+\3VO[&/[!P 'OV:?#MT,7WJDVKRQY4W%9A$P]+):3LH)=NLGK M^ O;H.:]+_99_8\^(W[9WC>Z\\
PX\.2Z[>V$(N;V4RK!;6,;'"&65*I8@ MX').UL @$UYH>!S7[_\ !O-\"+7X3_\$[M%U\PQ_P!I_$34+K6;F7RMKO$D MK06ZDJP(XMP[?O"1UKT^+L_EE.!]O22?)'&H^F(B:_+4 M#:![UV<-
YC7Q^7T\5B%:4KWMZV./B7+J.!S"IAL.[QB]/N-OX7?$N^^"WQ\ M.>,-,E>VOO"VJ6VJ0R(<%3%(K,/H5W _6OZB_C_^T7H/[/7[.WB#XDZZ,L3 M0=)_J/&K //E 8XE/]YV*J/+M46XOMK8+P6%LIVD?
W3-+$?^ "OD..,KACZ_LF_\$V_C+^VWH=YJWP\)&^T6RE, M#ZC??<=E:22C[T:/(1O9<\[0<="17%_M* LL>.OV/OB6?"7Q#T-]#UHVZW<* M"9)HKJ%F91)'(I*LNY2/4$+ MI/B7<^%
[30]&.GVL%GI$5]'=*\IE,WFF1<@@J ,<9R$S65#,X> MSHW=G9W?9WZW/T>'!6$Q>5QKY;/GK:-JZMYJW2Q_/KC'4<#UKW/_ ()B>-K[MX> \%$/@WJ.GNZ7#>)[>R;:
<&2&XW02I]&C=@: 0S_B%=TAAQ\#M334X].?08;=;IT5@H:02L5 MJ'SU.F9<=9-6PE6BIMN46DN5[M>AS97P-G%#&4]LHI*,D]ULF?"'_!P+\9[M;XC?\%+?$>FI=PF+P;IMEHB RK\KA#-(,?
[TO/?BOC!&##I@]37]0'[5G@'X M54P2=H7[Q/2GU]3?\$5?@99_'[_@I'X$TS4[.#4-'T9+O7M0M[B%9 M898[>$A596R&4S2P@@^M?6YCC8X3#3Q4]5!- B(JA0OX
"N3T3]G+X=^%]3M]3T[P)X.T^_M'$MO=6VCV\4T+]F5E0$ M'W!KPK_@J)_P4WV\?\$ZOA*D\:V^N?$#7XG7P_H!D(\TC@W<^WE+>,]3U=B% M'.2/P;/L\K<18FC0PU)IJZ2O>
[=M>G8_>L@R2CP]AJM;UT[-NW1=/Q-?\ MX*._MG^) P!F+X3FU^?/@7Q!\0/B-KR/!TEXIA)=0Z<,8^UW10'"*2-J=7/ M'0$C*_%/[!'[47QK\=:OXEUOX5?#*6?$/B"\-UJ-]?:5(LEU. 5RS8PH &
M/E5551@ >0_%'XU^+OC)\2=8\7^)M?U6_\ $'B"Z:\O;O[0\.]R>%15("(H MX51PH ':LW3?BWX@T)]D\7>(;(HQ*F/69X]I/4C#]Z_3.'^%ZV4T;4)0]I+ MXFTV_16DM#\US_B>CFM;]]&?)'9)I?-Z/4][T_\
X) _M-ZG'NC=#GBE5.?] M:8(CQ[,X-='HO_!#C]J+6HMP^&LEI\H.+G5+:,\]OOGIWKY_L?VOOB-I40CM MOBKXY@10%"IXEN< #H/]972Z+_P4@^-^A\ Z%\:?\'(?\ Y#,L@R.!P2>*
M]>LLZM[E2E]TO\V>5163;5I5?O7_,B>^V7 _;Z?M0WDRA_"WAJV5VP6E\1 M0?+[D#)(KI-'_P"#;C]HO4U4W$_PYTTL&)[69&*D'@?)"?HYZ\9KQ/PY_P4 MV /BO;_\ @I3\,_V0M7_:1U+1M!\?
R_"[_A$';1;_ $;PS_ +9;/=1L M?-D:<31B1@?EZ?+MQ7F7[(7_ 3,\&_MV_%]O"WPW^*?B[48M.B<UW7@+ M[+::7#NPFZ4WA >3#"-,$DACC:K&OT+]L+DV$P/MJD)Q6[ECX#.,7
MF^+QWL:52$GLN6WZW9TO[7PA\0?\%,OC(^@Z5\(/@,X6\)Z.Z3^(O$-EX6G MC;2HB[&>_G('F7,S?QRN1DD_08 KT'^S8_[B?K7YAQ!G:S M#$7HKEIQTBM7\W=[L_3,BR5X+#J-
=\U1[O1?+1=#^6+]MG5FUW]MKXS73;MS M^/-<3EMQ/EW\\77_ (/ITKS,Y,?O7:?M+7L>K?M0?%&]B*F&\\<^(+E&7." MLFJW3C'X'O7&+T]*_H[+8N.$1>EHQ_(.G3-K?
7:MG=$M!1'UOQ3J5OHVG[P=BSW$JQ(S8YVJ6W-C^%6/:LL@XR*^[O\ M@W:_9V_X7/\ M^)XIN8A)I?PNTJ35I&9,J;RX+6]JOLWO7U%6N9<&6Y)F?!_B8[MC^IK\Q+8.57$UI:OW5]
[9^E^*$HQHX>C%66OZ#G!(XZC\#2*<)BG#GZXI&& M?]3U-?L*1^/7Z'H/[*?[/%W^UA^TCX-^'5H' \5ZE':73J.8;4'=YK&OF]/#7]VE:_JVF_PL?NO M65O#Y3/$-
:U+_Y^@7_!MS*AXW_;VU3Q M#(B/%X*\-3W*[OX9;B1(4Q^'F5^N7_!2?][J&[_9_8D\>>/M-<T36M*LEAT@ MSH'B:\F=8H%/#OA_ M4/"G@+0[TZE)%??"2WFL7(7;,6LOAB5P"O'_ M #V /IBO;_\ @I3\,_V0M7_:1U+1M!\?
R_"[_A$';1;_ $;PS_ +9;/=1L M?-D:<31B1@?EZ?+MQ7F7[(7_ 3,\&_MV_%]O"WPW^*?B[48M.B<UW7@+ M[+::7#NPFZ4WA >3#"-,$DACC:K&OT+]L+DV$P/MJD)Q6[ECX#.,7
MF^+QWL:52$GLN6WZW9TO[7PA\0?\%,OC(^@Z5\(/@,X6\)Z.Z3^(O$-EX6G MC;2HB[&>_G('F7,S?QRN1DD_08 KT'^S8_[B?K7YAQ!G:S M#$7HKEIQTBM7\W=[L_3,BR5X+#J-
=\U1[O1?+1=#^6+]MG5FUW]MKXS73;MS M^/-<3EMQ/EW\\77_ (/ITKS,Y,?O7:?M+7L>K?M0?%&]B*F&\\<^(+E&7." MLFJW3C'X'O7&+T]*_H[+8N.$1>EHQ_(G3-K?
7:MG=$M!1'UOQ3J5OHVG[P=BSW$JQ(S8YVJ6W-C^%6/:LL@XR*^[O\ M@W:_9V_X7/\ M^)XIN8A)I?PNTJ35I&9,J;RX+6]JOLWO7U%6N9<&6Y)F?!_B8[MC^IK\Q+8.57$UI:OW5]
[9^E^*$HQHX>C%66OZ#G!(XZC\#2*<)BG#GZXI&& M?]3U-?L*1^/7Z'H/[*?[/%W^UA^TCX-^'5H' \5ZE':73J.8;4'=YK&OF]/#7]VE:_JVF_PL?NO M65O#Y3/$-
:U+_Y^@7_!MS*AXW_;VU3Q M#(B/%X*\-3W*[OX9;B1(4Q^'F5^N7_!2?][J&[_9_8D\>>/M-<T36M*LEAT@ MSH'B:\F=8H%/#OA_ M4/"G@+0[TZE)%??"2WFL7(7;,6LOAB5P"O'_ M #V /IBO;_\ @I3\,_V0M7_:1U+1M!\?
R_"[_A$';1;_ $;PS_ +9;/=1L M?-D:<31B1@?EZ?+MQ7F7[(7_ 3,\&_MV_%]O"WPW^*?B[48M.B<UW7@+ M[+::7#NPFZ4WA >3#"-,$DACC:K&OT+]L+DV$P/MJD)Q6[ECX#.,7
MF^+QWL:52$GLN6WZW9TO[7PA\0?\%,OC(^@Z5\(/@,X6\)Z.Z3^(O$-EX6G MC;2HB[&>_G('F7,S?QRN1DD_08 KT'^S8_[B?K7YAQ!G:S M#$7HKEIQTBM7\W=[L_3,BR5X+#J-
=\U1[O1?+1=#^6+]MG5FUW]MKXS73;MS M^/-<3EMQ/EW\\77_ (/ITKS,Y,?O7:?M+7L>K?M0?%&]B*F&\\<^(+E&7." MLFJW3C'X'O7&+T]*_H[+8N.$1>EHQ_(.G3-K?
7:MG=$M!1'UOQ3J5OHVG[P=BSW$JQ(S8YVJ6W-C^%6/:LL@XR*^[O\ M@W:_9V_X7/\ M^)XIN8A)I?PNTJ35I&9,J;RX+6]JOLWO7U%6N9<&6Y)F?!_B8[MC^IK\Q+8.57$UI:OW5]
[9^E^*$HQHX>C%66OZ#G!(XZC\#2*<)BG#GZXI&& M?]3U-?L*1^/7Z'H/[*?[/%W^UA^TCX-^'5H' \5ZE':73J.8;4'=YK&OF]/#7]VE:_JVF_PL?NO M65O#Y3/$-
:U+_Y^@7_!MS*AXW_;VU3Q M#(B/%X*\-3W*[OX9;B1(4Q^'F5^N7_!2?][J&[_9_8D\>>/M-<T36M*LEAT@ MSH'B:\F=8H%/#OA_ M4/"G@+0[TZE)%??"2WFL7(7;,6LOAB5P"O'_ M #V /IBO;_\ @I3\,_V0M7_:1U+1M!\?
R_"[_A$';1;_ $;PS_ +9;/=1L M?-D:<31B1@?EZ?+MQ7F7[(7_ 3,\&_MV_%]O"WPW^*?B[48M.B<UW7@+ M[+::7#NPFZ4WA >3#"-,$DACC:K&OT+]L+DV$P/MJD)Q6[ECX#.,7
MF^+QWL:52$GLN6WZW9TO[7PA\0?\%,OC(^@Z5\(/@,X6\)Z.Z3^(O$-EX6G MC;2HB[&>_G('F7,S?QRN1DD_08 KT'^S8_[B?K7YAQ!G:S M#$7HKEIQTBM7\W=[L_3,BR5X+#J-
=\U1[O1?+1=#^6+]MG5FUW]MKXS73;MS M^/-<3EMQ/EW\\77_ (/ITKS,Y,?O7:?M+7L>K?M0?%&]B*F&\\<^(+E&7." MLFJW3C'X'O7&+T]*_H[+8N.$1>EHQ_(

MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@""Y'S)VPW6ODK]D+_@GG\,O@/\ M@?&?XG:)I4S^*-6UQH[=KEDD@T5+B"* MXN%M$"#RO-DE8L26;&%!5/EHHKTLNJSC1KQBVDXJ_G[RW/+QU.$JM%R2;3=O B+3H?6T4(B<8STJ53D445YAZG86BBBF 4444 %%%% '__V0$! end XML 13 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	9 Months Ended Sep. 30, 2024	Oct. 22, 2024
Cover [Abstract]		
Document Type	10-Q	
Document Quarterly Report	true	
Document Period End Date	Sep. 30, 2024	
Document Transition Report	false	
Entity File Number	1-8036	
Entity Registrant Name	WEST PHARMACEUTICAL SERVICES, INC.	
Entity Incorporation, State or Country Code	PA	
Entity Tax Identification Number	23-1210010	
Entity Address, Address Line One	530 Herman O. West Drive	
Entity Address, City or Town	Exton	
Entity Address, State or Province	PA	
Entity Address, Postal Zip Code	19341-1147	
City Area Code	610	
Local Phone Number	594-2900	
Title of each class	Common Stock, par value $0.25 per share	
Trading Symbol	WST	
Security Exchange Name	NYSE	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Large Accelerated Filer	
Entity Small Business	false	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		72,422,349
Entity Central Index Key	0000105770	
Current Fiscal Year End Date	--12-31	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q3	
Amendment Flag	false	

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]				
Net sales	$ 746.9	$ 747.4	$ 2,144.4	$ 2,217.8
Cost of goods and services sold	482.2	459.1	1,419.5	1,366.8
Gross profit	264.7	288.3	724.9	851.0
Research and development	15.5	16.4	50.6	50.0
Selling, general and administrative expenses	83.5	89.0	253.2	263.4
Other expense (income) (Note 14)	4.4	5.6	10.8	22.5
Operating profit	161.3	177.3	410.3	515.1
Interest expense, net	0.7	2.9	3.8	7.8
Interest income	(4.6)	(8.8)	(14.8)	(18.6)
Other nonoperating expense (income)	0.7	(3.8)	0.7	(3.9)
Income before income taxes and equity in net income of affiliated companies	164.5	187.0	420.6	529.8
Income tax expense	32.4	29.4	70.7	87.8
Equity in net income of affiliated companies	(3.9)	(3.7)	(12.7)	(14.4)
Net income	$ 136.0	$ 161.3	$ 362.6	$ 456.4
Net income per share:				
Basic (in dollars per share)	$ 1.87	$ 2.17	$ 4.96	$ 6.13
Diluted (in dollars per share)	$ 1.85	$ 2.14	$ 4.91	$ 6.05
Weighted average shares outstanding:				
Basic (in shares)	72.8	74.3	73.1	74.4
Diluted (in shares)	73.4	75.3	73.8	75.5

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]				
Net income	$ 136.0	$ 161.3	$ 362.6	$ 456.4
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustments, net of tax of $(2.5), $0.4, $(0.8) and $1.9, respectively	74.7	(40.9)	6.7	(36.9)
Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2), $0.0, $(0.3), and $(0.5), respectively	(0.8)	0.2	(1.2)	(1.2)
Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively	0.2	0.0	0.0	(0.1)
Net gain (loss) on derivatives, net of tax of $1.1, $0.8, $0.7 and $(0.3), respectively	6.5	1.2	2.0	(1.8)
Other comprehensive income (loss), net of tax	80.6	(39.5)	7.5	(40.0)
Comprehensive income	$ 216.6	$ 121.8	$ 370.1	$ 416.4

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]				
Foreign currency translation adjustments, tax	$ (2.5)	$ 0.4	$ (0.8)	$ 1.9
Defined benefit pension and other postretirement plan adjustments, tax	(0.2)	0.0	(0.3)	(0.5)
Net gain (loss) on equity affiliate accumulated other comprehensive income, tax	0.0	0.0	0.0	0.0
Net gain (loss) on derivatives, tax	$ 1.1	$ 0.8	$ 0.7	$ (0.3)

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD	Sep. 30, 2024	Dec. 31, 2023

($) $ in Millions		
Current assets:		
Cash and cash equivalents	$ 490.9	$ 853.9
Accounts receivable, net	524.3	512.0
Inventories	401.2	434.7
Other current assets	134.2	135.8
Total current assets	1,550.6	1,936.4
Property, plant and equipment	2,990.7	2,738.0
Less: accumulated depreciation and amortization	1,419.7	1,324.7
Property, plant and equipment, net	1,571.0	1,413.3
Operating lease right-of-use assets	108.0	99.2
Investments in affiliated companies	217.5	210.0
Goodwill	108.8	108.5
Intangible assets, net	12.3	15.1
Deferred income taxes	37.6	25.7
Other noncurrent assets	69.3	21.3
Total Assets	3,675.1	3,829.5
Current liabilities:		
Notes payable and other current debt	0.0	134.0
Accounts payable	224.3	242.4
Accrued salaries, wages and benefits	79.6	105.9
Income taxes payable	33.4	16.6
Operating lease liabilities	19.9	17.7
Other current liabilities	159.3	155.2
Total current liabilities	516.5	671.8
Long-term debt	202.6	72.8
Deferred income taxes	9.4	12.7
Pension and other postretirement benefits	30.2	29.6
Operating lease liabilities	82.3	84.5
Deferred compensation benefits	15.2	18.6
Other long-term liabilities	66.8	58.5
Total Liabilities	923.0	948.5
Commitments and contingencies (Note 16)		
Equity:		
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding	0.0	0.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: September 30, 2024 - 75.3 million, December 31, 2023 - 75.3 million; shares outstanding: September 30, 2024 - 72.5 million, December 31, 2023 - 73.5 million	18.8	18.8
Capital in excess of par value	23.3	120.2
Retained earnings	3,856.9	3,523.4
Accumulated other comprehensive loss	(136.3)	(143.8)
Treasury stock, at cost (September 30, 2024 - 2.8 million, December 31, 2023 - 1.8 million)	(1,010.6)	(637.6)
Total Equity	2,752.1	2,881.0
Total Liabilities and Equity	$ 3,675.1	$ 3,829.5

XML 18 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Preferred stock, shares authorized (in shares)	3.0	3.0
Preferred stock, shares issued (in shares)	0.0	0.0
Preferred stock, shares outstanding (in shares)	0.0	0.0
Common stock, par value (in dollars per share)	$ 0.25	$ 0.25
Common stock, shares authorized (in shares)	200.0	200.0
Common stock, shares issued (in shares)	75.3	75.3
Common stock, shares outstanding (in shares)	72.5	73.5
Treasury stock, at cost (in shares)	2.8	1.8

XML 19 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:		
Net income	$ 362.6	$ 456.4
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	112.0	99.1
Amortization	2.7	2.3
Stock-based compensation	14.4	21.9
Loss on disposal of plant	0.0	11.6
Asset impairments	1.9	6.9
Other non-cash items, net	(9.7)	(13.5)
Changes in assets and liabilities	(20.6)	(47.3)
Net cash provided by operating activities	463.3	537.4
Cash flows from investing activities:		
Capital expenditures	(272.1)	(253.3)
Other, net	(1.8)	(6.6)
Net cash used in investing activities	(273.9)	(259.9)
Cash flows from financing activities:		
Borrowings of long-term debt	164.7	0.0
Repayments of long-term debt	(169.0)	(1.7)
Principal repayments on finance leases	(23.2)	0.0
Dividend payments	(43.8)	(42.2)
Proceeds from stock-based compensation awards	24.0	42.6
Employee stock purchase plan contributions	5.6	5.3
Shares purchased under share repurchase programs	(506.5)	(261.3)
Shares repurchased for employee tax withholdings	(5.5)	(12.8)
Net cash used in financing activities	(553.7)	(270.1)
Effect of exchange rates on cash	1.3	(3.1)
Net (decrease) increase in cash and cash equivalents	(363.0)	4.3
Cash, including cash equivalents at beginning of period	853.9	894.3
Cash, including cash equivalents at end of period	$ 490.9	$ 898.6

XML 20 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended

	Sep. 30, 2024
Accounting Policies [Abstract]	
Basis of Presentation	Basis of Presentation

Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("U.S. GAAP") for interim financial reporting and U.S. Securities and Exchange Commission ("SEC") regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2024, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as "West", the "Company", "we", "us" or "our") appearing in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"). The results of operations for any interim period are not necessarily indicative of results for the full year.

XML 21 R9.htm IDEA: XBRL DOCUMENT

New Accounting Standards	9 Months Ended Sep. 30, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]	
New Accounting Standards	New Accounting Standards

Standards Issued Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company does not expect the adoption to have a material impact on the consolidated financial statements and disclosures.

In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Revenue	9 Months Ended Sep. 30, 2024
Revenue from Contract with Customer [Abstract]	
Revenue	Revenue

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification ("ASC") 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

The following table presents the approximate percentage of our net sales by market group:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Biologics	40 %	40 %	38 %	37 %
Generics	18 %	19 %	17 %	20 %
Pharma	23 %	22 %	25 %	24 %
Contract-Manufactured Products	19 %	19 %	20 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
High-Value Product ("HVP") Components	45 %	50 %	46 %	50 %
High-Value Product ("HVP") Delivery Devices	16 %	11 %	12 %	10 %
Standard Packaging	20 %	20 %	22 %	21 %
Contract-Manufactured Products	19 %	19 %	20 %	19 %
	100 %	100 %	100 %	100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from HVP Components to HVP Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Americas	48 %	46 %	44 %	45 %
Europe, Middle East, Africa	44 %	46 %	47 %	46 %
Asia Pacific	8 %	8 %	9 %	9 %
	100 %	100 %	100 %	100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities:

	($ in millions)
Contract assets, December 31, 2023	$ 21.5
Contract assets, September 30, 2024	42.3
Change in contract assets - increase (decrease)	$ 20.8
Deferred income, December 31, 2023	$ (53.9)
Deferred income, September 30, 2024	(53.8)
Change in deferred income - decrease (increase)	$ 0.1

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2024, $32.8 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year are not material as of September 30, 2024.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Net Income Per Share	9 Months Ended Sep. 30, 2024
Earnings Per Share [Abstract]	
Net Income Per Share	Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Net income	$ 136.0	$ 161.3	$ 362.6	$ 456.4
Weighted average common shares outstanding	72.8	74.3	73.1	74.4
Dilutive effect of equity awards, based on the treasury stock method	0.6	1.0	0.7	1.1
Weighted average shares assuming dilution	73.4	75.3	73.8	75.5

During the three months ended September 30, 2024 and 2023, there were 0.3 million and less than 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.3 million and 0.1 million antidilutive shares excluded during the nine months ended September 30, 2024 and 2023, respectively.

In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The below table summarizes the details of the Company's repurchases of common stock under this program:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Shares repurchased	170,771	77,329	1,409,786	753,399
Total cost of repurchases ($ in millions)	$ 52.4	$ 27.8	$ 506.5	$ 261.3
Average price per repurchased share	$ 306.34	$ 360.25	$ 359.24	$ 346.86

XML 24 R12.htm IDEA: XBRL DOCUMENT

Inventories	9 Months Ended Sep. 30, 2024
Inventory Disclosure [Abstract]	

Inventories

Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:

($ in millions)	September 30, 2024	December 31, 2023
Raw materials	$ 170.3	$ 172.3
Work in process	80.0	87.3
Finished goods	150.9	175.1
	$ 401.2	$ 434.7

XML 25 R13.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended
Sep. 30, 2024

Leases [Abstract]

Leases

Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Operating lease cost	$ 6.4	$ 4.3	$ 18.1	$ 15.0
Finance lease - amortization of right-of-use (ROU) assets	0.3	—	0.6	—
Finance lease - interest on lease liabilities	0.1	—	0.1	—
Short-term lease cost	0.8	1.9	1.9	4.4
Variable lease cost	2.5	1.4	6.3	4.4
Total lease cost	$ 10.1	$ 7.6	$ 27.0	$ 23.8

As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of September 30, 2024:

($ in millions)	Balance Sheet Classification	September 30, 2024
ROU assets, net	Other noncurrent assets	$ 31.9
Lease liabilities (current)	Other current liabilities	$ 0.9
Lease liabilities (noncurrent)	Other long-term liabilities	$ 2.2

Supplemental cash flow information related to leases were as follows:

	Nine Months Ended September 30,	
($ in millions)	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 26.3	$ 14.4
Financing cash flows from finance leases	$ 23.2	$ —
Right-of-use assets obtained in exchange for new lease liabilities:		
Operating leases	$ 36.8	$ 6.6
Finance leases	$ 24.3	$ —

As of September 30, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.5 years and 9.8 years, respectively. As of September 30, 2024, the weighted average remaining lease term for finance leases was 7.0 years. As of December 31, 2023, finance leases were not material.

As of September 30, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.84% and 3.55%, respectively. As of September 30, 2024, the weighted average discount rate for finance leases was 4.92%. As of December 31, 2023, finance leases were not material.

Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:

($ in millions) Year	Operating Leases	Finance Leases
2024 (remaining period as of September 30, 2024)	$ 6.2	$ 0.2
2025	23.2	0.9
2026	20.2	0.9
2027	15.5	0.8
2028	14.1	0.5
Thereafter	37.2	0.1
	116.4	3.4
Less: imputed lease interest	(14.2)	(0.3)
Total lease liabilities	$ 102.2	$ 3.1

Leases

Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Operating lease cost	$ 6.4	$ 4.3	$ 18.1	$ 15.0
Finance lease - amortization of right-of-use (ROU) assets	0.3	—	0.6	—
Finance lease - interest on lease liabilities	0.1	—	0.1	—
Short-term lease cost	0.8	1.9	1.9	4.4
Variable lease cost	2.5	1.4	6.3	4.4
Total lease cost	$ 10.1	$ 7.6	$ 27.0	$ 23.8

As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of September 30, 2024:

($ in millions)	Balance Sheet Classification	September 30, 2024
ROU assets, net	Other noncurrent assets	$ 31.9
Lease liabilities (current)	Other current liabilities	$ 0.9
Lease liabilities (noncurrent)	Other long-term liabilities	$ 2.2

Supplemental cash flow information related to leases were as follows:

	Nine Months Ended September 30,	
($ in millions)	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 26.3	$ 14.4
Financing cash flows from finance leases	$ 23.2	$ —
Right-of-use assets obtained in exchange for new lease liabilities:		
Operating leases	$ 36.8	$ 6.6
Finance leases	$ 24.3	$ —

As of September 30, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.5 years and 9.8 years, respectively. As of September 30, 2024, the weighted average remaining lease term for finance leases was 7.0 years. As of December 31, 2023, finance leases were not material.

As of September 30, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.84% and 3.55%, respectively. As of September 30, 2024, the weighted average discount rate for finance leases was 4.92%. As of December 31, 2023, finance leases were not material.

Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:

($ in millions) Year	Operating Leases	Finance Leases
2024 (remaining period as of September 30, 2024)	$ 6.2	$ 0.2
2025	23.2	0.9
2026	20.2	0.9
2027	15.5	0.8
2028	14.1	0.5
Thereafter	37.2	0.1
	116.4	3.4
Less: imputed lease interest	(14.2)	(0.3)
Total lease liabilities	$ 102.2	$ 3.1

XML 26 R14.htm IDEA: XBRL DOCUMENT

Affiliated Companies

9 Months Ended
Sep. 30, 2024

Equity Method Investments and Joint Ventures [Abstract]

Affiliated Companies

Affiliated Companies

The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:

($ in millions)	September 30, 2024	December 31, 2023
Aggregate carrying value of investments in affiliated companies:		
Equity method affiliates	$ 210.3	$ 203.2
Non-equity method affiliates	7.2	6.8
Total investments in affiliated companies	$ 217.5	$ 210.0

We have elected to record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We

test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:

($ in millions)	September 30, 2024	December 31, 2023
Payables due to affiliates	$ 24.8	$ 25.9
Receivables due from affiliates	$ 2.7	$ 1.6

The following table summarizes the Company's affiliate transactions:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Purchases from (and payments to) affiliates	$ 30.1	$ 34.4	$ 83.6	$ 118.5
Sales to affiliates	$ 3.5	$ 2.5	$ 10.7	$ 8.5

The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended
Sep. 30, 2024

Debt Disclosure [Abstract]

Debt

Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.

($ in millions)	September 30, 2024	December 31, 2023
Term Loan, due July 2, 2027 (6.67%)	$ 130.0	$ —
Term Loan, due December 31, 2024 (6.32%)	—	81.0
Series B notes, due July 5, 2024 (3.82%)	—	53.0
Series C notes, due July 5, 2027 (4.02%)	73.0	73.0
	203.0	207.0
Less: unamortized debt issuance costs	0.4	0.2
Total debt	202.6	206.8
Less: current portion of long-term debt	—	134.0
Long-term debt, net	$ 202.6	$ 72.8

Credit Facility

On July 2, 2024, the Company entered into the Third Amendment to the Credit Facility Agreement, which amended the Existing Credit Facility Agreement. Among other changes to the existing credit agreement, the Third Amendment established an incremental term loan in the stated principal amount of $130.0 million (the "New Term Loan"), which was fully drawn at closing and matures on July 2, 2027. The entire stated principal amount of the New Term Loan is due at maturity and there is no scheduled amortization prior to such date. Together with cash on hand, proceeds from the New Term Loan were used to repay an outstanding term loan under the Existing Credit Facility Agreement in the principal amount of $79.9 million prior to its December 31, 2024 maturity date and to repay an aggregate principal amount of $53.0 million of the Company's 3.82% Series B Senior Notes due July 5, 2024 issued under that certain Note Purchase Agreement dated as of July 5, 2012.

At September 30, 2024, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million.

Term Loan

At September 30, 2024, we had $130.0 million in borrowings under the New Term Loan which were classified as long-term. Please refer to Note 9, *Derivative Financial Instruments*, for a discussion of the foreign currency hedge associated with the New Term Loan.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2024, we were in compliance with all of our debt covenants.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments

9 Months Ended
Sep. 30, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of September 30, 2024 the notional amount of these forward exchange contracts was Singapore Dollar ("SGD") 421.9 million and $13.4 million. As of December 31, 2023 the notional amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of September 30, 2024, the total notional amounts of these forward exchange contracts were Euro ("EUR") 143.9 million and $47.1 million. As of December 31, 2023, the total notional amounts of these forward exchange contracts were EUR 278.6 million and SGD 94.0 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)		Sell		
Currency	**Purchase**	**USD**	**Euro**	**SGD**
EUR	24.1	26.5	—	—
Yen	6,102.9	28.7	11.4	1.7
SGD	43.4	19.0	12.5	—

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2024, the notional amount of the cross-currency swap is ¥17.0 billion ($130.0 million) and the swap termination date is July 2, 2027. Under the cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.

Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2024, we purchased several series of call options for a total of 1,106,908 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.

As of September 30, 2024, we had outstanding contracts to purchase 187,861 barrels of crude oil from September 2024 to March 2026, at a weighted-average strike price of $85.66 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, *Fair Value Measurements*, for the balance sheet location and fair values of our derivative instruments as of September 30, 2024 and December 31, 2023.

The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:

	Amount of Gain (Loss) Recognized in Income for the Three Months Ended September 30,		**Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30,**		**Location on Statement of Income**
($ in millions)	**2024**	**2023**	**2024**	**2023**	
Fair Value Hedges:					
Hedged item (intercompany loan)	$ (16.6)	$ (1.2)	$ (6.2)	$ 8.7	Other expense (income)
Derivative designated as hedging instrument	16.6	0.7	6.2	(10.0)	Other expense (income)
Amount excluded from effectiveness testing	(1.8)	(1.5)	(5.3)	(0.4)	Other expense (income)
Total	$ (1.8)	$ (2.0)	$ (5.3)	$ (1.7)	

We recognize in earnings the initial value of forward point components for hedges of intercompany loans on a straight-line basis over the life of the fair value hedge. The value of forward point components for hedges of intercompany demand notes is recognized currently in earnings using a market approach. The expense recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2024 was $1.8 million and $5.3 million, respectively. The income recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2023 was $0.2 million and $1.6 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income ("OCI") and earnings, net of tax:

($ in millions)	Amount of Gain (Loss) Recognized in OCI for the Three Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in OCI for the Three Months Ended September 30, 2023	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Three Months Ended September 30, 2024	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Three Months Ended September 30, 2023	Location of (Gain) Loss Reclassified from Accumulated OCI into Income
Fair Value Hedges:					
Foreign currency hedge contracts	$ 0.5	$ (0.3)	$ —	$ 2.3	Other expense (income)
Total	$ 0.5	$ (0.3)	$ —	$ 2.3	
Cash Flow Hedges:					
Foreign currency hedge contracts	$ 0.2	$ 0.5	$ —	$ 0.1	Net sales
Foreign currency hedge contracts	5.3	(2.5)	0.5	1.1	Cost of goods and services sold
Forward treasury locks	—	—	—	—	Interest expense
Total	$ 5.5	$ (2.0)	$ 0.5	$ 1.2	
Net Investment Hedges:					
Cross-currency swap	$ (8.1)	$ 2.9	$ —	$ —	Other expense (income)
Total	$ (8.1)	$ 2.9	$ —	$ —	

($ in millions)	Amount of Gain (Loss) Recognized in OCI for the Nine Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in OCI for the Nine Months Ended September 30, 2023	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Nine Months Ended September 30, 2024	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Nine Months Ended September 30, 2023	Location of (Gain) Loss Reclassified from Accumulated OCI into Income
Fair Value Hedges:					
Foreign currency hedge contracts	$ 0.7	$ (2.3)	$ (0.7)	$ 4.2	Other expense (income)
Total	$ 0.7	$ (2.3)	$ (0.7)	$ 4.2	
Cash Flow Hedges:					
Foreign currency hedge contracts	$ 0.3	$ (0.4)	$ (0.2)	$ 1.2	Net sales
Foreign currency hedge contracts	(1.3)	(6.1)	3.1	1.5	Cost of goods and services sold
Forward treasury locks	—	—	0.1	0.1	Interest expense
Total	$ (1.0)	$ (6.5)	$ 3.0	$ 2.8	
Net Investment Hedges:					
Cross-currency swap	$ 0.3	$ 10.1	$ —	$ —	Other expense (income)
Total	$ 0.3	$ 10.1	$ —	$ —	

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2024 and September 30, 2023. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:

($ in millions)	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Net sales	$ —	$ 0.1	$ (0.2)	$ 1.2
Cost of goods and services sold	0.5	1.1	3.1	1.5
Interest expense	—	—	0.1	0.1

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:

($ in millions)	Amount of (Loss) Gain Recognized in Income for the Three Months Ended September 30, 2024	Amount of (Loss) Gain Recognized in Income for the Three Months Ended September 30, 2023	Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30, 2023	Location on Statement of Income
Commodity call options	$ (0.5)	$ 0.5	$ (0.6)	$ (0.5)	Other expense (income)
Currency Forwards	(3.2)	—	(2.7)	(0.2)	Other expense (income)
Total	$ (3.7)	$ 0.5	$ (3.3)	$ (0.7)	

For the three and nine months ended September 30, 2024 and 2023, there was no material ineffectiveness related to our hedges.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements	9 Months Ended Sep. 30, 2024
Fair Value Disclosures [Abstract]	
Fair Value Measurements	

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

- Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
- Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:

($ in millions)	Balance at September 30, 2024	Basis of Fair Value Measurements: Level 1	Level 2	Level 3
Assets:				
Deferred compensation assets	$ 11.3	$ 11.3	$ —	$ —
Money market funds	128.5	128.5	—	—
Time deposits	73.5	—	73.5	—
Foreign currency contracts	19.7	—	19.7	—
Cross-currency swap	15.1	—	15.1	—
Commodity call options	0.2	—	0.2	—
	$ 248.3	$ 139.8	$ 108.5	$ —
Liabilities:				
Contingent consideration	$ 3.7	$ —	$ —	$ 3.7
Deferred compensation liabilities	11.4	11.4	—	—
Foreign currency contracts	9.9	—	9.9	—
	$ 25.0	$ 11.4	$ 9.9	$ 3.7

($ in millions)	Balance at December 31, 2023	Basis of Fair Value Measurements: Level 1	Level 2	Level 3
Assets:				
Deferred compensation assets	$ 10.2	$ 10.2	$ —	$ —
Money market funds	404.4	404.4	—	—
Time deposits	47.9	—	47.9	—
Foreign currency contracts	5.0	—	5.0	—
Cross-currency swap	18.4	—	18.4	—
Commodity call options	0.6	—	0.6	—
	$ 486.5	$ 414.6	$ 71.9	$ —
Liabilities:				
Contingent consideration	$ 3.6	$ —	$ —	$ 3.6
Deferred compensation liabilities	10.4	10.4	—	—
Foreign currency contracts	2.2	—	2.2	—
	$ 16.2	$ 10.4	$ 2.2	$ 3.6

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, *Derivative Financial Instruments*, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the "SmartDose® contingent consideration") was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees' investment selections and is included within other long-term liabilities.

Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2024, the estimated fair value of long-term debt was $201.6 million compared to a carrying amount of $202.6 million. At December 31, 2023, the estimated fair value of short-term and long-term debt was $204.4 million and the carrying amount was $206.8 million. As of September 30, 2024, all debt is long-term.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss	9 Months Ended Sep. 30, 2024
Equity [Abstract]	

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2024:

($ in millions)	Derivatives	Change in equity affiliate investment AOCI	Defined benefit pension and other postretirement plans	Foreign currency translation	Total
Balance, December 31, 2023	$ —	$ 2.3	$ (10.1)	$ (136.0)	$ (143.8)
Other comprehensive income (loss) before reclassifications	(0.3)	—	(0.6)	6.7	5.8
Amounts reclassified out from accumulated other comprehensive income (loss)	2.3	—	(0.6)	—	1.7
Other comprehensive income (loss), net of tax	2.0	—	(1.2)	6.7	7.5
Balance, September 30, 2024	$ 2.0	$ 2.3	$ (11.3)	$ (129.3)	$ (136.3)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:

($ in millions)	Derivatives	Change in equity affiliate investment AOCI	Defined benefit pension and other postretirement plans	Foreign currency translation	Total
Balance, December 31, 2022	$ 0.2	$ 1.6	$ (9.4)	$ (175.4)	$ (183.0)
Other comprehensive (loss) income before reclassifications	(8.8)	(0.1)	(0.1)	(36.9)	(45.9)
Amounts reclassified out from accumulated other comprehensive (loss) income	7.0	—	(1.1)	—	5.9
Other comprehensive (loss) income, net of tax	(1.8)	(0.1)	(1.2)	(36.9)	(40.0)
Balance, September 30, 2023	$ (1.6)	$ 1.5	$ (10.6)	$ (212.3)	$ (223.0)

A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table:

($ in millions)	Three Months Ended September 30,		Nine Months Ended September 30,		
Detail of components	2024	2023	2024	2023	Location on Statement of Income
Gains (losses) on derivatives:					
Foreign currency contracts	$ —	$ (0.2)	$ 0.2	$ (1.5)	Net sales
Foreign currency contracts	(0.7)	(1.4)	(4.1)	(2.0)	Cost of goods and services sold
Foreign currency contracts	—	(3.4)	1.0	(6.2)	Other expense (income)
Forward treasury locks	—	(0.1)	(0.1)	(0.2)	Interest expense
Total before tax	(0.7)	(5.1)	(3.0)	(9.9)	
Tax benefit	0.2	1.6	0.7	2.9	
Net of tax	$ (0.5)	$ (3.5)	$ (2.3)	$ (7.0)	
Amortization of defined benefit pension and other postretirement plans:					
Actuarial gains	$ 0.3	$ 0.3	$ 0.8	$ 1.1	(a)
Other	—	—	—	0.4	
Total before tax	0.3	0.3	0.8	1.5	
Tax expense	(0.1)	(0.1)	(0.2)	(0.4)	
Net of tax	$ 0.2	$ 0.2	$ 0.6	$ 1.1	
Total reclassifications for the period, net of tax	$ (0.3)	$ (3.3)	$ (1.7)	$ (5.9)	

(a) This component is included in the computation of net periodic benefit cost.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

9 Months Ended
Sep. 30, 2024

Equity [Abstract]

Shareholders' Equity

Shareholders' Equity

The following table presents the changes in shareholders' equity for the nine months ended September 30, 2024:

(in millions)	Common Shares Issued	Common Stock	Capital in Excess of Par Value	Number of Treasury Shares	Treasury Stock	Retained earnings	Accumulated other comprehensive loss	Total
Balance, December 31, 2023	75.3	$ 18.8	$ 120.2	1.8	$ (637.6)	$ 3,523.4	$ (143.8)	$ 2,881.0
Net income	—	—	—	—	—	115.3	—	115.3
Activity related to stock-based compensation	—	—	(65.0)	(0.2)	79.4	—	—	14.4
Shares purchased under share repurchase program	—	—	—	0.7	(267.0)	—	—	(267.0)
Dividends declared ($0.20 per share)	—	—	—	—	—	(14.6)	—	(14.6)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(48.5)	(48.5)
Balance, March 31, 2024	75.3	$ 18.8	$ 55.2	2.3	$ (825.2)	$ 3,624.1	$ (192.3)	$ 2,680.6
Net income	—	—	—	—	—	111.3	—	111.3
Activity related to stock-based compensation	—	—	(21.7)	(0.1)	32.8	—	—	11.1
Shares purchased under share repurchase program	—	—	—	0.5	(187.1)	—	—	(187.1)
Dividends declared ($0.20 per share)	—	—	—	—	—	(14.5)	—	(14.5)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(24.6)	(24.6)
Balance, June 30, 2024	75.3	$ 18.8	$ 33.5	2.7	$ (979.5)	$ 3,720.9	$ (216.9)	$ 2,576.8
Net income	—	—	—	—	—	136.0	—	136.0
Activity related to stock-based compensation	—	—	(10.2)	(0.1)	21.3	—	—	11.1
Shares purchased under share repurchase program	—	—	—	0.2	(52.4)	—	—	(52.4)
Other comprehensive income, net of tax	—	—	—	—	—	—	80.6	80.6
Balance, September 30, 2024	75.3	$ 18.8	$ 23.3	2.8	$ (1,010.6)	$ 3,856.9	$ (136.3)	$ 2,752.1

The following table presents the changes in shareholders' equity for the nine months ended September 30, 2023:

(in millions)	Common Shares Issued	Common Stock	Capital in Excess of Par Value	Number of Treasury Shares	Treasury Stock	Retained earnings	Accumulated other comprehensive loss	Total
Balance, December 31, 2022	75.3	$ 18.8	$ 232.2	1.2	$ (370.9)	$ 2,987.8	$ (183.0)	$ 2,684.9
Net income	—	—	—	—	—	140.0	—	140.0
Activity related to stock-based compensation	—	—	(50.8)	(0.3)	61.8	—	—	11.0
Shares purchased under share repurchase program	—	—	—	0.2	(60.1)	—	—	(60.1)
Dividends declared ($0.19 per share)	—	—	—	—	—	(14.2)	—	(14.2)
Other comprehensive income, net of tax	—	—	—	—	—	—	14.6	14.6
Balance, March 31, 2023	75.3	$ 18.8	$ 181.4	1.1	$ (369.2)	$ 3,113.6	$ (168.4)	$ 2,776.2
Net income	—	—	—	—	—	155.1	—	155.1
Activity related to stock-based compensation	—	—	(23.2)	(0.2)	41.2	—	—	18.0
Shares purchased under share repurchase program	—	—	—	0.5	(173.4)	—	—	(173.4)
Dividends declared ($0.19 per share)	—	—	—	—	—	(14.1)	—	(14.1)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(15.1)	(15.1)
Balance, June 30, 2023	75.3	$ 18.8	$ 158.2	1.4	$ (501.4)	$ 3,254.6	$ (183.5)	$ 2,746.7
Net income	—	—	—	—	—	161.3	—	161.3
Activity related to stock-based compensation	—	—	(35.6)	(0.2)	63.1	—	—	27.5
Shares purchased under share repurchase program	—	—	—	0.1	(27.8)	—	—	(27.8)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(39.5)	(39.5)
Balance, September 30, 2023	75.3	$ 18.8	$ 122.6	1.3	$ (466.1)	$ 3,415.9	$ (223.0)	$ 2,868.2

XML 32 R20.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended
Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the "2016 Plan") provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2024, there were 1,338,673 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2024, we granted 88,588 stock options at a weighted average exercise price of $348.50 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $134.33 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.3%; expected life of 6.0 years based on prior experience; stock volatility of 32.0% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2024, we granted 34,188 stock-settled performance share unit ("PSU") awards at a weighted average grant-date fair value of $348.46 per share to eligible employees. These awards are earned based on the Company's performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee's targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2024, we granted 8,302 stock-settled restricted share unit ("RSU") awards at a weighted average grant-date fair value of $342.74 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Stock-based compensation expense was $5.1 million and $14.4 million for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, stock-based compensation expense was $5.9 million and $21.9 million, respectively.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Other Expense (Income)

9 Months Ended
Sep. 30, 2024

Other Income and Expenses [Abstract]

Other Expense (Income)

Other Expense (Income)

Other expense (income) consists of:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Foreign exchange transaction losses	$ 4.1	$ 1.8	$ 7.3	$ 3.0
Contingent consideration	1.2	0.7	3.2	1.5
Asset impairments	1.0	3.5	1.9	6.9
Restructuring and related charges	(2.5)	—	(2.5)	(0.8)
Loss on disposal of plant	—	—	—	11.6
Other items	0.6	(0.4)	0.9	0.3
Total other expense (income)	$ 4.4	$ 5.6	$ 10.8	$ 22.5

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, *Fair Value Measurements*, for additional details.

Restructuring and Related Charges

In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were implemented over a period of approximately twenty-four months from the date of approval. The plan is expected to have annualized savings in the range of $17 million to $19 million. As of September 30, 2024, the Company does not expect additional expenses or payments associated with our 2022 restructuring plan. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:

($ in millions)	Severance and benefits	Other charges	Total
Balance, December 31, 2023	$ 3.0	$ —	$ 3.0
(Credits) Charges	(2.5)	—	(2.5)
Cash payments	(0.5)	—	(0.5)
Balance, September 30, 2024	$ —	$ —	$ —

Loss on Disposal of Plant

During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million, within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment during the second quarter of 2023.

XML 34 R22.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended
Sep. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $32.4 million and $29.4 million for the three months ended September 30, 2024 and 2023, respectively, and the effective tax rate was 19.7% and 15.7%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the three months ended September 30, 2024 as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.

The provision for income taxes was $70.7 million and $87.8 million for the nine months ended September 30, 2024 and 2023, respectively, and the effective tax rate was 16.8% and 16.6%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the nine months ended September 30, 2024, as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.

The Company continues to address the change in tax laws enacted pursuant to the Organization for Economic Cooperation and Development (OECD)'s 15% global minimum tax initiative (Pillar 2). The 2024 forecasted impact of Pillar 2 is not expected to be material to the Company.

XML 35 R23.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended
Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to commitments and contingencies since December 31, 2023.

XML 36 R24.htm IDEA: XBRL DOCUMENT

Segment Information

9 Months Ended
Sep. 30, 2024

Segment Reporting [Abstract]

Segment Information

Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.

The following table presents information about our reportable segments, reconciled to consolidated totals:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Net sales:				
Proprietary Products	$ 601.4	$ 602.5	$ 1,720.6	$ 1,803.6
Contract-Manufactured Products	145.5	144.9	423.8	414.2
Consolidated net sales	$ 746.9	$ 747.4	$ 2,144.4	$ 2,217.8

The following table provides summarized financial information for our segments:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Operating profit (loss):				
Proprietary Products	$ 158.2	$ 181.6	$ 415.5	$ 546.5
Contract-Manufactured Products	21.8	21.0	56.1	53.3
Total business segment operating profit	$ 180.0	$ 202.6	$ 471.6	$ 599.8
Corporate and Unallocated				
Stock-based compensation expense	$ (5.1)	$ (5.9)	$ (14.4)	$ (21.9)
Corporate general costs [1]	(14.3)	(15.9)	(47.2)	(47.2)
Unallocated Items:				
Loss on disposal of plant [2]	—	—	—	(11.6)
Cost investment impairment [3]	—	(3.3)	—	(3.3)
Restructuring and other charges [4]	0.9	—	0.9	(0.1)
Amortization of acquisition-related intangible assets [5]	(0.2)	(0.2)	(0.6)	(0.6)
Total Corporate and Unallocated	(18.7)	(25.3)	(61.3)	(84.7)
Total consolidated operating profit	$ 161.3	$ 177.3	$ 410.3	$ 515.1
Interest (income) expense and other nonoperating expense (income), net	(3.2)	(9.7)	(10.3)	(14.7)
Income before income taxes and equity in net income of affiliated companies	$ 164.5	$ 187.0	$ 420.6	$ 529.8

(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.

(4) Restructuring and other charges were a benefit of $0.9 million in the three and nine months ended September 30, 2024. The net benefit represents the impact of two items, the first of which is a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represent the net impact of an

inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan.

(5) During the three and nine months ended September 30, 2024 and September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 14, *Other Expense (Income)*, for further discussion of these items.

XML 37 R25.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure								
Net income	$ 136.0	$ 111.3	$ 115.3	$ 161.3	$ 155.1	$ 140.0	$ 362.6	$ 456.4

XML 38 R26.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 39 R27.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)	9 Months Ended Sep. 30, 2024
Accounting Policies [Abstract]	
Basis of Presentation	**Basis of Presentation**: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("U.S. GAAP") for interim financial reporting and U.S. Securities and Exchange Commission ("SEC") regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2024, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as "West", the "Company", "we", "us" or "our") appearing in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"). The results of operations for any interim period are not necessarily indicative of results for the full year.
Standards Issued Not Yet Adopted	**Standards Issued Not Yet Adopted** In November 2023, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company does not expect the adoption to have a material impact on the consolidated financial statements and disclosures. In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.
Revenue	Revenue Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification ("ASC") 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

XML 40 R28.htm IDEA: XBRL DOCUMENT

Revenue (Tables) — 9 Months Ended Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Biologics	40 %	40 %	38 %	37 %
Generics	18 %	19 %	17 %	20 %
Pharma	23 %	22 %	25 %	24 %
Contract-Manufactured Products	19 %	19 %	20 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
High-Value Product ("HVP") Components	45 %	50 %	46 %	50 %
High-Value Product ("HVP") Delivery Devices	16 %	11 %	12 %	10 %
Standard Packaging	20 %	20 %	22 %	21 %
Contract-Manufactured Products	19 %	19 %	20 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by geographic location:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Americas	48 %	46 %	44 %	45 %
Europe, Middle East, Africa	44 %	46 %	47 %	46 %
Asia Pacific	8 %	8 %	9 %	9 %
	100 %	100 %	100 %	100 %

Schedule of Change in Contract with Customer, Asset and Liability

The following table summarizes our contract assets and liabilities:

	($ in millions)
Contract assets, December 31, 2023	$ 21.5
Contract assets, September 30, 2024	42.3
Change in contract assets - increase (decrease)	$ 20.8
Deferred income, December 31, 2023	$ (53.9)
Deferred income, September 30, 2024	(53.8)
Change in deferred income - decrease (increase)	$ 0.1

XML 41 R29.htm IDEA: XBRL DOCUMENT

Net Income Per Share (Tables) — 9 Months Ended Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Reconciliation of Basic to Diluted Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

	Three Months Ended September 30,		Nine Months Ended September 30,	
($ in millions)	2024	2023	2024	2023
Net income	$ 136.0	$ 161.3	$ 362.6	$ 456.4
Weighted average common shares outstanding	72.8	74.3	73.1	74.4
Dilutive effect of equity awards, based on the treasury stock method	0.6	1.0	0.7	1.1
Weighted average shares assuming dilution	73.4	75.3	73.8	75.5

Schedule of Repurchase of Common Stock

The below table summarizes the details of the Company's repurchases of common stock under this program:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Shares repurchased	170,771	77,329	1,409,786	753,399
Total cost of repurchases ($ in millions)	$ 52.4	$ 27.8	$ 506.5	$ 261.3
Average price per repurchased share	$ 306.34	$ 360.25	$ 359.24	$ 346.86

XML 42 R30.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended
Sep. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:

($ in millions)	September 30, 2024	December 31, 2023
Raw materials	$ 170.3	$ 172.3
Work in process	80.0	87.3
Finished goods	150.9	175.1
	$ 401.2	$ 434.7

XML 43 R31.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended
Sep. 30, 2024

Leases [Abstract]

Schedule of Lease Cost

The components of lease expense were as follows:

($ in millions)	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Operating lease cost	$ 6.4	$ 4.3	$ 18.1	$ 15.0
Finance lease - amortization of right-of-use (ROU) assets	0.3	—	0.6	—
Finance lease - interest on lease liabilities	0.1	—	0.1	—
Short-term lease cost	0.8	1.9	1.9	4.4
Variable lease cost	2.5	1.4	6.3	4.4
Total lease cost	$ 10.1	$ 7.6	$ 27.0	$ 23.8

Supplemental cash flow information related to leases were as follows:

($ in millions)	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 26.3	$ 14.4
Financing cash flows from finance leases	$ 23.2	$ —
Right-of-use assets obtained in exchange for new lease liabilities:		
Operating leases	$ 36.8	$ 6.6
Finance leases	$ 24.3	$ —

Schedule Of Assets And Liabilities, Lessee

The following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of September 30, 2024:

($ in millions)	Balance Sheet Classification	September 30, 2024
ROU assets, net	Other noncurrent assets	$ 31.9
Lease liabilities (current)	Other current liabilities	$ 0.9
Lease liabilities (noncurrent)	Other long-term liabilities	$ 2.2

Schedule of Lessee, Operating Lease, Liability, Maturity

Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:

($ in millions) Year	Operating Leases	Finance Leases
2024 (remaining period as of September 30, 2024)	$ 6.2	$ 0.2
2025	23.2	0.9
2026	20.2	0.9
2027	15.5	0.8
2028	14.1	0.5
Thereafter	37.2	0.1
	116.4	3.4
Less: imputed lease interest	(14.2)	(0.3)
Total lease liabilities	$ 102.2	$ 3.1

Schedule of Lessee, Finance Lease, Liability, Maturity

Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:

($ in millions) Year	Operating Leases	Finance Leases
2024 (remaining period as of September 30, 2024)	$ 6.2	$ 0.2
2025	23.2	0.9
2026	20.2	0.9
2027	15.5	0.8
2028	14.1	0.5
Thereafter	37.2	0.1
	116.4	3.4
Less: imputed lease interest	(14.2)	(0.3)
Total lease liabilities	$ 102.2	$ 3.1

XML 44 R32.htm IDEA: XBRL DOCUMENT

Affiliated Companies (Tables)

9 Months Ended
Sep. 30, 2024

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Investments in Affiliated Companies

The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:

($ in millions)	September 30, 2024	December 31, 2023
Aggregate carrying value of investments in affiliated companies:		
Equity method affiliates	$ 210.3	$ 203.2
Non-equity method affiliates	7.2	6.8
Total investments in affiliated companies	$ 217.5	$ 210.0

The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:

($ in millions)	September 30, 2024	December 31, 2023
Payables due to affiliates	$ 24.8	$ 25.9
Receivables due from affiliates	$ 2.7	$ 1.6

The following table summarizes the Company's affiliate transactions:

($ in millions)	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Purchases from (and payments to) affiliates	$ 30.1	$ 34.4	$ 83.6	$ 118.5
Sales to affiliates	$ 3.5	$ 2.5	$ 10.7	$ 8.5

XML 45 R33.htm IDEA: XBRL DOCUMENT

Debt (Tables)

9 Months Ended
Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of Long-term Debt Obligations, Net of Current Maturities

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.

($ in millions)	September 30, 2024	December 31, 2023
Term Loan, due July 2, 2027 (6.67%)	$ 130.0	$ —
Term Loan, due December 31, 2024 (6.32%)	—	81.0
Series B notes, due July 5, 2024 (3.82%)	—	53.0
Series C notes, due July 5, 2027 (4.02%)	73.0	73.0
	203.0	207.0
Less: unamortized debt issuance costs	0.4	0.2
Total debt	202.6	206.8
Less: current portion of long-term debt	—	134.0
Long-term debt, net	$ 202.6	$ 72.8

XML 46 R34.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments (Tables)

9 Months Ended
Sep. 30, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Foreign Currency Contracts

As of September 30, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)

Currency	Purchase	Sell USD	Sell Euro	Sell SGD
EUR	24.1	26.5	—	—
Yen	6,102.9	28.7	11.4	1.7
SGD	43.4	19.0	12.5	—

Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings

The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:

($ in millions)	Amount of Gain (Loss) Recognized in Income for the Three Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in Income for the Three Months Ended September 30, 2023	Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30, 2023	Location on Statement of Income
Fair Value Hedges:					
Hedged item (intercompany loan)	$ (16.6)	$ (1.2)	$ (6.2)	$ 8.7	Other expense (income)
Derivative designated as hedging instrument	16.6	0.7	6.2	(10.0)	Other expense (income)
Amount excluded from effectiveness testing	(1.8)	(1.5)	(5.3)	(0.4)	Other expense (income)
Total	$ (1.8)	$ (2.0)	$ (5.3)	$ (1.7)	

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income ("OCI") and earnings, net of tax:

($ in millions)	Amount of Gain (Loss) Recognized in OCI for the Three Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in OCI for the Three Months Ended September 30, 2023	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Three Months Ended September 30, 2024	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Three Months Ended September 30, 2023	Location of (Gain) Loss Reclassified from Accumulated OCI into Income
Fair Value Hedges:					
Foreign currency hedge contracts	$ 0.5	$ (0.3)	$ —	$ 2.3	Other expense (income)
Total	$ 0.5	$ (0.3)	$ —	$ 2.3	
Cash Flow Hedges:					
Foreign currency hedge contracts	$ 0.2	$ 0.5	$ —	$ 0.1	Net sales
Foreign currency hedge contracts	5.3	(2.5)	0.5	1.1	Cost of goods and services sold
Forward treasury locks	—	—	—	—	Interest expense
Total	$ 5.5	$ (2.0)	$ 0.5	$ 1.2	
Net Investment Hedges:					
Cross-currency swap	$ (8.1)	$ 2.9	$ —	$ —	Other expense (income)
Total	$ (8.1)	$ 2.9	$ —	$ —	

($ in millions)	Amount of Gain (Loss) Recognized in OCI for the Nine Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in OCI for the Nine Months Ended September 30, 2023	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Nine Months Ended September 30, 2024	Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Nine Months Ended September 30, 2023	Location of (Gain) Loss Reclassified from Accumulated OCI into Income
Fair Value Hedges:					
Foreign currency hedge contracts	$ 0.7	$ (2.3)	$ (0.7)	$ 4.2	Other expense (income)
Total	$ 0.7	$ (2.3)	$ (0.7)	$ 4.2	
Cash Flow Hedges:					
Foreign currency hedge contracts	$ 0.3	$ (0.4)	$ (0.2)	$ 1.2	Net sales
Foreign currency hedge contracts	(1.3)	(6.1)	3.1	1.5	Cost of goods and services sold
Forward treasury locks	—	—	0.1	0.1	Interest expense
Total	$ (1.0)	$ (6.5)	$ 3.0	$ 2.8	
Net Investment Hedges:					
Cross-currency swap	$ 0.3	$ 10.1	$ —	$ —	Other expense (income)
Total	$ 0.3	$ 10.1	$ —	$ —	

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2024 and September 30, 2023. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:

($ in millions)	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Net sales	$ —	$ 0.1	$ (0.2)	$ 1.2
Cost of goods and services sold	0.5	1.1	3.1	1.5
Interest expense	—	—	0.1	0.1

Schedule of Derivative Instruments Not Designated as Hedges

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:

($ in millions)	Amount of (Loss) Gain Recognized in Income for the Three Months Ended September 30, 2024	Amount of (Loss) Gain Recognized in Income for the Three Months Ended September 30, 2023	Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30, 2024	Amount of Gain (Loss) Recognized in Income for the Nine Months Ended September 30, 2023	Location on Statement of Income
Commodity call options	$ (0.5)	$ 0.5	$ (0.6)	$ (0.5)	Other expense (income)
Currency Forwards	(3.2)	—	(2.7)	(0.2)	Other expense (income)
Total	$ (3.7)	$ 0.5	$ (3.3)	$ (0.7)	

XML 47 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value

The following tables present the assets and liabilities recorded at fair value on a recurring basis:

($ in millions)	Balance at September 30, 2024	Basis of Fair Value Measurements: Level 1	Level 2	Level 3
Assets:				
Deferred compensation assets	$ 11.3	$ 11.3	$ —	$ —
Money market funds	128.5	128.5	—	—
Time deposits	73.5	—	73.5	—
Foreign currency contracts	19.7	—	19.7	—
Cross-currency swap	15.1	—	15.1	—
Commodity call options	0.2	—	0.2	—
	$ 248.3	$ 139.8	$ 108.5	$ —
Liabilities:				
Contingent consideration	$ 3.7	$ —	$ —	$ 3.7
Deferred compensation liabilities	11.4	11.4	—	—
Foreign currency contracts	9.9	—	9.9	—
	$ 25.0	$ 11.4	$ 9.9	$ 3.7

($ in millions)	Balance at December 31, 2023	Basis of Fair Value Measurements: Level 1	Level 2	Level 3
Assets:				
Deferred compensation assets	$ 10.2	$ 10.2	$ —	$ —
Money market funds	404.4	404.4	—	—
Time deposits	47.9	—	47.9	—
Foreign currency contracts	5.0	—	5.0	—
Cross-currency swap	18.4	—	18.4	—
Commodity call options	0.6	—	0.6	—
	$ 486.5	$ 414.6	$ 71.9	$ —
Liabilities:				
Contingent consideration	$ 3.6	$ —	$ —	$ 3.6
Deferred compensation liabilities	10.4	10.4	—	—
Foreign currency contracts	2.2	—	2.2	—
	$ 16.2	$ 10.4	$ 2.2	$ 3.6

XML 48 R36.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Sep. 30, 2024

Equity [Abstract]

Schedule of Components of Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2024:

($ in millions)	Derivatives	Change in equity affiliate investment AOCI	Defined benefit pension and other postretirement plans	Foreign currency translation	Total
Balance, December 31, 2023	$ —	$ 2.3	$ (10.1)	$ (136.0)	$ (143.8)
Other comprehensive income (loss) before reclassifications	(0.3)	—	(0.6)	6.7	5.8
Amounts reclassified out from accumulated other comprehensive income (loss)	2.3	—	(0.6)	—	1.7
Other comprehensive income (loss), net of tax	2.0	—	(1.2)	6.7	7.5
Balance, September 30, 2024	$ 2.0	$ 2.3	$ (11.3)	$ (129.3)	$ (136.3)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:

($ in millions)	Derivatives	Change in equity affiliate investment AOCI	Defined benefit pension and other postretirement plans	Foreign currency translation	Total
Balance, December 31, 2022	$ 0.2	$ 1.6	$ (9.4)	$ (175.4)	$ (183.0)
Other comprehensive (loss) income before reclassifications	(8.8)	(0.1)	(0.1)	(36.9)	(45.9)
Amounts reclassified out from accumulated other comprehensive (loss) income	7.0	—	(1.1)	—	5.9
Other comprehensive (loss) income, net of tax	(1.8)	(0.1)	(1.2)	(36.9)	(40.0)
Balance, September 30, 2023	$ (1.6)	$ 1.5	$ (10.6)	$ (212.3)	$ (223.0)

Schedule of Reclassification out of Accumulated Other Comprehensive Loss

A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table:

($ in millions)	Three Months Ended September 30,		Nine Months Ended September 30,		
Detail of components	2024	2023	2024	2023	Location on Statement of Income
Gains (losses) on derivatives:					
Foreign currency contracts	$ —	$ (0.2)	$ 0.2	$ (1.5)	Net sales
Foreign currency contracts	(0.7)	(1.4)	(4.1)	(2.0)	Cost of goods and services sold
Foreign currency contracts	—	(3.4)	1.0	(6.2)	Other expense (income)
Forward treasury locks	—	(0.1)	(0.1)	(0.2)	Interest expense
Total before tax	(0.7)	(5.1)	(3.0)	(9.9)	
Tax benefit	0.2	1.6	0.7	2.9	
Net of tax	$ (0.5)	$ (3.5)	$ (2.3)	$ (7.0)	
Amortization of defined benefit pension and other postretirement plans:					
Actuarial gains	$ 0.3	$ 0.3	$ 0.8	$ 1.1	(a)
Other	—	—	—	0.4	
Total before tax	0.3	0.3	0.8	1.5	
Tax expense	(0.1)	(0.1)	(0.2)	(0.4)	
Net of tax	$ 0.2	$ 0.2	$ 0.6	$ 1.1	
Total reclassifications for the period, net of tax	$ (0.3)	$ (3.3)	$ (1.7)	$ (5.9)	

(a) This component is included in the computation of net periodic benefit cost.

XML 49 R37.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

9 Months Ended Sep. 30, 2024

Equity [Abstract]

Schedule of Stockholders Equity

The following table presents the changes in shareholders' equity for the nine months ended September 30, 2024:

(in millions)	Common Shares Issued	Common Stock	Capital in Excess of Par Value	Number of Treasury Shares	Treasury Stock	Retained earnings	Accumulated other comprehensive loss	Total
Balance, December 31, 2023	75.3	$ 18.8	$ 120.2	1.8	$ (637.6)	$ 3,523.4	$ (143.8)	$ 2,881.0
Net income	—	—	—	—	—	115.3	—	115.3
Activity related to stock-based compensation	—	—	(65.0)	(0.2)	79.4	—	—	14.4
Shares purchased under share repurchase program	—	—	—	0.7	(267.0)	—	—	(267.0)
Dividends declared ($0.20 per share)	—	—	—	—	—	(14.6)	—	(14.6)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(48.5)	(48.5)
Balance, March 31, 2024	75.3	$ 18.8	$ 55.2	2.3	$ (825.2)	$ 3,624.1	$ (192.3)	$ 2,680.6
Net income	—	—	—	—	—	111.3	—	111.3
Activity related to stock-based compensation	—	—	(21.7)	(0.1)	32.8	—	—	11.1
Shares purchased under share repurchase program	—	—	—	0.5	(187.1)	—	—	(187.1)
Dividends declared ($0.20 per share)	—	—	—	—	—	(14.5)	—	(14.5)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(24.6)	(24.6)
Balance, June 30, 2024	75.3	$ 18.8	$ 33.5	2.7	$ (979.5)	$ 3,720.9	$ (216.9)	$ 2,576.8
Net income	—	—	—	—	—	136.0	—	136.0
Activity related to stock-based compensation	—	—	(10.2)	(0.1)	21.3	—	—	11.1
Shares purchased under share repurchase program	—	—	—	0.2	(52.4)	—	—	(52.4)
Other comprehensive income, net of tax	—	—	—	—	—	—	80.6	80.6
Balance, September 30, 2024	75.3	$ 18.8	$ 23.3	2.8	$ (1,010.6)	$ 3,856.9	$ (136.3)	$ 2,752.1

The following table presents the changes in shareholders' equity for the nine months ended September 30, 2023:

(in millions)	Common Shares Issued	Common Stock	Capital in Excess of Par Value	Number of Treasury Shares	Treasury Stock	Retained earnings	Accumulated other comprehensive loss	Total
Balance, December 31, 2022	75.3	$ 18.8	$ 232.2	1.2	$ (370.9)	$ 2,987.8	$ (183.0)	$ 2,684.9
Net income	—	—	—	—	—	140.0	—	140.0
Activity related to stock-based compensation	—	—	(50.8)	(0.3)	61.8	—	—	11.0
Shares purchased under share repurchase program	—	—	—	0.2	(60.1)	—	—	(60.1)
Dividends declared ($0.19 per share)	—	—	—	—	—	(14.2)	—	(14.2)
Other comprehensive income, net of tax	—	—	—	—	—	—	14.6	14.6
Balance, March 31, 2023	75.3	$ 18.8	$ 181.4	1.1	$ (369.2)	$ 3,113.6	$ (168.4)	$ 2,776.2
Net income	—	—	—	—	—	155.1	—	155.1
Activity related to stock-based compensation	—	—	(23.2)	(0.2)	41.2	—	—	18.0
Shares purchased under share repurchase program	—	—	—	0.5	(173.4)	—	—	(173.4)
Dividends declared ($0.19 per share)	—	—	—	—	—	(14.1)	—	(14.1)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(15.1)	(15.1)
Balance, June 30, 2023	75.3	$ 18.8	$ 158.2	1.4	$ (501.4)	$ 3,254.6	$ (183.5)	$ 2,746.7
Net income	—	—	—	—	—	161.3	—	161.3
Activity related to stock-based compensation	—	—	(35.6)	(0.2)	63.1	—	—	27.5
Shares purchased under share repurchase program	—	—	—	0.1	(27.8)	—	—	(27.8)
Other comprehensive loss, net of tax	—	—	—	—	—	—	(39.5)	(39.5)
Balance, September 30, 2023	75.3	$ 18.8	$ 122.6	1.3	$ (466.1)	$ 3,415.9	$ (223.0)	$ 2,868.2

XML 50 R38.htm IDEA: XBRL DOCUMENT

Other Expense (Income) (Tables)

9 Months Ended Sep. 30, 2024

Other Income and Expenses [Abstract]

Schedule of Other Expense (Income)

Other expense (income) consists of:

($ in millions)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Foreign exchange transaction losses	$ 4.1	$ 1.8	$ 7.3	$ 3.0
Contingent consideration	1.2	0.7	3.2	1.5
Asset impairments	1.0	3.5	1.9	6.9
Restructuring and related charges	(2.5)	—	(2.5)	(0.8)
Loss on disposal of plant	—	—	—	11.6
Other items	0.6	(0.4)	0.9	0.3
Total other expense (income)	$ 4.4	$ 5.6	$ 10.8	$ 22.5

Schedule of Restructuring Reserve

The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:

($ in millions)	Severance and benefits	Other charges	Total
Balance, December 31, 2023	$ 3.0	$ —	$ 3.0
(Credits) Charges	(2.5)	—	(2.5)
Cash payments	(0.5)	—	(0.5)
Balance, September 30, 2024	$ —	$ —	$ —

XML 51 R39.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

9 Months Ended Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Sales by Significant Product Group

The following table presents information about our reportable segments, reconciled to consolidated totals:

($ in millions)	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Net sales:				
Proprietary Products	$ 601.4	$ 602.5	$ 1,720.6	$ 1,803.6
Contract-Manufactured Products	145.5	144.9	423.8	414.2
Consolidated net sales	$ 746.9	$ 747.4	$ 2,144.4	$ 2,217.8

Schedule of Segment Reporting Information, by Segment

The following table provides summarized financial information for our segments:

($ in millions)	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Operating profit (loss):				
Proprietary Products	$ 158.2	$ 181.6	$ 415.5	$ 546.5
Contract-Manufactured Products	21.8	21.0	56.1	53.3
Total business segment operating profit	$ 180.0	$ 202.6	$ 471.6	$ 599.8
Corporate and Unallocated				
Stock-based compensation expense	$ (5.1)	$ (5.9)	$ (14.4)	$ (21.9)
Corporate general costs [1]	(14.3)	(15.9)	(47.2)	(47.2)
Unallocated Items:				
Loss on disposal of plant [2]	—	—	—	(11.6)
Cost investment impairment [3]	—	(3.3)	—	(3.3)
Restructuring and other charges [4]	0.9	—	0.9	(0.1)
Amortization of acquisition-related intangible assets [5]	(0.2)	(0.2)	(0.6)	(0.6)
Total Corporate and Unallocated	(18.7)	(25.3)	(61.3)	(84.7)
Total consolidated operating profit	$ 161.3	$ 177.3	$ 410.3	$ 515.1
Interest (income) expense and other nonoperating expense (income), net	(3.2)	(9.7)	(10.3)	(14.7)
Income before income taxes and equity in net income of affiliated companies	$ 164.5	$ 187.0	$ 420.6	$ 529.8

(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.

(4) Restructuring and other charges were a benefit of $0.9 million in the three and nine months ended September 30, 2024. The net benefit represents the impact of two items, the first of which is a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represent the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan.

(5) During the three and nine months ended September 30, 2024 and September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

XML 52 R40.htm IDEA: XBRL DOCUMENT

Revenue - Revenue Recognition (Details) - Revenue Benchmark	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
Customer Concentration Risk				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Customer Concentration Risk | Biologics				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	40.00%	40.00%	38.00%	37.00%
Customer Concentration Risk | Generics				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	18.00%	19.00%	17.00%	20.00%
Customer Concentration Risk | Pharma				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	23.00%	22.00%	25.00%	24.00%
Customer Concentration Risk | Contract-Manufactured Products				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	19.00%	19.00%	20.00%	19.00%
Product Concentration Risk				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Product Concentration Risk | High-Value Product ("HVP") Components				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	45.00%	50.00%	46.00%	50.00%
Product Concentration Risk | High-Value Product ("HVP") Delivery Devices				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	16.00%	11.00%	12.00%	10.00%
Product Concentration Risk | Standard Packaging				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	20.00%	20.00%	22.00%	21.00%
Product Concentration Risk | Contract-Manufactured Products				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	19.00%	19.00%	20.00%	19.00%
Geographic Concentration Risk				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Geographic Concentration Risk | Americas				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	48.00%	46.00%	44.00%	45.00%
Geographic Concentration Risk | Europe, Middle East, Africa				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	44.00%	46.00%	47.00%	46.00%
Geographic Concentration Risk | Asia Pacific				
Disaggregation of Revenue [Line Items]				
Concentration risk, percentage	8.00%	8.00%	9.00%	9.00%

XML 53 R41.htm IDEA: XBRL DOCUMENT

Revenue - Contracts and Liabilities (Details) $ in Millions	9 Months Ended Sep. 30, 2024 USD ($)
Contract With Customer, Asset [Roll Forward]	
Contract assets, December 31, 2023	$ 21.5
Contract assets, September 30, 2024	42.3
Change in contract assets - increase (decrease)	20.8
Contract With Customer, Liability [Roll Forward]	
Deferred income, December 31, 2023	(53.9)
Deferred income, September 30, 2024	(53.8)
Change in deferred income - decrease (increase)	$ 0.1

XML 54 R42.htm IDEA: XBRL DOCUMENT

Revenue - Narrative (Details) $ in Millions	9 Months Ended Sep. 30, 2024 USD ($)
Revenue from Contract with Customer [Abstract]	

Revenue recognized that was included in the deferred income balance	$ 32.8

XML 55 R43.htm IDEA: XBRL DOCUMENT

Net Income Per Share - Schedule of Net Income Per Share (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]								
Net income	$ 136.0	$ 111.3	$ 115.3	$ 161.3	$ 155.1	$ 140.0	$ 362.6	$ 456.4
Weighted average common shares outstanding (in shares)	72.8			74.3			73.1	74.4
Dilutive effect of equity awards, based on the treasury stock method (in shares)	0.6			1.0			0.7	1.1
Weighted average shares assuming dilution (in shares)	73.4			75.3			73.8	75.5

XML 56 R44.htm IDEA: XBRL DOCUMENT

Net Income Per Share - Narrative (Details) - shares	3 Months Ended		9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Feb. 28, 2023
Earnings Per Share [Abstract]					
Antidilutive options excluded from computation of diluted net income per share (in shares)	300,000	100,000	300,000	100,000	
Stock repurchase program, shares authorized (in shares)					1,000,000,000

XML 57 R45.htm IDEA: XBRL DOCUMENT

Net Income Per Share - Schedule of Repurchase of Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]								
Share purchased (in shares)	170,771			77,329			1,409,786	753,399
Total cost of repurchases ($ in millions)	$ 52.4	$ 187.1	$ 267.0	$ 27.8	$ 173.4	$ 60.1	$ 506.5	$ 261.3
Average price per repurchased share (in dollars per share)	$ 306.34			$ 360.25			$ 359.24	$ 346.86

XML 58 R46.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]		
Raw materials	$ 170.3	$ 172.3
Work in process	80.0	87.3
Finished goods	150.9	175.1
Total inventories	$ 401.2	$ 434.7

XML 59 R47.htm IDEA: XBRL DOCUMENT

Leases - Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]				
Operating lease cost	$ 6.4	$ 4.3	$ 18.1	$ 15.0
Finance lease - amortization of right-of-use (ROU) assets	0.3	0.0	0.6	0.0
Finance lease - interest on lease liabilities	0.1	0.0	0.1	0.0
Short-term lease cost	0.8	1.9	1.9	4.4
Variable lease cost	2.5	1.4	6.3	4.4
Total lease cost	$ 10.1	$ 7.6	$ 27.0	$ 23.8

XML 60 R48.htm IDEA: XBRL DOCUMENT

Leases - Assets And Liabilities, Lessee (Details) $ in Millions	Sep. 30, 2024 USD ($)	
Leases [Abstract]		
ROU assets, net	$ 31.9	
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other noncurrent assets	
Lease liabilities (current)	$ 0.9	
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	
Lease liabilities (noncurrent)	$ 2.2	
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	

XML 61 R49.htm IDEA: XBRL DOCUMENT

Leases - Lease Weighted Average (Details)	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]		
Weighted average remaining lease term (years)	8 years 6 months	9 years 9 months 18 days
Weighted average remaining lease term (years)	7 years	
Weighted average discount rate	3.84%	3.55%
Weighted average discount rate	4.92%	

XML 62 R50.htm IDEA: XBRL DOCUMENT

Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($) $ in Millions	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 26.3	$ 14.4
Financing cash flows from finance leases	23.2	0.0
Right-of-use assets obtained in exchange for new lease liabilities:		
Operating leases	36.8	6.6
Finance leases	$ 24.3	$ 0.0

XML 63 R51.htm IDEA: XBRL DOCUMENT

Leases - Narrative (Details)	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]		
Weighted average remaining lease term (years)	8 years 6 months	9 years 9 months 18 days
Weighted average remaining lease term (years)	7 years	
Weighted average discount rate	3.84%	3.55%
Weighted average discount rate	4.92%	

XML 64 R52.htm IDEA: XBRL DOCUMENT

Leases - Maturities of Operating and Finance Lease Liabilities (Details) $ in Millions	Sep. 30, 2024 USD ($)
Operating Leases	
2024 (remaining period as of September 30, 2024)	$ 6.2

2025	23.2
2026	20.2
2027	15.5
2028	14.1
Thereafter	37.2
Operating leases liabilities payments due	116.4
Less: imputed lease interest	(14.2)
Total lease liabilities	102.2
Finance Leases	
2024 (remaining period as of September 30, 2024)	0.2
2025	0.9
2026	0.9
2027	0.8
2028	0.5
Thereafter	0.1
Finance leases liabilities payments due	3.4
Less: imputed lease interest	(0.3)
Total lease liabilities	$ 3.1

XML 65 R53.htm IDEA: XBRL DOCUMENT

Affiliated Companies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]					
Total investments in affiliated companies	$ 217.5		$ 217.5		$ 210.0
Payables due to affiliates	159.3		159.3		155.2
Receivables due from affiliates	134.2		134.2		135.8
Purchases from (and payments to) affiliates	30.1	$ 34.4	83.6	$ 118.5	
Sales to affiliates	746.9	747.4	2,144.4	2,217.8	
Affiliated Entity					
Schedule of Equity Method Investments [Line Items]					
Equity method affiliates	210.3		210.3		203.2
Non-equity method affiliates	7.2		7.2		6.8
Payables due to affiliates	24.8		24.8		25.9
Receivables due from affiliates	2.7		2.7		$ 1.6
Sales to affiliates	$ 3.5	$ 2.5	$ 10.7	$ 8.5	

XML 66 R54.htm IDEA: XBRL DOCUMENT

Debt - Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Jul. 05, 2012
Debt Instrument [Line Items]			
Long-term debt, gross	$ 203.0	$ 207.0	
Less: unamortized debt issuance costs	0.4	0.2	
Total debt	202.6	206.8	
Less: current portion of long-term debt	0.0	134.0	
Long-term debt, net	$ 202.6	72.8	
Term Loan, due July 2, 2027 (6.67%)			
Debt Instrument [Line Items]			
Debt instrument, stated interest rate	6.67%		
Long-term debt, gross	$ 130.0	0.0	
Term Loan, due December 31, 2024 (6.32%)			
Debt Instrument [Line Items]			
Debt instrument, stated interest rate	6.32%		
Long-term debt, gross	$ 0.0	81.0	
Series B notes, due July 5, 2024 (3.82%)			
Debt Instrument [Line Items]			
Debt instrument, stated interest rate	3.82%		3.82%
Long-term debt, gross	$ 0.0	53.0	
Series C notes, due July 5, 2027 (4.02%)			
Debt Instrument [Line Items]			
Debt instrument, stated interest rate	4.02%		
Long-term debt, gross	$ 73.0	$ 73.0	

XML 67 R55.htm IDEA: XBRL DOCUMENT

Debt - Narrative (Details) - USD ($)	9 Months Ended				
	Jul. 02, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jul. 05, 2012
Debt Instrument [Line Items]					
Repayments of long-term debt		$ 169,000,000.0	$ 1,700,000		
Long-term debt, gross		203,000,000.0		$ 207,000,000.0	
Term Loans					
Debt Instrument [Line Items]					
Long-term debt, gross		$ 130,000,000.0			
Term Loan, due July 2, 2027 (6.67%)					
Debt Instrument [Line Items]					
Principal amount	$ 130,000,000				
Debt instrument, stated interest rate		6.67%			
Long-term debt, gross		$ 130,000,000.0		0	
Term Loan, due December 31, 2024 (6.32%)					
Debt Instrument [Line Items]					
Repayments of long-term debt	79,900,000				
Debt instrument, stated interest rate		6.32%			
Long-term debt, gross		$ 0		81,000,000.0	
Series B notes, due July 5, 2024 (3.82%)					
Debt Instrument [Line Items]					
Repayments of long-term debt	$ 53,000,000				
Debt instrument, stated interest rate		3.82%			3.82%
Long-term debt, gross		$ 0		$ 53,000,000.0	
Revolving credit facility, Due 2024 | Revolving Credit Facility					
Debt Instrument [Line Items]					
Line of credit facility, current borrowing capacity		500,000,000			
Line of credit facility, unused commitment level		497,600,000			
Revolving credit facility, Due 2024 | Letter of Credit					
Debt Instrument [Line Items]					
Long-term line of credit		$ 2,400,000			

XML 68 R56.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)	9 Months Ended	83 Months Ended								
	Sep. 30, 2024 SGD ($)	Sep. 30, 2024 SGD ($)	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2024	Jul. 31, 2024	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2019

€ in Millions, ¥ in Millions, $ in Millions, $ in Millions	$ / bbl bbl	$ / bbl bbl	USD ($) $ / bbl	EUR (€) $ / bbl	JPY (¥) $ / bbl	USD ($)	SGD ($)	USD ($)	EUR (€)	USD ($)
Currency Forwards | EUR | Intercompany Demand Notes										
Derivative [Line Items]										
Derivative, notional amount | €				€ 143.9				€ 278.6	
Currency Forwards | SGD | Intercompany Loans										
Derivative [Line Items]										
Derivative, notional amount	$ 421.9	$ 421.9					$ 601.5			
Currency Forwards | SGD | Intercompany Demand Notes										
Derivative [Line Items]										
Derivative, notional amount							$ 94.0			
Currency Forwards | USD | Intercompany Loans										
Derivative [Line Items]										
Derivative, notional amount			$ 13.4					$ 13.4		
Currency Forwards | USD | Intercompany Demand Notes										
Derivative [Line Items]										
Derivative, notional amount			47.1							
Foreign Exchange Forward										
Derivative [Line Items]										
Derivative contract term	18 months									
Foreign Exchange Forward | Purchase | Designated as Hedging Instrument | EUR										
Derivative [Line Items]										
Derivative, notional amount | €				24.1						
Foreign Exchange Forward | Purchase | Designated as Hedging Instrument | Yen										
Derivative [Line Items]										
Derivative, notional amount | ¥					¥ 6,102.9					
Foreign Exchange Forward | Purchase | Designated as Hedging Instrument | SGD										
Derivative [Line Items]										
Derivative, notional amount	$ 43.4	43.4								
Foreign Exchange Forward | Sell | Designated as Hedging Instrument | EUR										
Derivative [Line Items]										
Derivative, notional amount	0.0	0.0	26.5	0.0						
Foreign Exchange Forward | Sell | Designated as Hedging Instrument | Yen										
Derivative [Line Items]										
Derivative, notional amount	1.7	1.7	28.7	11.4						
Foreign Exchange Forward | Sell | Designated as Hedging Instrument | SGD										
Derivative [Line Items]										
Derivative, notional amount	$ 0.0	$ 0.0	19.0	€ 12.5						
Cross Currency Interest Rate Contract | Net Investment Hedges: | Yen										
Derivative [Line Items]										
Derivative, notional amount | ¥					¥ 17,000.0					
Cross Currency Interest Rate Contract | Net Investment Hedges: | USD										
Derivative [Line Items]										
Derivative, notional amount			$ 130.0			$ 130.0				$ 90.0
Options Held										
Derivative [Line Items]										
Derivative, nonmonetary notional amount, volume | bbl	187,861	1,106,908								
Derivative, average price risk option strike price | $ / bbl	85.66	85.66	85.66	85.66	85.66					

XML 69 R57.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]				
Derivative gain (loss) recognized in income, fair value hedges	$ (1.8)	$ (2.0)	$ (5.3)	$ (1.7)
Cash flow hedges, amount of gain (loss) recognized in OCI	5.5	(2.0)	(1.0)	(6.5)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.5	1.2	3.0	2.8
Net investment hedges, amount of gain (loss) recognized in OCI	(8.1)	2.9	0.3	10.1
Net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.0	0.0
Forward treasury locks				
Derivative Instruments, Gain (Loss) [Line Items]				
Cash flow hedges, amount of gain (loss) recognized in OCI	0.0	0.0	0.0	0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.1	0.1
Cross-currency swap				
Derivative Instruments, Gain (Loss) [Line Items]				
Net investment hedges, amount of gain (loss) recognized in OCI	(8.1)	2.9	0.3	10.1
Net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.0	0.0	0.0
Fair Value Hedges:				
Derivative Instruments, Gain (Loss) [Line Items]				
Derivative, forward point components, (loss) gain, recognized in earnings	(1.8)	0.2	(5.3)	1.6
Fair value hedges, amount of gain (loss) recognized in OCI	0.5	(0.3)	0.7	(2.3)
Fair value hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	2.3	(0.7)	4.2
Fair Value Hedges: | Foreign currency hedge contracts				
Derivative Instruments, Gain (Loss) [Line Items]				
Fair value hedges, amount of gain (loss) recognized in OCI	0.5	(0.3)	0.7	(2.3)
Fair value hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	2.3	(0.7)	4.2
Other expense (income)				
Derivative Instruments, Gain (Loss) [Line Items]				
Derivative gain (loss) on hedged item, fair value hedges	(16.6)	(1.2)	(6.2)	8.7
Change in unrealized gain (loss) on fair value hedging instruments	16.6	0.7	6.2	(10.0)
Amount excluded from effectiveness testing, fair value hedges	(1.8)	(1.5)	(5.3)	(0.4)
Net sales				
Derivative Instruments, Gain (Loss) [Line Items]				
Gain (loss) on derivative instruments, net, pretax	0.0	0.1	(0.2)	1.2
Net sales | Foreign currency hedge contracts				
Derivative Instruments, Gain (Loss) [Line Items]				
Cash flow hedges, amount of gain (loss) recognized in OCI	0.2	0.5	0.3	(0.4)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.0	0.1	(0.2)	1.2

Cost of goods and services sold				
Derivative Instruments, Gain (Loss) [Line Items]				
Gain (loss) on derivative instruments, net, pretax	0.5	1.1	3.1	1.5
Cost of goods and services sold | Foreign currency hedge contracts				
Derivative Instruments, Gain (Loss) [Line Items]				
Cash flow hedges, amount of gain (loss) recognized in OCI	5.3	(2.5)	(1.3)	(6.1)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income	0.5	1.1	3.1	1.5
Interest expense				
Derivative Instruments, Gain (Loss) [Line Items]				
Gain (loss) on derivative instruments, net, pretax	$ 0.0	$ 0.0	$ 0.1	$ 0.1

XML 70 R58.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) - Not Designated as Hedging Instrument - USD ($) $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Derivative Instruments, Gain (Loss) [Line Items]				
Derivative instruments not designated as hedging instruments, gain (loss), net	$ (3.7)	$ 0.5	$ (3.3)	$ (0.7)
Commodity call options | Other expense (income)				
Derivative Instruments, Gain (Loss) [Line Items]				
Derivative instruments not designated as hedging instruments, gain (loss), net	(0.5)	0.5	(0.6)	(0.5)
Currency Forwards | Other expense (income)				
Derivative Instruments, Gain (Loss) [Line Items]				
Derivative instruments not designated as hedging instruments, gain (loss), net	$ (3.2)	$ 0.0	$ (2.7)	$ (0.2)

XML 71 R59.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($) $ in Millions	**Sep. 30, 2024**	**Dec. 31, 2023**
Assets:		
Deferred compensation assets	$ 11.3	$ 10.2
Foreign currency contracts	19.7	5.0
Total assets at fair value	248.3	486.5
Liabilities:		
Contingent consideration	3.7	3.6
Deferred compensation liabilities	11.4	10.4
Foreign currency contracts	9.9	2.2
Total liabilities at fair value	25.0	16.2
Money market funds		
Assets:		
Money market funds	128.5	404.4
Time deposits		
Assets:		
Money market funds	73.5	47.9
Cross-currency swap		
Assets:		
Commodity call options	15.1	18.4
Commodity call options		
Assets:		
Commodity call options	0.2	0.6
Level 1		
Assets:		
Deferred compensation assets	11.3	10.2
Foreign currency contracts	0.0	0.0
Total assets at fair value	139.8	414.6
Liabilities:		
Contingent consideration	0.0	0.0
Deferred compensation liabilities	11.4	10.4
Foreign currency contracts	0.0	0.0
Total liabilities at fair value	11.4	10.4
Level 1 | Money market funds		
Assets:		
Money market funds	128.5	404.4
Level 1 | Time deposits		
Assets:		
Money market funds	0.0	0.0
Level 1 | Cross-currency swap		
Assets:		
Commodity call options	0.0	0.0
Level 1 | Commodity call options		
Assets:		
Commodity call options	0.0	0.0
Level 2		
Assets:		
Deferred compensation assets	0.0	0.0
Foreign currency contracts	19.7	5.0
Total assets at fair value	108.5	71.9
Liabilities:		
Contingent consideration	0.0	0.0
Deferred compensation liabilities	0.0	0.0
Foreign currency contracts	9.9	2.2
Total liabilities at fair value	9.9	2.2
Level 2 | Money market funds		
Assets:		
Money market funds	0.0	0.0
Level 2 | Time deposits		
Assets:		
Money market funds	73.5	47.9
Level 2 | Cross-currency swap		
Assets:		
Commodity call options	15.1	18.4
Level 2 | Commodity call options		

Assets:		
Commodity call options	0.2	0.6
Level 3		
Assets:		
Deferred compensation assets	0.0	0.0
Foreign currency contracts	0.0	0.0
Total assets at fair value	0.0	0.0
Liabilities:		
Contingent consideration	3.7	3.6
Deferred compensation liabilities	0.0	0.0
Foreign currency contracts	0.0	0.0
Total liabilities at fair value	3.7	3.6
Level 3 | Money market funds		
Assets:		
Money market funds	0.0	0.0
Level 3 | Time deposits		
Assets:		
Money market funds	0.0	0.0
Level 3 | Cross-currency swap		
Assets:		
Commodity call options	0.0	0.0
Level 3 | Commodity call options		
Assets:		
Commodity call options	$ 0.0	$ 0.0

XML 72 R60.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Other Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]		
Estimated fair value	$ 201.6	$ 204.4
Carrying amount	$ 202.6	$ 206.8

XML 73 R61.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]								
Beginning balance	$ 2,576.8	$ 2,680.6	$ 2,881.0	$ 2,746.7	$ 2,776.2	$ 2,684.9	$ 2,881.0	$ 2,684.9
Other comprehensive income (loss) before reclassifications							5.8	(45.9)
Amounts reclassified out from accumulated other comprehensive income (loss)							1.7	5.9
Other comprehensive income (loss), net of tax	80.6	(24.6)	(48.5)	(39.5)	(15.1)	14.6	7.5	(40.0)
Ending balance	2,752.1	2,576.8	2,680.6	2,868.2	2,746.7	2,776.2	2,752.1	2,868.2
Total								
AOCI Attributable to Parent, Net of Tax [Roll Forward]								
Beginning balance	(216.9)	(192.3)	(143.8)	(183.5)	(168.4)	(183.0)	(143.8)	(183.0)
Other comprehensive income (loss), net of tax	80.6	(24.6)	(48.5)	(39.5)	(15.1)	14.6		
Ending balance	(136.3)	$ (216.9)	(192.3)	(223.0)	$ (183.5)	(168.4)	(136.3)	(223.0)
Derivatives								
AOCI Attributable to Parent, Net of Tax [Roll Forward]								
Beginning balance			0.0			0.2	0.0	0.2
Other comprehensive income (loss) before reclassifications							(0.3)	(8.8)
Amounts reclassified out from accumulated other comprehensive income (loss)							2.3	7.0
Other comprehensive income (loss), net of tax							2.0	(1.8)
Ending balance	2.0			(1.6)			2.0	(1.6)
Change in equity affiliate investment AOCI								
AOCI Attributable to Parent, Net of Tax [Roll Forward]								
Beginning balance			2.3			1.6	2.3	1.6
Other comprehensive income (loss) before reclassifications							0.0	(0.1)
Amounts reclassified out from accumulated other comprehensive income (loss)							0.0	0.0
Other comprehensive income (loss), net of tax							0.0	(0.1)
Ending balance	2.3			1.5			2.3	1.5
Defined benefit pension and other postretirement plans								
AOCI Attributable to Parent, Net of Tax [Roll Forward]								
Beginning balance			(10.1)			(9.4)	(10.1)	(9.4)
Other comprehensive income (loss) before reclassifications							(0.6)	(0.1)
Amounts reclassified out from accumulated other comprehensive income (loss)							(0.6)	(1.1)
Other comprehensive income (loss), net of tax							(1.2)	(1.2)
Ending balance	(11.3)			(10.6)			(11.3)	(10.6)
Foreign currency translation								
AOCI Attributable to Parent, Net of Tax [Roll Forward]								
Beginning balance			$ (136.0)			$ (175.4)	(136.0)	(175.4)
Other comprehensive income (loss) before reclassifications							6.7	(36.9)
Amounts reclassified out from accumulated other comprehensive income (loss)							0.0	0.0
Other comprehensive income (loss), net of tax							6.7	(36.9)
Ending balance	$ (129.3)			$ (212.3)			$ (129.3)	$ (212.3)

XML 74 R62.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]								
Net sales	$ 746.9			$ 747.4			$ 2,144.4	$ 2,217.8
Cost of goods and services sold	(482.2)			(459.1)			(1,419.5)	(1,366.8)
Other expense (income)	(4.4)			(5.6)			(10.8)	(22.5)
Income before income taxes and equity in net income of affiliated companies	164.5			187.0			420.6	529.8
Tax benefit (expense)	(32.4)			(29.4)			(70.7)	(87.8)

Total reclassifications for the period, net of tax	136.0	$ 111.3	$ 115.3	161.3	$ 155.1	$ 140.0	362.6	456.4
Reclassification out of Accumulated Other Comprehensive Loss								
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]								
Total reclassifications for the period, net of tax	(0.3)			(3.3)			(1.7)	(5.9)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives:								
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]								
Income before income taxes and equity in net income of affiliated companies	(0.7)			(5.1)			(3.0)	(9.9)
Tax benefit (expense)	0.2			1.6			0.7	2.9
Total reclassifications for the period, net of tax	(0.5)			(3.5)			(2.3)	(7.0)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Foreign currency contracts								
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]								
Net sales	0.0			(0.2)			0.2	(1.5)
Cost of goods and services sold	(0.7)			(1.4)			(4.1)	(2.0)
Other expense (income)	0.0			(3.4)			1.0	(6.2)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Forward treasury locks								
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]								
Interest expense	0.0			(0.1)			(0.1)	(0.2)
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans:								
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]								
Actuarial gains	0.3			0.3			0.8	1.1
Other	0.0			0.0			0.0	0.4
Income before income taxes and equity in net income of affiliated companies	0.3			0.3			0.8	1.5
Tax benefit (expense)	(0.1)			(0.1)			(0.2)	(0.4)
Total reclassifications for the period, net of tax	$ 0.2			$ 0.2			$ 0.6	$ 1.1

XML 75 R63.htm IDEA: XBRL DOCUMENT

Shareholder's Equity (Details) - USD ($) $ / shares in Units, $ in Millions	**3 Months Ended**						**9 Months Ended**	
	Sep. 30, 2024	**Jun. 30, 2024**	**Mar. 31, 2024**	**Sep. 30, 2023**	**Jun. 30, 2023**	**Mar. 31, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Beginning balance (in shares)			75,300,000				75,300,000	
Beginning balance	$ 2,576.8	$ 2,680.6	$ 2,881.0	$ 2,746.7	$ 2,776.2	$ 2,684.9	$ 2,881.0	$ 2,684.9
Beginning balance (in shares)			1,800,000				1,800,000	
Net income	136.0	111.3	$ 115.3	161.3	155.1	140.0	$ 362.6	$ 456.4
Activity related to stock-based compensation	$ 11.1	11.1	14.4	$ 27.5	18.0	11.0		
Shares purchased under share repurchase program (in shares)	170,771			77,329			1,409,786	753,399
Shares purchased under share repurchase program	$ (52.4)	(187.1)	(267.0)	$ (27.8)	(173.4)	(60.1)	$ (506.5)	$ (261.3)
Dividends declared		(14.5)	(14.6)		(14.1)	(14.2)		
Other comprehensive income (loss), net of tax	$ 80.6	(24.6)	(48.5)	(39.5)	(15.1)	14.6	$ 7.5	(40.0)
Ending balance (in shares)	75,300,000						75,300,000	
Ending balance	$ 2,752.1	$ 2,576.8	$ 2,680.6	$ 2,868.2	$ 2,746.7	$ 2,776.2	$ 2,752.1	$ 2,868.2
Ending balance (in shares)	2,800,000						2,800,000	
Dividends declared per share (in dollars per share)		$ 0.20	$ 0.20		$ 0.19	$ 0.19		
Common Stock								
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Beginning balance (in shares)	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000
Beginning balance	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8
Ending balance (in shares)	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000
Ending balance	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8
Capital in Excess of Par Value								
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Beginning balance	33.5	55.2	120.2	158.2	181.4	232.2	120.2	232.2
Activity related to stock-based compensation	(10.2)	(21.7)	(65.0)	(35.6)	(23.2)	(50.8)		
Ending balance	23.3	33.5	55.2	122.6	158.2	181.4	23.3	122.6
Treasury Stock								
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Beginning balance	$ (979.5)	$ (825.2)	$ (637.6)	$ (501.4)	$ (369.2)	$ (370.9)	$ (637.6)	$ (370.9)
Beginning balance (in shares)	2,700,000	2,300,000	1,800,000	1,400,000	1,100,000	1,200,000	1,800,000	1,200,000
Activity related to stock-based compensation	$ 21.3	$ 32.8	$ 79.4	$ 63.1	$ 41.2	$ 61.8		
Activity related to stock -based compensation (in shares)	(100,000)	(100,000)	(200,000)	(200,000)	(200,000)	(300,000)		
Shares purchased under share repurchase program (in shares)	200,000	500,000	700,000	100,000	500,000	200,000		
Shares purchased under share repurchase program	$ (52.4)	$ (187.1)	$ (267.0)	$ (27.8)	$ (173.4)	$ (60.1)		
Ending balance	$ (1,010.6)	$ (979.5)	$ (825.2)	$ (466.1)	$ (501.4)	$ (369.2)	$ (1,010.6)	$ (466.1)
Ending balance (in shares)	2,800,000	2,700,000	2,300,000	1,300,000	1,400,000	1,100,000	2,800,000	1,300,000
Retained earnings								
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Beginning balance	$ 3,720.9	$ 3,624.1	$ 3,523.4	$ 3,254.6	$ 3,113.6	$ 2,987.8	$ 3,523.4	$ 2,987.8
Net income	136.0	111.3	115.3	161.3	155.1	140.0		
Dividends declared		(14.5)	(14.6)		(14.1)	(14.2)		
Ending balance	3,856.9	3,720.9	3,624.1	3,415.9	3,254.6	3,113.6	3,856.9	3,415.9
Accumulated other comprehensive loss								
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Beginning balance	(216.9)	(192.3)	(143.8)	(183.5)	(168.4)	(183.0)	(143.8)	(183.0)
Other comprehensive income (loss), net of tax	80.6	(24.6)	(48.5)	(39.5)	(15.1)	14.6		
Ending balance	$ (136.3)	$ (216.9)	$ (192.3)	$ (223.0)	$ (183.5)	$ (168.4)	$ (136.3)	$ (223.0)

XML 76 R64.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Shares available for issuance under the 2016 Plan (in shares)	1,338,673		1,338,673	
Stock options, granted (in shares)			88,588	
Stock options, weighted average exercise price (in dollars per share)			$ 348.50	
Stock options, weighted average grant date fair value (in dollars per share)			$ 134.33	
Risk-free interest rate (in hundredths)			4.30%	
Expected life (in years)			6 years	
Stock volatility (in hundredths)			32.00%	
Dividend yield (in hundredths)			0.30%	
Stock-based compensation expense	$ 5.1	$ 5.9	$ 14.4	$ 21.9
Performance Share Unit (PSUs)				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Granted (in shares)			34,188	
Grant date fair value (in dollars per share)			$ 348.46	
Performance Share Unit (PSUs) | Minimum				

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	
Target award percentage	0.00%
Performance Share Unit (PSUs) | Maximum	
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	
Target award percentage	200.00%
Restricted Stock Units (RSUs)	
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	
Granted (in shares)	8,302
Grant date fair value (in dollars per share)	$ 342.74

XML 77 R65.htm IDEA: XBRL DOCUMENT

Other Expense (Income) - Schedule of Other Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Other Income and Expenses [Abstract]				
Foreign exchange transaction losses	$ 4.1	$ 1.8	$ 7.3	$ 3.0
Contingent consideration	1.2	0.7	3.2	1.5
Asset impairments	1.0	3.5	1.9	6.9
Restructuring and related charges	(2.5)	0.0	(2.5)	(0.8)
Loss on disposal of plant	0.0	0.0	0.0	11.6
Other items	0.6	(0.4)	0.9	0.3
Total other expense (income)	$ 4.4	$ 5.6	$ 10.8	$ 22.5

XML 78 R66.htm IDEA: XBRL DOCUMENT

Other Expense (Income) - Narrative (Details) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended	
	Dec. 31, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) facility	Sep. 30, 2023 USD ($) facility
Restructuring Cost and Reserve [Line Items]					
Restructuring and related activities, period of implementation	24 months				
Loss on disposal of plant		$ 0.0	$ 0.0	$ 0.0	$ 11.6
Number of loss on disposal manufacturing facility | facility				1	1
Minimum					
Restructuring Cost and Reserve [Line Items]					
Effect on future earnings, amount	$ 17.0				
Maximum					
Restructuring Cost and Reserve [Line Items]					
Effect on future earnings, amount	$ 19.0				

XML 79 R67.htm IDEA: XBRL DOCUMENT

Other Expense (Income) - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Reserve [Roll Forward]				
Balance, December 31, 2023			$ 3.0	
Restructuring and other charges	$ (2.5)	$ 0.0	(2.5)	$ (0.8)
Cash payments			(0.5)	
Balance, September 30, 2024	0.0		0.0	
Severance and benefits				
Restructuring Reserve [Roll Forward]				
Balance, December 31, 2023			3.0	
Restructuring and other charges			(2.5)	
Cash payments			(0.5)	
Balance, September 30, 2024	0.0		0.0	
Other charges				
Restructuring Reserve [Roll Forward]				
Balance, December 31, 2023			0.0	
Restructuring and other charges			0.0	
Cash payments			0.0	
Balance, September 30, 2024	$ 0.0		$ 0.0	

XML 80 R68.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]				
Provision for income taxes	$ 32.4	$ 29.4	$ 70.7	$ 87.8
Effective income tax rate	19.70%	15.70%	16.80%	16.60%

XML 81 R69.htm IDEA: XBRL DOCUMENT

Segment Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2024 segment
Segment Reporting [Abstract]	
Number of reportable segments	2

XML 82 R70.htm IDEA: XBRL DOCUMENT

Segment Information - Sales by Product Group (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]				
Net sales	$ 746.9	$ 747.4	$ 2,144.4	$ 2,217.8
Proprietary Products				
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]				
Net sales	601.4	602.5	1,720.6	1,803.6
Contract-Manufactured Products				
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]				
Net sales	$ 145.5	$ 144.9	$ 423.8	$ 414.2

XML 83 R71.htm IDEA: XBRL DOCUMENT

Segment Information - Segment Financial Information (Details) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) facility	Sep. 30, 2023 USD ($) facility
Segment Reporting Information [Line Items]				
Operating profit	$ 161.3	$ 177.3	$ 410.3	$ 515.1
Stock-based compensation expense			(14.4)	(21.9)
Loss on disposal of plant	0.0	0.0	0.0	(11.6)
Restructuring and other charges	2.5	0.0	2.5	0.8
Interest (income) expense and other nonoperating expense (income), net	(3.2)	(9.7)	(10.3)	(14.7)

Income before income taxes and equity in net income of affiliated companies	164.5	187.0	$ 420.6	$ 529.8
Number of loss on disposal manufacturing facility | facility			1	1
Operating Segments				
Segment Reporting Information [Line Items]				
Operating profit	180.0	202.6	$ 471.6	$ 599.8
Operating Segments | Proprietary Products				
Segment Reporting Information [Line Items]				
Operating profit	158.2	181.6	415.5	546.5
Operating Segments | Contract-Manufactured Products				
Segment Reporting Information [Line Items]				
Operating profit	21.8	21.0	56.1	53.3
Corporate and Unallocated				
Segment Reporting Information [Line Items]				
Operating profit	(18.7)	(25.3)	(61.3)	(84.7)
Stock-based compensation expense	(5.1)	(5.9)	(14.4)	(21.9)
Corporate general costs	(14.3)	(15.9)	(47.2)	(47.2)
Loss on disposal of plant	0.0	0.0	0.0	(11.6)
Cost investment impairment	0.0	(3.3)	0.0	(3.3)
Restructuring and other charges	0.9	0.0	0.9	(0.1)
Amortization of acquisition-related intangible assets	(0.2)	$ (0.2)	(0.6)	(0.6)
Corporate and Unallocated | 2022 Restructuring Plan | Other Income (Expense)				
Segment Reporting Information [Line Items]				
Restructuring and other charges	2.5		2.5	0.8
Corporate and Unallocated | 2022 Restructuring Plan | Selling, General and Administrative Expenses				
Segment Reporting Information [Line Items]				
Restructuring and other charges	$ (1.6)		$ (1.6)	
Corporate and Unallocated | 2022 Restructuring Plan | Cost of goods and services sold				
Segment Reporting Information [Line Items]				
Restructuring and other charges				$ (0.9)

**EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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l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}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

O5Y40>GLI"NUF2 M>U]=#08NS:E$US<5:5[9&%NBYZ'=#EQE";-@5!:#\7#X?E"BTLE\&N:6=CXU MM2^4IJ4%5Y*DI M7/B%7=P[88]I[;PI&V,>ETK'?
WQJ>#@PN!R^8C!N#,8A[N@H1/D!/Q2NI@//T+)AD##8P-Q%F M_ K,3_#9:)\[^*@SRKZW'W!(75SC-JZ;\4G %55]F Q[.!Z.+T[@3;IS3@+> MY!6\19J:6GNEM[TA4H5.?
ASL7;>LB[^.G;@B'=Q'$]JY#R\ON^O^N%S=/T#;$F3Q:+8BS%5 ?\Y ML97ED%15O+"&7Q:+90?!?8R=>[*J/#A6#%U)-Y@M:*TMLJ+4&3NXU.:H]X2 MW)JR5"XTI=;+ZN-
MAV]I6Q>!4MI1ZYH.#.BJ1D^EN@SB0QS-%Q"53*L^' M[L,GT1>!]926\%BY)6J^,<1'3Y8:4G*.+ZL@&X0-*OOL0(PEL&??E7%**.PQEN-[(9097Z V"]('M*;H<-
GP31E&)=2,K9D@RY*,K66 S9;) HI2I,/%?2[2%\KDE"AXUMP@H8Z\F MZ=6LJAUO$E#^GP,Y1\"""Z-U#/OM^2- M$/*%G(=ECDQZ2K57*=NLN(,J)KO'V4[[P4ZQ?8D/AHMP?
VYVFGVX>NU4IM!* M59[%+):XCX%NR(K4V >73U.9X]HIS:"4=IZ+N$*][Y:;Z1V]G*E=,R.*;.9, M;;MRQZKB^A;-,$F\ (M8#G>Q%S);\GB T?#\MRX;TA$:\C^PP"+WH\#!],X.
MHI09F+R :%U'-16562KWG>+DHI"%YZ1"MK%4HYXP3(TT@P6K@VU$W-I2/Q M]H_=:H.#=T=)=AM>5PY"0XY/D&ZV>\ MXKOE>7M_7U&NU4<>4$;-AWV?WR7
M@(TOJCCPI@JOF+7Q_"8*GSEKDZQLX'5I6.U ''3/VOG?4$L#!!0 (+&" M6%D#@0,19P0 +* 8 >&PO=V]R:W-H965T&ULM59M M;]LV$/XK!PW8"V#8CN.T768;L-,%S8<60;,N&
(9]H,63Q(4B59**DW^_AY3L MJ("3;L/VQ1;)N^?NGGLA%SOK[GS%'.BAUL8OLRJ$YGPR\7G%M?!CV[#!26%= M+0*6KISXQK&02:G6D]ET^FI2"V6RU2+M7;O5PK9!*\/7CGQ;U\
(];EC;W3([MR?8;'U59A;@Q62T:4?(-AT_-M<-J_\ MX)MB)%MK[^+B2BZS:72(->><+]V^5#-4R>Y.1Y$*T.GRTNW?IY1WOI@ZUX9'M3* M=/_BH>=AH/!F^HS"K%>8);\[0\G+MR*
(U<+9';DH#;3XD4)-VG!.F9B4F^!P MJJ 75A_ VSK-[>GN,B7=!&&D<-(O)@'H46:2]TB;#FGV#-*/|-Z:4'GZV4B6 M7^I/X-7!M=G>M@CU-.&=/H-W+SZU@1F+"D
MBTJ8DDF9(2'73IE<-9KI]_76!X^\Q0LJ:IQ ML()T%@7Q!8I\5QB@22RN?;^M;%T\^M>C" JDUTT'MD"A! ;^<];'!$NE_%,T^.:B
MX#2%"-.4"NB!F4<6SM.62V5,I$<4@*6WG'=DGIRE!CA-'NQ--OBU\NM:\^@$ MTX6M&V$>25I$8FP75AY2BD1,8)R/H+@2<$U@O$0K< V4H]XI'D(RM\9;K6*_
M2#B_SZP/V$@1)Q<'O(YC51Q<&E0%TOV59/=4(^#PY1")$!Y)\U2AD80!6E#A\3M/N,M<$NU\=:Q3,!'>*0_3(F6(%())F_O9 M &L^4N:[$+4A9CL7Q("UQHBO56A4AU/
Y^3OF,PERNMDN6. @'"9"]DOF3\ ML(Q07$)*%<5!< Z0TCK55V&)NS>&*#D(I?O:548]T-%"_& .5:&0&41]'QFA M& #]\9;P6!EM42& @GM[9,;0S[!%FRD^@*U"
CGC5"R(SIZ+$]X4W85$8EA M"8+UJ"N*4?(7^[@:3;^>=EH'#MP1_=[%G/YLD0^I\BY7+P7P7S89VN46N8FI M;9U#=C X^%[H5J3!E9+;MT2!U= PV+*M^UMM,:(M,K8#?
_;_$:,$9;=0JP M(N+%#%9L@%@>N#0^=@E-!H^*FEV9GDZ>TACOWA>'W^% MO"?-!52GX]=G&?HM/9>Z1;!->)U L;<'#)WU6>&&RBP(XCS[O%|' X&ULK5=M;!LV$/XKA-
MU">#X/:]- CAINPY8.J/9V@_#/M#266(C MB2I)QW%__9XC)=F)'7= ^\$T1=X]?.YX=R3/%]KZ4\ZPYZO:-N+E71NCSW8Q-S>:[G+E,% M38RP\SR79GE%F5YN"C2E+'
]W+\U(F=$ON[W)B\-5M4&*54V&5+H2A MV45KW#^[&K&\%_BD:&'7^H(MF6I]QQ^_QQ>M'A.BC"+'"I)_]W1-6<9 H/&U MPFPU2[+B>K]&?^=MARU3:>E:9Y]5[-
+UDE+Q#23\Q]U(OW5-ESR'B1SJQO MQ2+(CHY;(II;I_-&0QR581_^5#Y84WAI/>,PJ!2&'C>82'^HUT\O+6PQZ@!$,O&%CV=#C#7=;)F9&Y^(: M7_TB -YUJ;CV?
B4C_AE/K1__=YL# OYH.SYGRYDM9407+:2#)7-/KN![%)M:7.ACOC,O"MXH8F9UTF"):QVKF8H"V[U7+TX&@]IK\>VU[_5?[NXCWE%'O-,9JA%K MLHDP#S"-
%OPBV>RU@)%5*I)IL^65PM)KEV1\;61>>IJIQ*-8L;=A\SY;4?G4 M@[=1/QP9I#7Y<0P65H9R51JHM(4$4?!Z9IZ=OXO#QGIA>R.=%.I;P*R=OT@) M#@-
;"9X+#A&G['=,G"X#I1D94SNS1(PIWl?-V)9C:BL78D8&'NI-2&A[H2 M((]8>5/]U-53AR'!'MM0-K%K+I7N%6!'_)5R(#;]+:<9DT3"%E6$RQ*<'U3.
M7H:E$29P'#$@LRUP,'*Z>&MQ;MWA.S%Z7IX!V1]*H/B V_EHQ&N9MP,UWI7 M2F[/-0_Y0;'A^P"25V @!$ P,N#GD9H2F MKG$'-[*8S]"9LP;VO[,WU6!@*"HSC19OD#?GN/(_;@
MD\P0KI598J_U_M.DM0_C\U(7GM^(/7+H'7M4]W9HQ]$,Q<8LT0EAVF>M?I^; M@?<(FKK B(F,IF3"7O%>#(W?A_[/W8(W\R:IV399+'^U2%9I+5F+6Y%C9S_Q
MK2+;1C$&O8(95MEOD>][^Z]S:1PGSLPLRTB,IQ"#8A;EK ^E?>HQ(2TR_4] MR/LS YY:]S!X_KCNC:V2'&5\'@G&X]|I]7LN6)KKS1CAX<(I_H>24Y4IAZ#8ZKMP M#<V(TZ
S%=;@V8)FG; XP&"TD]B+*?3V&;_7.<'"U6D!&9P- MVYGL'0X[I_N;LENXL.C)_AJ;^+$2V-0('FY7_Y'U!+ M P04 " "Q@EA9:C5I?MPS ![<"P &0 'AL+W=0320LAZM+P(WV|-
\D*W3LF:;PW9 MMJ]$V5VSTMO+T72T__!);DKG/TR6%XW8\!V[/YI;@]GD@%+(BFLK=4V&UY>C MJ^GY=>;WAPU_2M[:P9B\)RNM[_WD?7$YBCTA5IP[CR#P>N#7K)0' HVO/>;H
M\$MO.!SOT=\&W^'+2EA^K=476;CR.QU&!B0] 9)X-W]*+"\$4XL+XS>DO&[@>8' MP=5@#7*R]D&YY[E"29U#. MZ(.N76GI35UP\;W]!(P.M)(]K>OD1< [;B)*XS$E<9*]@)
<>W$P#7OH,WAMA M:EEOI).3l-?5RCJ#K/C[F+\'7'8?QIR^0 MS0YDLY?0?S@F+Z(*A%]2Z]!:0*/Z1#D8?G^!/:)K.H]B_Y],HQ3N=)]$<[VFVPC"BC+7$LH7N.*!#;H1P:[*9[WC:&?
6B;KP BV2Z)06&4 6:33UHXQNO$-H+\3K M-?]-%X2_MM+M2&R%*>PXM(Z"=*>=0_^TK=D1ZCN_IXJA3T$Q^$5!,8X6>$^_ MY]23$18MU#,),GK]022CQ:RC=.I',
[II30BG_UT0M.KDXR ?"LQQM8+H^RHC MN!=D&WL;A&WK'S$P>Y'#!B2$SPA18V5Z6.F(C9$UMN'09]5N3&NCJ\[#5YWW MT!2'B>URIE&BME3K$"+5%H/,PK;6'3+KI62A%>
<";>7MI"%9(>$=;05$]ITL M^]A$/L6?\VCHQ!HKS8_]NR*)T%&GXN-0E@CU1V]Y95]<@4]ZT[5&GGAW M;R1]SVD#%YK&Z A?
E4TZO#TGN8Q1$>OY'A>8N6B6R$;Y!ET:.+DB%!OUE@ MG[E'8-$4P*PQ\@%8:O>]YHUV4OBXHTDC9\(A;CN2=1N4A@.]*W!R-61=!/%#
MZLM0*7YK"V)#+)RT2N$$!XM0F((>A)&,FL7NM0@Q&/?)Z3%ZINB+A1R06?F+ M3=\UNZN-_*?OF@4[(550VD]?(Z]%O?O%#IA^%X9>1U=*N]?^!SOBL0YXU^DS M5&:ZB,>+!?
K68IPF9S0=9_'9>'$Z1]=(Q^G9&7W63BAPLJ&-#:G^M^>>T"Q! MXSFA9(&N@UD\1^/!-+38]IYK(:AY5[)#&EVBH0W#)LU"/XZCQ%NGL[,H"5^R
M>01>QT[4R>#&4['9A'N=!>FV=MWEY_#U<'6\ZFY,3]N[>^<'8382V:!X#5/T MWMF(3'>7ZR9.-^'^M-(.M[$P+"]9>,W8'VMM=M/_ \.%^KEOU!+ P04 M" "Q@EA9E@QXA:," "\!0
&0 'AL+W=O"A0MMAZ&'12;CH7*DB:/TLRD1+;Q40I]%5UI;SX+ 9"56S/BJ1DDGA=(5 ML^3J=6!JC2QO094(XC \#RK&I9?.V[UJG<[5Q@HN\5Z#V505TZ]+%*I9>)&W
MVWC@Z]*ZC2"=UVR-CVB_U_>:O&!@R7F%TG E06.Q\'CV3O)6W #XZ-V;/! M=:)2ZMDJM_G""UU!*#"SCH'1LL4K%,(141F_>TYO2.F ^_:,_:MG7I9,8-7
M2CSQW)8+;^I!C@7;"/N@FF_8]S-V?)D2IOU"T\6.8@^RC;&JZL%40<5EMI*7 M_A[V -/P'4#<_^*V[BY16^4ULRR=;]6 =M'$YHRVU19-Q7'I'N71:CKEA+/I MK=RBM$IS-//
$]';#K(>O.S \3O@"[A3TI8&OLH<\W_Q 14R5!/OJEG&1PD? ML?9A%)Y!',;)$;[1T-VHY1O]I[M7N.8F$\IL-,+/RY6QFGZ'7X)?T-PM!PB0R>G;+U8KRN[>_QJQWHC-X M8 W]|A8U9\+
"423T!^U:TSK$RG>4=5:42(#T] /83JADQLN.:DBA[52N8%H M'/H7!!K[$8&3,/)CMXX2?P*''B[84U2%>MW.#4-WLY&V$]>P.XRFRTZ1;^'= M7+MC>LVE 8$%04-_,O9 =
L,B&UL[5E;;lLV%/XKA)MV-N#(MGS)I4F)%VQ >U:-&V'8=@# M(]$V44Z23].^^OWG4)/L1W'0!>]S0^V2.F=KIN&2]2[NX4IF9GS=ZC?K%!SV9>GK1N3@KY43=*/^I?&\QZRRE
MI#I7A=.F$%:-SQN7O=.K(=$SP6>MYFYE+$B36V.^T.37]+S1)4 J4XDG"1*/ M.W6MLHP$ <;72F9CN20QKHYKZ:]9=^AR*YVZ-MGO.O73\\9Q0Z1]+&>9_V#F
MOZA*'P:8F,SQOY@'VAZ(DYGS)]^8@2#717C*^\H.*PS'W2<8XHHA9MQA(4;Y M2GIY<6;-7%BBAC0:L*K,#7"Z(*?<>(NO&GS^XHV"2NZLXR&+WG22BN\]\,5/
M\)V(MZ;P4R=^+E*5KO-W@&$))*Z!7,4[!=ZH,A+];EO$W7BP0UY_J5B?Y2\5*Y4@^9%9_1XWA'X;\;BBE ON*XQ'+P1$+;/@\>!- MLKUG5&&OH;^ID*!K0LC2LY!U=;E(*312KE FTRES1^CY&?-
PCW44,@'(;N4K MA%7+.MUXMQDI5Y68&]YJ76?P(2I!$MS,P0/75IYMBP(T[ZC&0<>3)9D78]EAKOE6: WAP*^_#.C5[9HI)Y?\U 7$4BYM9669T2"EU&IK,TG4["^:C:#]=R<-+;6J.RP-
=# K(#_4-0X- M@OS(<',X^1A%8*&D#7WI!%!YUH885RK>BV>+Z$EDWXMALSP 5457C/ZD:KR MGY@NU2ZA@.6^^+3-4 'SUEP/QH.G_^@K1XONL5(@^@D?
OY#!GHK_C,,N4LU$K_1_AYF1]2O0AIP!,3NFJM##;$B-![N1L2?!1?%[T>]?L= M?F^P93D5.B]GY)Q@D65';D((=I--M/+66I]<+[F];LPH^YV"\X^@Q7!X]AQ_R
MZ+&3;W_TV!\]]D>/_=%C?_38'SWV1X_]T6-_]-@?/?9'C__YT:.S$#>F$ M;]B<8/>':ZCEV^4EWF6XNWH@#S> ;Z6=Z()<-P9K-SK':<2&6[4P\;;DFZQ; MX[!Y>%426S7B #?
Q\;X>D(++*\V+_X&4$L#!!0 (+&"6%FK3I;;"00 M !,* 9 >&PO=V]R:W-H965TM MV%H@D^37I)EM($DSK -2!$G:?ACV@99.%E>*5$G*KO?K>T?);VD2>/LBBKR[MY]Z/G*R, _>)*1 _?
*]7=-"]JK\'3Q&4E5L+%ID9-E,+82GC:VD7B:HLB#T*5 M2OII.DXJ(74TFX2S6SN;F,8KJ?'6@FNJ2MCU)2]SFD:|:'-P)Q>EYX-D-JG% M N_1?
ZQO+>V2+4HN*]1.&@T6BVETT3N_'#)_8/@D<>7V_H$]F1OSA3?O\VF4 MLD&H,/,(&A9XA4JQ4!DQM<.,]JJ9,'],PWZ[\%W\F4N'%X9]5GFOIQ&9Q'D M6(A&^3NS^@,[?
T:,EQGEPA=6+>]H'$'6.&^J3I@LJ*1N5_&MB\.>P%GZC$"_ M$^O'NUM%P<[@R M52VT1#=)/"$S/(IU M#/(T!/II?_@"WF#KYB#@#9[!N_[:2+^&&_2ER>&]7]+S5%K>@=
Y_&FD!O") M]HU%!W]=S)VW5"]_/Q6)5M'P:47<0^>N%AE.(VH2AW;]7$SEGWKC]+<7W!AN MW1B^A'YTMEY$>=K&IZ#AH40HC*+.E7H'7LP5=NTK_R6R(]D8+"PN2 XR8>V:
M^41E&@ZM*< T%N1>M"7UX4Y1ME7D2^%!6(++,A8F(@T<:*B<;%"#;0*K-H&< MM/\,K8T_#OXP_6ACQL>!Z^@WTOC :_I(.[#!Z-_Q>>83XEA') !@_%"'14AAC^-
M1YV:%#XCE&))0>'129S>T/C-C,TIA(\5[^&?A)BN2IF54 AI.^]7PH70\Y4A MU9I&ID=+DXR+Z00H-YEQ_@04.K*03)*6T8B2_T/CK\N4:^:.%!.!S)PK-I1B
M;65&T2Z%7]"+V6X*@.>$.CSPG"%VV&0C:EQ20C-ILZ9R7N@,.3ZYS#A_H62X M+'Y,)) N(U=B';R;8X@1@:)E\5&=T[5)3L@48J[IPIIJ/Y>4L6"&H4+5+B1- M.Z-D'C(X%XH-AS#]W?
^LVENQ9N-V9AR4W9 *B991_!;N"$\N=[R/;26V^)2^ MO7A\C/?MD%G_XG880$-7.Q&N:W+GH;2(!Q<+?*!)=GCRO&-[+C:6:L21XF#S M:XYT+=9M KUY<^C%((UIO SC(2UG
W*'G.J=48/<"W;^<9 &;>N$+_4/QX"9 MGQKWR=Y%7:%=A.>(@S"3VCM[>[I\\5RT%_V.O7TNW0B[D-I1WQ0D2FI'$=CV M"=)NO*G#M3\WGAX1X;>D%D3+#$OOC/&;2O8O@-
GWP%02P,$% @ L8)8 M6&ULC5?; M+PW*J4R@]/CN';M3H]M';0R=.V$K\M2NOMSTG9],I@, M-@M?U*H(O# Z/:[DBFXH_%%=.[R-.BVY*LEX98UPM#P9G$T.SV8'_\#"!M
6GTNS$4O;R409X>.[L6CJ6AC1]BI]$-YY3AHMP$ MAZ*N'!Z28MP/ K0Q.^CK$6=-ZCT&=2!^&1-*+QX;W+*'^)'\S(]VX<9Z^ MJ/"&D1,QT.1CM/9" JF75C3J&_Z0ECB4OE,6U\
[$G^?+7QPH, _3P7;Z)H] MK8O;XM!7,J.3 7COR=W1X/3U]\G>^.@%3V>=I[.7M#];@)^CQ&U!8FDU^DJ9 ME0ARH:EM+O4O>6%K)I0UJW>!7 FF
F$76JTDMX,?"H.6MTM1&UE:%P#)&'R'E M?2U-1B*S/G@A30XB.D1C1Q+7A\).+-#B^72FN. MX:T ;P*5"W*1/)>4M2^3H;CE]#|::88BKTG\5NM[D4:"S<6;O61Q_LM;L2,F
MTW$ROQ_7K_;327KT&/5 (W.3H=,4T U@?P+\#3GD1)P+8Y&'GL'=#6J:[/=1 MN],MZN(9%-R<)6-&S5DZ_]3CYG>.WX_D_>%/RS=.9OA+Q:T-4C<2T)WLX7|8B\> MF ?+(EUE-
Q/NHQU.)/%'8P4?/():E22/<'P"XBGF3+;_-<@A_N? MY-@4Z\DJSO^2@ZY(740*_?;CQ.@2%.=;S%+/4;F"P15_>=)0'!0;0VTEVJZ) M+3D_\B+.ENT,NB'#_GSFH?+C),+Q@%QM,L$\
(1=P>HL <5T[](&G7A[R2(MF MA&]535)T3W@T@+>=O<"<; ;E3&+OC/RXDTK'8=X8Y_UI9W?#R[9*0^XO7&ULU5IM;QLW$OXKA&H4%]#(6DF67Y(8<.RX M==$DAMVT*
[W@=ZE))Y7RRW)M:S[I??,<%\D6;(3)\6A0&)I=SG#>7UFAMHW M;>MJ;>Y\=[>RZ>]IDPT2S= MZ_=ZH[V9U%GKY W?
N[(G;TSA4YVI*RM<,9M)NWBG4C-_VXI:U8UK/9EZNK%W M\B:7$W6C_.?\RN)JK^:2Z)G*G#:9L&K\MG4:';\;TGI>\+M6<[?T79 FM\;< MT<5E\K;5(X%4JF)/"'0^[M692E-
B!#'^*GFVZBV)5@[PN*X<-[,2F)(,--9^)0/ MI1V6" Y[6PCZ)4&?Y0X;L93GTLN3-[;A:75X$9?6%6FAG Z(Z?<>(NG&G3^ MY%Q9?2_),N)"9S*+M4S%9>:\+6!Z[]LL>>Q": ;?BDN.
[P+& A>.1^& R/W7B M?9:H9)5^+]5(O8K$=_UGV1XH_*N&/0ZHM_K#Y @-ZA5'C"_P?,J+RDJ9):(MGU4RT=E$G%*L:*^5$^?:O:EQA57B7Z>W6(XX^OZ]:)S_^$(UZKY]0:5BK-
'R*^XN\^&T3&*5$XX8VEU8;?+7:W;D.$"">"NG$."UB7X /'3F%0SC1!@HK`'> M(*,RY("U*HL78!A/9391808[2V6QF,Y-HOQ"YU;%R7?&;09YD !;A MIS X+NP=0*X48:X$9-
4@B66:@CMM3T(8Y'2M^KA673>J-_*OR"S<7.9X;/)@ M !*P4J*6/49J4 0Y>E1*X.BNT\Z#.;+?3SL5K<@,\<+V@7P.K'A/"L!Z%S%%ZE/<^3IL2-S*@G1[.5H?.38$)>E*DS_Q!W)NB/H
C,@K7SJ08HS"$VN*BX8)%\ MC7P>G0QEJS7%9(KF*%B5R,GQVT,BY+8W'F9_A 9?Y "2Z'UAC=AMO?|\W6J+ M:#*A8CX'A03>]IVP-@N\DR^=KT3\X[(Y61* 8.1IV>TU 7.)!
D3'!40,DU;30C MZ];H8,,DX.^=AQV7@_FQ.4C\&O()ZNB.4Q$KZ|&]BQS9P_LT.WYQ;4@#VK-]CZN*[>>;\O!NY%'V]1"QU1\A^PF%HO[K^O-/6'C4B7I]
MA&/_L'L@H@B($.$+T0X)']{CA$347R)&6-2!V>]%1VR"E;"0ZTE+A9D=O7-4 MQU>G3MBU$)&E@TNG92A'2W4/%CB7^FYAT%]0!&S8B-PAX72KT4HB.C$Y%)8: M$ZITF_(*7KP%
(!!2J@>"HT*C#'(L_%*@-0D <;ETM4GG# /05KVCP7=4_&FH MVEPD-HJFG: .>/|U= OWY9HL$O2-D#0YD E%DP#G3E7:"4;%$R"75B(@Z[X M3/W/MCW937,GO)<%F)#<5
6J7Z[^W$(% Y6P M18TE;SB'*EO;S2?PDHH7.$TX<%Y4O@!*JIQM4BU8AYJT*3"/I:;1[;4ABZ% M2%8*'*9E18:D+DU]ZH*).KRO@#'*%W.RAVF%.HTERMF+KCI+F-QK8HTQ@#?
M:3F><:M+*#35U'&3C,2V5%X'G4(?4(5?P\9Q3SK)|'^#L!@BS Q=YED]05S1 M!!'ZRP_$M\R(W!K,%LI+2T.&20IB1K/9 *!K9D)MT"[4%['4$_2[*ZL6[43 MNF-
LRXM)KEQY:U)5S,B\.N-^VAK,+Z%EK\&:UL[D?PP#22E/LX6XUQ)NRR:O M*#TPGN1YNE(%'98169"$'A#@QZDL'"#I _L@*N*RUHI$!V_3"*/"]XI0(Z,8\(*(O(8Z +B M8*R+6?
%%33FCX8!,,46!IBP:CQ6?ZD#,OPIM%1-*0JM8\1&X8%, .1'Q6E6, M@ZH+6X*P&E0K@R=U.A83=8TZ58[C M]AE432A0N ML[CCI8:A&
MMJW8W5AP>=PU&T66T.\U4K$_$'"6*Z&G7(61*[<<.5O))D_9|V6CNO% !W9HCBZNC-.^:C:OE2O20/NL.;&X2A5I MQ#A'8GZ$Y44$DUS06/$[P\D'+"E"G#D1ND>*Q]7Q-
36QK/=J9A)7N65IV%X> ML>6VJ9#8/&K&U[/-R]M4E6>K@#;'2UM0%?0/+;U"]UWNB)6FENW-HUGS;;)C:V]B6MD5SD!9)
M57QJZ.1S.]1WQA8(>]BFO_OXN]\=X&^O.]S*^3>&OYV2#)]|$F.G).7[!VVJ M8W7%)6LK::G0N;+S0%]"25VMJ\?&]B5CO5RD]4G4%50CC=U+)1PA!R2P.05 M'6C2>3WJ/<_A
S*3MT1K(=ZR*=0$F.E75KM,T(/?%B@$*/KJ4U=&DS('V M,IX&42IKKW8K%6T'X*A>>?D00.A)<7EJYVQA\<@P8; 58:C= #DTC.S JZO' M!'!K,T:@\\U#"*6+('$(B_^'P(,@<
^'YL'K$U)PR;!)X#3U= Y_?B)Z=IDJ' M]G1MFFK -33BI+]54_JMZ[ZV8W5^]^GLLCZ_(UZ-18DKA;-\^#+0!:<-B+M+ M!&U!!+0>C8+38UT!Q6D<%[.B-(%$SS/+&A0W*/LMW#8
^H9;+T3LB_5#D=!W-#M!TGS"K%[".K.F_8$7U$_3_ :3I&47"!9TY?94L_9IMPZ[7C<1'^-Q) M"M9GV5"Z!I'Y<0H O&9<>SRB:'SKG "9._^I><>(D";$DK.2NG#T.82L\9U[
M=''S_GE9#<*5@2]I[>[E&4AJ(-ZR$I<-NE0&>9LPR$!R ^[49N-><1BC>K; M<\7I&?)_?N(\;GL>W_D[T^8@^'#B4_!Z5_!TQA)>?39IMA"],F4%@,RS9<;M5 M1=L7I@PZ7I1A0R
R0, 6CQG9*&DI?^;TT6[-TK.\5]^AQT>QRVAU^7+L$. M$6WU@FQYAOJZ&HXH>OD8J!P\PLG"=Q_:,(MSW/,9L&YSWOZQ\5-4\I+&R/^ MK>)1^_&W#&/-CQ7;.XC;16D
FD2^W@K'7S9%?0EX-$FV7K%6D_&Y;*I*595] MC|)E6UY|%P_0*=/CV>N;Y^"RJ"'!^9+7/WA:Q<-%1C\D(Q3# MBQ&KX_/2(2DE8
B9[J;W>O:6WM2;*3OA]I'H!1\X/;RT5=^M7WDI#6]Z-&PO=\R:W-H M965T@#+=$V&XE42&]J_ON>(2595F5GT[S8HC0N9#7&VT^V;40CCWGF;(W M@[5SQ>5H9).UR+F-
="$4OBRUR;G#T*Q&MC"'IWY2GHWB\7@^RKE4@]MK_^Z# MN;W6I<[.]%YG>W PF@_K%KW*U=O1B='M=\)7X*-SOQ0>#T:C1 MDLI<*"NU8D8L;P9WD\O[&]
M^5%4_IR2OD1GUO^R39"=S@8L*:W3>349%N12A7_^7.'0FG ^/C AKB;$WNZP MD+?RD3M^>VWTAAF2AC9ZV*[ZV3!.*MJ4C\[@]\0\=_N62\/^X%DIV'O!;6D$ M$'?
V>2N2G$1&2:7H/BB*#RBZ8.^U=S4#GK5TD!9CZ^.&#QK#)X=T_XU6_.%#'__LF_EY:HC'DIXY:Y MM6"%D8G $W>(JS)+V4(@"!.!&$]9TPR!E3&.L+(6]4,;5G#I/P!,99?",,XR
MR1:M4F%R;9A:1[":2'<1@A5ZRBX<9*6(L=U6#W?@<%2D3$?L/;I4.G[44AIMDO65)!C/D4HH DU1%"8WPEP2Y7[])9*WDYQ(BI0UH54NU_M54J%|UH)II?
09(1@F7@2F;UDWW]W'L?S*_83C=F$7;+?%4__03* LL^EIC^/ MH_7^^[Q6^6D]6#*%2S(!K!XRV\8,AD>=%6*L\"[XH>$3@0U0]Q?R1.#P0"^(MYWR1B2/[,F1">DVI!&<[SFJHO.
M/@XO45GK:EQ5VE7K=!&;^CUI05'3@*:BK%#-\= 846@0#V0B2]R6U$S.KK#\ MQH=.F1=$&=NEGB.MEOFLHMP,Y>!IVW @2O1'W+HVNZC0$T;?2&-*'PB7!K'N>
M<86PANP]O2'N':Y3RDW@'8@7]I>-H@1:3^?L'AV'K"87D3GI#F\W=0_+3; M[$MH5\0FX@1,MR"X"L"E,[H,R?.G?CS:1L!>S\--%]PAJ%%%(]9^AENG MT3CL\ Q_]"T8\BT4?
$3]"0R:OQP9GP>YR!L[,6%GN#(U@2 M8+58^[F7?^GED5]S.LS+.%V[:WP#^)S M*6&*#YN.:5\V8:^6#OT"\+C5T83N@X(RZC#]FRP+H!D/\#)+;0 MKAYV.Y-
6ZIL'#TDE_\]AW#I0>$_OG3#V(?,B1\LH9.#&B(?X9'I&*(.#5@ MC>?E6ZE0,22ZN'<*1[4RU(;AW_UE::H^T^*PI&*JHU-&P4'S[I3977M.\O M\@ T(.KKOPAX[SXY.HUVW
*4BP.'+> GBSRA\D:!3B_J/QXL_$W)2+M M\GH8@I=:V@I#4%40X?>Y&LZ*=)@RR"TP"DO*)4ND2"F&KLP<61DSX M9,Z:V$%;8]_/.5Z:1>P7_[$_/O\4.0)G$Du9.!5YDG-
CO$T\UV4%@\?K>,%(MDB =KA|\??"<>98YT0&:@=X.0FP^< S4QSLEN FV0[HTE>F$.E#P&M(._CMO M4[%P?6#OEU!*1)6D+0/|? FM2Q.I"JL+*CQ;JX3/-_J7K8"OT/8YA(B8G>N
MU32350YU:=(XCT\X<3Z@^7"B]UWO9K!GUW=&-6E>IN3 K M?V&,;:)%PZU[|:YD[X+5|$[\7"A_9Z;E41D96*)J>/H['3 3+@D#@.G"W\Q MN]#.Z=P_K@5'X)(OB\UR%8-:
('FIO[V7U!+ P04 " "Q@EA9):A2#C4% M !P#@ &0 'AL+W=O"DW6Z WM!D=Q\6^T!+E64EV2BI/]^ITA)=EN+BVV#XL%
M$HF4.&=FSIRAQ:.MTE],R;F%NTK6YCPHK=V_;3YIG(UZE%Q4O#9"U:!Y<1XLX],+,:UW"WX7?&OV MQD"9K)3Z0I.K_#R(*" N>68)@>'MEE|R*0D(P_C:8@:]2S+<'W?HO[C<,9<5
M,_Q2R3|$;LOS8!Y S@O62/M9;7_E;3X3PLN4-.X*6[\VG060-<:]JC7&""I1 M^SN[:WG8,YA'3Q@DK4'BXO:.7)2OF66+,ZVVH&DUHM' I>JL,3A14U&NK<:W M
NWL8IEE3=5(9GD.'VW)-5RJ"LM;$N^W'-XI8\Y&%CW1^E'6HEYXU.0)U!-X MKVI;&GA3YSP_M!]AA'V821?F1?(LX#?7A)!&QY!$R?@9O+1/.W5XZ1-X;[XV
MPM[#G\N5L1]5\==C.7J(\>,0U"VG9L,R?AX@7X;K6QXL7KZ(I]&K9P(<|P&. MGT/_UW7Y>52X*3D42F*[BGH-EJTD!Y=A;0V@$60EJ]?<@*C]%"%4[=ZJ MML
MYT(Y%]F!"U'CG,,@6'Z\O J&,)#HK1"U$\,I#(XHDDI(B6UNAO":;W'+J-D-7+I0Z3WW%6=%(:3 Z/ 9+K"X MOUB@4-"L0'CMNPGLEQ*Q
MHAU6'"8^XEDXV1'ZL*2.QVB/S9@2IT%RTHV05QS]KZ2;_M=239"Y**1K'$Z) MQ9-P[-F<3;K1"6]/E;D5ATM4^K=$XR'[@&:*I8JQ.\C2=T^SFE'@8Q.U17 MO%,JNOI^$@=*1?
M=W$ZI?=P14?*T7KU&J4^(V$G;_VXZP&!:Q2:)8W;9??XX MO^5C#/XP&90+"-,I'E>U,O^F)1[J[J:4G!,\1L,'$O#!DW?*1P3X=VTQ"B= M#/O*L_^:6R8D/=AK*|>_CI3=Z"U^&QI//4?

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{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§X/D;4VK;I;=:,RR6S_+;D(<.,,5 M3_JV!,E/^A=V)MNU8- EA@6[4>8KC*=@&\NASSEBNWOB#5$=H7UQJ^JF$>AY M(%WU ZJUY[TY/K? HT*KAO@S8 :"(BRRG]&N[_EHX^)5$A+)UTO,5]U4+MS!^M/^!GL5+F[/ MXN'Z^PEUH%"A!2VABH_:X4"8<*4,&Z>K?XU;:(=+H5_FN(6380&\7VI,WG;# M!OI[_>Q?4$L#!!0 (+&"6%D<35X! P0 %$* 9 >&PO=V]R:W-H M965T8D36U>HV2VKQM4M%)]{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`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|1]J=C<9/CF%B?JHF#'PTB'B4C M<|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|\"!#-=,[T3S#;IZ9I:7"J;<%35M[2CAJ::;5%VR<:@I+R] MXY? N',X2#.=R0M@EA,Z[W!>ZA&:!+

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

MEA]I.[TU4 U!G3*_A(=:(;[2&MQ2'*]GWEU8(@T7@@CH]TY"]I,>]6Y?X"]@ MG.9A;-
M\'*;4IGD2YM1FDSS,X(N[X83+GE#1@P7DU5!D0^#TXFG#VLHFJ$C" M*109@11I.+:]S)\2O4" FPT]238A^+7GYAG8CJE*C]SK4H'TN3/TQ.I>/0,] M
>4C-$CYJ2 F/F/B&(<%M>,?.0UDF*97UC)Q:;3Y)R(9%!-/:6I[$S@CT.GORC$-?\U(TN239D[;<9A8[W0R"Q,WD^4A\3HEBNBHP#2H
MMJZ.:B+=M\;7FI/LH5)?^0+U8N[+_&>FMKS5('!#KJ1CTH'RI=,/C.Q&ULA51-:]LP#/TKA%<,
M+=#Y*TF39HF!IEVQ'@H4S;8>AAT4FXZ%RI(GR4F[7S_*=MP,2+.+)4KDXZ/H
MQ]E6Z6=3(%IX*84T,FO.'G0R4[457.*#!E.7)=.O"Q1J._%=0=!,JO8&I=H MOUNHNEBZ/P;AQ\87I_2!>[O=^BW3>U4RXH9O%;BB6>VF'L3#S+,62WL
MH]I^Q:Z>D<-+E3#-%[:M[R#V(*V-56473 Q*+MN5O73OL!(/_E/D*-]RD0IE:(_R\6AFKZ;_X=:CB%G!X&-'I96HJEN+< M(S$8U!OTDH\?
HHOP\Q&ZPY[N\!AZLB3M9;5 4#GL=>@0S:- AVGN]YS1.VR8 MJ#$#9L$6""13U"YQJHR%4Z<-P/$T-O4TK8JZT_[&7752O/- MO1UP]TRON30@,*?
0T!^//-#MT&@-JZI&J"ME2?;-MJ YB]HYT'VNE-T9+D$_ MN9. 4$L#!!0 (+&"6%E\[]Y9W00 ($. 9 >&PO=V]R:W-H965T M*TPS#L
M@98HFRA%:B15)_WK=T?*LIPX0O.VASU8(BG>Q^]XWQW-^4[IKV;+F"6/F9!F MT=I:F_Z?1-O649-3^5,PI=4Z8Q:Z.I-W^2;T<099:(?!
<&XGU$N6\NY&[O3 MR]DJK."2W6EBBBRC^NF2";5;M,+6?N">;[86!_K+>4XW:,7LY_Q.0Z]?H20\ M8!)P)8EFZ:)U$_9/S'7Q94\.NE/B#)W:
[:$U;)&$I+82]5[M?6>G/ M"/%B)8Q[DIV?.YJT2%P8J[+2&!AD7/HW?2SWH68P#5XQB$J#R/'V"SF6/U-+
MEW.M=D3C;$##AG/560,Y+C$H*ZOA*P<[N[QFX)(A[0>Z%LQTYGT+H/BI'Y< MEQX@>@7@ [E1TFX-^44F+#FV[P.9BE&T9W09-0*N6-XC@Z!+HB :-
N -*@\' M#F_0[.%?%VMC-8C@[U,^>HCA:0A,C)G):9D8>M9NPHIN1W6.AXI'U&N 0Y"@&993HN5/@8U%JW.=/4] 3S#:2_$UZ@7D$]<4AFS!ML;T.E?I
M>0&?V_>WGSM VS#P*0"L]^^F41A]A/:X;C]'Y-*"LT " /V8X'3-!;><(4I8 M0SFT5UO@<0Z66=V/H#^#^PW!HR]4<\R@^IRH-X+O0_!XX.8*$O%\6:$
M@=N "; ^(]$$M@%> \!>%7DN&!0_-(FIV9(4P@,N^#+L*Z*@%F)AE<T4;&&F5$74L M(.^CKT.<'M\N$X9IO5 &K]%$;SV(;JO2Z,4A5I:.)$\9A(.B
MD7:URF ,@4#!CH^EY!AX >\9-%2!454%1C]6!6Y3EC K]_D2D!8>((M(*M-NAC7.EC_(93 G70K8G6,>Q6:GGJDAMJ"PVM4VII7.FT6DHX= D(8/RO
MX%2A\NDG=S_9%0_]\M4^5=V'50;RA"D.,Z"Z5PEKZ[:<5D< MN6!&.#+R%01#"[TQ/ Z["1Y'(U?@H3?%VA1";P0'(W"GJ47@B9L?DC#$XVP M/PS)C/
L+S),(Y4!TX;0*(.:<-)U3DZ!HZ5$@:18SD Y ;%3"K%3-ZLF*.- M_&&]-*[SOU[^JWKIUZX%&=,;=_DQ4*ZAC/L;0C5:W:\N_+7B,-U?SFZHWG") MH4O!-.A-
X,#1_L+C.U;E[I*Q5A:N+*ZYA3LBTS@!OJ=*V7T'%ZANG" &0 'AL+W=OACW0TLDB M2I$J2=GU?
OV.E*S8G6UX>Q%%\>Z[[[LC>9ILE/YB"D0+WTHAS30HK*W&4632 M DMF0E6AI)5L'NPS-?%=9]B&:3BJUP@?;WZDG3+.I0,EZB-%Q)T)A/@WEO M?
#=P]M[@,\>-V7L'IV2IU!HQ .B&A\;3&#+J1S MW'_?H7_PVDG+DAF\5^(/GMEB&HP"R#!GM;#/:O,KMGIN'%ZJA/%/V#2V-\,
MTMI85;;.Q*#DLAG9MS8/>PZC^(1#OW7H>]Y-(,_R/:-L-M%]]I9$YI[\5*] M-Y'CTA5E836M<\&9Q0SN55DQR=' U0M;"C37D\A2"&<8I2W<70/7
M/P'W#AZ5M(6!!YEA=N@?$;6.7W_'[ZY_%G"!50A)_!;Z<7]P!B_I]"8>+SF! M]_"UYG8+CV@+E<%'N49C:8]9 TQF\)OBTL)GFM>:\O#G?&FLIHWSU[%,-
($& MQP.YPS0V%4MQ&M!I,:C7&,Q^_*$WC\Y(V/0R1B<0Y\MZ'!FM4!0^8$(+N%8 M18_1/QO@./V7
B%7@@XRERNP;I.TIYG_3>FRM,Q6*XTKB@%XFMK[%BI:L>- MJ*I:$\4#NNR5;MIM0%LP"TP37)HZ9UJD^P=JVE3:A\&FC&531E>Z_PPME;T, M?
@RT"2V62UIT._$]INVD]Q:NWKA()1>"[AAS[;>I>R0P_W MEC@C>5;Y>N1:E?L*)JS3!4E61H?4!HE>.:C+YE@,B5<=Y&9_YGQ)[;U]U9' MXR!E TH"#3?
A.W@F/+Y^M?V>*YF%M_3LA<-+U#?';/N3><4 NC:D8;[SD)R7 M0B,>7(WPB0[N><^; MGO5JWG3^1Z977!H0F),KA;T)0#?=M)E85?
D.ME26^J%_+>@'!+4SH/5<*;N; MN #=+\WL'U!+ P04 " "Q@EA9U+*$6J)%6W^_4[DK+J%([W011?[GGN.?)XG.^4_F1J1 M?&R'- M(JJM;:^3Q)0U-
LS$JD5)*QNE&V9J1:36RRH,:D61I.DD:QF6TG/NY1[V< MJ\X+O%1@^F:ANEO*Q1JMXA&T7[B/=_6UDTDRWG+MKA&^U?[J&F4#"P5;U :
MKB1HW"RBF]'U:NSLO<$'CCMST <72:'4)S?XK5I$J1.$ DOK&!C]ON M"N&(M2,;GGC,:7#K@87_/_L['3K$4S."M$A]Y9>M%-
(N@P@WKA'VO=K]B'\^5XRN5 M,+Z%7;"=3"(H.V-5TX-)0<-E^+.O_3X< &;I"X"L!V1>=W#D5=XQRY9SK7:@ MG36QN8X/U:-)')?N4-
96TRHGG%W>86'A_(D5 LW%/+%$Z1:2LH>O CQ[?X+ M/"AI:P-O9875^;PEA-N?#/L6 #U_@XE[L?UZ9E)2XBN@ &]1>,EJ]?C2;IFQ-*QX/2
M\2GVY9KN6]4)!+6]>R6W/UO4#7C]?Q:";YG+8G,)?]!-)9/;3FN4%AZ8[32W M',VQ@$ZZ/!
[04XVP48)N*Y=;L"XS^BO+_T4#JM,@!GF5DZ<.Y0E6KB,25#U<'2 SQ.$2(JW!%*8;S,S?=<"%< M#!= 26BQ*5#[3+S#LA^,+N')17VOF+R$JD/XO1/?
(//9.H7S23R9_G0!9S#* MTSBE_^M7LVR4O?D1]8S1);J#YAE!]X#9B/!KU+0GL *I:!\.'%[M47D\.T1= MY=]1MR^@2.8X3AUJZJQ]DZ6AG5)[C\9<_^_QI?
&8O@R>E&4B6!!W/*%V$L]Z MDOWYMHZ)*C =U@^9LQ<^RL?.];/%D$IG/>\93#,B/G;/DH/JUZ#>^AIO2&@G M;2B$P^SPC-
R$ZOG=/+Q!#TQON30@<$/0-)Y>1:!#70\#JUI?2PMEJ3+[;DU/ M(6IG0.L;19O>#YR#X7%=_@=02P,$% @ L8)86=U]'R-B!@)A8 !D M
!X;"]W;W)K&ULU5A9;]LX$/XK]?HQD!6UF$[MMX'$2=H /8(D[6*QV =:HBVBDN@EJ3C97[\SU&$[OG)T'PHD$D5S@YGOIDA M>3R5ZH>..3?
PD":9/FG$QDP.VVT=QCQEVI$3GN$O(ZE29O!3C=MZHCB+K%": MM'W7[;53)K)&_]CV7:O^L::%S$#QT4GCU#L\Z]%X.^"[X%,]UP9:R5#*'_1Q
M%9TT7%*()SPTA,#P=<\'/$D("-7XI\1LU%.2X'R[0K^T:\>U#)GF YG\(2(3 MGS3V&Q#Q$&]8^5G(*BT8A&#;M4*XW*B8R<9-
BI'TQL-.W=LF'#=.FX;G(ZVF)?59 ^VN@#^"SS$RLX2*+ M>+0HWT8U:UW]2M4*\]L'C!]K7/KYAE$7SDT5AD M8S@ET@@CN(9SH<-
$ZEQQ^.MTB,.14'^OLDHQ:6?UI!1DAWK"0G[2P"C27-WS M1O_].Z_G'FU84J=>4F<3>O\6@S;*$PYR!,A:Y&0&@UPIGH6/,$!WD-9ZE=8;
M<5=K?:II&O2*X>F0]JHUNS#E$+,(_EH@^8D2XY*;<)*F[#2!HR$2:["&(/+ M&A]C-H&0*X,Y!29,*#M/*8BNV 6F$2_!A*(/80<'I2)),,9U"[5!V7K%UQ7L
MM]MSN,B5A-L/V/AV W['\<#O.5UX_V[?]_RC^OTGSZ"WZ[F^$-KNO6KNL^VW47HQ$GRV!S#4DQH7TU,1I](%/T2$QI MT@X)9O@ZO?
6M::%TQEZ("53M^HT6JGW\6\M#UYU5!R*#.Z^!>C!'4" M/M,^FFDOYK2/N$8N,,,CZTIT,=RS)$?68-QQNSH"0HI$N# 04 M,JXPPPAQ:Y:/%?(7(7*\X7
M$AM\0;,M]GR2(;,U!_IN*V5IFLH]35@@+04-/8*YUB49Y;LURD=KE,/BC4HA M'K'><(5H$Y8]0B)9UH(F['@]IU\6;>%SPA3],R*0$0+]TY@FVZ):X
MS($SQP'!@XM8"(MSN([;6@=;VI8_A$E.-ADIF9;,P*DRKI$K7!N:)7=;]&S
MB\^N$^#3=3IKD>^DP1K5+,7P[9,:S+5+4]N_AJ&>ZAE1W\C370B9CF&$Z+LV MR#+"5)0LH.3ANT<8JK;E'14!R\N W;6HJ)QA#\^C M-R*MX/8.";2
!&A\PK06(U&YY#0,\S1/[!I)'GDEGY)^QN>WH*T(G15=KXR- MRZ?EQ;I@KL@TD;==8H=;L*3*W$WPG6 ;U3:)#H@)E\B$E^GBU[S.!=KTA?T
MN69$UJTPR'=#"6. M\(=>*H%/WU>4:Y#;M8$JNW0+NY0!6"P',X]=Q-4L'"K##!2RYO=Z/7K*)B2^ M[W@M:\R#!6M4K6UI8(OXKQ\XRP5FN>?
_#)N]PL=%&C3K!%\9 M,D$!TRGA;&&KV/;,D,':0.6E1Y0),&"PYORLH*'@I?^UP8)SNV5-[M([P$TD
MT7;_9>%2V,&CJ5X1+5ND;_@(I9%ZQ%XVE%BMBBW>-!9A_/,W>E-A8E%L]N1J MQ6E32M26N7K)?K .06-+C*W1A)060<-MT"P?7>S I>[
6;6=>*LUZBWAAW M\+$T .WY7FZ%P^?M5Y^3/&9!]K1B+0;CMFBJ2E45?4OALBZN-ARQ>041J_?L M(]:<]47:?"G>3<5T;CJ]+1YLL"F
S56=Z5O_F$5!9!6Q[_V1,2GGQ3&0GS MB)&$AWXY(4!=T+$[VX_@5Z]5]ZY)C_6-09GLL5($Q.F*A%C%]EHES[?M1X*B MT)6S!W/E;Q6%VW-
W=RE78WM#BW*!^9@H/:!H2 M/D)1G!"/]ZJXE2P^C)S8F\"A-$:FMAESAM2C ?C[2$I3?= $]=5P_S]02P,$ M% @ L8)867 V65C P 1 H !D
!X;"]W;W)K&ULI59MC]LV#/XK@AL4*[#Z+AGLC*GG4:3S'514 MA[(&@3NE5!4U**IMI&L%M'!&%8_2.!Y'%64B6"WW-B(]E(^6R%/XIE$%M
P"$WU@/%X05N@7/K"&'\V_H,NB.M87]^ M/\]Q8ZQ;*B&6\G_8H79+8-I0 HH:>@;3^()!VAJD#K<_R*&\HX:N%DKNB;+:Z,U.7*C.&L$Q
M88OR:!3N,K0SJX^4*?*%\@;(/5#=*,",&TU^>:(;#OK=(C)XBM6\M;CVGM, M+WB97;>I>VH%@]?9-,HX_ M7 &<=8"S:]Y7C]B)1<.!R)+<:
U8'BH*\HG1#>/,, 3?UJX@U)!C?.<"N7K4 M^4">=D!*R;%_F=@2XXA!W+8PQ. F/8+B/5 *L/ M>XKI.5E33D4.5G=M5VRP%\DY($Q@-W".C:W?
$62(@6H#RM'D$[P)TD[INTX M;%,W)W=0@K*YRF6%=YNF_GKP,0Q(DH3#X_#VS31-T@^]&;(;7K$%U3->F64C M"DV2=!J.VN]![3 ^X16&UT0M-
4/WDV%/Y43 .P9O$$%L6D#DKXA..#JB^UDX MZ?1.A%LEM7[?F>@]K4DR"I.C=E^XE54E"V;0-^6R=HLG'5J_3F&-0IC7^$,![OG@?
P,!>\@;QF8_#P#;16ZX;L8F,49!N._ MUQF837JY.!&NY-(FI*#6GY_EW!2Y42XR+]QCW_C7L#9=.SXEB49K@_()'&U M^G'ZC2_2;_P]](LM_>(?
HU_:ZZ3TI*N2\:&\EGZI$RR0&PO=V]R:W-H965TT6W'Q;[0$N4190B79**D_WZG2$EV6H<-T ?%OM@F93(
MF<,S,:&VET$2:%9)^N[7^BUL[K&5%#;M6 MXD^>V_(RF $GF_9^2],H8,[NA*,#.\&%EPB1-'66/^RIM/ MGC%_1CXH:4M#WLF
N)RLFH64)2!X$+,$SBM4+-!B%Z;#S!;WID$S#&9F$<[*L5(T!V,U"^FM+"JVJ%\?$ M \ U]+VTO1B_7 !^Z$$6]'.5APF'O$LG.P(?1I2QV.TQV:,"\=&3Y??
8ZB3I#8 M2:-_UQT F"9CDP29/;(=3+KM8/+B[>#+=_0[(G]B8SCN>=D>W!QGY:'HOSB0 M& ?"3:M6&-5(]#LY/]7,7:D9ZQTJR$<47^_->]42(LFM!11./ #
[QF?.6V8I M%_ABKR2XVN,"NFO]"]=:X],&CC]H+M]I]KQ37E9KS63V",:D.T68WK8 :94, M, 5!LDR&Y"/DGJ%PJ#IF!";.7#Z.,1%=;B:8C=?
N.6LE.K@&5@S M2N3'3':"2=%H#!(:3!&=SQ/V (=] T+Q$AFBI2W5.;%PX#8S@+7DM*=__1^'X*0MHQO_FKFS@ZCOVG[*
MS_&PSX)/IO8Y;=!X/T^5V6Y4&TA?E?=*WTESM'"$-OLK1N@$8X05D*+J0*R= M5E"YD""BSG?"Q8^U[5A'^]X7SSKJ,R
Z/%0#1WOWEXKIM;NEH4/8*_Q5IGO; M7027_OZS&^YOD1^H7F,X!"M@*N0/%#7M;V:^8]7&W896RL+=RC5+N,PRC0/@
M>Z&4;3OHH+L>+_X%4$L#!!0 (+&"6%D?S(]=*]R:W-H965T?C=R@>WTCU M1:^$,'!;E;4^&:R,61]-)CI?
B8KK0*Y%C5\64E7<8%U(/9L9-=J-FQ;$Q9U.)"@6ZJBJOO9Z*4-R<#,N@$GXKEREC!9':\YDMQ M*_2Q/E[F]+$#^MH(_SR]UD8A)/[: M%Z-
7$>U78;?)D5[S7)P,S5"Y*$K^]Q,.H=C.[3/KO$;3=O2@%R M 9=&YE_:Y+2YV>?NO0KWNWNU$K"0)6[)HEZ"L>D&][4V&@Q^S%>\7@H-10UZ M
R*O7F24I*!!^&5$4G"C:[0)E<^\L)D'S)L1U;50??*.X%Q6. 8\Y'4NQO!&Y&U Q 7$((T#!B^!9$%F&QH&%(A['R8L#9(1OK%Q3%D061F)
M6)!9&1UG&0E"^(B<6]3HAP"WKO3U/[:$6)MW>Z>6V&PVE/#Q&0G:+L//EJ[F M+E",DCL6W%8X3.(@',$0?1!.D5/=TQ&*&R7>=TH!
(95VF'6E8<&VNWDB"&Y M5+PZZ'\8I#"D26IM[KC2RM]@-'-$D49VS4LT,(?A2_0OA'5G[O<=!ACB"\9"AFWA)\LA0&,8TB/8@OHOW
M9=,OTJ/RZ?:H>_2YW*V$6PG%^L" ^KI!QB&N5%LYLCCQ*;4):%D@1?<)_/?E MF_W?RC?=R0)UY9O:!6=IV.VA*1*,3TW&;'7R5!QA8AZRKZ)PPS-<
M!,37:99,N]I-"$,=%C!)9IG&[5HD8OH@P. !@6SU'EF[64O$^(PLW'=,9D* M&%N[4[:7B5OYDT.&C+:[SU.[\?2-NMMF;^W>P4R<.9)Q_P-
Q2#P^V)C&48L9 M))FXQ4R48)%_"&:2.^>]Y/'G/1:[0XK#3,(V -FU-,4\/QUF",(TM;RVBUXG M?
IYT,G>6:IO#Y7OWOX]:XO!G^"A)+!AL3B/$A3^0T;YP9(G-_[Y;@LG&%4XE MU-)=5&F,L:F-O\WII?U=V*F_ OHQW%^D(6LMBUI#*18X%?^XX@$H?
SGE.T:N MW870M31&5NYU)3CFR@[[PLI3=>O!OH;PMG?4$L#!!0 (+&"6%G0%X$$ MBP, (<(9 >&PO=V]R:W-H965T:99SPS'J9[J;[K$M' -
U,)^ZO7LUG\J=$;S&>P5Z5U5,O2Q0R/TL2(+#Q@/?EL9N M1/-IP[:X0O-WGD2$C5C3*6\"%!TQ_ W@+GV5M2@T?Z@*+4_V(MR'4,TP/#17H1<(5-
"%E\#6F<#B[@99W'FB&Y3@+J#@TJB<,YF_?)*/XW07.@X[SX!+Z?$6U6.P$@MS M^8B=8WP1\SQC#XX'<-ZF0RZI"K719'\"CZ5"/(DR_$78ISN]*^
U):P05'NZ M[X)GA^QH1F5%15.3N:QD]1:!+K_6S)>KD-K&Y H&84)C$HYIO DS&K,PAB49 MXZ13&T^N0,6<7A*F$(&X#W\22R"K!=>-U$S8 M
#6"$:N#].MODH2C-H;<8*6)[,B"#?HTNZ5?!H_26*3SH; 7,J!Q2&IT+;&[MEY0HP84\&W9Y-OS?>79Z+0\^0\ZEV47(\VGV6")LI*".8+&-?6O G=KXN(>:
MFYF? BHK0.<;*&ULK5A=;!LV%/TKA!=L#N*DBS93IH$:+.O NM6--WV,.R!EFB; MJ$R)!4G_?4[EY1L)7'<;MB+24F\7^>>>W6MBZTV'^U:",?N-
I6REX.U<_7Y M>&R+M=AP&^E:*#Q9:K/A#I=F-;:U$;ST0IMJG,;Q=+SA4@VN+OR]=^;J0C>N MDDJ\,\PVFPTW]Z]%I;>7@V30W7@O5VM'-\97%S5?
B1OA?J_?&5R-=UI*N1'* M2JV8$420+K3_2Q9OR39@16.=WK3"\& C55CY78M#3V >/R.0M@*I]SL8\EY^SQV_ MNC!ZRPR=AC;:^%"]-
)R3BI)RXPR>2LBYJQNQ L2.O5$AP834\ -?5,*>7HP= M+-"Y<=%]>QVTI<]H.V-OM7)KRWY0I2@?RH_AVK6PSH 9[)&$+U#B3#<&I4E8
M^I,VP&M'N%EH5.5_;&9[*HA? M53!J3ST/Z&?2V_V*WF4)H'."I#92./27#A[+3M@T3J+,KVF48TU&LS2.IGXW MCR?87<,HL>#9%6ZZ:)3:-@?6=BB3+
(9AD673&LG02S5F69%%*8OO 5.<'],ZR M*8[2.O.6TQ$)AUV:S*#@"$'R'4/RKV?($V;W2GKDJ1-.'"+*<3.'.:%O98E0 M0S>7GQ'_4BJ.G//J
5&P\S3IN/$_)OZW6ACN8X4[2^G8L-+6GCY+@R2?(V=8 MYXE/?I;DG@XYDI5_B0)I@J3A)V;Y-$I8/HDF[-1F2T:"_>M[4)D^K%?9#*& MY
GY'4S/@@OYV1G47FN#K(%$C*N2_:XXP"X\IVZ<+CZ^H/=.B2K:X%UL ZSB MCO8"*H9YE)R&] M.+%!YGX!O S&2VEK#:H3\>J*>M$0
M]^,T^3],63=9@@5O+#.N3T5ECG49*; MFDOCM\/)7GHXB9Y,:2@C!"IAI-U:&%:LN5F!A$/$&Z/>.BG:#V."Y=6& MJN%SP
S>\N)3(ZVDRQ=&5#XXJ1Q7*TFTYM8*@8_)?FT]SOM?D/.G_8,)E' M,QQ.N./L85 Y0H6A%#U=\"9+ @ Z.ZI M.$E-
^YB072YE)7U,1%2NI&^$R30++7<^\P60M8TW3XGXQ,'G^ G554,M1MR) MHJ'AS=LO)=XM#DVE7PXC5@B\@^!4W0Z,>S",D"
<$[T&)I@;!C^YSC%0A@UWV@/)U5'7CGNC7B#?X_S3&'_]!B,9V2 MK'>/AU>%5J*[U9KS=3-[:3%9=]V/7.]AT5HCF8/-M0T]8O2R %K(2QB["[1D
MA%'NP; T&I3L4\,-F$R>4/B1;P(]S)Q_2U ._B?TJ&'_-_"XZC>K@PA^9SVI M>OV-6)!]N75M4*@M4U0L-0Y,.HQ JZ.M\?,\<;

MD51"S<+*4F*8$C9DL/.37AB26B+JCH8M'YR_"X+Z0A4""0QV.@?[!0U\?0&' M1-M90PN%%NZ!N(FNQ@I3'O:UO=GHY!1+@>(ZG84$0* M+?
Z>;0W(R4J]54\JH\V9KSH\6VE=AI9-_V1D0:.IKLJ00I*I20/^2 MLY3%9YE*,\5_;6^9/_C570_1IKMH2?(DWA<_3>SM?!?0ZK[D8>\/R1U0'3H
M/)Y/,"+I(KSG ^G5DP$J3%GF*]I^'!WZ&S3N?<_8"-"-OMI0@VV4"Y\V=G=W
M'X9>A>\A^^/AJ]);L%4JB]I80C2.9OBK8*7FG#A=.V_CBRT&ULM9S1;J.X%(9?!;'2:D;J-_&3I.FV MD=K8.S/25HI:
[>S%:B\\X"2H@+.&I#/2/OP:0N.8,89T3FY:(,>?#/%RSE.:7?,,R^L!OE&.!I5_MC=)DX ^'XT%*X\R=W53'%F)VP[=%$F=L(9Q\FZ94?
+]G"7^Y=3WW]^4Z$5O2;5(\\I=/K$YH5)"GN33^=E'SM!KA-N\X*G_M=6/Y#=(XV_^FW^H3<=1 @;A#T[6%4-ZA2'^QS
MKTXKL5ZWE^8JSR1[5BV9_F;@(M__Y#ACJ?"Y;F_YB*$T 6!Q*&(6$$"*859W0HSLA^N6A7B9!7R86S8:()O_" MFHJRYWG#"EC^!=_-O)O![OA4=X?
@[A!B#=&2'1^2';]5&YS_G/N8)WP5A[DI M:ROXU*$("<.0, ($TZHS.51G@3A(U!Z*HA%^:HB5DQIH>TIS^A&!]9QD2+8%BYIXY)2!B&A!$@F%8<
M;ZAN^X=GDHP:#%0?4!H&I1$HFEZB(V?F 0M'#6QI^WA$T;XM$2-FFH MASG,-
ZN'YZOL_9_0C\6:BI0:SX$5>_+PA*1A4!J!HND%4F[10^=2$%#K"$K# MH#0"1=-+I.RC9S5 ;U&0P'@QHZ:"F,/\IH*8PT9-!3&'!2T2H@R:U^'0K!(B
M#\HC8?'A@6;;I=S8"A8Y"\&C;5@8;TSLW9T\;B%I&)1&H&AZX939],;GDA90 MMPE*PZ T D732Z0[I:)7H^ M*;7#3AZ4D#0,2B-0-
+TLRG)ZTW/I!JCI!*5A4!J!HNGS+Z:DC%I2&06D$BJ:73QE1WS^3J/B@5A24AD%I!(JFETA94;]CYO)T M44'&QZ>CIJX8PT93-93'#QDUQZ8#IR2N3Y]M-
WEOE!;,DWC'Q76[LXI"9109T M'A&4AD%I!(JF%U%957]T+I$!-:6@- Q*(U TO43*E/H=4Z"GB\S8Z#[&39$Q MA_UP_V(.:U]>EK 6E5%^S[?
[/:O*/!4TBZB(G 4-G^DJSE;&TP$ZV0A*PZ T M D73:Z7:\HW!+U@Y28 MPUJT!"D/B.P>T*HEIS^6M?=V\DHTT E)4!J!HNEU4T86>6?2%01J5D%I&)1&
MH&AZB91911VSIB?K2@WL>BS;+PR;PYK"T@G3LS]:P&KW@1\97PFZ6<=AWS6L ML(M885>QPBYC/<=,)%(F%9UK)2L"M:"@- Q*(U
TO43*@B+H]:RHQX+6'C&X M1PRQQ^@I*TN'D;.JA?R7N0N+1>I4?-=!^A,(R@-@](%$TODG*>Z%R+6Q&H MX02E85 :@;+I)5*&TO<47FY:O-
E6HM8>.F@)C#@J:&F,-:GL B9>:0W!F'QI,!.@,)2L.@-)%TPNEG&=PKL6P :@%!:5A4!J!HNDE.GJ7 M$GHQ;&!5$6C.Q?Q]_MOU/P3?7"^5=>%#RM-
M>,1DR4 ?+S)>?%ZT[9P>&_(LS^!U!+ P04 " "Q M@EA9[.<^UNL" !Y" &0 'AL+W=O18NKP II^LN,BQ MTE.Q]F0A *?
6**=>Z/M]+\>$.?'8KMV)>,PWBA(&=P+)39YC\3P%RG<3)W#J MA3E99\HL>/&XP&M8@+HO[H2>>8U*2G)@DG"&!*PFSG5P-0U\8V!W_""PDWMC
M9(ZRY/S13+ZE$\>[KU =]&?T$DZE_46[B64*H#*L>> MT@!&QDLJ9]/267C V0C=:B>91)]9"NEK>T^#-_1A33\-CPHNH'1Y%^@T ^[
MZ'XQ0YVS\R.Z41.5R.I&!W3K6* 'HC)T8Z\!Q 6ZEE(7RL\IYQ3II-AAD?YJ M"T.IWFU7-X5V)0N8%FD$"^ M!%%ZB (;K:@-NQ3N6V%3SMLX#-S>V-
NVX/0:G-YI./K.U#Y/=7MM/*7R8(^G M&[I1.T^_X>D?Y\DP6X/)X^0UF2X!PA+]9I. .BF4H_,VK/X;K-!WA^U8@P9K M\$\95]?A\SNR;O ?LF[8\ ^/AG4&*Q
"4A-#37Y*U@W?A/.R%[FC]GB.&I[1 M:3PGI-VH%>C !0?^RYO6?V?FI: A=.;5^88Z=0ZV9E[E8;]"?3?X"\S;ZP8Z MA]:VYTF=
[ANFRL;0K#9]];KL)B_;RZ9\B\6:,(DHK+2I[PYT18JRSY43Q0O; M6Y9>JGA@'S==&_ =02P,$% @ L8)86:<@L1-. M @ Y00 !D
!X;"]W;W)K&ULA53?;]HP$/Y7 M3EDUM=)&0]"L8R$2T%7; Q,"=7N8|F"2@UAU[,QV2+>_?F<',B91]I+XSG?? M???+2:/TDRD0+3R70II)4%A;C#9V]-
_C*L3$G9W"9;)1Z=.N6R8P;D2WWANBTEP%T".6U8+ MNU+-)SSD<^OP,B6,_T+3VH[(.*N-5>7!F1B47+9_]GRHPXE#'+_@$!\<8L^[
M#>19WC/+TD2K!K2S)C1W*EZ;R+'I6O*VFJZY>1GTQ7N4=8(;^$+TYJY$L'U M/5K&A;F!*^ 2%EP(*J!)0DL!G5N8'W8 MQD>VL_@BX!JK'@RB-Q!"\1
>U_=P?75S 7?056'@<0?_J<)6JQ+FQ%G3M% G M; %SWP/4\'VZ,5[_XUPA6OSA>7RW66-3L0PG :V.0;W'('W]JC^*/EQ@/^S8
M#R^A=^PU9FHG^6_,P1:,^#-#_'^E&IX,GI4I9U?, .9JJ5MI[#3=CL\;4?WKWG["R8WG%I M0."67*/>N]L
=+M4K6!5Y0=YHRRUQ!\+>H=0.P.ZWRIECX(+T+ULZ1]02P,$ M% @ L8)866G'TE0'! =!(!D
!X;"]W;W)K&ULK5A;;^(X%/XK5G:T:J49<@^4!:2V7,)*756#9N=AM0\N,21J$C.V M]-_/\=)R(1@,G0W>8#8.=_G8_N2 I?-I0E6$"1;76^8P0'.2B)=R
Q/8PU4SM6?(ZVH9 5^F2TPUNR(N++[IE!2:]8@B@A*8]HBAC9C+5[M<[CL2_O_)(XE@2@1O?2DZM M:E("Z^]'IGD>.\3R@CEYI/'7*!#A6!MH*"
;G,7B,SWXI(S'E7QK&O/\%QU* M6T-#ZXP+FI1@\"")TN(??R_S4 , CQI@E0"K"7 N .P28%\+<$J >=/L<"3$:,'Q*0UL,F77$$Y
M&OH\2J765X+!UPAP8O(7#*=ENJ8)0<^$H56(&4&?T K&5)#%!-$-4IK<3(G M4S-""! N^WX^]:\#JDJLJ7=^\K8#/KW=>!5]<[[P*
[O^_S^__<^PG0K"K@6/G?/8% MOAEF:91N>6U,_'/_P@6#Z?M?E=_+.D=-)Y>T(=_A-1EKL&9QPO9$F_S^F^D9 M?
ZA4UB79M$NR69=D\R[)%EV2^5V2+3LB.]&Q4^G8:6//%X HG]U5HBVP@QPK MMTW[B6E[(WU?UV)AX]5M3+-GGUI-559NTVJFL/+.N.8**]?
MF:=6"X7OCG%J MXY\SV9[5:T2X/+=R7*_G5%8GB7>KQ+NMB?^:[\-(@/">,-A6(NB#!+9_Y2H* M^U(N9#P($:A,A00(.23QC;PAVF^M7E!
1TN!7HO/.@C":X^:QU2J M TW]0CE]U8"Y(/]"1ZV.O5='79+-%+&<+6KS+EM<=$GF*[NBL7(LE3&Z#3'I MM2-
H0M@VO[_@L*9EJ2@VU55M=45RG]\,-.H?S.'"5-3[YG!9W(#\I"_N8^!< ML8U2CF*R@:9@+,"P9L4=1U$0=)#[AE)Q+,@&JHNF MR0]02P,$% @
L8)86?/$9D$$ P [H !D !X;"]W;W)K&ULK5;?;]HP$/Y7K$R:6FDC(0'6,8@$!;0^M$)%VQZF/9AP
M$*N)G=D.=/OK=W9"1KN0L14>B'_<]]WY[GR^P4[(!Q4#:/*8)EP-G5CKK.^Z M*HHAI:HE,N"XLQ8RI1JGNB, MVOU9U\A;@<\,=NI@3,Q)ED(\F,G-
:NAXOB!((-*&@>)G"]>0)(8(S?A>)8E57 MDB]LI>.A<^60%:QIGNA[L?L(Y7FL@9%(E/TGNU+6 MN3NWO3SWV&PD7D+5(X+TAON=W:NRY/AT>U!WG
M9=JG+],^:X;/8-DB_E4=_(DO@RJ# LL7'.&;4LD9WZB#_/DZ6BHML6A\J\N5 M@JY33V<*:5]E-(*A@Y52@=R"$[Y^U>YY'^H"=4ZRR3G)INAK;K-%/
M_QF%;A6%;F,4%EI$#_B49[E,8GQ*22;%1M+T3>E,0G,="\E^HM__XN)&1?]Z M <|)-CDYGV?2<9+/ND0QYDB5%8-V#US@%N;%]D\([DG-=E-5JM6K-
1K8C>;8^ M;O>OVS7KDW9_6G1>O^F+/O"6R@W#VYG &E5YK7=HL"QZJV*B169[@:70V%G8 M88SM*$@C@/MK(?1^8A14#6[U"!+ P04 "
"Q@EA9J;%.$-@# 7$ M&0 'AL+W=OV@22^%D@1Q$WW8;$/C$3;0B11)6E[^_<=2K(B*XS@[>K%$JDYAS.\
($>A[FF1\K.V$R&\,@X<[DF*NTYQD\&5#68H%--G6X#DC."I :6+8 MIND;*8XS;3(J^A[99$3W(HDS\L@0WZD80>QYJEG3J>XNU.R YC,LKQ MEJR)>,X?
&;2,FB6*4Y+QF&:(D!S(/4D2201N_%-Q:O60$MA\/['/B]@AEA?,R3U-OL21V(VU M@88BLL'[1#S1XY)4\7B2+Z0)+W[1L;(U-13NN:!I!08/TC@KG_A[-0\-
/"H M 78%L-L]P. 4P&<2P%N!7 O!7@5P+L4X%<_U) 4 &"2V=I4 $&EXXPK ## M0@YE_HKD3[' DQ&C1\2D-
;#)ET)!!1IR'F=2ZVO!X&L,.#'Y$Y;3*@MI2M C M86B]PXR@W]:UE2T3PBB&_1$\CT+=Z HV;JG:0HB70L:OJ*K*1$X3O@U0)[7
M4W3UZ1I]0@;BDH:C.$//62SX9^B$]XEE_8'7CKH M@69BQ]$LBTBDP"^[\<,.O $S5D^;?9JV.[N3<$UR'3GF9V2;M]OPY[X;_L<^ MZX1/N^$/F '<^A
^N]QY1P&?7^Z\"KZXW'D5?/ES,[_ZW[&?"<&IUX]3\#D? M\,TPR^)LRQNKY^OM"Q<,=O%O*J&7=*Z:3IYL-SS'(1EK<'1QP@Y$F_SZB^6; MOZM4UB?
9M$^R69]D\S[)%GV2+?LD6_5$=]9CM]:QV\4^*:5[VN@C= 7[=;F+ M7ZM47))Y!9F\3ATF5F &@34R#DU]=H[YH_KLDVSV/H @<.SAN?_S/H=<]$FV
M5"3 -8?!P#^/8*6(TW.6_EFVZ>E(CS3U[U67A1>^9;NJ-DUVGQ.]-R>R ,"A24LSB$7SB1WE(3 ME&%1"KS5(XU;+CH0"!..U.=+OWH&N^3;*8(
/)EMU(Q[W/, M19]D2T4 WE"W6QE8*A?0M5;%JEO]&7)#'>^;9QQE) -#&7J =U"Y$R8-X/N&4G%JR 'J_P(F_P%02P,$% @ L8)860Q37Y.% @ MR08 !D
!X;"]W;W)K&ULK55=3]LP%/TK5H8F MD+9\)V6LC02MT'A JN@8#],>W/2VM7#BS'8;^/>[=D(42NCVL)?$'_<*J20%<65' O
M]/W4*R@KG6QLQ^8R&XN=YJR$N21J5Q14/E\!%_7$"9R7@3NVV6HSX&7CBFY@ M ?J^FDOL>1W+BA50*B9*(F$|<2Z#BVEJXFW #P:UZK6)<;
(4XM%T;E83QS>" M@$.N#0/%WQZFP+DA0AF_6TZG6](_^^T7]FOK';TJ8*IX]LI;<3Y]PA*UC3
M'==WHOX&K9_$\.6"*_LE=1,;IP[)=TJ+H@6C@H*5S9\^M?O0 P3Q.X"P!83_ M"HA:0&2--LJLK1G5-!M+41-IHI'--.S>6#2Z8:4YQ866.,L0I[.;<@^E%I*!
M(JG)$3PDIRRSC'/5=C3^.2!NCE+?U50Q^^0[^ RB61 M_XF$?A@/P*?'X3/($1Y8>/0:[]'1SFW8N0TM7_07M\]DQE3.A=I)(#\OETI+
MO$^_AOPUA/$PHW?=^W,!05]])>:8L[;?%1;0^8ZN:B55+D MH ;5-01);]US_T!:$S+JAXS>4Y9TRI*CRJY9R3"[5F0CQ&I06/)FU2#QW2\' MV@:B1HD;#
(M+.W'I47'?A:8<]ZU+X2%]Z9L#B_W #0_T#41%L3LZT.?U"HTI M\K=4;EBI"(86WQJ0)@#GUT+HEXXI9]WK ME?T!4$L#!!0 (+&"6%E0CY5W=0, &,,
9 >&PO=V]R:W-H965T MNH>A M#[1-VT0I4B7IN-VOWR6E:+*D*-Z:%YNDSCF7>)#5].CD%_5GA"-OJ>,JYFS MUS]I\SSP0=[;0;
<>)KA'5D2_9C=2^BYI S)4=5:2/C9"7$5]/YN)DY S,APLA:&P4,?T]D3A@S M0C"-;X6F4X8TQ&K[6?W6>@F\3Q RG\#(W>
M6C!E?]$QQPX!O#XH+=*"##-(*<__\?$J!I^/?"619 MH1ZR#3072J.+A&A,F;J$X<=E@B[>7Z+WB')T1QF#U5535T-H(^"NBS W>1C_MA3 !NA-<[Q5:\
W9M/"3;OZD@^^"Y=*W_^S[QN\47)*LCX+!K\@?^&'+?.;G MTX,V.S\7??&_HY\D(R@W06#U@NY-\-?U2FD)1_=+VP+G$F&[A+G.KE2&UV3F
MP'VEB'PB3OS+.R\;_-:6W;<42]Y2;/%&8B?K$);K$':IQY\R(K&F?(>8/8UK M.(UM2Y&K1%;%O B>XJ@/V^BIFN$F)NP'IYBDB?'&?>\4M,A!XRIH6$).; Y+
MF\-.F[>48[XFAPJF0FOZ-[9M#;)$TEWM/;'L'>'SQ\.GQ$F&EB&Z]=_)0 MH\KT!G62\OPSK&)JF6A3B6]Z%(YR4-4YB'Z3WF@7!/85!I!&O(Q1O&*,JHI M:?
4>M? MU%R>@5DT,6'E7)WX')<^QYT^/V,):\C(*R['C2/:A:,,GY0V36Y1[=2 M-:5$[FRYJF#^!Z[S=V%=SKV4\@0HZ+WC_E<_+[SLL=Y0K MR-
@60@WZ(SA9,B][\XX6F:W95D)#!6B;>_@*(-(X/E6"/W<,0'*[XKX'U!+ M P04 " "Q@EA9_9W]ZKP" #A!P &0 'AL+W=OPZMB9 M::#][.=D#
(US=2I7\"O>^XYQ[ZYT4[(1[5&U/"4,JY&WEKK[-3W5;+&E*B6 MR)";G:60*=%F*E>^RB22A0M*F1\&0=]/">5>'+FUB8PCL=&,7Y/WDJ?#@("(=O!
(1%0.AXYXD:.!W?H)&DH ECI5 K&/,%W% RIXQJBJH!-V@V$(XO4!/*U D< >5P M2QDSIJK(UX:$A?*3(N%9GC!\(^$4LQ9T@@:$0=B%V?
0"CH]_H;QC8922%@* M"1UNIU(PWBNM#1W_:N*6@[1K8:P[_J4923!D6<>N$*Y12_^_*G=#[[6$.R4 M!#MUZ/']W0R(,[D!"45O1R@[P!L-6WC3KOU)?
*W%6F[9=IN;=HKR@E/$)P_M#7!5UQ3+YDQA?N<-F&JBT12:!K&$_#PE#"9"45C*YT7N7#VRIL7I0"AV\U^J7&ZUT>_#*[; 55KL]
M+$D,_]/M[R67CS6\GD]N.!-\U=0HTW]9[A]\L6WSNR5R1;D"ADL#'[0&YH'* MO*'D$RTR]Q&?"VU:@ANN30]&:0^8_:40>C^Q?:'LZO$?4$L#!!0 (+&"
M6%D%2/$$=P(+T' 9 >&PO=V]R:W-H965TC%TH]DDL:EN>I,3-O]^1[)BD M.(:.[L:6Y/.^.H^.)845%T\R!5#D.<*.;-2IP<\H**PK-
VI(=^KC!6P$D3N\YR*XQUDO)I9KG4: M>&"[5.D!.PI+NH,UJ!_E2F#/;ET2ED,A&2^(@.W.FKO31:#C3PPL$B\EXKGC1@SR%E1O^ES MLPYG G=\1>
U N^%P!M=$?B-P#>@=68&;TD5C4+!*R)T-+KIAED;HT8:5N@J MKI7 KPQU*OH&N ;2?"*F01X--B1D?@"!520W2U"49?)#:"N<3HOLN+&^]ZV]
M*]9K* ?$=SX2S_&&'?)%OWP),2^H9/[^?]-=\(Y7 O^=W M%U%M,>RVT#MJ*DL:P\S"+2-!',"*WK]S ^=S%]\;F5W0^BVMW^<>M86D32$% MZ#W-
BAW)3*45B)S<'(&*[MKVVT^(49* Y+Q0J>S"[W>X;1QN&P?B3DA"C[*' M?=BR#_\O>[_]N,Z\"[E7^(\5'[74H]=1)TS&?%\H(]B"+LS:SZV/!GW<'R)G
MX/@3W*R'1<- F'+QQPD%G(L-;[T7"O?.^M@SVV>&J+[;O5.Q8 M(?%7VJ*],QCC\HCZLJ@[BI?FO-UPA:>W::9XOX+0 ?A]R[DZ=?01WM[8T5]0 M2P,$%
@ L8)86&ULK59M;]HP$/XK5E9-G;22D$!@'40]=-4JK5I5U.VS22[$]F-G MM@/=O]_9@8Q"BOJA7\ O=X^?>^[LRV0CU9,N QY+KG04Z\PIKKT?9T64%+=
MDQ4(W,FE*JG!J5KYNE) ,^=4,G%K]RJ9R-IP)N!>$5V7)55_ M9\#E9NKUO=W" UL5QB[RX:2B*UB >:SN%<[\%B5C)0C-I" *\JEWU;^+?&N;
N05"&G^VF%Y[I'7<'^_0 M;USL&,N2:IA+_IMEIIAZ8X]DD-.:FP>Y^0[;>(86+Y5ZK#G@#C=#N'6(3QT&+SB$&T=(A=HP\R%=4T-329*;HBRUHAF
M!TX;YXW1,&&SN# *=QGZF>0'H ::7! W(.J"W*#J2549&115Q4'S)FAG-R* MIF:L^.?78"CC^A,Z/BZNR?G9)W)&F"!WC',TT!/?
(#E[A)]NBC^\8Z/^H#=HC5[0 M'K:TAR=IWS!!1=I%.W<[<()T@SS:)QWUP@/2C=%PSRCH9ARWC..3Q>@>ZPN9
M7]187E1KP%*42[S2HBE%>$X+*E;@:E7@6_RV0HS?LQ#?">R%/J-6G]$;"_'U MS(V.,A?%O?%!YHZ-XE[&PO=V]R:W-H965TC%TH]DDL:EN>I"3-
O]^1[)BD.(:. M[L:6K/.^/H^D(T4'+AYE!J#(4Y&7T"\I**X[,MZ6((]Y3.2MA*8C<%045QSO(^6%FN=;IPSW; M9DI_L..HHEM8@?I1+07V[-8E9064DO&2"-
C,K%MW.@]UO GXR> @S]I$DZPY M?]2=+^G,?[M4I7-K+%%4MC07:[N^>$S-#R!]DMX+LV3'.K886B19"<5+QHQ9E"PLG[3IV8> MS@3NZ(K
:P3>,X$77!'XC< WH'5F!FM!%8TCP0]$Z&ATTPTS-T:--*S4J[A2 M D<9ZE3\%7 .)/E OE,AJ)Y2<;/[X?[=;N62N"&^=U%5%L,NRUT
M$4UE11.865@E$L0>K/CM&S=T/G;QO9+9!:W?TOI][O&#V;*0$KH'@16(1:;+ MF)5;DNN)(I$06Z.0$7WVO;;CXE1DI
4O%29[,+O=Y@T#I/&@;ACDM*C[&$? MMNS#_\O>;S^J,^]"[A7^XXH'+77P,NJ4R83O2D6PE*$+L_9SZ]- G_#[V!DX M_AB+=7].=24N"-JXBX3#-
N'PE1,..Q,93KQG"??^]Z7+8)^=I_HN^T;%EI42 MM](&[9W!"*='U/=#W5&\,D?LFBL\L$TSPRL5A [\0WGZM31IW9[2<=_5!+ M P04 " "Q@EA9?
D#9VF0# <#0 &0 'AL+W=O][CN-'9KZ7ZJO> ACT+1.Y7@1;8XJK*-*K M+61,A[* W+Y92Y4Q8X=]$^E" 4O+H$Q$%.,XRAC/@V1>/KM7R5SNC. YW"ND
M=UG&U/=K$'*_"$AP>/# -UOC'D3)O& ;> 3SN;A7=A0U65*>0:ZYS)&"]2)X M2ZZN:1E0SOB7PUYW[I$K92GE5S?XF"X"[!R!@)5Q*9B]/,$[$,)ELC[^JY,&
MC:8+[-X?LK\OB[?%+)F&=U)\X:G9+H)9@%)8LYTP#W+_ >]")B[?2@I=_])] M/1<':+731F9UL'60\;RZLF]U(SH!E X$T#J EKXKH=+E#3,LF2NY1\K-
MMG< M35EJ&6W-\=RMRJ-1]BVW<2:Y!5N21A?HCIF=XH;;@5RC?PI0S/!\@UB>HO<\ M9_D*4#D9W7*VY**;>G8#AG&AS]$KQ'-
TQX6PO=;SR%AO3B%:U3ZN*Q]TP,H+-7Y_31+:TIC[:U$?+O*.!O&TA5:4^9U6&L3^#VQ97 MNF K6 3V?Z]!/4&0O/Z+Q/C-$7^CQM_H6/:D+/=,@=M
SJ6URV6*6+D*MBD& MLB6H2N[0GG-?$95,7,JXK?B4Q"&=1T\>;^/&V_@E;Q.?5!4U[4C1T9#6I-&: MO*05^[0F?2T\I!4W6O%+6E.?5MS3(I-PXM>;-

EK3E[1F/JUI7VL<$K_6K-&: M'=7ZM 4+YK4!Y5.<]11'TZ%.7C:*ET<5V]TE*HZ(#AL*]MWBVVB4[L!GZ++? M A*'8[\C@EN@X:.>;D'K*\2S8F<@K7Q9--FF@#9>+N&>CPN[%@.=(1VPDN.K M(0T3M7ZG+5X+I-*3 DE+0G(]=@((29^HR.TI:#]-=RD'HXB,/1@(T6@_27 M8;#.%#_KP\\+$W7.NNZ[X8ZI#<]MPV%MHW XM;M%54?Q:F!D41Y_E]+8PW1Y MN[6?+Z#&PO=V]R:W-H965TD7:WOQ]J4MD76A&S@K-0RQ1,^=P MSM"C(;TXDNPKW6+,P/,[!]!R,KH-UQL&L',RA#%;E8 UEL"L'>ZB#4SDXA?:E6(72 M+F)HM,QUX,9;X+>&%/)]U1@ZK\ 0S[T4 MT/G;[[RX$2U%]JAF47I!"[-XB!*;TQ*OP2;MBCUFK"ENEVK;DM5?T"OZ#GF M13K<8\#(27"AS"76I#$!:,]4LR.SE/%2F0=1>F-2^B)*6S7$0CNUT(Y4Z$<<MX.APTGJ3D>0=M9W^/$RK,8]2;2GMI6H/HO3&I/1%E+8Z%:L!]=6>R)?U/@NV MO$_3F9.HJ[@_Z14 +I75-G+[2%-3M6?-OXZX M?5@(I]VZXDO#_V"EGM;B3J7B/J%\$;];+*:]T'>6HW;"78NL)CT9^U8&M'IJ M>P*SO"A/.^))P_N@>+-:O)E4O$:'[*6,]S8BZ:00E_8N8X*Y8X)Y8X+Y(X&UMD@KUT[Y'_Q]ZUHIDI,2/BN:.BN:-BN:/A=9.?F/3"Z7?Z2KA29EP>56LH-JE M3._U4'+&BW,WB-0;E=07D>KFN3X*&B>U#:G:?Y#'T,[Y$<:/_BNEU47+.B_4> M0.F-2ND+*)US710\[<2A=,MWX?:@ FMEW.J^?==RRHNE'L+ICDZUOUVW]Y:)>^\+3&@6^"LY?B:)Z"@.Q35A[; MU:/U\?]-<>C=&;^%\S44C+MP[I6'^R?X\K>&>Y2]1"D%,=YP*JX&#RPKC^_+ M&T9VQ7'S,V&,),7E%J,09[D!?[XAA+W=Y 3UCRBK_P!02P,$% @ L8)8M6>>1F]NR! L1P !D !X;"]W;W)K&ULM9LMC1G\\VX9H_] M]^X5\YPBH&SQ>\2?\]9[4AS*(LN^%!L?5M<]I^@1C_E2%HA0_=OQ6Q['!4GU MXVL-[>US%H'M]Z]T5AZ\.IA%F//;+/XC6LFGZ]ZD1U;\,=S&\E/V_#.O#VA8 M\)99G)=_R7/5=C3HD>4VEUE2!ZL>)%%:_0^_U2>B%>">"]!U #T,&)T(\.HM[IP,@SI@<&Z&81TP/#?#J X8E>>^.EGEF?9#&1BI-SGR\D>4=^#84("XW)&Y_+,(KSMVKOYP>?O/G^[:PO5::B M?7]94V\K*CU!G9*/62J?D&H0P>FM_MC#'_CFDGC.R7#__'#/$!['8PWV^5.'NR7!VSK$/BW"76LZEMY?<*WF>3?(/M:2[%5@T1DOQYIQJ0#Y(G^5^&WMU4M(&95HQ\5_DF7/+KGAK:5.4^*" MK$66YR9!K)BN@E2P8>LT4\WPEF M +5BN@H[.9ZGZO'S< !%I@V0, :"::I-]ZI-SQMC+\AJRXFJ9E](5CP6^- $D-I/I060&D,1=-E M;AD&KO5^OA=1NHPV84S")-NFQD>*&G'&H'EKS]99-R0M@-(8BJ;K1AO=J%6W M\O:,]K?G!J\;3J;'R@5I"4%H I3$439>PL852"_" [I[..QX[04?D#M8)J6GM(MF;A&+QV55Q>D<7IC"'0M,&4!H[XR!TE1IKAX*L M'3NGLRK'ULYA30--&!@2F@<(ALJK"](X._3??DVSR^)=E*]4O!5),ECN(SB M2+Y<$^5-V59\S=I6MU6K5C=R8@=U/"!TGPH+8#2&(JF7PF-X4.QA@^%&CY0 MF@^E!5:0]%TF1O#A]H-GU)55>0[+K1"%[HM,*&@Y(H2]'Z=NV,8*HW0@Z*>TVW>:J%%IF21+)\N:..^8['1EVAGE!- M:^LZF(Y'1EVA1A"4QE T7=?&"*)V(^B\.?J.2U58%?I7<[117:A3!*7Y4%H MI3$43;\ &N.)3K%3,]1L@M)*"V TAB*IJ]:,.PFS^IRM!Z.8FTD-TEL1W5> MMN EPNO M#O;?NE=^M9"LP53KVCZ&8AVEN9J,'Q72N1RK>5)42\6J#9EMRJ5-BTS*+"G? M/O%PQ4710'W^F&7R=:-(L%^P-_\'4$L#!!0 (+&"6%G].@!);0L "RB M 9>&PO=V]R:W-H965T<\N)+>2-E)?YBFJFY/Q^-R<2/727F4W\JL?N5S M7JR3JGY87(_+VT(FRTVG]6IL3B;3\3I)L]'YV>:Y#\7Y67Y7K=),?BA$>;=>M)\777^0J?W@W,D9/3WQ,KV^JYHGQ^=EM-QTV+?Z5RH=RYV?1[,I5GG]I'H3++Z-)LT5R)1=50R3U/_?R M0JY6C51OQQ\M.MJ.V73<_?E)]S8[7^_,55+*BWSU[W19W;P;S4=B*3\G=ZOJ M8_X0R':'CAMOD;_*S?_%0]MV,A*+N[+*UVWG>@O6:?;X;_)G>R!V.ECV"QW, MMH-Y:>K[6#M=WAID^RV@WUHA^.VP_&A':9MA^E>!]-\H<.L[3 [M,.\[3 __MM,-)V^'DT [&Y.DW-SFXR_:7_3CI'F?)9HHY296HIVX]M,3/A_KFX2;)K*3XFE11)MA07^7J=+]/JJ_A0I(OZA;3\(MXXLDK25?FC^/O? MYM;4_DFDF7B?KE9U!)5OZR>-Z?'>:'"^O='(NKJU7S7]]&\]0SA/QTJ9]G#N$W)AK"*$>_!XL/QHR3_FU2 MXL+:OOE8&]=^P;VX*PJ9+:XV;S$/2;$LO;?-IGZKWX$J62SRl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|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{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

MTX·!J?N@0I/S!)SXQY\Y&$RO>M9//0BC#>IYXD&#R&<" U'50HJ'Q0X M)XF&R"3!-H2X;3#KPX3#>WPT1*8)ZA!BZC[4I
M\]WY=)$NJ.>F&H+$A[C$3^J[A,.]>#1$Y@IJ'.(- L.5Z ^3Q$)DDB"E(2ZE M$WHNH2J7FNG7!?5-?^<3<*,T=73/!8!(II-"A2;G#8H=33YC'Y%NZ:G0Y#Q!
MJ".\L3^N^*+A3CX:(I,#D8[&G/ISQW=;<#SCJ7F)A^\1:'\T^=A?1+J+IT*3 M\P3?$.&^8?SN-AKV#&B(3! \0S3FR)]KU&?!(8UGZ"6>"D1@0Z+)9_\B4L=!
MA2;GV?DT/_Z P6!ZCT 15HE8R)'@HO--,/77\-S&Q4.2E5;*MV*,/;\-<''\ M9IOCFRK?-U\.5[_>U-\W<_I^H=7_4$L#!!0 M (+&"6%G919YY7P(,,% 9
>&PO=V]R:W-H965T$"KJ& /TQ[<]-I8.'9F.PW\ M^YV=-"I;8'O82^.S[_O\?>?>I8W2CZ8 L.2I%-),:6%M=1X$)B^@9&:D*I!X
MLE&Z9!9#O0U,I8&M/:@4012&DZ!D7-(L]7L+G;6]MH)+6&ABZK)D^OD2A&JE M=$SW&W=\6UBW$61IQ;:P!'M?
+31&0<^RYB5(PY4D&C93>C$^GR4NWR<\<&C, MP9HX)RNE'EUPLY[2T D" ;EU# P_.YB!$(X(9?SL.&E_I0,>KO?L5]X[>EDQ M S,EOO&U+:,TC)
(U;%@M[)UJKJ'S<^KX@V5< MF!/,NU_R?'1"3DB7));+@2^CDD#B^+<%4'>";ELA42O"%E"-2)Q^(%$890, MP&=OP^>0(WSLX?%+>(EZ>L2]76)/%_\]
[K,NR%^[AW'[_%GGTQEF.+P)IL M7!UVK@Y#AEN6B6=Q\V*71>%X-$F#W:&3H:QDE/19+R0FO<3D38DSIO4SEUO" M2E5+.Z0N&;@W^D/=4-
9D=/:;NN"@Q=QXNV5ZRZ4A C:("T>?3BG1[#Y1BF[#UPC]W,[^P502P,$% @ L8)8661ID%/J M"0 >&8 !D !X;"]W;W)K&ULO9UK]7V,182!8P M>9-\Z':
<QSENXR&JX/3-A]IX_%TM VC9'![??CN2W9G>Z+.$KHEXSD M^^TVS'[#>8AS.DBC?\3K8K-S< :D!5=A_NX^)H^ M^[0:T*3D+=,X/_Q+GBO;\8
L]WF1;BMGUH-ME!S_#[]7&^+,@7'D#GKEH#<= MS L.1N5@=‘4P*P>SJ\.D[^Z[9\\)?'S@G!..U(QH%G7-J1?ED$
MY*XHLNAA7X0/,25%2KZ$&=MG/I)_LU6+[3>_AM_)?[^F<4S8@?HYS%;_D^T! MQW9,>3OEXG>5[\(EO1FP/2ZGV1,=W/[];]IT_ ^9_) P&PESD#
7"?.0,!\) M"T P3N#F2>"FBGY[3Q^C)(F21Q9R)&P9N9T../-7)D9ZYG.FWG2GIG#.6_F=^E9
MT,KBYF%RFH>))*FS3WO4"T^61.+HER>A+E5"G*NVVZ+X/# M6G,L-&3G5F2=I5MV1E/'BVF;?&4J53;>5Z5(F(V$.4B8BX1Y2)@_%12H-0_7
M@6AS4:.SDT9GKSMP?B3),4XKPN\R\(YD)A)8A%;8B:)11R)F36UFO&#*^N;&(UX,C.Q&O&[C31H M[1LW$?/31,R5$_%K6H2Q:/LKW?H>C9$P&PESD#
7"?.0,!\)"T P3J_:N,YE MC=_I'+QJ"*1Q*,V&TAPHS872/"C-A](%(V7^EG:5GO]V7C%X../;=H\FUW(M[+2Y/C0:2Z74SC2:2ZHCM;,,
(5B1VK&%RVRLEI7=I,%K+)8=>Q>TT?@9T>L9 MT=\VO*SX?>)+B8LLP)2922),F9DDQ)2926),B9DDR%1OU-X[)8C&2Z!. 6O* M!%R'T+4"\-
O.F#;WM$5E-VW9ZG7Z6%/GC[N%L] T,)1F M5[3S)6S<7(.AZ5THS=/$?.M8R$:UCS%HX?#JJ!.WVBLSM[U*7NK&>LL(2;.A M- =*>RS&F1(K:VB-
SW^T"V*MT]>:.G_]QJ4P=>N]U8NDV5": M Z6Y4)H'I?F:)($OBM<2KCZSU"JM,_R:.L7_^IP%M!8 I=E0F@.EN5":!Z7Y M%>U<:'I3BW/)B?
U9HHV_E++.W^O*I&F'_$D%4/1MH6ZCKXB@-*>B-;9;(R?F M0MOTH#2_?0*"MD'RXJ@SWKHZX[W8A,EC>7@B],]!5/P@X7H=Q1%;2=EW3S0O
MMNR\F)3GS%+A*.%]#U10F@VE.5":"Z5Y4)H/I04H&B_ONGR@Z^^4[-&1*?4%
ME&9#:0Z4YD)I'I3F0VD!BL9+O2Z3Z.HR2:=DCYK16\70Z^!UL:XAEER@3;I0 MFB<9@!"&^%U&&;20>(74E1M=7;G!)GS4C?66$K30
Z4Y4)H+I7E0FE_15+G(MRJ21$[J0W]'KJHRNOO[^C?,[ZM9[BQ5:JH'2'"C-A=(*,VO:$JQJDQXI=9% M%5U=5'EU=D?-[ZU%:,$%2G.@-!=*\Z
T7V\OXNAB$4=QX*RK.+JZBM,ANR/F MYX6(8Z%NI;>,.H 47R0 TX?HI:),>E.9WF8&@992\/.JZB:ZNF|ATS;Y9L<@N M89*LJN>]!
F+ROI+LV+C!911@^IGAW3D3S>@Y9(H#0;2G.@-!=*\Z T'TH+ M4#1>ZG7919^_5ZX'6G^!TFPHS8'27"C-@])*"U T?B'(M0E'4-=TNF4ZU$S
M^JH82K,-635CW+S:V8$VZD)IGFP(<^%BW6X##=I@O$[JZHZAKNY@,S[JQGH+ M"EKM@=(<*,V%TCPHS393?37-3KV<.
(U"665Z=^U/S>BL0^A@C[""+L@XBP M3R+"/HI(=CM.\RK?H,V*5V1=TC'4)9WV[(\AR==KFI#_4;?36TO0^HMT",). M[T(;]:
TO]LL!*TCY6525U<,=76%G>S2Z#$ARWW&3H>7/TB1A4D>'T(]J6B@ MY1(HS8;2'"C-A=(*,V'T@(4C1=T780QIN^4ZS&@U1@HS8;2'"C-A=(*,V'
MT@(4C9=Z7> QU 6>;KD>Z-TW4)I=T2QN43.:3P*"MNE":5Y%X_@GDW$9(_D MP4W"2 :#]C0ICL8KI:[U&.I:#SC; ZWW0&DVE.9
:2Z4YD%IOB'>$B,\12N0 M&'TRII>>$V?4]1E#?5O,6V=[H$4;*,V&TAPHS872/"C--\2;9IJ752A-^$?R MUN454UU>>76>1\WQJT4HS8;2'"C-A=
(*,TWQ1*->.R4&"F.G69=R#'5A9SV M/$\%X&,4?2XD>M0-]183M.PB&X.N"9?*N-!6/2C-[S@/0?M8CU(9G;V%8DNS MQ\,K3')V<&)KZ?
$Y^J=O3Z])N3N\'*3Q_;UVY6F2[WWM*CB^!*7&'],)\CG, MV*E'3F*Z9DV-AS-VD,V.KSDY_E*DN\,[,![2HDBWAX\;&]YH5AJPOZ_3M'CY
MI6S@]+*9V_\#4$L#!!0 (+&"6%EZ.$T-S0@ .E1 9 >&PO=V]R M:W-H965T:![8-LF!Q8+'[9)>D^X.)C>C_*#BD+MD70 M/AK1\7@ZV@=A/%A>%]]]2)?
7R9%'8=_O]"= MHO&B,9^#C*V2Z%_AEC_<#.8#LF6[X!CQC\F3QZH&37+>)HFRXE_R5)4=#\CF MF/%D7P6+&NS#N/P_>*X,Q%F X'@#:!5
VP%61X!9!9A]ZPJP.H;,*D")GT# MIE7 M&_ K J8]3U*\RI@WC?#H@I8%'(HSU]Q\MJSTH?_]1AKP]?Z\/=!*L*-SG"[?^5-1;C3O_*J<+=_Y57A
MWO<=>?]WM[TA!/-T^9@%S^S@M>5/Q'A"DAWI=5G]^Q=!(SYG^^P_JHNB3&VI M4^>CX%5V"#;L9B# &4L?V6#YYS\9T_%?
5(I$PM9(F(V$.4B8BX1Y2)@/@C4T M;YTT;^GHR[^)*5@61$S9D9>ATR(TGV@]+F?6=+BX'CV>BU&;X%(Q(F&VJOZS MH=6LOX-
,Z2)AGEQ_;EA6NP&^HA@U9L/YJ5A#&9.3,B9:9;R2K.C]I-DFY$@ MWI*\ON&&921+(M7 ?5<"9V<5>6?-Z9"V!*/->ZE@D#!;U8#)8FBT%(/,Z2)A
MGJ(!AF4LAI.69%3ES.FT2S/3DV:F6LV4HR-[%JNWC)$W8;Q)]NRM2BI3Q9%N M"WNE37:I4) P6U']R7#:D@DRHXN$>8KJ&^.SDU^*1%&*TC,I-
20R.TEDH6(M7VB"?&9B;<|(J1#"@V=6]C'LMV/(O^8KC%B,3-7/HA<*=KLP"HLIF/CJ$,2A M>LB:274VIE9;_BMM%2\5%A)FE[#)>?WGLY:ND
E=),R3C[Y%Q^WKPI=+3>BB MJ^N9GW0UU^KJ"\&$&%7,=B$G;ZH>2-GSS&55FU3J>K3)+E4($F8KZB^.7GM2
M@TSI(F&>HOZS\;"E<5]1:MXYI5F<-++0:R3A0412:9=#=5C%SDP-(PV?Y< M=#VBSQ&]DDI "_D2-5L27RVD*9EA&$.S66JM*C5IE[(7BBY-
8CD*UF32GKFX M9:GY>2EKW"SCR?G,*94N8KF4-9F>R;!Q@HQQO8,UUIZB[UF#*_>BM.DN77=# M:6LHS8;2'"C-A=(*,U'T9J"/]NR-
5YOTZG*C5(_DK&TFPHS8'27"C-@])\ M%*VI?EJKG_X!(W*5I#%;&+='R)6^*A?
+%TFS52TPI3$>FM.%TCQ5"PQI6JUV1^,2RMT3$;X7N'H/K&NHT:%J@;1;X$!SNE":5]$FC1E3 M>[:A:.6B<[91FQR&WN7HO=5HR#OH8\D-TR>
[6"90FT/1 $.R.: I72C-4YX! M:5(J%Z*=*JE]#D-O=("6-O)FN>A]VGZ&OBH7:PCJ.*A:8+9;X$!SNE":IVH! M;2_.?$.V:M[-.D14FQJ&WM7XH0L;4<-1XV-X'Y/-
,4U9O/DJQKV8I\&&J\<] MI!&P@M+64)H-I3E0F@NE>5":CZ(U+Y?:WS$6K[CJT9I+%ZL?25M#:3:4YD!I M+I3F06D^BM:\C;GVSJC>.]/>RU?%G@]/+>-
OI<=?*DDHS:YHK7E0:R[M0'.Z M4)JG:('4 %_53*/KEAM:FTQ4NXW_>^[EJXC?6./J\UXL&@EI&J!(=TH J@56>Y7N5Z4:$T_:H9C:F*%Z8Z;_G7P52-
NQ0)T7*,VF2N=%4@G4>8'2 M/,4)D"2B:.1TV"62VG:AKVB[E*N3IR#=$IZR(#NF7TF4;+ZH1S>H'P.EK:$T M&TISH#072O.@-!]%:UXJM1]#7]&/H5
_!DI;0VDVE.9 ;2Z4YD%I/HK65'_M MQ]!O^3&<"2Y_F5 H12QOZ$OS"*BC J795.D)M1T5:$X72O-ZM M"M5[*M\YE;C=)RD/_UN%[O(GY$6"[Q:)
M%,3J6SWT%;^X<6B"=E!64MH;2 M;"C-@=)<*,V#TGP4K:G^VB&C>H?L=L./01H&$;G/EY-*#K[U/Y$:-QUP-&9FV2F'J3Y ??&F:J=OG;?8V^BI?J"DJS
M^S3 @:9TH31/V8!V7Z,HU&FSF+7-8NIMEMXWAIE*<\5HRP1JKD!I=J\6.."< M+I3FJ5O0-N34I;IZH=I>,?^(YUZJ)-.&U-
OW%^IK^[9GZ7WQSL!,##;'F)>OL#I]>WHOX6WQ-K[6]W?&E6LH MOO>,*[I\ZV"-+U^^#Y(W.G)F(D6H\G(E1.2W?
*UA^X,FA>.GSN=ULMUMDWKZW*7%>POCV6U M31OV:_4TK7=5EJX.1MM\2F8S9[I--\7D[N;PW8?JIJ;<-_FFR#Y41KW?;M/J
M^WV6E\^W$W/R\L7'S=.Z:,^8WMWLTJ?L(6L^[3Y4[+?ID66UV69%O2D+H\H> M;R?OS+>>)Y;4&!\0?F^RY/OELM%7Y7)9?
VE^2U>UDUGJ4Y=FR:2E2]M_7;)'E M>'RK/*?$[K;%'F_]ZLFO7MQ)L8J^PQW>?-Q_(Y MSOH*V2W?LLSKP[_&V-F0?;3='JGW[K&^+$@/' !J0W(**! M=<:
]@94U\#J#2Q= [LWL'4-G-[T35P>P-7MY6\WL#3+6'>&P/Z=#%[Q\ M/VW2NYNJ?#;J%LW8V@^'##I8LYAOBC;9'YJ*_77#D)[AW5:9>LR7V75[[41
M_+G?--^-5W[6I)N\?FU<&9\>?./5;Z^-WXRI4;?@VM@4QJ=BT]1OV)?L_M- MGK.\K6^F#7.HI9TN^\+ON\+)F<*I\;XLFC4KMUAE*_^5MO/%?
93UA#'UB O MK7%/E(0/V>[:H+,W!ID1"_!GH3;_^[Y0FOMJ_=IQN"C9_B28LDN'776=H7NT^LVU1^:/R#\]YCL(YJ0FQ7>?:X^NQ &"._[MV>)C?
P;Q3F,>9 M0HX 7*]E7+L\+(1@S#/"PR+0,^MZSL-B'<^2BUQ<')QC''S<<4!)-W8QSC]GG*K/O'^R.?E,LRRW8_5VY!E3H MU(L.XYYB3/.:"EW?E?
J.:=HB*@"X'(DK!%"V?2WTU@CPW1):/I:]H@X1AZU$ M1EFV=5O6*.,)4+8 *9:.',#2$8*$N M%9V+()PS$WV+P:K.'''02D#ON*L.'ZX3;
<]4ALMGX_LJ*U:UL5G7K\8!9NHE8]&DWX#LXA(2@N*%8CMAZLLN"P$)=[-BK-RI;@,H6HK)%]&RQ=KP2K'+Y-!PD1%.M M(?)I"*:>!4SY M[!\?
DD%5,]6RVLB1P98RC4 :P4)=ZNB! 9,M0&4+4=DB5+98-UP)5K%\$@Z2 MHJG6%.6II[$[WBFT*;DJ<_9U/7P+9R>JU-BSS4\:;R;V7U\'%*#Z%8)%FG-Q M
-)!Q:B>)5AL?!8-TJ"IU@87Y79;]H]=P?10FH].#TPV'Y4M0&4+4=DB5+88 ME2W!8N,3>)!8S4[>^S7K"$Q,87*!RN:CL@6H;"$J6X3*%J.R)5AL?+H/3*/3:"-
];62@C0RU-MD9$V,M9&)CI(/ER#6$K48NEET8/(PB#48W10OA8JT$*%6JA("Q5KH9)+*#X$ M@_Q)U/+G(MUMFC1O)U/!MV56UZTT_2&MC#_2?
^'!*45)BJ;C\H6H+*%J&P1 M*EN,RI9@L?$I/4BIQ/J%]PH$=;$F*IN/RA:@LH6H;!$J6XS*EF"Q\>D^R-0$ M8?5GSW'Z&(Y2\0G; D#9MB3L 2B3R-
(>!+/EQP80S#.EI0(C% B/330\RVY MR.;8E!KB5JM_+&E8#T]_U!5B&$H\YA_ MQ.V!@(E#Q>5=(8"R3++EW 5RF=-NA;L_16XZ1V%P(]F(]D6H\G(E1.2W?
*UA^X,FA>.GSN=ULMUMDWKZW*7%>POCV6U M31OV:_4TK7=5EJX.1MM\2F8S9[I--\7D[N;PW8?JIJ;<-_FFR#Y41KW?;M/J
M^WV6E\^W$W/R\L7'S=.Z:,^8WMWLTJ?L(6L^[3Y4[+?IJD

A&;Q6,&\&XRGV=_MK"K3(99X,>-LB[B>K6CZH+*K4JL$DUROK ?)U:]$Z>3B#[D!CJ)GM5(%H+.;
M/&$4SM$'}!ESCK7KZ"P$B4DFSM$[1')T2[),K0DQ0]NB79OW@-7UDUD\->E?EK4U>L$O>=6 $AI!$* O M#R$Z>W?>=U]FS ,4"N-
5F*$!$[X=,S!@HA^X&K3""T MI'U)-PI/3;I-6&@3%MF$Q99@'2LGK963G_D>,K%IMTU8:!,6V83%EF =NZ>M MW5/CDQNM5NK?
L:ZMJU)Y#@@PSY7SZN4#4U;V]T_3[[8#_D;8I;&]*=:9Q.6 MV83%EF =ZWSOY5^O9RZ[^/E8V34K3WT0K=)"]J3(*BVV1>LZNM?'\']F]6WH
MMERW20NMTB*KM-@6K>MZ\.)Z8+\(-\Q.%9X>5&%SW),=M$F+K-)B6[3:07>O M%4F!KZNFL4")1J)NZ;2C;6/Z8]6./1A?^E>AWS,>Z49VU?
I\P===\%O,UR07 M*(.5"N5=7*K7=%XWENL3R8J]$?K(&2T.MP 3H'K">KW%6-R=Z(#M.W]Q?]0 M2P,$% @ L8)864+H#E11! 1QT !D
!X;"]W;W)K&ULM9E=C]HX%(;_BI6M5JW4DCA\#,P"4L&IMA>CC@9U]V*U%R8Y M0-0D9FT#TW^_=I))2">82>NY&>+@\QR?UQ]S#IZ>&/\F=@
2/:9))F;.3LK] MK>N*< PXTRHW2Q/4];^2F.,Z<^31_=_G4W:0 M29S!/4?BD*:4?U] PDXS!SM/+QIB[4I]%^Y\NJ=;6(\NK_GJN56E"A.(1,Q
MRQ"'S8^_8CB)LV>D0UDS]DTW/D4 0TU M+V2)R/^B4]G7AB4!H.7>AB6!GGH;A%[+ARADLZGG)T0U[T533_DZN?62]\XTPME);GZ-E9V
MX]\SQ^TC&?Y\-,?K56NGGO/X%7OLR^.>!)0E2N_9$>?1OVYP7U$$[59^$MV)/0Y@YZJC+ MF<[\]]_PR/NC37";,&(3%EB"-:9F4$W-P$2?+VA"LQ#>
(P(AI&NUI?OXXJI; M&%E=)\0FC!2P<0[3_^..XHWT+K M>5< 1V4&LC5 HWG7M6031D;/-?.>:6,)8T;FTK;FY=M6G50RW+77C[L%P5L>'F5 M+
(WNNLIWU5U@R5U#NW&EW=BHW0J.P+5Z^39<0P:;N'V!&CE=%ZA-&+$)"RS! M&I,QJ29C\BJ)P<3FU-B$$9NPP!*L,378JQ-\SV)J8(9UG1.K-
%+2AH;LP);# MIM9GQ12VG2"8B9T%MTDC)>U*VF'+9U-SO];<_[4,Q6S?66&;-%+2KB0IMGPV M%;[+/FPL7;KF*27-E*B8'786\:K#P);#IH)U=8;-
Y=F7JZ> U9+,*HU8I06V M:,V9J"LX/'R55 4;*\/.$V231JS2 ENTY@35]28V%YP=TQ6KY:=5&BEIQF/I M-?*V%R
*_DRZ8K/&?%JE$7RJ9+7EL"EX7;1B<]5Z/5>Q6JU;I9&29I3W M-;I07)>AV%A*=4Y4)M=^=UN:'796*K#P);#0D'W[&(H!;6G]8V<0"$[9++X
MW;J26IWZ?* MW-H5#,R;>&=E#=G<[_!U!+ P04 " "Q M@EA9TN3&'L$" "W" &0 'AL+W=O%F%J9E.78MD6<08Y%C¥50]#Q%;XRT
MDS5C#WIRDTPM1R<$%&*I%;!Z[& .E&HAE<;/6M-J0FIB>WQ0_V2*R]K+&#. MZ#>2R&QJC2R40(JW5-
ZQ_6>H_9@$8T:%^47["AL,+11OA61Y3589Y*2HGOBQ MWH<60>ET$[R:X)T2@F<(?DWP7QHA] G!2R/T;X*Q;E?>S<9%6.)PPMD><8U6
M:GI@=M^PU7Z10O]/5I*KMT3Q9'A3Q"P'] 4_@D"7$4A,J'B'/J#[580N+]ZA M"T0*=$LH5645$UNJF)IIQ[7^K-
+WGM'WT2TK9";0HD@@Z>!'Y_E79_BV\MH8 M]@Z&9]Y9P164/>0[IY'G>$%'/O.7T_TN._\??:'(T8 VPV^]!QL]_Z_51Q$1
M,65BRP%]OUX+R=41_M%5[THQZ%;4U]I8E#B&J:7N+0%\!U;X]HT[<#YV;?9K MBD6O*;9X);&CL@1-68)SZN&2LQTQ-[%J!.K\F2))?
42["E)I#8R6;@N[T/=Z MZL^U:V_T4Y!W=0J*GH*&3F]X#%H\!8V&O5$#.C+<;PSWSQI>I"F8CM$RBSB6 MT.6WDG+=5@9.S[TZR7/>#>N?
P*)NV&!TXOH9V.#$M]VZB7/@&],"!8K9MI#5 ML6Q6FRY[;9K+R?K,'<_=CO5(=>6JB?Z1KUKZ+>8;4@A$(56A5-U4RKQJD]5$ MLM+T@363JJN88:;^+
(!K@'J?,B8/$QV@^58)?P-02P,$% @ L8)86269 MZ&4D @ J 0 !D !X;"]W;W)K&ULA51-C],P M$/TKEI$02%"G:7>!DD1J=T'L85=5*^" .#C))+'6L8/M-
,N_QQ]I*%*W7&*/ M/>_-F\F,DT&J1]T &/34#';L;XPY(EG2T MACV8KBU668M,+'5K06@F!5)0I7@]7VV6SM\[?&,PZ),]0$ M 8?"._9JEP/< .>.R,KX-
7+B*:0#GNZ/[)]][C:7G&JXD?P[*TV3XO<8E5#1 MGIN='+[F,^5XRLDU_Z+AN"[C#$J>FUD.X*M@I:)L-*GL0XG@/@Y0#P"8J\[
M!/(J;ZFA6:+D@)3SMFQNXU/U:"N."?=3]D;96V9Q)MM#;4MLT)T(/]A5ZBUZ MH$I15R[TZA8,95R_3HBQX1R(%"/U)E#'SU!_0/=2F$:C3Z*$\E\\L3(GK?
%1 MZR;^2+B';H86T1L41_$2Z:#\ N]BJL'"\R[^4X,==%(9)FKT8YUKHVS'_#R7 M=F!;GF=S4[32'2T@Q79,-
@#X.SEB_EU]/&"UN6D=7F)/7OHVQP4DI6=">6 MYAR.I=#GQ :Z*T_G)O20Q0DYG"H@)]W3@JK]C&A4R%Z8T$C3Z32&Z]!]?]W# M#-]353.A$8?
*0J/9.QM7A;D(AI&=[\5<&MO9?MO8IP24<[#WE93F:+@ T^,4 M_0%02P,$% @ L8)861]L=?V@ P SA !D
!X;"]W;W)K&ULS5A=;YM(%/TK(UI5]=3P;6RG-E)CV-U(21O%ZO:AZL,$ MQO:HP-"9(6[__=X!3(%2-DUYZ(L]#.>:<._?#%ZY71\8_BP,A$GU-DTRLM8.4
M^85AB.A 4BQTEI,,[NP83[&$2[XW1,X)CDM2FABV:7I&BFFF^:MR[Y;[*U;(:MA&;DEB-1I"GFWRY)PHYKS=).&W=T?
Y!JP_!7.=Z3+9'O\UL.5T:C$M.49(*R M#'&R6VMOK(O0,A6A1/Q+R5&TUDBY<>._Y#:H9G2 MBU@BRD]TK+&FAJ)"2);69#A!2K/J&W^M
]$B@,XPP:X)=I_@_H3@U 3GL1;< MFN ^UL*L)I2N&Y7O9> "++&_XNR(N$*#FEJ4T2_9$"^:J4+92@YW*?"DOR5[
M2+M$5UE5="IYVVB+$R+0_3=TRUE<1!+]5$F1HI. 2$P3\1(@[[LAT^VW@F&TU2'4^HY_U,==R1G M7-)L_PJ6$PX2]%)1#*T@1IA M"8VQ)#'Z>
W62@WQ::APJJ.YPT=3#?1"Y#@B:PTZI"#\)@6C^BV>69[X>RMJ4 M8L&48N%$8IW\NDU^W3%U_RT\B83ZK0_%OZ)Z)54];Q[\N>OIRY7QT [L$&JN
MNUU4\"/*MERW#PL'8+8UUQ<-K./EK/%R-NHEU&3.*:0NWC2T08='57ZUX*84 M"Z84"R<2ZZ3":U+A_;D-Q9LROU.*!5.*A1.)=?(!;_(I?
WI#J:CSUJ_:,ZU^ M#]@,H6Q]UFLH/Z*LN6WJ7J^A#, 6IM."=;Q<-%XN1KV$JL,<7G'/;W!6[&!1 M<"B_L=8RJO>KI3>E6#"E6#B16"G.IN>UW!\N=|?
OO&9A#F]MJ@@&8:SNM%Y$]'D,PR]7M7GLQ6O-92OB^ M'(P%BEB1R>IEO-EMAN\WY,R=.%,M#\A>'_!U!+ P04 M " "Q@EA9I=-:>H+,' #J,P &0
'AL+W=OPZ.N7FGVC:T0XN M30B[[JPX7U_V M^RQ>H31B/;I&1#Q9T"R-N/B9+?MLG:%HGC=*DSYTG&$_C3#I3*_R>P_9]{IN M>(()>L@
VZ1IE/VX10E]O>ZXG>V-1[Q<<7FC/[U:1TOTA/C7]4,F?O4KE#E. M$6&8$I"AQ77GQKT,O9%LD$O\B=$KV[D&4I5G2K_)'W?SZXXC1X02%",)$8D_
M+VB&DD0BB7%\+T$[59^RX>[U%OUSKKQ0YCEB:$;3O_"026F!)B]RZ^>MA;TP MD1/EB6?B*1;M^/0)+87;.;@CQ:23SNN"[=W/F$0DQE&B/+\
($()PPCZ"#P 3 M<(^31-QF5WTN!B1A^W'9^6W1.=S3N0?N*>$K!D(R1W--^\#&J*P! MM]:XA4;)[3N <_Y!* #!^#K4P N/GS4C&MV/(QG@ G>,1JPB&*
<8/Y#@Q>^ M8UA[\!3S>=5D\O(.O .3Z1&M:<8Q62K3YN\OA$<<92R?W1SI< >Z+%EP+QD MZRA&UQT1$1G*7E!G^O-/[M#Y1>
<@FV"!3;#0$ICBH$'EH($)??K'&F51[IAU M1A>8Z]Q0(QS!+G,O$S=H=OSKOHON_;52(U&3:F@+35PG:94V);R7;_G5E**
MJGZEJF]4]8G3^%M7KB%S$--4+*RLF(;H35XCG>I&Q%-GH$VPH ;[9BHZPYZ M@X8A-5+0[4WTAAQ6AAP:#?
F%,@:$W>:8K2D32P%=@'42$>WD*:#\G1$XC8ES M4"(X*!$. -=9P>T.]GJ-*SY%1ST?$>+:)^2:3[T=$YH#R%*$'0Q^V;L:,[H816*
M(6/[>"O_"1"DG03CMGN\'FS812,TZ0TGRK^&H31---%$)S7HC?3&FE3&FAPP MEE09/".QG"%0& #PZ VQW%KH^T:LH#
*(9$B;9/A;O2;18B+4UXF4,B@C63Z1) M:\S<-"2I/65'+'HX:-)NV("YV=5Z.P45O*AY-]$\IUZES2.5KI]TWZ+&:- M4#QI:HTT(AN1:91OUS;G
*/^9TIE,G!F2K:$&)IGBC866CB&KBG73=/7(% M+Y,M?=IM!#G9<#;1 JMHH2TTU1VP=@<\8\9;@MMRDTVTP"I:: M-=5/-2UQC
M5GU4WEM"J.&UF;V40LIB[KH8X<1^^1):1,ML(H6VD)3O503%-<_9^RP2E:LH@56 MT4);:*J;:OKCFOG/4;&CS4A75BXU98"#1B T&(FYQ
(^8/ACMBJL(U M#W+-1$@:/6:4\$SD;]WI*I$32:TQCAA[.7F"VD0+K**%MM!4?]4\SAV?,XX8 M6>+);K*)%EA%"VVAJ6ZJ&:1KII!'Q9V83N3CY0&KE-
!*';C"%M)'_8:S$4 MC92WPZC53?2:!T(S#YS13$Q%07MS,MHIK:(%5M%"6VBJFVI*"8U%!,U;NF/!!<
MH#FIKE!BF0H+AT6"PR(AU%5:]M868,TBH)E%S(1/ 28OB/$\".-T'>%,7FK5 M/5Q'@9HBB-=^M0\74PX!J0K7+):+Z=
795CTM3[<$'E&)Q0(]1U]A4=89V, M0W-5Y2:5:^N_10"3%8#X^P8S+']V,Y3DI0!,>$26^#D1^1%C:,^[KJEC."U& M64H-C5*!'JNY&W5(2K5(G?="<]Z[-
QD4K!(Z$)UICR($""$_)%/EK+L>,^:-G-D?@+1'-A6QSMR>;_(@N0XW0WK*W5R?8GCG!?E] >D*) %I^_K^669IL M?#-/,
<%".I+'"4$9IO0VMEKKL8H66$4+;;&I[MTY@W;60VAV3Z'9/89F]QS: M.0ZB>37M\4SHMC+')D.$8,,)IH]^K,XSCY[;!:=+**%MI"4SU:TT5O>,X@9N2B)
[O) M)EI@%2VTA:.ZJ2:YGG62:T8\V3=6RV)6T<(2K<%-F_ME_9UO%(DK"8_&F$@ MIAO"BY/GU=WJPY2;_'.,OOU;IW+F:NX'[F58'92PQ=?
P=P+)V'"0((6HBNG M-Q+O?%9\6%+\X'2=?SGQ3#FG:7ZY0M$<95) /%]0RK<_9 ?5YSW3_P%02P,$ M% @ L8)868T9#]-M P QA8 T
!X;"]S='EL97,N>&ULW5C1;MHP M%/V5*%VG5IH:0M9 5D#:D"I-VJ9*[*D,@5:L'I]912Y5>N]4*O90PX0YZ8I9>IJIPQME,J+X;U2;' MG#[&?
=V[MR>OO\TR=?'*,>>C-T='K;/6[>G%)G)20:>N9R4^ M7R=NB!YS#'=0A.K!2#L[I;DM3Y2Z:TGTN,[S&'.+K.,SX@D=Q+G3L]?
SY\X:>HRZO0LU3ES2>E5A#WI))IKZ#EQCT'%)2IT[POON MD' VD@R\$I(ROC#F-AC&&<^DH_3"TD)\L:3W!O9-#]9>UP+9K#(->3I2B4ESJ3GEQ:7P
.57[9I%KA1-)%G[[W&T7ID&/TP3D2#:9PEEEN0>@4EFJ&S$CDTR04L/2HVIHVC'E_!IN M2%^3->YYLC*C91V*NJD%54U#8SK O\IFN%=IPV?
Q.CF[R]2'F4Y'E'VH%'HE M:<+F97^>U (P=A]G)WG.%^\YFXB4FN1M#CCHD:6?,\TDN]?1H%3&VD"EZ]Q1
MJ=AXU?)=DOR&SM6RG.8)KKE]@)K_[3A/J*"2\%71NO;W>92?K3CHO)3D\]ZR M*=BJL=IE[+O(\T,0&1Z"R(.HR>XAB(P.0&3GQ>Z:3Q'I'X+
(]OZ+#/:S)+UJ M3[FR<5W;MM96!UX/^NX7> WA35!G-&-<,5'UIBR.J7BP>]7TBHST2_H:O[X^
MI@F9<753@WVW:7^F,9NE47W5%0Q$=573_@3IZ:WP\MU$QV(BIG,:#ZNNG(S* MIJ,;.FIU@,,F=@3S,9@= 0R+@RG ?
(P7%N=_RJ>+YF,P3%O7BG11GR[J M8[QLR+#\8"'L/I$^]DE&41"$(3:BPZ%5P1 ;MS"$KYT-TP8>6!R(]+2QOF<; MKY#M=8#-
Z;8*P3+%*Q'+%!]K0.SC!AY19)]M+ YX8+. U0[$M\>!FK+[! ', M*J8-6\$X$D48 K5HK]$P1$8GA(]]?K!5$@119$< LRL(@R!U8@CF +0@"%! M4#X'-
YY'WO(YY37_7 _^ E!+ P04 " "Q@EA9EXJ[', 3 @ "P M %]R96QS+RYR96QSG9*Y;L,P#$!_Q="> , ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C|$%)I6M6X 4BV)8]ISI%"KM0L'C6' MTD!$VV-#L%HL/D N&6:WO606IW.D5XA-
/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T M>EOH^7%H5 J.W&,EC'%BM/XU@LD/[']X 4$L#!!0 (+&"6%D2*M(/D04 M (LN /
>&PO=V]R:V)O;VLN>&ULQ9I+<^(X$(#_BHK+9]9P*_,I$*J MF)#LIBHA5*"RQRUA"U"-:;&23)+Y]=.V(9&)Z=E+AQ/8&//1DOMK/2Z>E?XQ
M5^H'>\G2W PZ*VO7Y]VNB59E7K^6VGY4^66I]-8JS0==/KU!T]"6QE_.#TM(6=\;JHS MEL\?.8 ,.E$/;KB0VMCJBNK^'!@W
BZNCPJK;F1JA1YQ*_[2JEC+?%G>!OY% MU_D;51QVKW40S_7_":-:+&0L1BHN,I':.HY:I"5@;E9R;3HLYYD8=*[41F@V
MX4M1_BGXE=ND_H,6R)QPZ7,)'^C;I&(DY'D8CZ['T^L1@W?3A[O;T7 &!],9 MO-Q?CQU(#X'TC@CYK^= ^@BD?TQ(WX$,$,C@*)#?AW?
#\=4U48+^9T:,9A:L(D6!BZMKG#0OB)H7VG1QB"*81RK(K>0 MB]G4\CSA.C$.W3>$[ALMW:/8B+QHY.@>EJ1[U,&R[#:/52;8!/0Q77'=8$,%
M0FR0VQQ"9<'EPFVI/J:+/K$OI@0W31K,"WUB,0SAPE3"CR?L2F5KGN]%"M-! MG]@'(S&W+@N6]?O$:.7\DM-SPLFYC-
S+G>2QY"KW>6%U]T\7$\GZ?./'?<*G9 M$T\+P>ZAGQ5:E%]HM"B6\?O$*1]R:I$5:=7='NP*LD79Z;18B=Q :%U,+/OW MB=-_E<)6*DV$-E_8]7\%C!9<-
BSW]XF3_]2J^,L28F_)5M3%E[5%_/8\%&TL2I*M.? M"XGYPR/V!ZA"0CIA,\V3LJ0<:LVAC?>SLX?)PR.61VM!SDXF*I7[71&3B$5MMWDI?+02XF)IN
6#;OF&,.)6*5 M.T]&PG*9-IH\P&03$,NFM=(Y95.X=5*D;LT=8/H)B/5S ',76!<37?4@U@\:
MS49>#$H]!.0C&*=R;.N1F'0"8NEL2\=35KV!1]S8=DA,.@&Q=-X@A\8(2#_# MJ_1CF^.K)-.0"R=O5C^(^1R5=8Q9"#'U MA,3JP3'=M?80DT](+!\
<,W0Q,?F$Q/(Y-!;?2M/%Q.03$LOG,&8ULG1W@6#R MB8CE@T\9N(]0A/DGHIYA0S'=1RC"_!,1^\>9V?ABWF8V6M)FA/DGHEZI.;! MN"5U,3'_1,3^.3
#LQOWN)B8A")B"1W$K,7I8J+[O8@EA$:SN2L-DU!$+'"%W M^;7]R<'<$QUAMLVID%Q,S#T1]0Z 5LPI3R&F\U=WF^09YIXS8O<O7$Q M,?
>VEWNT#O_P%4$L#!!0 (+&"6%FP!0"]-@(!PJ : >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'/-VDMNHT 4A>&M6"P@N.Z+I!5GU)-,HVP
M.>6'8AM$T4JR^[:<@7U0#WH2<4:H0%Q^.?B$@,>7?&C'?7KB=43T]WLY< MO'[U^7\F=IO-?IU_=^L_QWP:_S&X_NB&]
[++>:P6K^VPS>.JJC\/U]VEOFS2 MW7ERM7A^6U7#\UNJZKF#!OD_B"%OT_R"#(Y@]R"/+Y@P*"8OZ@!H*:^8/N M(>A^_J ""J8/R@M4<8E0=
($:P*M$W*=*"+Q."'8B$#LAV8G [(1H)P*U$[*= M"-Q."'0J"WH-Y"H+>@ MWD*@MZ#>0J"WH-
Y"H+>@WD*@MZ#>0]"WHMY*H+>BWDJ@MZ+>2J"W3EZ6$.BM MJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NAMJ+
<1Z&VHMQ'H;:BW$>AM MJ+<1Z&V3E]T$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z
M.^KM!'H[ZNT$>COJ[01Z^^1C)8'>CGH[@=Z.>CN!WHYZ.X'>@7H'@=XQ^=F$0.] O8-
[T"]@T#O0+V# M0.\&]6X({&Y0[^8G]2{CUR&7:_W&J__DU2/YW/S]?*7Y??.R4VXX%S?5I2G MOU!+ P04 " "Q@EA9X"K5-FBQO5O 5$VP!98<_&-33-
NH26S9!LKM<5) D$% M*A)OTZBU/6_BD;Y5S^Z>/<7)MFO[N"C6*?E3QF*UIL[&TGGJ\\K2A^_I3RO0UH7[@-=S-X\40E/3Y-:& M=&V[O(MM6Q;3_Y=]")
^)$@?"]0/#=*' >EC#M+',4@?)R!] M\!E*(RBB&UL4$L! A0#% M @ L8)86;4>])CN *P(!$ (!KP &1O8U!R;W!S M+V-O&UL4$L! A0#% @
L8)869E&PO=V]R:W-H965T&UL4$L! A0#% @ L8)8661+>>TO!@ O1L !@ M ("!'0X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ L8)86;?
HA.*B!P <"$!@ ("! AT 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ L8)866,Z?0:D M! X@H !@ ("!R'X 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% M @ L8)8698,>(6C @ O 4 !D ("!I4, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L8)86&PO=V]R:W-H965T&UL4$L! A0#% @
L8)8626H4@XU!0 < X !D M ("!!VP 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ L8)86:#^3QDA!0 XPL !D ("![WP M 'AL+W=O M 0,$!1"@
&0 @(%'@@ >&PO=V]R:W-H965T&UL4$L! A0#% @ ML8)86<\G%68D"0 YQ@ !D ("!"(H 'AL+W=O&PO=V]R:W-H965TF !X;"]W;W)K&UL4$L! A0#% @

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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html3583021false780false11 falsefalseR1.htm0000001 - Document - Cover PageSheethttp://www.westpharma.com/role/CoverPageCover PageCover1 falsefalseR2.htm9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)Sheethttp://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITEDCONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)Statements2 falsefalseR3.htm9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)Sheethttp://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)Statements3 falsefalseR4.htm9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(Parenthetical)Sheethttp://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParentheticalCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)Statements4 falsefalseR5.htm9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)Sheethttp://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)Statements5 falsefalseR6.htm9952155 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Parenthetical)Sheethttp://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)Statements6 falsefalseR7.htm9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)Sheethttp://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITEDCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)Statements7 falsefalseR8.htm9952157 - Disclosure - Basis of PresentationSheethttp://www.westpharma.com/role/BasisofPresentationBasis of PresentationNotes8 falsefalseR9.htm9952158 - Disclosure - New Accounting StandardsSheethttp://www.westpharma.com/role/NewAccountingStandardsNew Accounting StandardsNotes9 falsefalseR10.htm9952159 - Disclosure - RevenueSheethttp://www.westpharma.com/role/RevenueRevenueNotes10 falsefalseR11.htm9952160 - Disclosure - Net Income Per ShareSheethttp://www.westpharma.com/role/NetIncomePerShareNet Income Per ShareNotes11 falsefalseR12.htm9952161 - Disclosure - InventoriesSheethttp://www.westpharma.com/role/InventoriesInventoriesNotes12 falsefalseR13.htm9952162 - Disclosure - LeasesSheethttp://www.westpharma.com/role/LeasesLeasesNotes13 falsefalseR14.htm9952163 - Disclosure - Affiliated CompaniesSheethttp://www.westpharma.com/role/AffiliatedCompaniesAffiliated CompaniesNotes14 falsefalseR15.htm9952164 - Disclosure - DebtSheethttp://www.westpharma.com/role/DebtDebtNotes15 falsefalseR16.htm9952165 - Disclosure - Derivative Financial InstrumentsSheethttp://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivative Financial InstrumentsNotes16 falsefalseR17.htm9952166 - Disclosure - Fair Value MeasurementsSheethttp://www.westpharma.com/role/FairValueMeasurementsFair Value MeasurementsNotes17 falsefalseR18.htm9952167 - Disclosure - Accumulated Other Comprehensive LossSheethttp://www.westpharma.com/role/AccumulatedOtherComprehensiveLossAccumulated Other Comprehensive LossNotes18 falsefalseR19.htm9952168 - Disclosure - Shareholders' EquitySheethttp://www.westpharma.com/role/ShareholdersEquityShareholders' EquityNotes19 falsefalseR20.htm9952169 - Disclosure - Stock-Based CompensationSheethttp://www.westpharma.com/role/StockBasedCompensationStock-Based CompensationNotes20 falsefalseR21.htm9952170 - Disclosure - Other Expense (Income)Sheethttp://www.westpharma.com/role/OtherExpenseIncomeOther Expense (Income)Notes21 falsefalseR22.htm9952171 - Disclosure - Income TaxesSheethttp://www.westpharma.com/role/IncomeTaxesIncome TaxesNotes22 falsefalseR23.htm9952172 - Disclosure - Commitments and ContingenciesSheethttp://www.westpharma.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes23 falsefalseR24.htm9952173 - Disclosure - Segment InformationSheethttp://www.westpharma.com/role/SegmentInformationSegment InformationNotes24 falsefalseR25.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes25 falsefalseR26.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes26 falsefalseR27.htm9954471 - Disclosure - Basis of Presentation (Policies)Sheethttp://www.westpharma.com/role/BasisofPresentationPoliciesBasis of Presentation (Policies)Policieshttp://www.westpharma.com/role/NewAccountingStandards27 falsefalseR28.htm9954472 - Disclosure - Revenue (Tables)Sheethttp://www.westpharma.com/role/RevenueTablesRevenue (Tables)Tableshttp://www.westpharma.com/role/Revenue28 falsefalseR29.htm9954473 - Disclosure - Net Income Per Share (Tables)Sheethttp://www.westpharma.com/role/NetIncomePerShareTablesNet Income Per Share (Tables)Tableshttp://www.westpharma.com/role/NetIncomePerShare29 falsefalseR30.htm9954474 - Disclosure - Inventories (Tables)Sheethttp://www.westpharma.com/role/InventoriesTablesInventories (Tables)Tableshttp://www.westpharma.com/role/Inventories30 falsefalseR31.htm9954475 - Disclosure - Leases (Tables)Sheethttp://www.westpharma.com/role/LeasesTablesLeases (Tables)Tableshttp://www.westpharma.com/role/Leases31 falsefalseR32.htm9954476 - Disclosure - Affiliated Companies (Tables)Sheethttp://www.westpharma.com/role/AffiliatedCompaniesTablesAffiliated Companies (Tables)Tableshttp://www.westpharma.com/role/AffiliatedCompanies32 falsefalseR33.htm9954477 - Disclosure - Debt (Tables)Sheethttp://www.westpharma.com/role/DebtTablesDebt (Tables)Tableshttp://www.westpharma.com/role/Debt33 falsefalseR34.htm9954478 - Disclosure - Derivative Financial Instruments (Tables)Sheethttp://www.westpharma.com/role/DerivativeFinancialInstrumentsTablesDerivative Financial Instruments (Tables)Tableshttp://www.westpharma.com/role/DerivativeFinancialInstruments34 falsefalseR35.htm9954479 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.westpharma.com/role/FairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.westpharma.com/role/FairValueMeasurements35 falsefalseR36.htm9954480 - Disclosure - Accumulated Other Comprehensive Loss (Tables)Sheethttp://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTablesAccumulated Other Comprehensive Loss (Tables)Tableshttp://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss36 falsefalseR37.htm9954481 - Disclosure - Shareholders' Equity (Tables)Sheethttp://www.westpharma.com/role/ShareholdersEquityTablesShareholders' Equity (Tables)Tableshttp://www.westpharma.com/role/ShareholdersEquity37 falsefalseR38.htm9954482 - Disclosure - Other Expense (Income) (Tables)Sheethttp://www.westpharma.com/role/OtherExpenseIncomeTablesOther Expense (Income) (Tables)Tableshttp://www.westpharma.com/role/OtherExpenseIncome38 falsefalseR39.htm9954483 - Disclosure - Segment Information

(Tables)Sheethttp://www.westpharma.com/role/SegmentInformationTablesSegment Information (Tables)Tableshttp://www.westpharma.com/role/SegmentInformation39 falsefalseR40.htm9954484 - Disclosure - Revenue - Revenue Recognition (Details)Sheethttp://www.westpharma.com/role/RevenueRevenueRecognitionDetailsRevenue - Revenue Recognition (Details)Details40 falsefalseR41.htm9954485 - Disclosure - Revenue - Contracts and Liabilities (Details)Sheethttp://www.westpharma.com/role/RevenueContractsandLiabilitiesDetailsRevenue - Contracts and Liabilities (Details)Details41 falsefalseR42.htm9954486 - Disclosure - Revenue - Narrative (Details)Sheethttp://www.westpharma.com/role/RevenueNarrativeDetailsRevenue - Narrative (Details)Details42 falsefalseR43.htm9954487 - Disclosure - Net Income Per Share - Schedule of Net Income Per Share (Details)Sheethttp://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetailsNet Income Per Share - Schedule of Net Income Per Share (Details)Details43 falsefalseR44.htm9954488 - Disclosure - Net Income Per Share - Narrative (Details)Sheethttp://www.westpharma.com/role/NetIncomePerShareNarrativeDetailsNet Income Per Share - Narrative (Details)Details44 falsefalseR45.htm9954489 - Disclosure - Net Income Per Share - Schedule of Repurchase of Common Stock (Details)Sheethttp://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetailsNet Income Per Share - Schedule of Repurchase of Common Stock (Details)Details45 falsefalseR46.htm9954490 - Disclosure - Inventories (Details)Sheethttp://www.westpharma.com/role/InventoriesDetailsInventories (Details)Detailshttp://www.westpharma.com/role/InventoriesTables46 falsefalseR47.htm9954491 - Disclosure - Leases - Lease Cost (Details)Sheethttp://www.westpharma.com/role/LeasesLeaseCostDetailsLeases - Lease Cost (Details)Details47 falsefalseR48.htm9954492 - Disclosure - Leases - Assets And Liabilities, Lessee (Details)Sheethttp://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetailsLeases - Assets And Liabilities, Lessee (Details)Details48 falsefalseR49.htm9954493 - Disclosure - Leases - Lease Weighted Average (Details)Sheethttp://www.westpharma.com/role/LeasesLeaseWeightedAverageDetailsLeases - Lease Weighted Average (Details)Details49 falsefalseR50.htm9954494 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)Sheethttp://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetailsLeases - Lease Cash Flow and Supplemental Information (Details)Details50 falsefalseR51.htm9954495 - Disclosure - Leases - Narrative (Details)Sheethttp://www.westpharma.com/role/LeasesNarrativeDetailsLeases - Narrative (Details)Details51 falsefalseR52.htm9954496 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)Sheethttp://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetailsLeases - Maturities of Operating and Finance Lease Liabilities (Details)Details52 falsefalseR53.htm9954497 - Disclosure - Affiliated Companies (Details)Sheethttp://www.westpharma.com/role/AffiliatedCompaniesDetailsAffiliated Companies (Details)Detailshttp://www.westpharma.com/role/AffiliatedCompaniesTables53 falsefalseR54.htm9954498 - Disclosure - Debt - Long-term Debt (Details)Sheethttp://www.westpharma.com/role/DebtLongtermDebtDetailsDebt - Long-term Debt (Details)Details54 falsefalseR55.htm9954499 - Disclosure - Debt - Narrative (Details)Sheethttp://www.westpharma.com/role/DebtNarrativeDetailsDebt - Narrative (Details)Details55 falsefalseR56.htm9954500 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)Sheethttp://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetailsDerivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)Details56 falsefalseR57.htm9954501 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)Sheethttp://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetailsDerivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)Details57 falsefalseR58.htm9954502 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)Sheethttp://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetailsDerivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)Details58 falsefalseR59.htm9954503 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)Sheethttp://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetailsFair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)Details59 falsefalseR60.htm9954504 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details)Sheethttp://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetailsFair Value Measurements - Other Financial Instruments (Details)Details60 falsefalseR61.htm9954505 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)Sheethttp://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)Details61 falsefalseR62.htm9954506 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)Sheethttp://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetailsAccumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)Details62 falsefalseR63.htm9954507 - Disclosure - Shareholder's Equity (Details)Sheethttp://www.westpharma.com/role/ShareholdersEquityDetailsShareholder's Equity (Details)Details63 falsefalseR64.htm9954508 - Disclosure - Stock-Based Compensation (Details)Sheethttp://www.westpharma.com/role/StockBasedCompensationDetailsStock-Based Compensation (Details)Detailshttp://www.westpharma.com/role/StockBasedCompensation64 falsefalseR65.htm9954509 - Disclosure - Other Expense (Income) - Schedule of Other Expense (Income) (Details)Sheethttp://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetailsOther Expense (Income) - Schedule of Other Expense (Income) (Details)Detailshttp://www.westpharma.com/role/OtherExpenseIncomeTables65 falsefalseR66.htm9954510 - Disclosure - Other Expense (Income) - Narrative (Details)Sheethttp://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetailsOther Expense (Income) - Narrative (Details)Detailshttp://www.westpharma.com/role/OtherExpenseIncomeTables66 falsefalseR67.htm9954511 - Disclosure - Other Expense (Income) - Schedule of Restructuring Reserve (Details)Sheethttp://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetailsOther Expense (Income) - Schedule of Restructuring Reserve (Details)Detailshttp://www.westpharma.com/role/OtherExpenseIncomeTables67 falsefalseR68.htm9954512 - Disclosure - Income Taxes (Details)Sheethttp://www.westpharma.com/role/IncomeTaxesDetailsIncome Taxes (Details)Detailshttp://www.westpharma.com/role/IncomeTaxes68 falsefalseR69.htm9954513 - Disclosure - Segment Information - Narrative (Details)Sheethttp://www.westpharma.com/role/SegmentInformationNarrativeDetailsSegment Information - Narrative (Details)Details69 falsefalseR70.htm9954514 - Disclosure - Segment Information - Sales by Product Group (Details)Sheethttp://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetailsSegment Information - Sales by Product Group (Details)Details70 falsefalseR71.htm9954515 - Disclosure - Segment Information - Segment Financial Information (Details)Sheethttp://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetailsSegment Information - Segment Financial Information (Details)Details71 falsefalseAll ReportsBookAll Reports wst-20240930.htmwst-20240930.xsdwst-20240930_cal.xmlwst-20240930_def.xmlwst-20240930_lab.xmlwst-20240930_pre.xml wst-20240930_g1.jpg http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "wst-20240930.htm": { "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20240930", "dts": { "inline": { "local": ["wst-20240930.htm"] }, "schema": { "local": ["wst-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["wst-20240930_cal.xml"] }, "definitionLink": { "local": ["wst-20240930_def.xml"] }, "labelLink": { "local": ["wst-20240930_lab.xml"] }, "presentationLink": { "local": ["wst-20240930_pre.xml"] } }, "keyStandard": 290, "keyCustom": 12, "axisStandard": 26, "axisCustom": 0, "memberStandard": 54, "memberCustom": 22, "hidden": { "total": 8, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 3 }, "contextCount": 358, "entityCount": 1, "segmentCount": 78, "elementCount": 600, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1108, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.westpharma.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil":

"false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R3": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R4": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R8": { "role": "http://www.westpharma.com/role/BasisofPresentation", "longName": "9952157 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.westpharma.com/role/NewAccountingStandards", "longName": "9952158 - Disclosure - New Accounting Standards", "shortName": "New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.westpharma.com/role/Revenue", "longName": "9952159 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.westpharma.com/role/NetIncomePerShare", "longName": "9952160 - Disclosure - Net Income Per Share", "shortName": "Net Income Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.westpharma.com/role/Inventories", "longName": "9952161 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.westpharma.com/role/Leases", "longName": "9952162 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.westpharma.com/role/AffiliatedCompanies", "longName": "9952163 - Disclosure - Affiliated Companies", "shortName": "Affiliated Companies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.westpharma.com/role/Debt", "longName": "9952164 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "longName": "9952165 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null,

"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.westpharma.com/role/FairValueMeasurements", "longName": "9952166 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "longName": "9952167 - Disclosure - Accumulated Other Comprehensive Loss", "shortName": "Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.westpharma.com/role/ShareholdersEquity", "longName": "9952168 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.westpharma.com/role/StockBasedCompensation", "longName": "9952169 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.westpharma.com/role/OtherExpenseIncome", "longName": "9952170 - Disclosure - Other Expense (Income)", "shortName": "Other Expense (Income)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.westpharma.com/role/IncomeTaxes", "longName": "9952171 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "longName": "9952172 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.westpharma.com/role/SegmentInformation", "longName": "9952173 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.westpharma.com/role/BasisofPresentationPolicies", "longName": "9954471 - Disclosure - Basis of Presentation (Policies)", "shortName": "Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.westpharma.com/role/RevenueTables", "longName": "9954472 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "longName": "9954473 - Disclosure - Net Income Per Share (Tables)", "shortName": "Net Income Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.westpharma.com/role/InventoriesTables", "longName": "9954474 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.westpharma.com/role/LeasesTables", "longName": "9954475 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesTables", "longName": "9954476 - Disclosure - Affiliated Companies (Tables)", "shortName": "Affiliated Companies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock", "unitRef": null, "xsiNil":

"false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.westpharma.com/role/DebtTables", "longName": "9954477 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "longName": "9954478 - Disclosure - Derivative Financial Instruments (Tables)", "shortName": "Derivative Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "longName": "9954479 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "longName": "9954480 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.westpharma.com/role/ShareholdersEquityTables", "longName": "9954481 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeTables", "longName": "9954482 - Disclosure - Other Expense (Income) (Tables)", "shortName": "Other Expense (Income) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.westpharma.com/role/SegmentInformationTables", "longName": "9954483 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "longName": "9954484 - Disclosure - Revenue - Revenue Recognition (Details)", "shortName": "Revenue - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "longName": "9954485 - Disclosure - Revenue - Contracts and Liabilities (Details)", "shortName": "Revenue - Contracts and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.westpharma.com/role/RevenueNarrativeDetails", "longName": "9954486 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails", "longName": "9954487 - Disclosure - Net Income Per Share - Schedule of Net Income Per Share (Details)", "shortName": "Net Income Per Share - Schedule of Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R44": { "role": "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails", "longName": "9954488 - Disclosure - Net Income Per Share - Narrative (Details)", "shortName": "Net Income Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails", "longName": "9954489 - Disclosure - Net Income Per Share - Schedule of Repurchase of Common Stock (Details)", "shortName": "Net Income Per Share - Schedule of Repurchase of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R46": { "role": "http://www.westpharma.com/role/InventoriesDetails", "longName": "9954490 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":

"46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails", "longName": "9954491 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails", "longName": "9954492 - Disclosure - Leases - Assets And Liabilities, Lessee (Details)", "shortName": "Leases - Assets And Liabilities, Lessee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "longName": "9954493 - Disclosure - Leases - Lease Weighted Average (Details)", "shortName": "Leases - Lease Weighted Average (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails", "longName": "9954494 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)", "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.westpharma.com/role/LeasesNarrativeDetails", "longName": "9954495 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "longName": "9954496 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "longName": "9954497 - Disclosure - Affiliated Companies (Details)", "shortName": "Affiliated Companies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R54": { "role": "http://www.westpharma.com/role/DebtLongtermDebtDetails", "longName": "9954498 - Disclosure - Debt - Long-term Debt (Details)", "shortName": "Debt - Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R55": { "role": "http://www.westpharma.com/role/DebtNarrativeDetails", "longName": "9954499 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfOtherLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R56": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails", "longName": "9954500 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)", "shortName": "Derivative Financial Instruments - Foreign Exchange Rate and Commodity Price Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "longName": "9954501 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "longName": "9954502 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)", "shortName": "Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-158", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextB "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextB

"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "longName": "9954503 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails", "longName": "9954504 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details)", "shortName": "Fair Value Measurements - Other Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954505 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-273", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R62": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "longName": "9954506 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-244", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R63": { "role": "http://www.westpharma.com/role/ShareholdersEquityDetails", "longName": "9954507 - Disclosure - Shareholder's Equity (Details)", "shortName": "Shareholder's Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R64": { "role": "http://www.westpharma.com/role/StockBasedCompensationDetails", "longName": "9954508 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R65": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails", "longName": "9954509 - Disclosure - Other Expense (Income) - Schedule of Other Expense (Income) (Details)", "shortName": "Other Expense (Income) - Schedule of Other Expense (Income) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "longName": "9954510 - Disclosure - Other Expense (Income) - Narrative (Details)", "shortName": "Other Expense (Income) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-320", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-320", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails", "longName": "9954511 - Disclosure - Other Expense (Income) - Schedule of Restructuring Reserve (Details)", "shortName": "Other Expense (Income) - Schedule of Restructuring Reserve (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.westpharma.com/role/IncomeTaxesDetails", "longName": "9954512 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R69": { "role": "http://www.westpharma.com/role/SegmentInformationNarrativeDetails", "longName": "9954513 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "longName": "9954514 - Disclosure - Segment Information - Sales by Product Group (Details)", "shortName": "Segment Information - Sales by Product Group (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-329", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } }, "R71": { "role":

{"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails", "longName": "9954515 - Disclosure - Segment Information - Segment Financial Information (Details)", "shortName": "Segment Information - Segment Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:NonoperatingIncomeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "wst-20240930.htm", "unique": true } } }, "tag": { "wst_A2022RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "A2022RestructuringPlanMember", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2022 Restructuring Plan", "label": "2022 Restructuring Plan [Member]", "documentation": "2022 Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r70", "r951"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1112"] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r73", "r138"] }, "wst_AccruedSalariesWagesAndBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "AccruedSalariesWagesAndBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries, wages and benefits", "label": "Accrued Salaries, Wages, and Benefits, Current", "documentation": "Accrued Salaries, Wages, and Benefits, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit pension and other postretirement plans", "verboseLabel": "Amortization of defined benefit pension and other postretirement plans:", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": ["r3", "r4", "r10", "r20", "r94", "r1090", "r1091", "r1092"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r35", "r203", "r749"] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "verboseLabel": "Gains (losses) on derivatives:", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r221", "r229", "r230", "r573", "r901", "r1090"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r228", "r229", "r630", "r631", "r632", "r633", "r634", "r635"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r19", "r20", "r95", "r212", "r745", "r787", "r790"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r228", "r229", "r630", "r631", "r632", "r633", "r634", "r635"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total", "terseLabel": "Accumulated other comprehensive loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r10", "r20", "r588", "r591", "r660", "r783", "r784", "r1090", "r1091", "r1092", "r1100", "r1101", "r1102", "r1103"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency

transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r2", "r10", "r20", "r92", "r93", "r229", "r230", "r631", "r632", "r633", "r634", "r635", "r1090"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r1016"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid-in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r83", "r951", "r1219"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capital in Excess of Par Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r799", "r1100", "r1101", "r1102", "r1103", "r1149", "r1220"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r1029"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r1029"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r1029"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r1029"] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": ["r8"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Activity related to stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r47", "r48", "r505"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AffiliatedEntityMember", "presentation": [
"http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity", "label": "Affiliated Entity [Member]", "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity." } } }, "auth_ref": ["r176", "r835", "r883", "r973", "r1141", "r1174", "r1175", "r1176"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r1062"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r988", "r998", "r1008", "r1040"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r991", "r1001", "r1011", "r1043"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r1063"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r1029"] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r1036"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1036", "r1044", "r1048", "r1056"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r1054"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r535", "r539"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AmericasMember", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Americas", "label": "Americas [Member]", "documentation": "Continents of North and South America." } } }, "auth_ref": ["r1080", "r1081", "r1082", "r1083", "r1222", "r1223", "r1224", "r1225"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of acquisition-related intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r8", "r381", "r382", "r917"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [

"http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r274"] }, "us-gaap_AociEquityMethodInvestmentParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociEquityMethodInvestmentParentMember", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in equity affiliate investment AOCI", "label": "AOCI, Equity Method Investment, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) (AOCI) from proportionate share of equity method investee's other comprehensive income (loss) (OCI), attributable to parent." } } }, "auth_ref": ["r221", "r228", "r229", "r230", "r349", "r573"] },
"srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific", "label": "Asia Pacific [Member]", "documentation": "Region of Asia Pacific." } } }, "auth_ref": ["r1080", "r1081", "r1082", "r1083", "r1222", "r1223", "r1224", "r1225"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r8", "r33"] },
"wst_AssetRelatedChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "AssetRelatedChargesMember", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Other charges", "label": "Asset-Related Charges [Member]", "documentation": "Asset-Related Charges [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r137", "r149", "r206", "r240", "r278", "r285", "r304", "r308", "r355", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r571", "r574", "r624", "r739", "r828", "r909", "r910", "r951", "r979", "r1134", "r1135", "r1177"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r199", "r215", "r240", "r355", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r571", "r574", "r624", "r951", "r1134", "r1135", "r1177"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": {
"totalLabel": "Total assets at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r601", "r602", "r938"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" }
} }, "auth_ref": ["r1051"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r1052"] }, "ecd_AwardTmgDiscLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r1047"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r1047"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r1047"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r1047"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r1047"] },
"ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r1047"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534"] }, "ecd_AwardUndrlygSecuritiesAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r1050"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r1049"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r1048"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r1048"] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Time deposits", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": ["r145"] }, "us-

gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.westpharma.com/role/BasisofPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "wst_BiologicsCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "BiologicsCustomersMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Biologics", "label": "Biologics Customers [Member]", "documentation": "Biologics Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r567", "r1096"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r49", "r130", "r566", "r603", "r604", "r605"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r23", "r201", "r895"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r201"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1151", "r1152"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, including cash equivalents at beginning of period", "periodEndLabel": "Cash, including cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r23", "r112", "r236"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r112"] }, "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "presentation": ["http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]", "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in unrealized gain (loss) on fair value hedging instruments", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": ["r135"] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative gain (loss) on hedged item, fair value hedges", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": ["r135"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r1027"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r1024"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r1022"] }, "dei_CityAreaCode": { "xbrltype":

"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code",
"documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [
"http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label":
"Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r209", "r210", "r211",
"r280", "r450", "r451", "r452", "r454", "r457", "r462", "r464", "r793", "r794", "r795", "r796", "r923", "r1066", "r1097"] },
"ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount",
"label": "Company Selected Measure Amount" } } }, "auth_ref": ["r1028"] }, "ecd_CoSelectedMeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company
Selected Measure Name" } } }, "auth_ref": ["r1028"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel":
"Commitments and contingencies (Note 16)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of
the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its
resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a
company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately
be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r79", "r140", "r742",
"r817"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies
Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.westpharma.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and
Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and
contingencies." } } }, "auth_ref": ["r123", "r401", "r402", "r878", "r1123", "r1129"] }, "us-gaap_CommodityMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityMember", "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Commodity call options", "label": "Commodity [Member]", "documentation": "Trading in a derivative instrument whose primary
underlying risk is tied to commodity prices." } } }, "auth_ref": ["r62"] }, "us-gaap_CommodityOptionMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityOptionMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Commodity call options", "label": "Commodity Option [Member]", "documentation": "Option contract in which the
underlying asset is a commodity." } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [
"http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared per share (in dollars
per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each
share of common stock outstanding." } } }, "auth_ref": ["r129"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common
Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r970", "r971", "r972", "r974",
"r975", "r976", "r977", "r1100", "r1101", "r1103", "r1149", "r1217", "r1220"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"], "lang": { "en-us": { "role": {
"terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face
amount or stated value per share of common stock." } } }, "auth_ref": ["r82"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"], "lang": { "en-us": { "role": {
"terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum
number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r82", "r818"] }, "us-
gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesIssued", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
"http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in
shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares,
Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares
that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may
be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } },
"auth_ref": ["r82"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"], "lang": { "en-us": { "role": {
"terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of
shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r82", "r818",
"r834", "r1220", "r1221"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"],
"lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued:
September\u00a030, 2024 - 75.3\u00a0million, December\u00a031, 2023 - 75.3 million; shares outstanding: September\u00a030, 2024 –
72.5\u00a0million, December\u00a031, 2023 - 73.5 million", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated
value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock
repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another
section within stockholders' equity." } } }, "auth_ref": ["r82", "r744", "r951"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company
Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r1033"] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [
"r1032"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } }
}, "auth_ref": ["r1034"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder
Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r1031"] }, "us-
gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"], "lang": { "en-us": {
"role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation":
"Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other
comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to

owners." } } }, "auth_ref": ["r21", "r225", "r227", "r232", "r735", "r756", "r757"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r91", "r231", "r734", "r754"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r24", "r26", "r67", "r68", "r315", "r877"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r24", "r26", "r67", "r68", "r315", "r792", "r877"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r24", "r26", "r67", "r68", "r315", "r877", "r1070"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r24", "r26", "r67", "r68", "r315"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r24", "r26", "r67", "r68", "r315", "r877"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r147", "r156", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r242", "r278", "r287", "r302", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r909", "r910", "r1084", "r1085", "r1134", "r1135"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r147", "r156", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r242", "r278", "r287", "r302", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r909", "r910", "r1084", "r1085", "r1134", "r1135"] }, "wst_ContractManufacturedCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ContractManufacturedCustomersMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "label": "Contract-Manufactured Customers [Member]", "documentation": "Contract-Manufactured Customers [Member]" } } }, "auth_ref": [] }, "wst_ContractManufacturedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ContractManufacturedProductsMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "label": "Contract Manufactured Products [Member]", "documentation": "Contract Manufactured Products [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.westpharma.com/role/RevenueTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r1138"] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Contract assets, December\u00a031, 2023", "periodEndLabel": "Contract assets, September\u00a030, 2024", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r466", "r468", "r487"] }, "wst_ContractWithCustomerAssetRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ContractWithCustomerAssetRollForward", "presentation": ["http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Asset [Roll Forward]", "label": "Contract With Customer, Asset [Roll Forward]", "documentation": "Contract With Customer, Asset [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Deferred income, December\u00a031, 2023", "negatedPeriodEndLabel": "Deferred income, September\u00a030, 2024", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r466", "r467", "r487"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/RevenueNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized that was included in the deferred income balance", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r488"] }, "wst_ContractWithCustomerLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ContractWithCustomerLiabilityRollForward", "presentation": ["http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Liability [Roll Forward]", "label": "Contract With Customer, Liability [Roll Forward]", "documentation": "Contract With Customer, Liability [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate and Unallocated", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r14", "r303", "r304", "r305", "r306", "r309", "r1108"] }, "wst_CostInvestmentImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "CostInvestmentImpairment", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost investment impairment", "label": "Cost Investment Impairment", "documentation": "Cost Investment Impairment" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "verboseLabel": "Cost of goods and services sold", "negatedTerseLabel": "Cost of goods and services sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } },

"auth_ref": ["r99", "r100", "r698"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods and services sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r408", "r1132"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r408", "r1132", "r1133"] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Contract", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": ["r1140", "r1148"] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": ["r1169"] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r116", "r315"] }, "us-gaap_DebtDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": {
"terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [
"http://www.westpharma.com/role/Debt"], "lang": { "en-us": { "role": { "verboseLabel": "Debt", "label": "Debt Disclosure [Text Block]",
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } },
"auth_ref": ["r124", "r238", "r387", "r388", "r389", "r390", "r391", "r407", "r408", "r420", "r426", "r427", "r428", "r429", "r430", "r431", "r436",
"r443", "r444", "r446", "r637"] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } },
"presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r17", "r139", "r447"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r421", "r637", "r638", "r919", "r920", "r949"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r434", "r623", "r919", "r920", "r1152", "r1153", "r1154", "r1155", "r1162"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Debt instrument, stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r75", "r422"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r242", "r421", "r422", "r423", "r424", "r425", "r427", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r918", "r919", "r920", "r921", "r922", "r949", "r1098", "r1170", "r1171"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r17", "r40", "r43", "r69", "r127", "r128", "r242", "r421", "r422", "r423", "r424", "r425", "r427", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r918", "r919", "r920", "r921", "r922", "r949", "r1098", "r1170", "r1171"] }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred compensation benefits", "label": "Deferred Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Deferred compensation assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": ["r1088"] }, "us-gaap_DeferredIncomeTaxAssetsNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit",
"calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets",
"weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"],
"lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r543", "r544"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": {

```
"en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r543", "r544", "r740" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r492" ] }, "us-gaap_DefinedBenefitPlanOtherCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanOtherCosts", "crdr": "debit", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Defined Benefit Plan, Other Cost (Credit)", "documentation": "Amount of defined benefit plan cost (credit), classified as other." } } }, "auth_ref": [] }, "wst_DeliveryDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "DeliveryDevicesMember", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Packaging", "label": "Delivery Devices [Member]", "documentation": "Delivery Devices [Member]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r34" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity call options", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r216", "r217", "r601", "r602", "r615", "r623", "r800", "r801", "r802", "r803", "r804", "r806", "r807", "r808", "r809", "r810", "r822", "r823", "r863", "r866", "r869", "r870", "r871", "r872", "r900", "r938", "r942", "r972", "r1153", "r1154", "r1155", "r1218" ] }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, average price risk option strike price", "label": "Derivative, Average Price Risk Option Strike Price", "documentation": "The average strike price on the group of price risk option contracts such as put options or call options." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract Type [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r808", "r810", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r829", "r830", "r831", "r832", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r863", "r865", "r869", "r871", "r970", "r972", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1163", "r1164" ] }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "crdr": "credit", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, forward point components, (loss) gain, recognized in earnings", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method." } } }, "auth_ref": [ "r150", "r1146" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r56", "r58", "r61", "r134", "r808", "r810", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r829", "r830", "r831", "r832", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r863", "r865", "r869", "r871", "r900", "r970", "r972", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1163", "r1164" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r132", "r585", "r594" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r12", "r56", "r58" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r12", "r56", "r58", "r61", "r65", "r66", "r584" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r584" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments
```

not designated or qualifying as hedging instruments." } } }, "auth_ref": ["r60", "r1071"] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r594"] }, "us-gaap_DerivativeNonmonetaryNotionalAmountVolume": { "xbrltype": "volumeItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNonmonetaryNotionalAmountVolume", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, nonmonetary notional amount, volume", "label": "Derivative, Nonmonetary Notional Amount, Volume", "documentation": "Nominal volume used to calculate payments on a derivative instrument." } } }, "auth_ref": [] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1144", "r1145"] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r12", "r50", "r51", "r52", "r55", "r57", "r58", "r63", "r64", "r66", "r594"] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative contract term", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r12"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r486", "r924", "r925", "r926", "r927", "r928", "r929", "r930"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r486", "r924", "r925", "r926", "r927", "r928", "r929", "r930"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.westpharma.com/role/RevenueTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1139"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.westpharma.com/role/StockBasedCompensation"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r503", "r508", "r536", "r537", "r538", "r935"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": ["r129"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r983"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r1015"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r1026"] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East, Africa", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": ["r1222", "r1223", "r1224", "r1225"] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "EUR", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "EUR", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "verboseLabel": "Net income per share:", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r233", "r252", "r253", "r254", "r255", "r256", "r257", "r264", "r266", "r271", "r272", "r273", "r277", "r564", "r569", "r598", "r599", "r736", "r758", "r902"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"EarningsPerShareDiluted", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r233", "r252", "r253", "r254", "r255", "r256", "r257", "r266", "r271", "r272", "r273", "r277", "r564", "r569", "r598", "r599", "r736", "r758", "r902"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.westpharma.com/role/NetIncomePerShare"], "lang": { "en-us": { "role": { "verboseLabel": "Net Income Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r263", "r274", "r275", "r276"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r629"] }, "us-gaap_EffectOnFutureEarningsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOnFutureEarningsAmount", "crdr": "credit", "presentation": [
"http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effect on future earnings, amount", "label": "Effect on Future Earnings, Amount", "documentation": "The quantified amount of the future effect on earnings." } } }, "auth_ref": ["r121"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [
"http://www.westpharma.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r546", "r936"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance and benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r981"] }, "dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r981"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r981"] }, "dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": {
"terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1065"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r981"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r981"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r981"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel":

"Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r981"] },
"ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r1020"] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r1061"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r1061"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r1061"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r11", "r195", "r228", "r229", "r230", "r243", "r244", "r245", "r249", "r256", "r258", "r260", "r279", "r357", "r360", "r384", "r465", "r552", "r553", "r559", "r560", "r561", "r565", "r568", "r569", "r587", "r588", "r589", "r590", "r591", "r593", "r597", "r630", "r631", "r632", "r633", "r634", "r635", "r639", "r641", "r660", "r754", "r783", "r784", "r785", "r799", "r850"] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity method affiliates", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r278", "r296", "r308", "r350", "r1087", "r1117"] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]", "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": ["http://www.westpharma.com/role/AffiliatedCompanies"], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Companies", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": ["r154", "r353", "r356", "r1067"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-equity method affiliates", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r348"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r1030"] },
"ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r988", "r998", "r1008", "r1040"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r985", "r995", "r1005", "r1037"] },
"ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r1036"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r601", "r602", "r615", "r938"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r601", "r602", "r615", "r938"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r434", "r495", "r496", "r497", "r498", "r499", "r500", "r600", "r602", "r603", "r604", "r605", "r614", "r615", "r617", "r668", "r669", "r670", "r919", "r920", "r931", "r932", "r933", "r938", "r942"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r606", "r607", "r608", "r609", "r610", "r611", "r616"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.westpharma.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet

that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r610", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621", "r732", "r938", "r943"] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedges:", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": ["r53"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r434", "r495", "r500", "r602", "r615", "r668", "r931", "r932", "r933", "r938"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r434", "r495", "r500", "r602", "r603", "r615", "r669", "r919", "r920", "r931", "r932", "r933", "r938"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r434", "r495", "r496", "r497", "r498", "r499", "r500", "r602", "r603", "r604", "r605", "r615", "r670", "r919", "r920", "r931", "r932", "r933", "r938", "r942"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r606", "r607", "r608", "r609", "r610", "r611", "r616"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.westpharma.com/role/BasisofPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r434", "r495", "r496", "r497", "r498", "r499", "r500", "r600", "r602", "r603", "r604", "r605", "r614", "r615", "r617", "r668", "r669", "r670", "r919", "r920", "r931", "r932", "r933", "r938", "r942"] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease - interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": ["r645", "r649", "r950"] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r643", "r657"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (current)", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r643"] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": ["r644"] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.westpharma.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lessee, Finance Lease, Liability, Maturity", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1173"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (noncurrent)", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r643"] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": ["r644"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Finance leases liabilities payments due", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r657"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":

"2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining period as of September\u00a030, 2024)", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1173"] }, "wst_FinanceLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, To Be Paid, After Year Four", "documentation": "Finance Lease, Liability, To Be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed lease interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r657"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal repayments on finance leases", "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r646", "r653"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "ROU assets, net", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r642"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance lease - amortization of right-of-use (ROU) assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r645", "r649", "r950"] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": ["r644"] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r656", "r950"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r655", "r950"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r445", "r462", "r594", "r622", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r755", "r915", "r938", "r940", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r952", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1113", "r1114", "r1115", "r1116", "r1150", "r1153", "r1154", "r1155", "r1162", "r1165"] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": ["r601", "r602"] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": ["r601", "r602"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": "wst_OtherIncomeExpense",

"weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange transaction losses", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r625", "r626", "r627", "r628", "r847"] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency hedge contracts", "verboseLabel": "Foreign currency contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": ["r900", "r931", "r937", "r938"] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": ["r822", "r826", "r831", "r841", "r845", "r867", "r868", "r869", "r972"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1044"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1044"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1044"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1044"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1044"] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForwardContractsMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Currency Forwards", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": ["r1147"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r1025"] }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount excluded from effectiveness testing, fair value hedges", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings." } } }, "auth_ref": ["r136", "r579"] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on derivative instruments, net, pretax", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": ["r56"] }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Derivative gain (loss) recognized in income, fair value hedges", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period." } } }, "auth_ref": ["r59"] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of plant", "terseLabel": "Loss on disposal of plant", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r8"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Corporate general costs", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r103", "r837"] }, "wst_GenericsCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "GenericsCustomersMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Generics", "label": "Generics Customers [Member]", "documentation": "Generics Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": ["r25", "r877"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-

us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r204", "r370", "r733", "r910", "r916", "r939", "r951", "r1119", "r1120"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r96", "r101", "r148", "r240", "r355", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r624", "r904", "r909", "r1105", "r1107", "r1109", "r1110", "r1111", "r1134"] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r12", "r584"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r12"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": ["r12"] }, "wst_HighValueComponentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "HighValueComponentsMember", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "High-Value Product (\"HVP\") Components", "label": "High-Value Components [Member]", "documentation": "High-Value Components [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes and equity in net income of affiliated companies", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r97", "r143", "r148", "r737", "r752", "r904", "r909", "r1105", "r1107", "r1109", "r1110", "r1111"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes and equity in net income of affiliated companies", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": ["r148", "r759", "r904", "r1105", "r1107", "r1109", "r1110", "r1111"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in net income of affiliated companies", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r8", "r98", "r142", "r278", "r292", "r308", "r350", "r751"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r385", "r392", "r395", "r607", "r611", "r616", "r780", "r782", "r838", "r891", "r941", "r1188"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r392", "r395", "r607", "r611", "r616", "r780", "r782", "r838", "r891", "r941", "r1188"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.westpharma.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r241", "r542", "r546", "r547", "r548", "r549", "r550", "r551", "r554", "r556", "r557", "r558", "r798", "r936"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "negatedTerseLabel": "Tax benefit (expense)", "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r151", "r152", "r259", "r260", "r278", "r293", "r308", "r545", "r546", "r555", "r760", "r936"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in contract assets - increase (decrease)", "label": "Increase (Decrease) in Contract with Customer, Asset", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r1096"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in deferred income - decrease (increase)", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r697", "r1096"] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-

gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedLabel": "Changes in assets and liabilities", "label": "Increase (Decrease) in Operating Capital", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": {
"http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r267", "r268", "r269", "r273", "r507"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1036", "r1044", "r1048", "r1056"] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r1054"] },
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } },
"auth_ref": ["r984", "r1060"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": {
"role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } },
"auth_ref": ["r984", "r1060"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r984", "r1060"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r380", "r1121", "r1122"] }, "wst_IntercompanyDemandNotesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.westpharma.com/20240930", "localname": "IntercompanyDemandNotesMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Intercompany Demand Notes", "label": "Intercompany Demand Notes [Member]", "documentation": "Intercompany Demand Notes" } } }, "auth_ref": [] }, "wst_IntercompanyLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "IntercompanyLoansMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Intercompany Loans", "label": "Intercompany Loans [Member]", "documentation": "Intercompany Loans" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r278", "r285", "r289", "r295", "r308", "r636", "r909", "r910"] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": ["r15"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": {
"role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r289", "r1093"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [
"http://www.westpharma.com/role/Inventories"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r369"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/InventoriesDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r119", "r897"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
"http://www.westpharma.com/role/InventoriesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r213", "r896", "r951"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit",
"calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } },
"presentation": ["http://www.westpharma.com/role/InventoriesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label":
"Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r119", "r899"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "parentTag":
"us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/InventoriesDetails"], "lang": { "en-us":
{ "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r119", "r898"] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet",
"crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
"weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Interest income", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r104", "r105", "r107"] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/AffiliatedCcompaniesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "verboseLabel": "Investments in affiliated companies", "terseLabel": "Total investments in affiliated companies", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": ["r1089"] }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAndAdvancesToAffiliatesTextBlock", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments in Affiliated Companies", "label": "Investments in and Advances to Affiliates [Table Text Block]", "documentation": "Tabular disclosure of investments in and advances to affiliates. Does not include the tabular disclosure of the disaggregation of investments in and advances to affiliates across legal entities." } } }, "auth_ref": ["r1226"] }, "currency_JPY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "JPY", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Yen", "label": "Japan, Yen" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/LeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r648", "r950"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.westpharma.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r1172"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": ["http://www.westpharma.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": ["r640"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.westpharma.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1173"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Operating leases liabilities payments due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r657"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r657"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining period as of September\u00a030, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1173"] }, "wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed lease interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r657"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.westpharma.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r640"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember",

"presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r17", "r72", "r73", "r74", "r77", "r78", "r79", "r80", "r240", "r355", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r572", "r574", "r575", "r624", "r816", "r903", "r979", "r1134", "r1177", "r1178"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r87", "r141", "r747", "r951", "r1099", "r1118", "r1166"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r74", "r200", "r240", "r355", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r572", "r574", "r575", "r624", "r951", "r1134", "r1177", "r1178"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r602", "r1151"] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term line of credit", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r17", "r139", "r1186"] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": ["r71", "r76"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused commitment level", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r71", "r76", "r408"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "terseLabel": "Carrying amount", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r17", "r139", "r433", "r448", "r919", "r920", "r949", "r1186"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r207"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtLongtermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r208"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r17", "r1124", "r1125", "r1126"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r17", "r37", "r1124", "r1125", "r1126"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [

"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r315", "r926", "r962", "r967", "r1139", "r1187", "r1189", "r1190", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r157", "r159", "r161", "r162", "r164", "r193", "r194", "r403", "r404", "r405", "r406", "r502", "r540", "r605", "r696", "r779", "r781", "r791", "r809", "r810", "r856", "r858", "r860", "r861", "r873", "r889", "r890", "r914", "r923", "r934", "r942", "r943", "r947", "r948", "r963", "r1136", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r1028"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r1028"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r157", "r159", "r161", "r162", "r164", "r193", "r194", "r403", "r404", "r405", "r406", "r502", "r540", "r605", "r696", "r779", "r781", "r791", "r809", "r810", "r856", "r858", "r860", "r861", "r873", "r889", "r890", "r914", "r923", "r934", "r942", "r943", "r947", "r963", "r1136", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r1047"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1140"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r1055"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r315", "r926", "r962", "r967", "r1139", "r1187", "r1189", "r1190", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r1029"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r235"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r235"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r112", "r113", "r114"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "verboseLabel": "Total reclassifications for the period, net of tax", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r102", "r114", "r144", "r198", "r223", "r226", "r230", "r240", "r248", "r252", "r253", "r254", "r255", "r256", "r259", "r260", "r270", "r355", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r564", "r569", "r599", "r624", "r753", "r836", "r848", "r849", "r978", "r1134"] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges:", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a

foreign operation." } } }, "auth_ref": ["r54"] }, "wst_NetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "NetSalesMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Net Sales [Member]", "documentation": "Net sales member" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": ["http://www.westpharma.com/role/NewAccountingStandards"], "lang": { "en-us": { "role": { "verboseLabel": "New Accounting Standards", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": ["r153", "r196", "r246", "r247", "r250", "r251", "r261", "r262", "r316", "r358", "r359", "r562", "r563", "r565", "r569", "r592", "r596", "r659", "r661", "r662", "r699", "r700", "r701", "r786", "r787", "r788", "r789", "r790"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.westpharma.com/role/BasisofPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Standards Issued Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r1028"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r992", "r1002", "r1012", "r1036", "r1044"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r1019"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1018"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r1036"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1055"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1055"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r12"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest (income) expense and other nonoperating expense (income), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r106"] }, "wst_NotesPayableAndOtherDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "NotesPayableAndOtherDebtCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "verboseLabel": "Notes payable and other current debt", "label": "Notes Payable and Other Debt, Current", "documentation": "Notes Payable and Other Debt, Current" } } }, "auth_ref": [] }, "wst_NumberOfManufacturingFacilitiesSold": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "NumberOfManufacturingFacilitiesSold", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of loss on disposal manufacturing facility", "label": "Number of Manufacturing Facilities Sold", "documentation": "Number of Manufacturing Facilities Sold" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.westpharma.com/role/SegmentInformationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r905", "r913", "r1106"] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": ["r16", "r20"] }, "us-gaap_OciEquityMethodInvestmentAfterTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciEquityMethodInvestmentAfterTaxParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively", "label": "OCI, Equity Method Investment, after Tax, Parent", "documentation": "Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI, attributable to parent." } } }, "auth_ref": ["r349", "r570", "r573"] }, "us-gaap_OciEquityMethodInvestmentTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciEquityMethodInvestmentTaxParent", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on equity affiliate accumulated other comprehensive income, tax", "label": "OCI, Equity Method Investment, Tax, Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI, attributable to parent." } } }, "auth_ref": ["r349", "r570", "r573"] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Operating profit", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r148", "r904", "r1105", "r1107", "r1109", "r1110", "r1111"] }, "us-gaap_OperatingLeaseCost": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r650", "r950"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r643"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r643"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r643"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r647", "r653"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r642"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r656", "r950"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r655", "r950"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r302", "r303", "r304", "r305", "r306", "r309", "r909", "r910"] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options Held", "label": "Options Held [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": ["r133", "r824", "r829", "r839", "r843", "r863", "r864", "r865", "r970", "r971"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/AffiliatedCcompaniesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "verboseLabel": "Receivables due from affiliates", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r214", "r951"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r205"] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2), $0.0, $(0.3), and $(0.5), respectively", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": ["r3", "r4", "r10", "r94", "r95", "r131"] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit pension and other postretirement plan adjustments, tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": ["r6", "r10", "r131"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, net of tax of $(2.5), $0.4, $(0.8) and $1.9, respectively", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r6", "r10", "r131"] }, "us-

gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r6", "r10", "r131"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r218", "r220", "r576", "r577", "r586"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r580"] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fair value hedges, amount of (gain) loss reclassified from accumulated OCI into income", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": ["r219", "r220", "r222", "r579"] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on derivatives, tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": ["r219", "r220", "r222"] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on derivatives, net of tax of $1.1, $0.8, $0.7 and $(0.3), respectively", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": ["r219", "r578", "r754"] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": ["r219", "r220", "r578", "r583", "r586"] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net investment hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": ["r581"] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": ["r582"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of tax", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r6", "r10", "r131", "r224", "r227", "r256"] }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liabilities", "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent", "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "wst_OtherExpenseIncomeMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.westpharma.com/20240930", "localname": "OtherExpenseIncomeMember", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Other expense (income)", "label": "Other Expense (Income) [Member]", "documentation": "Other Expense (Income)" } } },
"auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income
and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [
"http://www.westpharma.com/role/OtherExpenseIncome"], "lang": { "en-us": { "role": { "verboseLabel": "Other Expense (Income)", "label": "Other
Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both
operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from
dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [
"r1072", "r1143"] }, "wst_OtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20240930", "localname":
"OtherIncomeExpense", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-
gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 },
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": null, "weight": null, "order": null,
"root": true } }, "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Other expense (income) (Note 14)", "terseLabel": "Other expense (income)", "negatedTotalLabel": "Total other expense
(income)", "label": "Other Income (Expense)", "documentation": "The total amount of other income and expense items that are associated with the
entity's normal revenue producing operation." } } }, "auth_ref": [] }, "wst_OtherIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.westpharma.com/20240930", "localname": "OtherIncomeExpenseMember", "presentation": [
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other
Income (Expense)", "label": "Other Income (Expense) [Member]", "documentation": "Other Income (Expense)" } } }, "auth_ref": [] }, "us-
gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent",
"crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag":
"us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails",
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Other
current liabilities", "verboseLabel": "Payables due to affiliates", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities
classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r73", "r951"] }, "us-
gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight":
1.0, "order": 7.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": {
"en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities
classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r78"] }, "us-
gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncashIncomeExpense", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Other non-cash items, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense)
included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r114"] }, "us-
gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0,
"order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang":
{ "en-us": { "role": { "negatedLabel": "Other nonoperating expense (income)", "label": "Other Nonoperating Income (Expense)", "documentation":
"Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r108"] }, "us-
gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": "wst_OtherIncomeExpense",
"weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails"],
"lang": { "en-us": { "role": { "negatedTerseLabel": "Other items", "label": "Other Operating Income (Expense), Net", "documentation": "The net
amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that
are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other
Performance Measure, Amount" } } }, "auth_ref": ["r1028"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous
Compensation Amount" } } }, "auth_ref": ["r990", "r1000", "r1010", "r1042"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding
Recovery Compensation Amount" } } }, "auth_ref": ["r993", "r1003", "r1013", "r1045"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual
Name" } } }, "auth_ref": ["r993", "r1003", "r1013", "r1045"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs
Performance Disclosure [Line Items]" } } }, "auth_ref": ["r1017"] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit",
"calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow)
outflow from investing activities classified as other." } } }, "auth_ref": ["r1068", "r1094"] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit",
"calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Shares purchased under share repurchase programs", "label": "Payments for Repurchase of Common Stock",
"documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r110"] }, "us-
gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of
exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [
"r394", "r1095"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedLabel": "Dividend payments", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the
form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r110"] }, "us-
gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Shares repurchased for employee tax withholdings", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r234"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r109"] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r1027"] },
"ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r1027"] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": {
"en-us": { "role": { "terseLabel": "Pension and other postretirement benefits", "label": "Liability, Defined Benefit Plan, Noncurrent",
"documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": ["r78", "r490", "r491", "r493", "r933"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r1019"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r1036"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r1029"] }, "ecd_PeoTotalCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r1018"] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [
"http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Performance Share Unit (PSUs)", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "wst_PharmaCustomersMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.westpharma.com/20240930", "localname": "PharmaCustomersMember", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pharma", "label": "Pharma Customers [Member]", "documentation": "Pharma Customers [Member]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r1020"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [
"r1064"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r1019"] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionAxis", "presentation": [
"http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref":
[] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionDomain",
"presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang":
{ "en-us": { "role": { "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } }
}, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockSharesAuthorized", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"], "lang": { "en-us": { "role": {
"terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r81", "r818"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"], "lang": { "en-us": { "role": {
"terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r81", "r450"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockSharesOutstanding", "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"], "lang": { "en-us": { "role": {
"terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r81", "r818", "r834", "r1220", "r1221"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr":
"credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel":
"Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding", "label": "Preferred Stock, Value, Issued",
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r81", "r743", "r951"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"terseLabel": "Borrowings of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r22", "r793"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit",
"calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": {
"terseLabel": "Employee stock purchase plan contributions", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r5", "r13"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": {

"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock-based compensation awards", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r5", "r13"] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": ["r117"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r166", "r167", "r168", "r169", "r170", "r171", "r192", "r311", "r698", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r893", "r924", "r961", "r963", "r964", "r968", "r969", "r1086", "r1130", "r1131", "r1139", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r166", "r167", "r168", "r169", "r170", "r171", "r192", "r311", "r698", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r893", "r924", "r961", "r963", "r964", "r968", "r969", "r1086", "r1130", "r1131", "r1139", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r120", "r202", "r750"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r9", "r658", "r738", "r750", "r951"] }, "wst_ProprietaryProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ProprietaryProductsMember", "presentation": [
"http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
"http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proprietary Products", "label": "Proprietary Products [Member]", "documentation": "Proprietary Products" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r1017"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r1017"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r157", "r159", "r161", "r162", "r164", "r193", "r194", "r403", "r404", "r405", "r406", "r494", "r502", "r531", "r532", "r533", "r540", "r605", "r671", "r680", "r696", "r779", "r781", "r791", "r809", "r810", "r856", "r858", "r860", "r861", "r873", "r889", "r890", "r914", "r923", "r934", "r942", "r943", "r947", "r948", "r963", "r972", "r1127", "r1136", "r1154", "r1180", "r1181", "r1182", "r1183", "r1184"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r157", "r159", "r161", "r162", "r164", "r193", "r194", "r403", "r404", "r405", "r406", "r494", "r502", "r531", "r532", "r533", "r540", "r605", "r671", "r680", "r696", "r779", "r781", "r791", "r809", "r810", "r856", "r858", "r860", "r861", "r873", "r889", "r890", "r914", "r923", "r934", "r942", "r943", "r947", "r948", "r963", "r972", "r1127", "r1136", "r1154", "r1180", "r1181", "r1182", "r1183", "r1184"] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r230"] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": {
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified out from accumulated other comprehensive income (loss)", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r16", "r20"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r230"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r230"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r230"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [
"http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive

income (loss)." } } }, "auth_ref": ["r230"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": ["http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r30", "r31"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r985", "r995", "r1005", "r1037"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r317", "r501", "r663", "r664", "r741", "r748", "r811", "r812", "r813", "r814", "r815", "r833", "r835", "r855"] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchases from (and payments to) affiliates", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r317", "r501", "r663", "r664", "r741", "r748", "r811", "r812", "r813", "r814", "r815", "r833", "r835", "r855", "r1176"] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term debt", "terseLabel": "Repayments of long-term debt", "label": "Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": ["r111"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r541", "r891", "r909", "r1185"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r986", "r996", "r1006", "r1038"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r987", "r997", "r1007", "r1039"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r994", "r1004", "r1014", "r1046"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r201"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": { "xbrltype": "durationItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related activities, period of implementation", "label": "Restructuring and Related Activities, Period of Implementation", "documentation": "Restructuring and Related Activities, Period of Implementation" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring and related charges", "terseLabel": "Restructuring and other charges", "negatedTerseLabel": "Restructuring and other charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r8", "r397", "r398", "r1128"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r393", "r394", "r398", "r399"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r393", "r394", "r395", "r396", "r398", "r399", "r400"] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel":

```
"Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, December 31, 2023", "periodEndLabel": "Balance, September 30, 2024", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r394", "r399" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r129", "r746", "r786", "r790", "r797", "r819", "r951" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r195", "r243", "r244", "r245", "r249", "r256", "r258", "r260", "r357", "r360", "r384", "r552", "r553", "r559", "r560", "r561", "r565", "r568", "r569", "r587", "r589", "r590", "r593", "r597", "r639", "r641", "r783", "r785", "r799", "r1220" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Sales to affiliates", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r146", "r147", "r278", "r286", "r287", "r302", "r308", "r311", "r313", "r315", "r485", "r486", "r698" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r315", "r1069" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r155", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r892" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.westpharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r155", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r489" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "wst_Revolvingcreditfacilitydue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "Revolvingcreditfacilitydue2024Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility, Due 2024", "label": "Revolving credit facility, due 2024 [Member]", "documentation": "Revolving credit facility, due 2024 [Member]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r654", "r950" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r654", "r950" ] }, "wst_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new lease liabilities:", "label": "Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]", "documentation": "Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1055" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1055" ] }, "currency_SGD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "SGD", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SGD", "label": "Singapore, Dollars" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r20", "r1167", "r1168" ] }, "wst_ScheduleOfAssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ScheduleOfAssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Assets And Liabilities, Lessee", "label": "Schedule Of Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Schedule Of Assets And Liabilities, Lessee" } } }, "auth_ref": [] }, "wst_ScheduleOfCommonStockRepurchasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ScheduleOfCommonStockRepurchasesTableTextBlock", "presentation": [
```

"http://www.westpharma.com/role/NetIncomePerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Repurchase of Common Stock", "label": "Schedule Of Common Stock Repurchases [Table Text Block]", "documentation": "Schedule Of Common Stock Repurchases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.westpharma.com/role/DebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r56", "r58", "r584"] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Currency Contracts", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r12", "r50", "r51", "r52", "r55", "r57", "r58", "r63", "r64"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.westpharma.com/role/NetIncomePerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1104"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": ["http://www.westpharma.com/role/SegmentInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales by Significant Product Group", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r240", "r351", "r352", "r354", "r355", "r624"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": ["http://www.westpharma.com/role/AffiliatedCompaniesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": ["r198", "r240", "r351", "r352", "r354", "r355", "r624"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1151", "r1152"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.westpharma.com/role/InventoriesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r18", "r88", "r89", "r90"] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextB { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments Not Designated as Hedges", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": ["r60", "r1071"] }, "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Expense (Income)", "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]", "documentation": "Schedule Of Other Income And Expense, By Component" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r393", "r394", "r395", "r396", "r398", "r399", "r400"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Reserve", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r36", "r122"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r27", "r28", "r29"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.westpharma.com/role/SegmentInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r27", "r28", "r29"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements

by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r504", "r506", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r38", "r39", "r40", "r41", "r42", "r43", "r125", "r127", "r128", "r129", "r209", "r210", "r211", "r280", "r450", "r451", "r452", "r454", "r457", "r462", "r464", "r793", "r794", "r795", "r796", "r923", "r1066", "r1097"] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stockholders Equity", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": ["r11"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of each class", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r980"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r982"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r146", "r147", "r148", "r149", "r278", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r315", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r383", "r396", "r400", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r906", "r909", "r910", "r916", "r966", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r158", "r160", "r163", "r165", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r313", "r314", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r802", "r805", "r807", "r857", "r859", "r862", "r874", "r876", "r879", "r880", "r881", "r882", "r884", "r885", "r886", "r887", "r888", "r894", "r925", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r965", "r972", "r1139", "r1187", "r1189", "r1190", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.westpharma.com/role/SegmentInformation"], "lang": { "en-us": { "role": { "verboseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r149", "r278", "r281", "r282", "r283", "r284", "r285", "r298", "r300", "r301", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r315", "r905", "r907", "r908", "r909", "r911", "r912", "r913"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": ["http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r103"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "wst_SeniorBNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "SeniorBNotesDue2024Member", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series B notes, due July 5, 2024 (3.82%)", "label": "Senior B Notes Due 2024 [Member]", "documentation": "Senior B Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "wst_SeniorCNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "SeniorCNotesDue2027Member", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series C notes, due July 5, 2027 (4.02%)", "label": "Senior C Notes Due 2027 [Member]", "documentation": "Senior C Notes Due 2027 [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "negatedTerseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r7"] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Target award percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage", "documentation": "Share-Based

{ "Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r523"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrant { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDat "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r523"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (in hundredths)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r532"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock volatility (in hundredths)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r531"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (in hundredths)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r533"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r504", "r506", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r46"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options, granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r1142"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r526"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options, weighted average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r516"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.westpharma.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r530"] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortMember", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sell", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r651", "r950"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.westpharma.com/role/BasisofPresentation"], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } },

"auth_ref": ["r115", "r237"] }, "wst_StandardPackagingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "StandardPackagingMember", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "High-Value Product (\"HVP\") Delivery Devices", "label": "Standard Packaging [Member]", "documentation": "Standard Packaging [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r146", "r147", "r148", "r149", "r197", "r278", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r315", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r383", "r386", "r396", "r400", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r906", "r909", "r910", "r916", "r966", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r82", "r85", "r86", "r195", "r228", "r229", "r230", "r243", "r244", "r245", "r249", "r256", "r258", "r260", "r279", "r357", "r360", "r384", "r465", "r552", "r553", "r559", "r560", "r561", "r565", "r568", "r569", "r587", "r588", "r589", "r590", "r591", "r593", "r597", "r630", "r631", "r632", "r633", "r634", "r635", "r639", "r641", "r660", "r754", "r783", "r784", "r785", "r799", "r850"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r158", "r160", "r163", "r165", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r313", "r314", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r802", "r805", "r807", "r857", "r859", "r862", "r874", "r876", "r879", "r880", "r881", "r882", "r884", "r885", "r886", "r887", "r888", "r894", "r925", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r965", "r972", "r1139", "r1187", "r1189", "r1190", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r989", "r999", "r1009", "r1041"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Activity related to stock -based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r11", "r81", "r82", "r129"] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": ["http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, shares authorized (in shares)", "label": "Share Repurchase Program, Authorized, Number of Shares", "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r1137"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r82", "r85", "r86", "r118", "r820", "r834", "r851", "r852", "r951", "r979", "r1099", "r1118", "r1166", "r1220"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.westpharma.com/role/ShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r126", "r239", "r449", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r465", "r595", "r853", "r854", "r875"] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r1035"] }, "wst_TermLoanDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "TermLoanDue2024Member", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loan, due December 31, 2024 (6.32%)", "label": "Term Loan Due 2024 [Member]", "documentation": "Term Loan Due 2024" } } }, "auth_ref": [] }, "wst_TermLoanDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "TermLoanDue2027Member", "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loan, due July 2, 2027 (6.67%)", "label": "Term Loan, Due 2027 [Member]", "documentation": "Term Loan, Due 2027" } } }, "auth_ref": [] }, "wst_TermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20240930", "localname": "TermLoansMember", "presentation": ["http://www.westpharma.com/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loans", "label": "Term Loans [Member]", "documentation": "Term Loans" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1027"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r1034"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r1054"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r1056"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.westpharma.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"], "lang": { "en-us": { "role": {

"terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r445", "r462", "r594", "r622", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r755", "r938", "r940", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r952", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1113", "r1114", "r1115", "r1116", "r1150", "r1153", "r1154", "r1155", "r1162", "r1165"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r1057"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r1058"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r1058"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r1056"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r1056"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r1059"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r1057"] }, "us-gaap_TreasuryLockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryLockMember", "presentation": ["http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forward treasury locks", "label": "Treasury Lock [Member]", "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": ["http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Average price per repurchased share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": ["r44"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r44"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r44"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost (September\u00a030, 2024 – 2.8\u00a0million, December\u00a031, 2023 – 1.8 million)", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r44", "r45", "r85"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share purchased (in shares)", "verboseLabel": "Shares purchased under share repurchase program (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r11", "r82", "r129"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails", "http://www.westpharma.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total cost of repurchases ($ in millions)", "negatedTerseLabel": "Shares purchased under share repurchase program", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r11", "r44", "r129"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringReserveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r393", "r394", "r398", "r399"] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": ["http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateandCommodityPriceRiskDetails"], "lang": { "en-us": { "role": { "terseLabel": "USD", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/DebtLongtermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less: unamortized debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r1053"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.westpharma.com/role/LeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r652", "r950"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r1023"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r265", "r273"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails": { "parentTag": "us-

gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r264", "r273"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r1021"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4F", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org/323/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" },

"r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r294": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481725/323-10-35-18" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, r440": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"

}, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r636": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" },

"r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column

E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r912": { "role":

{"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1025": { "role":

{"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1028": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1029": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1031": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1041": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1042": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1043": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1044": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1045": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1046": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1047": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1048": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1049": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1050": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1051": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1052": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1053": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1054": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1055": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1056": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1057": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1058": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1059": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1060": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1061": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1063": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1064": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1065": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1066": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1067": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-

01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },

"r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 91 0000105770-24-000081-xbrl.zip IDEA: XBRL

DOCUMENT begin 644 0000105770-24-000081-xbrl.zip M4$L#!!0 (+&"6%EY++""[@8 , A / 97@S,3%Q,S(P,C0N:'1M M[5I=
<]NV$GWOKT"=:>+,4{]DC\217<_DP^W50YLVUS/I6P#@7AMLK:B MVHO,DO2D1.MT/17O%+EK,1AT5J],L[!Z6GAQ.#P\%N^,O=8S&9]![4NZZ/LY M?
Q*OSY^$0ST^'F:GQX_DW2BCC(Z&:5/ M3Y_^.=I#4YC'-LXO2OIQK]+UH" >?_SLL/%GRU--Z'.:S%YOVCS-3&CM^, Q_9_QDD,M*EXOQHRM=D1._
MTER\-96L'R5.UF[@R.H\&CK]%\$GN!($W:*<#F M33-^CL$;J12VPZ"DW(^/GN).6">-Q:G]>#`Z;?Y^!&V?Y.B@G\.W'WU]64;# M@Q-
>AHDHY(R$I9FF.8C$%I]J]ZVT'D!:X'YCK!>F%C\96XG18BD)28%SHK MA&OY8]E^3I:Z3G@"E78E1(>U;:Y]@0FZAK+@(/?;P#6C,,T9FBF1+E:7X9X@
M\.B?@T 2N:X18X;+,J8)X =S/+8KSW6=@U"":N%[5K8*20(W*P%,@#G-)-0@ M!(Q81G)9+B'9H<'=&AJH5YH[3MBB+6$ "!J)0SG@C^9=(7(2S-
W/4@M3;7S M5F(@R3>CW_ R6<&:ZYW9\/:>P.UXY^ !VM1:,1ZZ#4I<=.,#68/(?PV'WW.(1L MCJ2E X$6Z(FQR-81G=R_ M8,Y: 6T$$?MRYX'RM8%R#,3SO
UE6+#"?WD"%7+W78&GW!UXC@Z&SW@=7I-# M88)@!2W[-)(2EME,MN[N35CO4@(JNI&B@IK6HH.&TRX7V Y65(=^.&5>\N0J
MUUHJ98!9)Z%+J"0=#_-##VH=BV_8 MF"XH=>!&XP@.H;(,C1KDE#IK2\F4CFD%)Y8BCA8Q)5C-9/ M)38$ZZ(]J2]G MV9V"<;H[,.Y8=AW%=V:K#3#?
G>?NC&GL@YE6#%7I3"V9T*4#S#F;9/Q*JWHL M =U:IKK4?L&ROFU8WED!=@%1<5.LF:YDHT$W/G03:EK; -$NI"$92FX5' AY
MZ91J9!=S(NC7+XA"ZE@QNOOV&< [@JEMVG9LHABB^(X>E)(M=Y-,,,4%@),*W'!FW_'R E7_.97=2<& M^:0K%N3KX+Q3]=7)SL'Y"^JK<&2H
M^FV0+&F(67$5EDM&8GA]1E:QD9W"+XGL!/ ME(9/H?D^8 M:=4S;^,^Y<;^_Z'VKX7+846V=A>."Q_^63G^7:+\HD6XA_=/
M%Q>K7/9FFH"&3GYO2I@YR6O6TYA^!44-B6,XLNQ/=CX+8UVU$8*MA"85&CH MZ(;_MN"Q2S1A;/DG&&R$(.<.6N[:"L# ^H1I=/JP]?
3K'DGU[E4U+Z#(N05/ M) @W!5X#8,+)L)$]FG!'K7"VGW0&Y[:B0JJ8T"\+3>6B^SH]7A6: MCH\ M.SQ.XBL+'^7$U?<*4)6'X_YQ/-
N:T<;;!GVKU'AOJO%PV42FSI2M_WB3E5)UQ:ZS_@&Q9/PYL;_%!+ P04 " "Q@EA9[R4 \>D& "W(0 M#P &5X,S$R<3,R,#
(T+FAT;>U:76_;.!9]WU_!33%M"MBIE8\V<3(!VDZ+ M\3Y,NVTPW;<%+5Y91"A1)2F[WE^_YY+R1V)WFK:8PA-,'AQ+NN2]Y#T\YY+6 M11DJB
^*_+7H]SNKE[:9.STI M@S@<'!Z+#]9=ZZE,SX,.ABX7_5P\2=<73Z*3B[%5\\L+I:="JY_W=%:<9D=/
MU=G9Z=G1\1D=RI,BEQG)3)X5X^SIZ7^S/32%>6KCP[S0SWN5KOLEL?_AL\,F MG,^T"N4P&PQ^VHMVEQ>%K0.<.31.7U,?
&ST%^A3ZTNA)/8SCV4M-%X]S:ZP; M/AC$OW-^TB]DI"/2K__PZ>C&Z$D?9P>'-B)>C^;$AG<>)491;)X.V];"M%3FV
MVKM\^>K=U>CUZ.7SG]&;WSX3[9:Y_P$C.=XZN:,>>$&NEDZ)?QV(%]I=4P@] MD9,+NIB+4,KP\,')Z?E&N$NX23DYOJG'Q/C.K\-D[
MNP<).]RYA+V0'FE"0[JYN*[MS)":4"_EK)"Z%K*>B[8.KB6, M *(1]0-IE*+"E=/(7B%SW'+"5CJ(8)/=AD%-2+"7;LXFE;PF^%WKT^.>0C!P M::+XP <;Y-
I!;&!6H[F(3"5FI&M;\(IB-:.\)W(YW#FY7 M-W+SR'=0ZJH#I@9;%! >M^\?QY2-A'04P8%DZ[$A3J* 8LFQT;[D%FQ6@1F9 M'?E::9\;ZUNT8\YTUB24-,
[FI'#;BWV 0A%0EC+_ZE->RGI"XCGHZ%UK8)$= MR7YVLD\IBNQ$I:MT"5]&8'@V<\#[^0Q^X$R8I:]F4D]5AF<]GZNS=AO1L34-%Y2@I] M6X<.&BZ[?
&0[6%$=^^&2><63ZUSKR,@(LTY"5U#I=3S,#S4X$[%X:[2*FTS? MCKU66CK-_!)Z"/[U]Q3ZUE\X\+T4:DC-UI/" C;R]BH04VI\]9(IG0,*P:Q
M$G&T2"7!>B6#;V-B0[NVI/Z=I;=*1B/=P?&'1/&=V6H#$'?GN3MC&NM@ MJA5#57]L;2R9TZ0%SKB89O]@W+K $=&U3UC>:.\LB+L(J+2HKAANE:-
M1MWXU.VH:5T#1/M8AN38=ZL80*Q+)U2CNC -IY0PRN&35!S)_!B9>D&U'U/ MX)OO#GP7+/QJ*DT;J8J32T6!PE!/D1:_I>LXYVM:>:._ROJ
.SEOC0K$A"ZZ@QNQOV%< + @ MJEMV79C8#%$\#^"C@KI=QO(X15)*ORPFF.(BP$E%[H^C[WAYCEW_-9GN<."6 M?>\[)N3[X+Q3^ZN3G8/S-
^ROXI&A6BR#WHJ&F!778;EB)(;75U05&]4IXI*H M38-U?BGA\08ZJRH= M%6GAl;/E;&$Z414VR^#]B"5CW3-OY$:;Q87_2QU0@Y MKJBVSN-
QP>._MTY_EF@_-RBW4/YIX(LWJ[SMS34!#9W\+KI_(J* M&@O'>&2Y.-GY*HQUNXUT5+"%P*1"0T]+_MJ"QZ[0A+'CWV&P$**<>VBY;RL M
_,3A]'IPl;3KWLDU;NWJWD.12X<>**'=%/D-0 FGBQWR.HEB=/UU)HIL<[5 M'_T8^3#!\?/SGW\ MW/(KWTZ$OW>5XL&]IUH#A[]#?\5;!!
(T+_*>>%EJ*L3K)8[>)(7>>:"@>,;Z MBX(JWD"-Q^0>/LB>#LX/CWOI387/LN#ZZP38A\<#_F$ZS9K2Q@L&BU9C&X*M MAH-
5$SGVUK3A\TW6WCC@&H;5N@^TXL33^(+&_\'4$L#!!0 (+&" M6%FVENU=OP, /T, / 97@S,C%Q,S(P,C0N:'1MS5=K;^)&%/W>7W%+
MU&PBV<0&DN6U2 1(%ZD-62#*]E,UV-?Q:.T9=V:/!#_T??A[&,RAR%@4@A,QA#J;FXA[L8]1?P_8W7 M2!9KQ>]3 XV@T8([J;!P!U;9#3<9#K9Y^F?5=?
_,%>FO9+P>]&/^ #S^4./M M9FO5:3:2=LC:K6C56<7MA'5:43L(FJR37/P>UBB4W*L8;=89?JCE7/@IVOK= M]XW"]!YY;-)N& 0_U9S?H)]
(8;B8HN#JM,KQ52:#3\9G&:\77<>G5H5NS9',MI.H>!>[7LQ8_8G(UMUW2YZCAFMA+G,F7CG;2:TKU'QI'+4_$\D3 3/73YN M\%*>C OC4= M#9?
3V37!P=/:+B X7AVLYR,7[`9 MNG@EC9%Y]X(J@JOY<<)+(;SR^'U9.'//O\R^0V&HR5Q MH5D/&M],Z%^`WWH3_E1)(7 R' IX)&:,%$R**EDBC3-
UC#'0BH#9+R2*H

>(3:@ZF(ZG!B$QT?M1N-H#>2><'$VEV% MO5-(I')U"D(M8T 1T]JYP,)@OD)U?!1>!+UFX+GUT@.F(>$9>>SP+3 J%3>< MA&
BALE3E#)QC[32YCG7VG*AQ_6,:5F&%!42Z)>(*EY;0 39@XGB$?Q:AY\5 MHO#@1J'FL5W<;8E1RC&A0E38|
>$69(05^61@7%E);')+R53L;T8>F^=;)3L\F_8&K%!&I_ M]I3A&H:1L1;;@Q[9&3$]; _<.OAU/PE-8$IM-UR5E1BT8D729?=2[QZ_PCY($ MMCNF$_A9M!-
V"M1;X?E)?+J3YKE9=HVRT2?L-*O^8KGK05*IT[//^_"5:E1* M<4&SE#-'GR;9,/*,Z:YCOI61.I1T+*BAK6*>-;,L PJCXC2Y9"A(0NVYJ(0+ M)B)
[GQ+&W*6V(T!>598)+FEP7S_^/T2M]!08(UEQZY;4$LIZ MU0:'1ZWW/>V.K]>)@T!.KT0'B.F264#WD#E.6!VZ[(; MV-
Z1>/E27DCM)]VK,&-6H*]>T[=1FPD*GD/82LNL-/M#ON-=^-6Q^OPX#,R,G$S,C R-"YH M=&W-5^]OXD80_=Z_8DK47"+9Q#:0\.N0""$ZJE/(
6FNGZK%'L>KV+ON[CH) M_>L[:P-)++D%J/K0%(829F9WWGM.LFGYBLG303Y!%@Y_Z/[LN7,BPR% 8"!4R M@Q$4FHL[N(U0WX/KKK-&,E\I?
1<8"+R@";=2W?,'5L4--RD.-NOT3ZKK_DG9 M1+ ^4T6K0C_@#\,ASC;>;G3-LG[;:80>;C;C="<$1>,M6V&%1'+>\/_P;E5)Z M5;/-*L7/M8P+-
T';OWL6Y*;WR".3='W/^Z56Y@WZL12&FBDJKKY6:[Q9R>"3 M<5G*[T2WY%.K2C?A4*92=0^\\M6S$3=F&4]7W4\+GJ&&*WR$FGE3A894W?
DXJ4T1F;=4^]X+[F67\8P"\[. MAU?CN3OJ_G7\.PO""^)"L^[M=N<;0O\Z_.:\"<"0BD$AH9+ 8_<)& 2A&\% M4Z1INH(9YE(9H."E5!GXGOL-9 RWJ
U<)TQE+,3")"E,$?UP$/4#DQ$6(V=<\P-9DM4AP?^J==K>$ZY M7SK_,0\I8PMOCF&A>*&DQ!,1#!^"A,F[I!VVBSC6ELN]+:9$6W+D*!" OT2 M4<5K
X@@.W",2C 5P:]U..?]'HUQD\@A/4WX@77"C6/R&P.C!*,,5QRP43(MB?HTCBE#665LCS5=!^@WPV/ZDA=*%XSNKY$O)WBMNYW@DB;+9&Z/D9?
IFR0[M(NOUYTPMF4#M3I]27,$P-#9B#>=0G!&M5KNW]]X[\H]A06S6%HN+E/P6DG2I MO;_;>ZWPSX(KM,>CMC2?13MBQT
WQV\=1<=;:9Z=L77%6A^_TZC,Q++2<*12 MIV?]L_]*!9527-#@9*RD3V-K&&5&]&O)?",CXW9NHU0$282@K M;MV"+*%L5FUP>-\Z^GR\YU-
82_@UP9[^QC6^8.T/MCE-K@@B:GW%%A&AJY M/9_L763(RP\QV&!_^3R>2UW.75=A2E\Y\P#=/Z)NJ]3QXSR5LJ65;F-TE'W@.M?O59_2,X*?_Q_
U02P,$% @ L8)86?@4;,G+25&74*B)6&;^?3_B)0$V B0($$IR#XS+AMTR8SX163<,O*7_WP= MV9>|=!C!GF+?C_UH:!L'X_-.GEY>7RHM><;VG3V]JW?
[TBM>4 MPHO.)X'WYL+71\]FEVK5;OL3?!M?^.(:Y](_6 \)-Z(5 QW]`D)4(5!Q)?[MWOSR ?$?V3/A0W;AL.5^^8F0\?
*%T1=O+G[UK:0IP3C53__[_;IO#.F(E"W' M#XACT/@N:IBSN]C1!P!=O!P%?6NN>^VYVUNNJBU6\& 9-$=KSRX/DZ^>7?@H\XO@(48?
QO'A3/9]USU'JYVBKKZN):3,3XVS>47.+F6T+BUX_$#PEY;A/0""7JE'_T2YU?AI28G5]&-" *WE^F M?TVLYU]+%ZX3@'8H/TS'<)L1_O5K*;"OP2.ZY#X?
W6ZSE>2+WP5\LT MJ<-^A>]O0$-YEA&^_C6XIX-?2T89:.]0$3Z)6N<[!UXWO8#|><2^L$=7.Z;,U_1*G7^1]_^!5UXNLG> M8).GDA**PZ\E$*'S@?5*S?*
V/Z<:.U2AWV0Z86-^(61TCS_:CFH(ZXIX/L> M5Z?;P0^?=GV?!OT >(3CN1V5UDP;=>W4$1[KP!HWWJTZ;7E!_&8:KI>ZJQ3
MSW^[A1728T_W;UPG%,: WPRN+?)HV8CH\,G;3*&>9@KQBRSJ7^QM$G,*;3,/ M9L9YK."I[>]Q:,#BDJ4^@D*$97EN<_65YBLPM;"\P#4X*\EWQJ-
;=2B[+.A MA[18U'V55]\$Q-W]'J$K?G7CL+[;LG4\<*V!3]<&LH'XI_GP$%)QXM!/^
M%7[RWZ>WW\5_XS.6GC>!,;Q_6+1"G__H7V9I%NB)@YB]DQ0Y99)%R|E9";! MZVWYVYJ7[\<-+ZK@C@$K"8]L2YLTC/KT=_;I9.Y/1(_56<&0.OV:BH?
^TFA_] M;]GX02?+PXJ?U?MQG^E9?XZG*Y_U7W?_5/2LQT=[Z5E@39_#YUO@[7*(=OC/^,AO8Z!-]V<0'1M^E>5ZD[-DC<9&//Z?,VHK_
M@OG!WP.+>@K3ES312KZX^N^W5MC[FV/OT,3-0XK_$_ "M+F8$52NJO"_M^+[Y=[-AF@N7MLMZ=?Z*\)OX[_@EG]
[,.YD,F@!D"%VB(OR96BUKVNQ!T3?;MS$P78&;O&=P\/(-KHI%!3T\&G1\9Z@*2(;VXJBX@1_$%O-CAB'@_WP|EGCY3 M9T* >NX(@X4>,8(_K&
8CW##@#Z]8THQ+ 1U[Z:PQ.KQ834?,T[=N[\BL7I\ M6,W'M5;W[H%*K!X?5O/Q"]6]APEX8O4;=3 %(J&:NUK-PUS=>RA'0O7HH)J3
MM;KW<)N&ZM%!-2=C=>_Q4PG5HX-J3K;JW@/B/*%ZQPIL)5#SUJEY6*I[SV|(+MH!X94/.Q4]5'9:LD4 4 :D[52H5*54F@"@#4?&Q4K5!YJI@MWXDS&
<"_$X^: M$KY9YZ]<<+%:M4"DK"5OA8)N3_5JH[)6$K7"PS AEK5;B4B,2]^%C-R68M=A%Y$8O64+-9B9UTD5D_)7BUVCB'*R,&6RZ1C MDY.=)
I,_QP">G*PMF9 Y!O#D8_/4A6@:Q0V;AUUUV M&"PY[;\^5!.'JKY6%AUX9(D$JK"0S6G@Q>%RY)(J H/U7RLQ[IPF1$)5>&A MFI.M*EPV9
-48V;UOO>Z$JHG9:L*EP&14!4>]CG9JL)E/214A8=J3K;]<#D6 M"57AH9J3K2I<1B>-6^5;Y(X8\)#HO6DS%7A4D@2K45 .SX6:Z.0.2N)UKS1
MFH_1VBADVDJB-6^TYF.W-H3+7$G\%,F2; B73I+X*91M)UR.1^*G4.:6<(D7 MB9]"V3|[SX:DH(/EP&R!9N'4M++6FCTH^F:KJ0D7/9\#S09^F7?
X>F#1QP2 MD 87^^FB]\L>"># @65;^&6J380_$A^ 7E:UL]YRX8!P M@4YQ.2" _]$+4>M)7$';E8[PWA0MU%81=^=C*36%C/9*S*Q_3M"EL.,7:=9X"
MZHTNZ6,P]VEP4_L#?'KM$N=R0H$8S:(8:DUAHQ!BD)JC1=84UF%/2^I:85 M M7*6?6*3FB6IA?>W5I.Y3QW*]+S=N0/VB(5M8QUH<]"9R7RR0NS#6
M2$M8+U@<T D8/'275S-5@%=_MS8.LIR+PIH"^Z8%M'5@*D-QU+BI*6/_TPJ.F%7PEAF5;<3!L(77KVL^6_3V M(EXYY-61"\VB^5/M(3UE-
BM97UWLAGAF7P7!K//&56!X[',+ M]-HBCTQ^+FSB^W->7P$=/<,=C8DS3_&A,G%Q/.H8T0*Q(C^.N]_NRP MEH2-/D@L+6#I1[\
6&H+&UJ16#J(7N(8-VH+&S>26#J(7N*))6$#8X7"TB4= M$<=D88<]{JKWX[X *YVP(3V)J(+:3L(&(B6B#JBC>*YZPL9:);(*:I,+&\A-.MC2AJ/3F]5V-(G"<:
>PHY'];PL9A\BJU&.X/;!P=O?^AZW+)4$KV[H+?X$76I M>O< WO^Z^Z?XX%6KQ8_A2]UPO M?MI *M]"^==^!V'(/D!;.DX?C?B.5)-3CE:M%CQ3L"_>
[$E-J<*&M]\< MPQW1V2D"UZZQ$'O @I3;8$B]WNL8;J3AQ?N7B!PZ%*JJL.%\5B43U="514V M1BD>BW):5U1AXW#BL2B?
[H.J6JA@518/:59>FB(,E+DQ0J M'KC,K_>/$G_B30%#FY6+*H8%RKBERN"\I*A0L7T$H](@HJ?_@L9'ZD,%2I]
MERN"\I(A&9<[HI!*3LD53<;EC@A$.64(=!F7*X*_E).*T65WH0S<%76-JIQ(U*>A24SN5@$515QQA8P6"\2>O MA4?
82(%@_,EK_1$V3I"%/W';HFCW!&N0<)&@3D45[K4#%C!;G)42YK43'# M!KG)41[K45W8"$+*J*@[&KDFC#M5GZ;4+]_4(_G&=+Q6O<4A."W!=
MV.B)!&7^H,S)XJ@+&SF2H,P?E#F96'5APV42E/F#,B^;4M@88;Z'LDI4YFI4 M"AL9E;@4)5Y697"QH,E*@5 95YFI; 1<(E* 5"9EUTI,,R?)RZ*:EX)&^P7
MB3DY61D-8:/\(C$G[\6V(6RT6R3FY+3F-(2-^LYVR'^9SC?+PQ.)9PRGU_29 MVBMVU%\YXTG@LRM4_DS;T[DF#6$#G3SXH!6'#\+&]GCP02\.'X2-
9ET0?]AU M3/RG]]<$G#4;]O??TOZ[Z]#I=^+!L,'7B6/NH=9O7V07-ERS!]+++I2@9 \(& M1XJ.@0(M@*&(HJ.@0(MP<)&/-)@X MQ?C[
K9=T[/K6QA"I.&1O"AO+V /9 MY1**?.?&$C7IOI'1>8%X?8PH:6"K;&%H_S MP@:4"K; %H[S+6%C6@5;78O'>6$C6>)'%/6RJI5UE0\?A(TFB1_5X\H'<2,Z
MPD?6N/)!V$B/%CD? Y F*PQ)A TMI6>(:5GC%=QH,7?/*>:9^ M@/<5C1/"AG>R"\(:PQ(03;A U6B+_8[6>7B]86/HJ0[\O*E1.%#QZ(X+)R MY<@1!1$.
[[)RY<01!0]R<5FY,N.(X@(,(J MSI4C1^3J'WX5Y\])(_+:=1*<>3$$04/,']<^NIM:3TWLUAL1YHA=N>(8UKQKW YL2]<=U3PV;^#Z0.#S>^G82 MW
Y2X/+ML+=]ROXK*7(XDUG3A(W>2%$X55'(YP1L31)/O.FU;_R4^"\P_G-R$'1A([X2_R>%_[R\ M F'3"Q+_)X7_O%P!89,Z$O\GA?^|
[/AC2J%)%!;6"C^B]*%$86%M86'SIA*% M)V21"INRE"@\';NP)FRV\+#%;A*$.9J%-6'S=!*$)V,5UH3-D$D0GHQ16!,V
M325!>#HVH;"YHJ/F=E[&E["9D:/F=EY6CK!Y@*/F=E[FA++@Q]/F=E[K=M'C MVA=XZ(33#S;GN+?@T)X:5M<*\8U30MEA]AWQ#*OG
LRM@)B%X8!J;)`,/2 M#H;[4 2*0 RB1^[N:4#02^T1S[& MT"D*(80-*HBV3@K!+6&# B(MJD)P2EB'7N2.#$)P3ECG7#!W[1W1=S.,BNXC MY^&N<65
T?WE0[MK/(G?*+JO?%!WC2OEB^XHY[TXB2LS]NVISBWHE<0'#XN M4$MO_#5XQ>H;>W>'BT*(HGN:N<4%FHVBNZ4YQ06X,.!9=-BYU\/'Q?
(HQ][*=WA(G%+NL-%X91TAXO*,>D.I[86N!TMT93N<+X, M:$EW.$?B2W?1MJ^@IXSR4/5<&%-TW/[2RYTK\HGO%$$7W1/.)S>7%K;*[L(>/S>7$J7;1?
=W\ M8W-Y<:[HCO+A.@[PJ_!M%]U'SJ?C $<&%-U?/GS' 8[$+[JO?.", QPI7W1' M.>]2%:[,V+OOG./X*(0HNJ>96UP@!V[IU:)[MF[G$!7+A5-&]2R'B
KEPKN@NZ@'C KPJ?/5JT=W2G.("_!A0=-BYU\/'Q?(H<6\7I7N<(&XI4IWN"B< MDNYP43DGW>'4U@*O4G)=E>YPS@R0[G".Q)?N<%Z4%]8=
[KX0SWR8CM\=HG-'MO8'KC8ACT/Z0>%2L3OS\%F%AL\J<^++Q?;X?G-\3YREZ#_[YW7*LT61TI!P7 M-EZ0)\?)ZQ%S7-
C0PPJ.WU,_\"P#/")F9/QPK,"_[_\X3NYB>P\U9"4$V\V4 MCA#O-C[M1@CA//G'Z0=N:;R3^BQ^<=WV?!O>411(OP%!Z
MVH?/LB_2"^N8BX1[(ETXKUUH+F5K"L"/2\)Z]BFX= %S\8@1?"?.9$#0>J#FD2]0PL8" MQ&977BN5L\$#L=F5UY(E;!!!;';EM78)%TO 1
#PP7=MRR18#G8%7'M7*W,+ M8A;OFC84V;_):)X6+=$AHB+(F"Q>>)D= 09/VO"1?^D= 0Q-:H"1=S M$AT:I^>$F,B&9]U(2+MTF,"&>&"!?

ODAI3,K3XR,GS7K6D4M0[MKV4==F&@0!^QA<[2S5DOE=]2Z6%U^_MB[C=96EK-]N13M;B*7=NAA/"396*Z4X>;3KCR&{B)1{Q_IXCA8Y(\;3?U-YU-M3YJB*4U&LWZ[DL@=[;FY()(R9:2G6]C_3Z2S=)++:W-NQE!3I+-+)!/ 9[Y M' >>%F*;"\|O*%#=RRM^V:=4(0:FD8@SQ3ZLCAO XP,7T6!2QV?-!AU&&Y9W M&E@.<0P+# \?Z^'9YNS*VP#;PCRC=S4U&,S8]5EMQ[E';1)8S_3SBV4&PQB: M"W=%+*O.;R&/,())L/J6O1-
4K;:B9_U=K"\A)XX6P6ZUZX/6P!RT'VMMQ:95 M]<>&V31J=4VMF)3_+9 3/"?Y"YGZB+4% M.HPLI[Q(/?T6DF5P6
KF,5$80\|QUH=R]A(IE",0!>X'FN4=P["2SV\"@9) MQ!V<,O10-_YM,P=!F3V@Z&/Y((8M0"GYY1/I)*%C'5^CV?U.^7M_^T5<^_+CI_KB\@FL^
M+=@E/M+V!_4#Y6Y(8*$QZ(0I8J5/O6?+H/Z982]>/OF5:Q%ML7Y7O MR#!83IR>\&?49*O%?7 FRU0D&9).Q3_C7SZ;EC^VR?3<5/GT^'H@I>9P?P5G-V86>Z2P<\Y!)ERKIDCD"+$$%/.+4L(45T?0@1(S,L@ MDT*"K5)';_[M!8 P7J)=9'FE@7K]1VQWBYU:O6&W%N1$ZN!Y\3/^H0&{B* M1X&
[AF53Q9FM6_@Y_F6@!3GVW&<+_$KE<L,/KO]E-\=7U%DF:!'@-=!^(<@#X"6\9/+PJS 03'6$B M2F^44S,+6953^9'X[T[@E";BMBJ2!>G[@@1=/#@Q"?
@UW HKC'LL;<4#*LCT M(,%-"JHP'4].S6K$T)8"K,8"%=LWP|N M/ PV!=,[)"L6VHY'[*C$U)VW;PW1.F]+6W.OJG1%6-PJI2:7MNZ9XC*:]FE+P
*^,IL;]$#7OY"&-52-/SD+YY M:HRT2QUQ>NUMT(IQ!3$,E*Z&U#ZO*OH C\YV9QVJ%)A]F:4WK8"._#-,=YZ8 M[9ZIX*[JO21U/ZM52IYT0_Y7=XHH-
D0WK2R:(8)NK MI ,<9#,X/3>#2UM:/"3,$QY!XR@$6!8:P'X,]WRA[7'W{TO#? M*^>C&(,[A77Q_29%RWFF_CX]S NG?+?
MB%AT*P133"B;>EB;DB7A2&\S$.S)EN<8'MVO\-;$|^B9;W'7, M=0GC>@/<[V92SUKI?Q<;-1L,O=U0@X="UY.<"]$<<>%S57* .!\WV%6%]9&D' MF=
[CLRI^=3W0:$ 2T_*QC]C[55LL*_W9EO)!Y?(I%^Q@9-R8=P!.*S:9)>, M1D$S@:D&J2>X[\-R$KWQ7;R+8PL6[J9D5Q2LK@@;IL.7!IYMU=03ZK,R6Y-"
M1*DY.2@G#;RTE=*[4]%-Z8M//!XA*H/V?0KK\X8>PY5%W!U?!^]COJ#!IHAU UIV1*T2H'U!O!VO1X;LXY3]|\ MP:^Z\OT)]"1Z.[@&ZCX
<2^!MDF+-1Y.V:C)+@Q'B9A-3GD*Q*3>9=G01=ME M>6H9P'LZC](LG-3]B>1T-NC5.5EO!RQ>M4FE8MN&1CNAQY=,_A4;*!O4:6:@ MU#$4OLO^%
[":;@NC*,\\"]RU,;$5;T%E.I$?1Q4;2Z=W]K\]=DG8H#*_AH2\ M1CK.B\VG)(D >LE](G6?W!?V\'M#"W"2]Z=DLF.E9P.Q_P6WC2PLCV8ZI
MQ/I>&L0[%P'<#F*]^A?N:.0ZK%=(M3>(P%!0F-/P531\5\D(\\]0LXSW%:)D0W([QD7[OE7]&!>1.$(HF M)O)KN[<,EQ:R@'C)$*%-
C1>5*=%C[%96!$W:&XUM=TIJ$25\<0SAJ'!(65=(-MQGS/>IPP)IZ8";KW5!?KF>K_P*.+KQP\>]!ZIGA.>V(K52S(3PI%-+52!WY,
MQR])5.V6#N.#*AU1M?.N<6G<;M?#G+%PIHI- EP4_'Q8PP!SU2TYSYY9'1J M]NV>-@CH7&)F] 7I47*Q@.71OG=VH6[CX4Z3VU24#-
!_>!O/XQ)RU(3.HC IH- M-#YV4:[2FA4102F5*P\$80-T380_BET0EG:?)547RZ[@^6S^>IKS(NU>V"\-M+5"Y=9U'D(H>4Q0"D4!""^K\
(8W.,B*@AD!)9131^5 #6!65O=$#PE1%H M@Z&/,4"4-Y2CT2/UPC5'KYXI6E6KG0$@W8D-->,'->H2Q$%[XY\0)?4+&PR < MSX91L/>&MO^0>A0<
#'^#T*7=# I0WZ(2Y1S 4[]D"BI\!RXT*N\^"^T?D M3Q0E2,R#0?/K\O%1\;E2>W&>P5/I3=(U?/W4]8P@JU?]$S2?B?4)-^PD'K%;KS69U
MX5>MQGZO?WKQ@S*R0H7_58;!J-2!OYBM?7(3UT]SVF\E>='-RL-&BQ5.N! D M+C'A0N5,9S9.N(JPM0[-@WA%L]@J;H+;Q7)/B-^7*R@!A-8-
5%+O0O!?'IG M47>6? %>3EE3$*=,V\$I@W$L."^>Z\"O1K@N=AWS@JW]_I6S>$ULQ"Z[-^WJ MLLO6KBZ[;#CY^1/1HG;,L(48;RV-9->
[[^UEZ;RRG[CT\X1&#.:*MBS A9Q M0(KKR3S#@NZ;+?DFV,$4^Z@3LZAOWF9D>S.((C:.O,Q.N'4+*%Q?^43Z4QG;[M7TH?%2N<_=/$"DW[8$@"Q:?
T)POT6J.Q!V^(W"L6M?+I$[.=YWY%[)I$MCEX M<:-0/X'5ZDZ>AF E#?'9YAM?A#RZX/;X\YC'[,GL*&8_V-S/=:**]Z. MBA4+N8P)U1 M;0&X@,@->
(S0@(ZA.PHWSB]B"]X8A_N_WOC#\/$C#9!7Q =<^LWQX-0GW)*$$PSZ$K]F5\#8?N1]NNH,)>IT+/F)% MP9W#5LC*A3&S^\%;=8&;MD5"CY,!
WAJ,JQ'J/87D8Z^KFDR!Q4P "L_?7*] M.+[Q!$X>3M&D ;'L2+S00@!R3$+G.'P=>CD 'ICU,U)$P0F ",)\P2;S<9\S MN.P!.-V^.Q_&(CW'8^_1,P<'!?G
X2:SOP&7P M8N*#^%)OI>^@)SA'^K)SQ'4P"0"R2[:+BV;H\&7)PQ)6^-= MZ8?RKI+UW2VL>5Y(H'E< A,AN.X\>5Y(H'E< A,AN.X\3/5ST*&U'5LCU]]>-.K8[BC4HM:+1.0$'M8%2&[,&K-U7U5ZZ+*$"/'2A
MA*IT?F")\>]A/KR'CBQ3I+.JE3FVY!8WR[^^\T^;_QI?_C=+'7VYL;/0 M_#]AYNM\F=|'YB_W*$YD_BGTJ_B&NS]V-5EVG*]XV'R3,DN-T!I?A+9+'96S
M>N+<4ZOXC,[*XCI/%NM5[*2[W!M#LCA/%C?XLE@%%J=<9R2+#\3B)E\6:QCG MV),I4<#P1[BA;)?8Q^DB|\47F3H@<[GKFP@>SNFRN,V7Q35@\!?
*I\9+%,;)8 MXQJDU*MXZM_R&6:2Q7FRF&LH4]!V*![&8V8=<^,ZLW*WXDS&< O$ZSENO-< M*I7F])U%8[%7$.D>K4E62PD)
(X1NJ5#%4614Z(2X1DA$A?".=JB81/D(.2^YT* M4Q.O|SL59K]3\79;R TJO-D'XEP]SD_P7EO|\$_UJ*[W\GT+UT1I[YI+:%@QU"K^PEE2R%&D;^/(M
M8E!QHQ1G]26+&'9D,=\B!@V+&%3)8]%8S+?Z0,/J \Z%@)+%,[*8;_F QLH' MY$:IF!MQTU'E#F9#GF@8KH M$,(W8*GON&DJZR&?
^6RBNIS,SB.+3E[^AZ]X-#SP-SX]^MWN*(L=NCH[_#4Z MK\S'@W)-Y:\)\? P6+@M/*+8"$^]G3TDF(YA^.PXUD=*'67D/N,QJGC*W6^_
MWRU4K^*X()/W]1\5Y<95B/GGQ_"HUE?J$>5$3'G)ZN|&^^_2'SZ&IYMYZX9 M;D59P9^N"?J/GED/+0.A1UI!].46^/$VO EY*#DUKC")^0
M6^,*LS5N@WDG(%%V-%4/)(=8G=<\;BR$Y!.'D6G4-S59:X6D6> MZWPK M173<^B;/ 2H*_G6D.@-N?6I6/SG6Y&AX]:WE(V7)?]%X#_?<@V]E7[?\RG4
MD/4FGCNF9\IWRS1MJO2('YPIW0%;,K* ;!NX\BT]T=O\U94L/=F1Q7Q+3VI5 M_A:)9/&.+.9;,U)3@<7R3#"Q6,RWZ*.FI9?
BDXB&^!;!;6[6P#+D)K=M\,FW MY*2FES!BQCQ.E\-]2T9J-O0EL4D[Z9%-E>DSQB"Q-#>@V=GV+50-[U(;'--YE>Z_OV5C!*#J_!;R
M"%B9!*MO62JM.3SK625UZQV-%WX.O7DAUA,M/WJ4_"R3 8SUG-@O9.JCQ"U, M:60YY47ZO9_ZR@D.!MM,L!W/CSWPW J
FL;&&8=2"NAU0WR>@U:@'EX%@R3B M#DX9>BA\?[/:]4%K8 [;C[6V7M.J^F/#:!JUNJ;6S&:[K5?_#VRV!U:U[@X4 M[-T0=LDFG21&KRKOUT
\#U+>WTP$9=QR0NGZ/@U\A3BF,H7VS5^SI48/(V" M;ANC;'L3*MKN""\R&A$/"N*S'1!&3&$RI[ ][_!YH?8_M&J5=KW);ZN!OK<" M^N7+BE%J^>'ON
4*"FR#EO _YEIUF8=8O6F$\5J/EQ&-9K"%5'&Q5,W)9QJ*K6I6K?]GRM\YNJ1K$7U/ MGZDSH??4<)\@W-G,BJ;+1OIXO.3\
\J=71MIN%KU)>"+:OB]\'E'$!^VQ&](2E!"Y\"LX[VL'S\(,D)5ZFAG"Y)C5'Y$_7 M Z+'HQ]3CQ';,:CB/H(PLBRV/T/=0J(SQ+0/%_@#:P&83D@#Q04 4A_P=K?
B MF?-;'^D4V^K-;L4'.VZ@8+,Y$R(VR 8,< 4V*^^,T^RE*@BHM4'IO2'0.>$O'L]E&:@'S6[0?19>2D;?T,#
MY2J4!7B8PIZVI)QW[8L8O3EA/%HI8RU"WQA2 1688UC8@Y&UJL29^QVD%[%#&F3>/EY IL+4>8@V5S*-H^RS>,.:T>V>5Q-FSVU
M>2Q"1&!=\9+L3IEAQB?5T_,0#2H+21@)I]WA= IQ[9N9[2W+0F19R*88G+X^ M!@=@"KWW-]?
W$Z)H#3PO26]4EG<1"5CYP6';O!0A*4)+A\/L*$)XH%1#5$I& M*45(BM#1B-"&3-!<&$=)+'9"CRG*'+BE"4H1.0X3J.XI0#3OG-BK+W4@%%*%3 M;-
WI!_N#F@J!4>$96L"\$6 @RMBXD\ /B(/361D7T#93)%W).#W@8S=6?HM9C6 MV]F*/0CT.G,J+!T#53[T+9?D]9X<5P@]W+ MRLOQ!&1B7S"W(Q3
;A!XUN.$%6]N'%5'#7OR!0O[GH>;JE@)R4BE!]^3@/":FC@-0&^W,_MD,(,'[>M5C)XND7P-(]:$M^?C+ 8GA6] P\XQ$[WM<.S**V76PUVEZQY/$E
MR97.X@R0X.4:G!M.\.S?I% *\A6U]L-!?(&#[Q](T&&!M"['"J_PQO]*CR@C_X MVJ5=)[#,* S=IP8,$QLB]%[#3?Y?/7<$GN$8?$%\U_(VX>X(,)+4(Z_)&FXL
MK_?Q#JFP%SCU<6,NL(,OO;*W2;62NXC,)A6.]DR!'V-JX.OMZ9DR@=!<,>,?MR M&,|WX.W4\<-=QV,;<,6V]B^V5F!]D^>#Q-3
NNW&RB,UR,1'=%'+4ZS1&/ML M8+\&LD"+BO*P-8XVK+)[WD[!8[XZMQ]3;55W8">15;%/CR-7]N86W0H65 @-MBXC6!X+O>K
4G,>>^XQQPFC1\,AXXAE#;/T&WSQY9*0P&BHO0\L8PC*AC,AT M\;K)&-M@K&Y[E*QO&V\:!%[=?(TUKN\%YWU<%^]GK[@+Q_&V%*([''88N'BMB
M/KA?Z/SBE&V0VG,5K*[++H#U&>MB:UYT.9H6H.$RV?]ZFG>G2<"$?$E#@ 3Z M,K9";"HF">@&XBZ^*4[YNV GP'7>3UCS70]'-O:L9WB6/2T[],D-+
((F0> ! M?L*Y^.$@PS.U< +15(!OCXNC-MGBP Q2:Q3U:O(G,+#%9RDO0!+@'8R"52$0 MY9EX%@U[(PT(@]599+?@,Z*1 OM-
QI,NH8T+WZPT(PF2D:\18;_H@=-2UON MA=/2EGOS/+#.5+;[LGQ6#5+!I &Q;#]N^H1+/'&F__72+:$AXBAP=#R8Q"<-M^O[.:S0(6S
LDV,0,U/A!R4;!-3F-WXLDW,P=O$G%2K!]D@0_9;D7 2"DZG MT&\E=,@6_8BMBDJX;-TM?/)'7^$7QY'(AZC@FWE"D2ML_#4!ASZEYUN=>TDZ M>+[-
ZEFSR;D)MK#;QB4.MTNG[!F'6 C2/-.UY8-+) Q/'(J 6%8!W5X5]NV MSY]M4^FC(9&X789PSTAD]1GZF=XNA$8\A7KJ!S<@-LS.#\(#$>;QWPU-7K,0
MX=B:T21-L: Z(7OCP#?ZX'=B3VBL#BX 1=_91LVDBH!FJ5/7N)5T"U -:*"7@ M6"5@0\G5MA+0*G6T)K?26BD!4@+R:MNWK02T80VH-
K@5Z$H1D"*05]N]+46@ M785%@$=/6$XB< IQ_&A# 983&6$=\6)ID!\>7+7]5MUC$^OBG4V]3JSC4N6U M7HZV5KICP8YPA/(]?
^I2D*,MECHZ+'(ZKX;, H33I#@Q $;FM?,%4VM

*[!#Q\]\PWG,]/>4,]?D%^PSLK`'+.<&?ZVZ/WZ\$E!XH2&=BA,@1SG_GM<'BKY+#[K (-VQ/S MI,"58 .2C$?WF4G<($@O"VNVD/SU2,E T?G7Z=VI?^K' F]NV^P*V/J).1;K,< +;'"'>@\76R *[= M5(5'E'T\C4@!JSJ!'INJ]\FC!L>GE6R](EVVL?'87_^5M7-]F.5Q&^(_>PBL^ M@9&* [/5PE=C1N/Z%7V_-5W\0FK#HD"!Z6GH%5]AP.H988"9F![E)%O11! Q_:J5E= M5ZZ&Z5A!LD!DJD=FB>9JI=, M"3N-2\C.<-#6Z5,D-[)VOD.EH=!#I3-[== <'V*SK586:9H[V">0U$<"3/Ł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{6}[_0<)5X.E]=^/7;%\L,%LC5_B#D;)0>B)XO5^GRD!1JTKYCIM=_MPD6H..5^9_,EN0B[;)%7KIKA%.(<* <13BUC6EMP4G4,7B+$$Q&%+%%*/FI& MI9IU[Q,IB91$2D*4.%LKE,$M/Z%*=*73,7>"0;)V_2L$Z5F8XV,9!_() !VO M3T$;R7Y;95^>Y(PD+R_]*DD_27]3I#^G"B5/^@O7HI023%(,8XH1NY< M35&*4;LFDO:GO7K3/UR'O4I+P_N3!=(#-@]@>: [OWVYA"ZNW!72Y=TPI>)5B0+;DKI#>EW8ZI0$X=2Q$;]?2F@_ZH)D$& MQ;]BY2.W_^IT$UF[<2 D.V)E)Z=VHXAMTS3[T*+4L&7;X_6Y_@3H:87.SA1L3MC,NH/!458Q7A1TW8^TJ(N:5'NB7>YX!>L&'F&VTX<$V M?-^:6\S|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

[VCNNEO90;H:OJF1MI8!'^/6CR,T(7<$029D]:'"TMP9W_>/AH^,WGK M#G-\#M9 <_UHV JQA]ASCF[SHJ?V]^;_UWZP1%R6'^X]4_7O;=A?
#D"64G["&F/_Y[E#BTF1)[TT'E: / M291J&6/E#$6X@MD:#GK3D2RL&I $CAP;8@^QIZ[L$9H2NX:YQIXCN7J2C<8S M%A:9""]KM?9F"Y[LX-
*"8(;ZCY+'XL:3B$3H"(/80>X@]S6=/]33! MD>[B<%^YGX$GX*4BJPP5S)4[B\F:;EZ5NF47,">K'!W,!:5!]YQK0/ M;F#>6\^6R1S31\-A@[-N2F_^>LSH?*
&4>=^ISC,^GSQ^/P"UNGAK?[7WT(WU_M&6RMSQ C!#G9%"NMX@S5U@Z%PU>H(>R\,0>8@^QA]A#[""V=(X]VX\$]&/XB+53D[4TI^5RJZ]J=D)*
.UYH]8E,_971X7!<=[D+EQ9>4L3 A M0L>-Y+ YR\%QD\JN"L-+&'V$/L(?80>X@]Q!YB3RW94RIHT0?'@Q;N&S_L MNL9;=(;/+/@R_V'_.IZ^*#[(/"LQS6?*
_?[#_6IXS G28IU)CVU&5&_61GG M"X+/(]$ZK>2L"S -FUF)?QC>,:\&/2E1I4. +D;VZ+&I0XFA @Q*%"5;M5(^ MX@MY-*
*3G:5&C:PDBF08FD2!U7)!$31T<**I+3WE/![#QJQF#Z+I0QBADLML,&%0AMNNM'FS4Y(U&I6J$X-1IP]DRL M)=82:XFUQ%IB+;&66'O&^*/BD**
<1U@@.A]7/9YT3RO>E"',"2((<0>8D\KV5,]35!EGM=8PRS L"9X&"0M0G.9 MY62E^("9\1)(,,/[&'V%-S]I0\.\H)YD^UMZ/:V%N:Z$577>0J
M$C2Z]@Z")KRT]@6CX_;W.7&CX\9C&AU"!S[$'F((L8?80^PA]A!['!"T0G&Y"D4_;Z#C;]7T;'$>G'\0>8@^QA]A#
M["'V$'N(/;5G3\E"M,2,E8S>1O$COR8#!'JH%..04-51]%("XH" M,LAFA-Q_K1TFJ0.:(%>YB#QG5$_Q"7(3A2;("1.LVFD>(6@7\FY$##Z:J#1!
*MCA2IXXJ4, ^"KF")IZ)M-FH$U?^'#L<[[/3DS>LL,D)M@%U1GYA22O>Z&O2Z9 MUTGH4Y5)/)-1;SH(A=6]D.I73IL1<*$!&3>"9CG'"G###6:($>*UBI% M*
*JEO)69>5=JWL!1RHJ; *_"^1>K42'4JITTY5<4"]BV=3Y#31OUQ$_:M+E0S MT@0Y\64+-)^"6$NL)=82:XFUQ%IB;7=96R[^J#@+2L<2P9%E-*
*UF'+V2Y@=_M#9*ZC-HV^;+SXW25YLBYC;.IWD8SMI"[&E@9Z MT547N8H$C:ZJ@Z"UHJCJ;)CUS4W/T^D)L8?80^PA]A![B#W$'F)/4]A3,OU]*
M/]-55T$G@P)5:V$JBAK@"T?(8BNA%N_ MWR46OEI:HUC7 5YE4<#V\'A9#+]<-9=Z;#FRK)9.Q4OC@TFGD -5=I4-TL M>#X\5A&#GD_*2LI*RIJMK (*
^N&Q..I"4:ICT+9%6\D%%.D"BL/XAP7@,_GR M 6E;H6WEK+DVD7,$8 '#WE0:C43,YR.5)97MB,J6T]ASSRJ -8UP6($F#_LZ
*MJ;^DS*3,YQNEJR00W*OMQ|CBH:C] >V_I+*DLF?8?Q,@4^)W7^P M6A53N3G7'S5=U92!^C@RQS-MJ,B:_=9U=?_XT$O*
M_M'"BU]A93RQVT>/&7_>&G-XPSO#?C%>?>3B#B&6EG.[2_5#@F6293X_A2QZ M3!5^PSM$SK!FN70!134S/6X0-UQ: :\"A9IU'=QTL)#0_.7*
ASL37^@4F$Q M^_/:"?P?_O5I*9)QS&N"|+6<;JP?G8#)LGJ76BX(O.5&K7/ZR7<\F>VZZ\|]F6^CY/"P4:Q"6L', ^VK\1J"KL =WJE@BW?LJAI;'.;?*
LMO)SWL89?N+3QIDK+MU8%UVUD3/CYM54J.+IW5 MQ/Q8,.E?S ^DKT#8I3%C:VI;I0B2QK^1/CFSOJ0,Y)'T9>E8CVL?/P'"8YO" M+LVDKS8L_TT -
\0;/67PEO\(/^7_EM_^@N@HSY8)]X>-4L(KGSP#"?$DLV! M9"5WA3>#YX;_-%8K#S;0\ E\^X&O/%@PL 4!:*.K7@S/]"7#,:45_@N#&N, M/PYC:*
M5^GQ-?P)+"/8EK2$>A35M6@W^$2/22_X1\FD_=XXMD^?/R;\F514PGL/5O[$ MU_GN-:%\][A@4!)8Z)=Y!&7P;%@V&JN/KO=W?.MB7M%@J[TR0L7?
*J.KD9C1. MG@J$D#*L^$'!I6 Z2TG(X'S;2QH5KO@[CH1T]_LE]/=JFACB1/)7@==BTA)^ ML? E!ON%F2T/+QO9*BL/\KGDX4NHP9SY_B*?@VTCL)_-*
*F%D=D CN&"OG78X_K)*_S5$]*;5IY)E77\)-(T%P?F\@@8D\D# MAUOTH^17A9%_0]'[[<*_P;(_PIH_14O^!BO>$!P*S;\G=<:]J;C M;6HO=D,EO,K?*C28-*
MC]\$4]BX'#\S;2X&<78V(;@?!KS>:8+/_;T7A0 MH:1D,_^V)HP1%BI% M\/O2]YW=D0N' [N@A1X3!Y;\7R3607S5!G^%&SO2K@ =;8+/]2"KA.;%D'RP9=;
*<.A"ET-3TI?<,N,?BW=F"TL> #2/HZ^-RO# M',#*XL%RG"G8R"D(XAY5G,#BGP.9X6<,\Q2&-&~&\OA1:>WR2,(^%O.UZ@ M%MX55&#X>43<32>*
*WC],GG+LON)*H\3A7>%S\X77#O9\$:\89?W74 MLHFY&1#(U%U#@= Z;0L%4I5^D\EUWP3"0V60]BZ8>G$V>K-1A%"4T"R%21:, M8?;-4:946?Z^CBT-*
*[T\6; /+;>@$!G 39(6A$*K*_MX+[G^*6^VX:1^W$@& MQY6&'V Z [?I93AQB;\'/#/ 9K4HGT6[=K%=6V_JKJU 1#^Y40?)<\(#L=U-*
MC2;W[&_7VK/UYN[9BHI[MM(?:P+W!$((I9)Z)^G9)$U4@4I .SJ-'_1>QPP= M.[)1XC.BY'R[#8ER\UD)=<@9*&#;[@QM?;I:? @?*
*FU9/H&B]Z3"E(E<"]MFX M*F1UJ;4F^O.%+778F\I:/T6GXK7&1T3! I-7?)LKODF .&(@#;Z?_=J7/IY\ M*S4ZAQ+*_[R!$J<3=83\3U9RGL[_G*
*K4"DO%C7YR%H/=)BT)E(Y%Z=HL<2H M5Y3.$=*W"23K?!D,X@WO'Y/^">+$]8T\Y-U#OISZ>=:M9*4_T%6],]#),^).6T^8S>G4E2%-0?!H0\OWFKU@'*
*M$_E.?J(%(*W"OD0E<,WYCCZ_J#=.58BV4BT;**F@I6@K84B M_!-S ;,%)BNEP(.[18$U@G@SORST6Z9(M+H1J=S+MZ?)*)$+S&@*C 3M8>UY*
*MS)F[_MB*V=\-RT',PG=L#M?\,'ZFI5O4 =9)B9KN7(Q+5\+")/TB_2J/!EI5 MOV3$L*D,C4;Z52])(_TJ?4!T)OU2>M-Q=8PHTJIZ21KI5^D#N#/I%Q8YI%17*
MUTV_NH!K_<"/FYZP#)?Z IHZ;4TT&MVX1)6+ZBXATVSC#??W"7CY;#B;DE M\L,NC7=;MQYX1/_)N5\"00-L24[]R>^6\+@AJ+@'6J M4)25[2. MXYI2-*
\3ND#%)70NE+J^M9$#9%ABW6'/=.FH5LZEC^K]QT@X)I\CTB'Q-_I3=5@URI"BV MAN8QQJ%*EX[=5MWY_V_OS;O;5HZ\X:^"H]Q.*
*[.>0,.&==N+WZ,KRC2:VY$AR M[C/O/W- H$DB!@%>+)*93_]456,C"2[@VB#[S"21)1+HKOI5=55U+=9/9E;_MPSPW%S6-9#ZQ(.ZHA,]>U*
MOWGN!'8ZQ3Z< 7;_F(S9?(O=-39>V\VBHP "_BH-2;N 0#5D8 Z9T"MB3L> M*
*%!="-AS!M2FQO&FR.I!4._JHZ;M/OM81B\W!@!O26$%'QI<LL>FV0(N&:%ELOB7C3L(!Y1#A MR2T 4T? [&M&K$2-2*C9U!I; C6_ ";U,C7O8-V!W*
*#C;KG]P::LXMEBEN0% M5:+M3)WST2/KC%OLWI?IV;>B.62+IKHLFB<[5:/MRBFQRT&EE$HIW4M#A)2 MVL)NL_L*LD@IOA#5NU[3/]1*
MU0>PV/>Z_:I/?61'9D6IRZEF"3B_]Z4[' RVV6$OWB]\#W."+.,M5OF2 .I M.SX[CP=\\C74O^.3Z M+.]47G?25EL;;"5' Z(^KS;4G%;],F$2Q&
<)WFAX.L>T,.1*,5%EF@*M]L M!@L%5@QP)&K*$8M8JR9KW;:8%TO2+JJ/VO;G,EU=:N/N)\+(4&9"E?@2NA*
*MQ\;SNNH4Z*G0C""T4G!W./67!;IEBS;\+E]Q+I9[/4;E7C=SY5Y";"*? W>. M\HD9O+E^O5:O5[(S2!5],O'<%YPGQL?2);O%I&"4;3[BD(;3N?&]$N@!^!4J*
M?Q$GP5@Q= H(->AD9Y\NIGAN0!KQQU;!NAD(W]5-$#0*ACX$/PD?VH)T4\ MA2U6Y; ,8]B]P"84I\/8^&0SFA^)"]) Q?*
*MZ>]YX8UZ+6OCSW#UVC$CGE[C M&"- *?/Y(+]'P5W\?I+,W)'@KV"9PR&4<0VZ5Q^#5_C.M#K #?+Y50M#PFDP M*9+)C,:VM2Q8^WTOX7[M@/IL_**
*(]?Z%X.QC "AZLW8<[7LIY\?PKV&K! M+=+2/N(4V%F8ONV./MJ JUS2S=NGDLZP FB[W7&#B-=951E=#L*S/&7")RKZ*
*MBN[IKF&1$GJU@A%)$8IUCOBJ]\5B82)5.K9I1D3@'\QI8;].GZ<3A@U@_"!G M8E,[;PA36UN<2T43$UW;=E]QG7S@46+*Z5P(ITE=+:*
*!=SB[.;+]Z[-4RRYW67Z;13*VNVFVT]C7;IU//_]-!!@[ML]A'R UNQJC&/B8J ME2&J67PB3KGF;3PQG&+K&(P.0C0@^\QA*
VM%.Z;"0UWV61%7+NKR?.9UG1< M$[1<1*!LHHN;Z?*K;J-855+7IJ'Q8;:![ZX-\6?=$%W5GVZBO*>G,LW]SO8'Z M45IR"W(A>P +38JE%,N.6!;I_9**
*(Y>95B^W]]7XIBZ/TJN\2ZLV]:NA_.LO+]%1/SL>C-(-MSX5X%\M;=X&X@/UICG4NEQ=P>SV7E^.MP-GBYJ.LY#H&=<16ML5.[*UBF)N?*
*UAUMWVYT"4JG MCQO1DLI *H/]*H/N@5!72]#C>X410!=Y"@(M$Q;<1WTJ/?!&]7OO4=4@+ MQ51;/3-YX%-F\L"WF*E!%BXX< ?H](>A3DF.Y?*
4>31FZSP\+/'# M3\9/\AB_I-KFXL%74"&I K MHD M0X'6U4]N@"+YW=?):3%Y;W'K/ MX18I[D+E3;RMQ[/^$S208;M8(IM3Q]1IY]0Q==J+=4S|*
*<0H\CRW4]Q50:G7'!JD9<$, -#]89"Y]Y6W0!;M" M7LZ)>2X0]&C?RBNHU&(%DZOMK41,H@8XQ_**E=PSH7/UL5'/;0(9E_1OS72A MQ:W) "VRN.*
[5QWIOU>)BG 0CCVUTI#=I/_QLQW)GCFA[6J'?$ ^X3F,?()OXL MI8!#Q]1#C7RZUGA'0DQ'N$]O%%&"'(1M?\%,4O(4JUGZ()%N#UUL0SWS[2+*
*M@DMM'G*I72RV;>4M=9;^O&@;I,*C?A31V9K#"U!7<-R.=0^D%(Y7*E_7<0,S M7\2/1W5:V?)2/X"#HLKU%.P&\1>I,*!\+%Y>WP0 XR^$1@*
MZ38LUAT"2!8H_2FLUQ]9@R#I=@(;T-!>][PV9._3TR0B.PD1%CJV?%ZGDUES'M%= C73B&.[4<$&ZOY-;D-Q197/WJ8[>3TS-P0JX7!T7AP-
*B%\/G/59,8+7/35_J@$([!Q;9 M^BL26J8 71>N/:+&[%QOQ\?+Z#3;G2)?Y[\V]>SQ#9)-"M\19WF":%)P[@M'<(X("^&%L!I5%=.V;2&=*PF+\RI--*
MY81TN]W%D$[F!;0V M9UYQ@!@/K>&$!])GZD)ECAT^:3!FTJ&,?S-LW1K[<&8[!YTS22!>L96?0"D+,P M(,<$OAJ'JK)AZ?@\!=>G]8<>;U$VP?HL/
*V)R'UF6^R%GF9Y2FA'<2XP_#H M09#X(S>T33I'>>NO]/S4S1<@?VS]8= LVTNMH@PL1P<*P2#UZJG+G M\%L:ZE>[?*
*PU,:\Y;T)$Z]N:#_"$CSEEI1=7L\NCX]@MT5NY-6'P(XU>KZ54>[#W^ MB*H@K7*_O/@:]##QW)ID/@Z^RP]]"+"M$*%TRZ%/QFJ8K\'TPB&0S08_ K\2*
MO0%\7-MUAKP/G^[H]I0N[<%IZRN8IF 9+'M&XMW)T"-/>^:OR:LJ&<<=/28+ MT#;TC
*H_0$$0\=.3D0Y,,%C(WT4K,T+PVT$F(F]LIE@>72BIPN>7LWC/,LTN M-G.NN/"F]);&9*AY*YF+3L:C1'H(R^&W/[X/^I5|>XH&V.PG?(WVGMTMGN^S*
*M&ZLHIJ4/'1=.7X,_=(S')S60Q:]G]ER24TNY&5ELH"3#^?#LX='.K_H/@,>; MJYN'3U^QWBH,>U<#]7@\ #Y.8H>G%1[=P-]8;**
(]LW""QSL8,]@9D9"&U\M# M('#,7H<%=,L>H3%9 0!Y8 6J$NO:^;^ V_8(; Y-N& A][$I3 3MH"%5[R. M+&.$IA5^#C[/C)""'!B0UEL>P[>M,)*FR-,8$
L@\%$ %?Q6'+OB./!98O-Q M$K6*%!^)EV]JZ=X&AB9,,//![/2-]JHFD%9JEKQ-$O?M/.B.LJUI.OQA0P MN56,=X,>O0H8Y0Y=Z5B9:'.@=(LWH8?*
A8ZI\=A %"QT]&;EG\0N2:D2)\;OK,..I31(ULV57U M%H@:3'^'16>,FD?P L#T0%?L]B?8]\#VFUU_3J-E3;XNT_1F9%G5'7GK:?3 M:KJE[5VM=-
*^*W@H(+4R%7)2FUAL] 1>UAE(-.GO+=;HE;6E)5VD?^6W3+=XRT0Z M>*;,;-*
=VGV6ES3U>P!4@S44W"R[25$IPON>556Z[XS657>=%M86&L$4UQ;D2 M1L)I=SA=0M^;^SAX\'X3P.RCOY_0Y,@O&3I
*:Q=)2DE*24HA2+FG=AZ\H+6N MUEN"DR#O.F67EG!G6LI[IO6XC7IO745N$K*,KYI^MX)1'+:\I9 YSE;S?0;_ M;S[K/W-SEWM7']LU+:="H[3-*J50G*U0-*
*&I'$8I>#85B#[/%5!(H3B\4*PI ML]E** H6IO>TJX]:I5.O+:.U-ES(C *ZDS.0R4Q= 9NHH.]U:0QB9V5.DK30N*
*MUNH*UE1R[PM%K:N/S7HCIYY9HN@<4+2V]Y^4-0&%&E-M2X(BF1W<=E=?)5] MG"9\)OGKLK&X;$5Z4%5\'$7NB#'?V*
*M=GDI95C*L)3A#;NW'25$WKOZ6*]@[$;*N!1Q*>+[%O%#1,Z*B3BL&46\KN7U M3RR=B"^9###3+D-V5MNXLUIK>6PEE6NL&36?*
Z%8^_@4G;^;&FK'BHM7=/?E.UBA)T!\>]&M& MJF>JRAZ"X?&BM!+P P).ACT*]I>[IZ)N89KV'PB$)>@GZ@X. ^N::MP::@*
M;UU];#7;PH!>EI/&.X*;6,TZ?2*=S M+9N!LF7JZ$6G1U],JG.CN2;_>4,]H 4PPE;;W;0HQ A!PQ!2A"Y+A-;T3=A4*
MA#3"MA;D%]*D@"\@DB*T7H3V<[FIU;\^-CO[N^>1(B0(F*0(K1>A_5R5:@UP MZ']?5>B':K0[,P3YFZ24:(X+/)[.HKSE!,6Y/?*
*W_/U+BEH\+1FZ&X]UE1EM M9;[R?5/LR%J3Z/ TTCWV*T+E)H.4W%.K":=63JAZH;)#)CE(Q)\0\;TU60X%*
*M$(^)#CF=NR3B14"%1'R"'^#5I#040W\86QCE=<"3D18"%A'P"'^35)&@4@S_,T M!-#RQW:V.VU+HD=4\?/QVR!!IW;%A\QAGFX#'?S 5V),[*5-*
*;;6UP:)R6N!@ MG*7:4'-Z3J#+Q=NHO-%2^/!>(Y>1CK=?Y^0WCH)KQ[PVQY9C^8%'++CE?FRN M.'?I\%M,EMA/&54]0G*
*MP5)VL*PQ)KJ7Z1KMUS/2+0=!\> \Z=AN$AM?P%ZGWQ 4MW^$U@03 ME6>[Y ZLG\RL_H=Y:NZ)5;_Z^%]_ZM;U^@=!$LVEF;-72*WUG_8/J8:$U'E#*
M:IV7M7](-26DR@:I79TQ'W8 /VT+KAP0M:X^:GD9K&?OG(EGV=ZX?J!8S@OS M R]MLL83W?+HQQ:MHU=3-M-KR7%D_"]F+:.O?O*
*>T7"7@.$NP4*A(Z*]MR-" MG+OL,P?0?FX"5B,H!RF=]X]Y=;5E3'8XOVL=3##4;.4XR1[@U9*7_,FC*0NH6UN<2=G,"#0=% MGD@W:EHP#__[#"R[=@:*
*(;?X06-^^J9-XQ4[&<0'>&%@Z_ MTWV?E3/#N769L<[]9CAGT?(PN$MP<4VPR!7U)HKZ+HEE,N8@)%36V9Y;0*4E MH7*>4%EC-*
*FP!E39"99<;40F52X%*1Q"HK+$UX[':L$:V'%F7^^E+Z.K#.[<6 M[^VS@5>Z0].OLFN3C:.I&W;",:F"U7E?M[.ZXGKZ-W)YB'A>,KD4+>$=T];X^ MUEOJ*
*65Z#H#=&T:FMT07V)M%ET54H;753=&E7'[M-L4_&2~JIQ^U) M8#K1CZ*X<@K #IU1+]YI%V:QS9QM&SNJ2-:ZUC9?5D*T%X%;# _#=)HXIK;3*
*MD0(D!>C2!&@_PP^;-/*V)@5("M"E"=!^QC@UL:NLEM=)630!NH1[@CM@L,?\ M0'EC$=?>QDW2.RGBP*/4UXO_'"^^HCALP?7;2]#D(N(FJT7J/D-*
Y+E4K>BXU-MVUALL8>62QMSLPAN4M UQJ7H1BZ.EP>-QTETE0M=.^SI8NC"B] \HUK"MZU+AM<;;+ ;O'G7%%5U[7=% N>9TF<#UV,*-*
R:50^);T#+D_T16L$4?H_F M9?QG3"V5YNJR%8Y#;3;6U7_]Y5WZ+':&2LBYE?1\NT[%E7R+F5]G0-[;%G'P=+UO,H">M2UJ6L'_3NZMBRCA.PZWN?*
*@'T*6:>8 MQ;M A[?%E=#T7WP#?0_DBV33OYX1+34*?BDO566#=BR',,.37@7^\F,$&O M*0AA6AXS M>;F2)<40R@A6XY"OX*<9?*
>E'DL@!0]\X^Q&!?P%E65#I60- M)VP;"NPH!"'C-<{IYH\Q'#91TOD/@*O 8Q6=#?(VO+J&N6*2OOU4^\<93 MN'8'/]"_X5LC(+ACPJ:>V*
0$J,\\#O]&K:+4;_5&A3Y^0W&>*1#70"",R16D M.U!^.6UOW6SG&R<<5TTWJ$8OR!7[YI+&NWS;0'D;]_!J!2. %X?+XGVK#G ! M8OBA'2)"
*WP)OQY*34BJ$U7FD!W]Y^SC=[N0^3(P^"K[H3P?=Z$XW."V2?7 M-F>UW54NZR.Y5R0%R,IVQX1>@1>;4QE]\.FLSS;1+XHLOKY;>06Z.@(O-"']J;'JI-*
M;FWA?6TLL!Z;@ Y'54RT1!5N</UU54L])GY03RP/)]^_SJRC)%BH?(O> O M7-*
(=$E+M6E'$+]PK'1YVM7'>LX%X1K$!UR+S&59[02=W,#C]1C+Q:;U3Y[M ;._ MP1*;@&MBZ;8]!1$9^"A?TZ+BL2;^M1_8U8M*1?L8]**IQR?*
*>XTP@#**$3\O M#SZC %\E"2*MBM]DP%\G/],?SYBV]Q$+7-NS[EFGI MX//Z7./&Z\3J7 O#6> /C^'OA!?Z+5C1Y$ S!@]7OR=>8#8T!49U%1;$HJ@8*
*M#W_!4_0@*Q^2$$^'H "@'*LKK,>]^9)[1<3S?Q^H;,0@(<6BU>FYQW_'@LR M1QZZ,.":.(`K3957#TX_Q71?*
G2THU#D&A5JK^NI..7'D=\$^AJYK\E@F:.,7 MRP#^^ZYM4!4F/M#AW;&5]L IR8.B6M (05U MQW_.$5R*N$%+!O^V\U-*
*HI<4"@[NZW\6:#A957IT]M_G?]_JZ^7U8UQPNR*6" M9\::C(Y\[ZM7E.X[-J,LN+Y.+:]3Y6JZ5U A3E!3OC![6B'3)=O3.],[\6$P*
MUP4&.WJ!L_0YM:NL]#OES<%]S:XAZG-]>HY?2A&%2"(:U_E8SG?R& 6P$ M[.5[%XP]K5E9=W@/!KLMB[IXW@ITVS+6+I/?
*\9NHX8BQ[T/0UQYO;OY77>#5 M*7#:.@#S]R>JU!MV!.>CUF[U&LUYK]-MFQVBVZEK3[/1ZC=K_=L"]>R!CY38V*
*M5G@"Q]N_OM,_GO)HJ!:S,0@]6IUI^4;H^Y\;";^"E5)T+ ?]!:]-T;DDK_ MO*_HY9TZK&ZQW_VK90:C.*DF\ZTHGZ26?D7O@T$?!'LN_DDD<,1AFP!P_-*
X@'-M=MISI,O\-RX7=>1Z-'4QLLV_-/+B+4ST(:OV/:;_J.H#V.%[W7[5ISXFPV0(-M,;:<:I;]\P3;LQ+HB;P#]KZX-BK@ZN.SA2U L#"M"V/16>&?

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j8"'T=>.'LR^.+'S*3WFPQ?G?:2 6A@?1TQ_]?[.;)., W G_:RG3O<K[PKP]_A0?.!?0S*2O M$B#A;0?FH?J96Z 4- <3JE!>D)L:,|=.>_40"1'],3YE4O<3?)_7 60'<0%\ ,3W"'- ^P^$%G<#XC](DL^#(O ML*(VD*D*34Y^!R&*.@_?@?EI0/=,%"'#*H6J#_%C$='
*DAJP2G1LX7E/0$K) MA\\++/(O8/?&#YOG/L'G+5]N/15,,>:K&81-/_3A]^CP9(X43.TB_8_?!2N M2]FPD1**Z_HJ^75-2(B;2*JI:6$6/.C;C&+ (_3(W94FW1*_!?$+D4A$-L5+V M;3#/T/%J2RR#D9M]PB M:?YO'64)/_R5_:0,MZ L7NZ%5&?YA92\6Q)H<6=VM_15-SP733IW#!KSLX[U M[**:Z5]+F^DC':,!Z='}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|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{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|']?+1[RDOBKZDFV!-6'[ST"*(K'>*H)EN>53^AKVT:.(U47U --F0),> M6W94G%P.^!F"K-@8_]=$- :U42$*>^]12R'/A"BFOUDHP6GAA2?KDTV\D;==GEC\9;XLKD0R<]|UK^:]5VSOF'I0]M4 BN.0(;FL[IIA)!(O! MR(M%L-9I2 A+")<;PNW"@P&. >$+F0NTHIO)E.!2MCLO[UF8*4 W+FK;#AZ7O#@DX;[K;UC=+IVTCIRW-FII-J=IR?-GEQ5 *[U]L M@>LV"@M<40]IM1V).3$)80%FCC!7;QV\1C M0'A/43$.OI[@Z$LL>IR#I?P9ZZ\<%O >X;O$QBYOK#-FU!^^[\YCG4^ :S4<-QTA7$ADH]@U MU-XA)Z[M.(CQQ'V"1.=?5H!/22I2'GJ"?^K6\Q- 5!LNJ!C]PC1_5?]0WYE3* M'JKG"%KDB"S-[S*2.XHZ?Q3MR>&7N]95*O&DTMPLP_S+;8?U[CCK?"G39H<> MGK2AX.&LD(}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c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|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l"5FW+O@,2PIOV+FITA&S^\+_OS!_LR/D:"2l M1#+QIMXY8.7SYE:CQ, I_=#JR>KWO:]] 6]%OY/E?#ZRL-D6!1>25JNA=@JG M_I7 O)4X$VEO<"#75.WH.%N5\2A4%!Q5+47"OV4"%0)}H.(Z4;?*?_VI6|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

*V=;>M^RZ67E:'V]G+ BE&\| MA!Y?6,X*X\;DP.AE'8(-U_$M:F@+K*<'C)A-)1@FHW:5KC=5}/C:X=4*L-VY M\|\-7=!(W]MUX=3WX2K("7]O$]TE&L-C]'R&(53"M*/[(]8)JP+QQ|""%"(F\|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{6D4'L1DWH<"8G?PM:[%-^@XTDZ[N>1Y.F?'P'_AY6R.\>I0U_[C9\MH0O$F_THXY^B/FT'UZD3#Z!E\Y]9X9\5_C(Y6:OD_:R5)7?P61R,7) (3$#U?)4\;VA8PTL_M0R!,Q-<.8%M^*<#W+?3\$+<9:>"HM&2A:P2[8:3K()Z)=#K{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|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|>-X&#U&4H0A>H%'N:PY MHK!P$"<0HOCQ@.(P+Q_?^:@4$X\ADME"!VT&IG$SL&P,^-GD5$UMGY68K63 M,,EW>2,\#*QXE*(2A?,LU\S:A]P1Q)RK*H_)(!,I)L#CO[$^HEYXJ.;H'>#VML0"C:W%TW,7P#@:0)>,/Q?@X'YT[:NB-8V3 270[RBT:##"GR4GRFC|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

^1:GEIVI";P:A%9>L]IG-K5>$Z^_#GT_M6]{=[(;K6);7VS&5A)(QB%F1*2,"A)!\K &EW*#4WIG6O>]6P#@^73]&OAW"
M!ZY#^G4T3$M446B>E";,E;"H4"/%7:WQZ632QG#)5>O4G-5(CD_QCY3RVMO] M#O>NOY(=$]:#S[C;I>N=QS2[<;T?8.?K5LXD6(8QJA*D
M+JV#S_=XWLV,MI?#=LFJ+[5 MZ]:M-+;95=MCQ+T_,F2;L/#"P;I EDM."@*7!4KFD2N;LP[B&9/@,=>M'3BP MC90[7;1 M4]?
(AN658!#.AUK=55C+:7BUA*B6#)R*AI$KRM%L,^$.=)(;3W&/D5.7J]-5 M]IGH(F=!<""?@983DVF(D3:$G(T+:583:I.F.$__*ORQZV8;T36>B._P\^CI
M\V#X(8TQ#Z8EI)KM]37?#+U0/I;D#5G["6MKL 21$9FU40%IV%RRL(%]-WG7 ML]=R3/L.BF/Q M<'>4;W>-+RB^":9.WNTJ/(?Q;7?5U;VJWT'0'?
S;E=@P!A;*1.!!+NKC..4=_MR!B9C=&B;!X,LS_E/=#3[D/WV\BW2]FHQ79T$!QB'I(R,6\- REJ']^K-F3B M'C2/3/G"(OK6%YWW CI)_2==78W%
[&1P#L$._V,4S)UWI0YMF6-;IFY%5F" M*;3)J3S;Z68MV:TRPO*46>LB,:MP'('N=Q9OAP7@IFU#@UT6ET&6C%D60*<: M:66B
6>$!,F,BHSDKYK',JW#\G0NO-O=@3U2TATF_3O\%+[.LJW?E'E-C^OA-M-T$)75*V((-4\UKN1$Q75R3E2!1%R=:S_UY
Q\&%=C+OOB3<&YPKI5')DVU>L(G^LWT*XF$>;&#AZ)*;=PE$[@2%:02C\XN---(ST" M+:.]A/0TN2E5*!!M##?I'!*=9A"P#XP*=%
[=/^INRX_BTOY5$>\14KF#B.ZRB M(0K>Y:)QWI5@.,$CH*J6?/&R%NEE/@1-;K?WK8L#;H?P^!C26"L=*B_=GQB2 MG2/OV0+'FMF-
QD$0CMPT&;13F2<=-NK&=72I..ULCQTDOK\>2>/!YUD4[$^# M81BF03B[PC_Y:33&P8?AJR_I8QA^P&I#A6%MNG(^H@GP]>UXD+!VM]DEQ+?E
M^QO%!G<32;.@XB7"*]:JX&4LFH/V-M%2(Q@$3>N-LX[-K\!R^Y#;.S!V7[&6 MCUST0+4B6:DLD#='<]&R>FGH-103=%*&99=:]Y*Y!6%_0<2[Z?
3N2O1X23Z5 MX.&K.5Q-P#JW9A<+F9%W5BP'46L9TFH:H69.0^2H(_,L\,V:ACZ*&G?Q',Z] M=0<]K^7.CO+NO
MUV\)EC*X;.*;I#.US[9Q9(0SY.!J74R3.09.YE9(K3>-#:$=$5%Z**/#A:7*J%H,*AOZPM-4R%Q(SS7-1UJ/9O]W22&6C+O+NX.R^'4WF M$JU<)R\|)<2)B?I
M=BWE9Z'D!_;X7CK>1Jj=;J(L$QI,22H1$IL">;SU_#UHA;1[;!.M-(9^:!V[M-3K<=KR+'E:4/'F$$#OLN>_CL;+0RK'409&_$Q,$TF3H>W?>@[.YJ"X,1A\
MZX,A:Z]_U@IJK\CN5TO<3+X, R7*Q *&H%B'J169#)RLN(X!)0@%FFES2KZ MU@<]JY$<@V750.8=0F_OHEJFLV_J^\5U,A[&[6NCM02KL(/2]+ <+?
(Z; MXF7M@B.$7I3;%]&:!]T5(AGRPO,V00HF07G&0W1UMA_GA)$SQ(477OQ;"O*9MX:/?@:">BG*P+57O[\[-=&B1UKAE$T";J4_B"H(2%QS+)$E=F_*Y-
9:I7?N;QMN M)_W;ZMQ6= WWV$L,_^OM_W_J["+:)0662TZ;?:%)6$=VA$I82E$IV/OB_[=6 M'IWS&-2WK>AZS+
[W_WAY6F@I<=DBL%F7LI(%N%P,&*L5?9(8%TW51^\!O5M M*[J&<2R7&'Y__(TVTA@=00?Z[:0)0.OR],YC4-^VHNMP M@_A3&(S_&'B G4Y-
NP_N,,>O#0FUCJH/B@T!,H*Z_M#U1RSYU5 D1 LI&U#A!1>>"&)1V8ETFWQ@5\!G1_X(#Y,;-]&Q(T+D0^RZ\(MH_-/8?
CU>N7\;%46A2P/+T,FW\TA..9B+9YG$*W+]/E-7JZL/;[F\?L_:'YB M2ARUU4#C_A[7(;W$\S#,L^KY"V FYJ)=\:!]]>TJC3$*%<'*&"07MB2W2;N(
M>U_R%T%Z:*-K)C6!HK&'LT49&Q:B3T(2?9TD!X@[#H2M(M0FY*X->UON%9C M.60.U,^-RW3L(.4.\4S7_!\?B1'5H?@ ME%D':Y[;^7XZ'OPQ__!4
M\TR@ZG&S+*9R.T+@44 6(:;"N@35CS(/PCLFTK35Q=]SR+V6I'M5"]:I9%16 MYGZ-AF]^?$UVU*LPKA49)
[T*TST.Q1[*TS403_,B=2MR\ZZ8[I3V2DH.PCA6 M6W4AQ!C(Z"U&<".9(H9V6PWN0[,_1/(77U\/221W*&N(-M"^9=%F&:34HO4R<0^Y?-_[&?<_?OT_:4
6CQO)K:?M*I?]A[/+0W>F1.I*&2#K MCM/0M (?7S2(U6W&_BMU.3-IQZ+_G:058\"?J/)]+$V#YA0.#+E1,'B/1 M.$1M0 0=))F21@>_SS2UGY]A):1.,Y.KF !5L4?DP-;.FH$ M-.)YV-NJ^K
MR%^5D#KQ]8"5D+:AQ%.IA'1OG#!GQL0B!=1\:U "W>P(#PPKP@072RBM:X]\ MXVD=6U%HF[2.;52Y[WC]3;#]E=:QM1:W"=Q_C KV39. Q@<=>$GB>
RCFZ&_! M5LB;IY+16-5O-7H.:1W=V+&-Y+N47SD_\^7!J.N\]NPRUEBSJ'4R@(&0*>=T M!97!Y^(*"F.
<:VW$K@3RQ"*ZM]+5G2HLNPJZ0YCM3Z/QGV&UG85&,Q:>,$+U0!$9,EDY
KE]JW#UN)Y(CTWT#4_K2PA"6SM@*U&\I=9-]J9VD!]_6JEW&T:OPFNQ[52]F ZC"': M0F\/4F$'H>]EI5E6"@U2V.(-1$Z30.6$X#BS$ E?
U%9:Z5JW(MDQ&1XP,_?) MA6UDW8$#OXZ&^?+,=K$!H@@<<$R:0LM3R@SP F=,!O$P\<:6R8JW#V5; .%A] MDQUU-&HKX XFYGWE99%I9GEDX-
'7H5J$H#49P\R*;#!G7UKG!GI;Y?'Z&#OY<"C1..LT&!DKCV78H9@:'"%.4KE" MBS%&U[K:UO.J!JZ/']N(?F_EP!VS6&C/C+RVB->E0& Y0F*.9* -E^RAR_;G
M5 Y*Q5L5 Y\"_GMJ:C:S:B!D\G=1.3EOENS/-')XG0AZSO5P[D:Q.RYUE'X MT"8)6:](JW$-O0WH)QOST_R>N9LJUW*Q<2S096+HHHWM/'lI,L'I)
SSM3:W M-8F/@.0PO?PGCX__:;"6)C$_S8??*,[G\B5S+"Y5[T\E\N=R]"^^7J7_#W!, MR#Y^_1D_X]G,GDXEDEWE-: ,O/8')5LI8@;%"FV-
3/"@NE'Z7F2'.@HY$&O6 M<;>=]GJ6C+Z^?I[%NI#N-P';Z1!D*Z"'.13IH?%UI.JFKH-S+:)88#@UI.JFKH-EEN%2A M.2&, .;8!\5U D*$M,G+
(@5:7YJW!KL'SK=&D,=H84\KB%Q \TDI(Z0$;54 M560&ES*'P-'EP*WVI5O#C+MPOC6"/$8+'>*/5N20S4,JC&.*<0/,UL8AL5B(
M@39;8R)BD.&@;EV9>@V4;]R_;]"?#K3Y.1R&DX+C*I;W./X\2#3D-V551F*- M"9VI_M4RZFJ#L73RMUJ.XT#N6 N"W"FC?F#M=M@)FXXIVNBD2!YT,
F4L;1H MRYS "$>_,*4HW=KX?OI,?^I$W4;I^^D4H))W42L#+JM:.C>3:(1F@-8J MFC"\9-\\M>0)= HXG%8?[BRPC4IZU'I?
9L8LF[%Q)T1.C*Q23:.%Y87\SVR@ M)$2M0V"I><.S6Q"^97KLH(P>"TB8?"21U/^]^C\7@_A;'9+7-=8EV)0]7;* M165IC:UI.4ANC$N<2RV9*+9UW/AZ--
^Y0=[2QTB0\A38Y!FF)>C7'UIPON M;X*]DPV_"[#V.RM.# ZL ([+&((C2%ZCA6"!$D+<2W?)H%V:T$_T@ 82T+]MULO-WLK+E
1D/\^DL8_X'3GRZ&^1*5"5XQZT%8$4#IZ$@2 M-1_ J*)112%%Z_/1U4CV;V+M3YNCYJKH8'6_",,_?J,9]A(_C2:#RX'6;L=: M*H2D)7FNB4R]F,D6R
0MHM3:FM85F5%[QGK;V62;!V[,PG _,31[+]_F):.C[48DI""(+8@'R9*SS1K3FT_V(M]D^FQB]\$T??
3/Y[_57R.)4:9H&1@7P]61"&5F#92*C/VC)36BX"\V;_&T* M[M@XTT;RT(K,^FL@FNRX;SV/I(H#"@RP,))),_,RNU,UR7 MUFW1MH1X;%3JJ:&N7=$6ZR-
'S$YKLMB=I/71%Z*ZJ'_H4AQ+IFC6K]W9L>Y(M.\BX0V^RM:,]=09UL&28<643*)MKRQW/H? 8192\UN38E[%[;"QH(_4.?:RN M6?
+WC5WG$JPN'+A0M5:+C>|+21 D,AV]LC:T#B$:#-FW[UUT%T'H_?%Q610 MN\J221X'\SHPA\Z:T'P@,XO^-AG0>\
(\OW(^G]^G64MM4M+@HL]D:+D,D>8) MB.Q\(=O+Q]#Z@O01,/?/O1X:OWU4TUE='1@VR\]?Y?F=C,>U5_?LYO@2[8^+ M?AQ8IV6:66K3T^RD-
3Q*$A;YA,H+$E8P"E QKE/(.9[10XX<)LZF%1Y(YK@*RGOF;/,X_T?@/$K*=5=8!]?M?K&< M%F6,S*86OY*T(@?#("01H2CA"PJ*!M;ZVO7JB(Z2. V5L-
,3:UR2XR2EB_.+ MLUI1Y$X/$JUD/P66OULFHW/OE>26F.O8BI43F/#5Y_LU!-24E& M5Q.0WTHNIT^2&
(KDS6IKA3>*7_ 6YX+;8MSYE&.S\\T#PYQ@G)- P&M&1@-Z M02ZXE< U\]*B"+YY.YYM\.VKM$97'MTY$.EEH*=2(,.R"%F]4R!#]7*]F 7M M,.NY824
#*!XN0Q.<4*J**=HA52"M^:PO3(LAY M$U"=@C-7 CI,U&5:#Q8UZ27UOE)":A8!<@" &5GF$)CI$'UT#>]TTY(VN\&]#/2*[3(N*0229H&A+#JH*&:(0$GP*
M-8F& ,?F-W];03S /6 ?9:^G5'--]5B+1FDPGU>_X/3C*%\UN[Z!TBDIDBJ, M###132_P$"UYJ#2*X&I)>K+2M$VPW0W:T-&JOEPX'XM=D\;**'O,+'-)?IC4R
M;W*2_^MBCGD9;,R=YS)K0)=J)5M"&S!$0-K?M2#"']'Z\F\[A$?+IGYZZG_" M?@WM++=TWCSB#DK)M>?.%M"R1'(;;:WUQ%D%;;E),;GF]7(V0_8-
L*B57GJ$ M0;WY\?7)=#H>Q(MI/5SX;31?,6D7?E-^"U_>C<[.%@WM3E&[8)6O30&D!MI[M+40N(N3DF/)&%-
\\&'<+>$^21PT/"CL[HV_7XZ2G]\')W1TR;S7;G>+G&F M:X,C&8GE@1GP7 EP09OLD PWU_I:]RZ* S"DE]+NG.KM)/$>L2A\ ++:(SO
M,"UB$^8]*";+L.^2RZDU7)4@9:TBEFMR50T#BP$XZB@M4];ZUC;/XY >+Y?V MH+D.MO5ML#^1_*I7,]FF+[%\6"4[QU M-D4E BV-F)37'-
R#J(#K6VR:'@,_MO/7IT%^]5G\!/\/HM@B?OM:#S3UBKXWB9I9Z5=;*W8&_JMY#*1DZ%R M5B9D947KBO$[0CY>,NY3EQUL_!76@2+G);O$0?
M4"T%%"3'7XQ#G22"NB&A: M>X/K[+%]!_:L_O3.9M&Z_[,I7?G-!DVP3=^O2U=*^_MGA!S YQK2U-.L9JL*($<:IN%$&AR:T.R(?S6UM"F
.;Q!44ZDXSRM$A)DIWV M'J*Q"H+&[+4-KICVA6AV +ROP*!#\?,AVZB?=I]*$-%C1SSO9>FC+%EF8,I* M1=%#$\D=MEDEKR)SS9M|]H+W4"%
(>V15(SYOK=TN%;\>AWW9+7<#]-T*S^V" M_#!!4/MC2B.*IJ#FIT=6P4)A @5$ZP7-<8<054G@M$?R(06\;G8!0<,SWJN M'-
U&NT^(FXMKM&Q5UBD94$G4A#=O:]B;@YIA(IWR'9LG[>^&^!!5S_;'CT;4 M?(1RN]QGW1=PJ(VBF1^C-3W%M..QG,6C02>F?;.P5\><-Y:#PDBKHZR!
(ZQ80"VY2SP[9SIFYCW- M .4&BMTU&'D+K?2-A7F.6#D7B?C#?W_&PLG[4JA MUCKIL Q=U62[:BWR;C#Y8]
[9R&JR[^M=Z:R>NN6TZ!JA:%=705MMN0ZZ,5_N MP_/MF;7-M-.U8N*R2DAM5K/,,=H 6R?C]CY'/2%%D7CMXQ&03*N2(5I5P D?BM-
)V?:]Y>\#M'^SD)WN5A=X;B#X M#N;L,^-9S36LP*!S;KEL02!UV:+Y VZX#/:YL?[Z]%\NZ1JI*&&2]B? MD^D\'@^S%=?:H5./&4I1R?)Q2LN,C+:7 +GD@?
F1)!>*MIA;R7)W0D@7?WD M;T_W#233D]O'@B=I>A'&@W"V/'0^I<$*6^\[HM;D_5FE M(-!"1LCSV3C:>]ZZN@#6!]NW1JK,..1YW(2Y$,IE.3@5A0E:-?
%EJ_ 3W M$*P)4*137 5CM&CM1]V'YR\B[:RE#ATPKE*:EI;[8'A1>Y-_6M2YG\S30I?' MVU]P\LM@..!H/IE^7RRU99C>?LKHF"\G0FL(LL|
=5B]^O:JF@V5@:[%UE$E+ MUCK!]P: ;Y<>CI?#75*X+DFL[^EGO)$K^_ATU/7/:D8NB'41EFBLSXG;\HL ME_B*#!EK\XD80#A3;]D+
(Q7R7"MPQ>RU*^#L*^5R=WW?"19N)..G MDAKY0.1D-(RL) X^)%K<]V5CM9&B,K[(JW7GP3]=6;:7V[T/,MI+ ^W.,-- M0'WSH>?;*&ZST/-
'2'UOE+!N*>1;(\ )9QG0@QG;\.@OQI^&#X-IN%L60PY"Z7)7@+*%.8)B M6!ONZ@*V(^>.VFP=1C%O8"_@0+M)-YAYB^C?V8,G9/U$EC@J#36HK/$4\$2
M./*K08>DG;<^AM(ZU'LMF&.@01M)=ZF22*[Y$/.K,!X.AA\F"U0!#5/)&Y Q M.E!1NWJCSJ"PC%)F'DUL?
3^T&LDQ*+^!C/M6"7\@V5JBB2C)N5;*T1\F>AJV MS)"EL5Y;8PL_0!>XX^%''TUTN%(F+'4=PY3U9'*!^33I M@L'G"/6RKB90*O
2(V0FN4]1!]6\U^0:*/LG15<5KG=*'BW_#K;HBI*D/F:= M1(GD6G,)BJ8!A.@S)'3T&UKPBF!]"/$42L3ODPP[2KV#0;K"4I[3]%1KX6DO MM>0L%R(H*P[(-
B8',LG@D>4.S2;6@CEN5K3100>;]>8];>9."6T#E,QIB";0 M$+4P(&1T{GG!;//Z[>^+]\G"1XOZQY-:2X# R;_C=:(4EE,ICB(D-@7B?
^';;1A[FV9KWI3U7P@2&QKF,?-R]YZZQ"X>&.[GP.]2224/,D^A2A/,. M,Z]-UFQ0!]$X4Q7(T"EUG<"\\ Y;N]TTD.'0,4;7&;KXQ)9C52?A^*>9L^8
MK65KB,"UP10&&KMU($76F)RQPK2NL+\)KF^(-"TTLS:B<8=4E,'G0<9AGEP[M>ZA%M$X+)X%?E=8ZS.?=5B.FR5--'"7&?[0/9&T M%[5.?
*PXANQU.2VU,82P# MN;H95,X&O.P%T"2>HA1:-.^5N['A=)-SUJ(DDV1-D*C9K"]:O;OB#(QAM5(9
MMX:U3BY]Z)RUY;FAS;'X6L6&5RJKK'"*X8B7('%%Q'K-6!SHWW(F?ETLZ.1BS MA[^LR1355J2)BJ;.V%R[YR7A<:V/5HZ877Z^^\C9\K1^=U#WS
MBER&9QN=)DI*ON!)-?,X=.79[']@ M(FEOLH_R8X@[PD31)I!:(;,PY19<+ZU^W$#P!-(GMDG!VY? 3Q:%SWB%QXM MB*MA#',M
/%KN,JPLL&8.F7F!:0]-LRKVL^[5BU9)(KH0VL9G0)0ECEFO>4V0+>ZQ*VF[-E?5)V6Y4<.NWZ9LPRN6M%F!*
MN7JZQ[P"1YLOJ*)3THG[K%N$^3ZA)(O&VER91K&-5#M&WV\"X_C2*+82_IHP M_;=(KJ,B1;8ZJX.3.6\4;_D\TB@>K;Q'RZSAS*LG%FMV|I-$G@O)$"?S
M@[0WY75UMJH--:\5G4L*M*AH*+/\$:JJO[A$(D 3?6"ND+.ZP6'3(U^_?[^^ MF^F\+R5TR$AX50JFZ9OA3Q>$')=MY4[.1Q?
#Z:E%A=88!I&K4F_]D/YF$70* MP>I83%&MSX3NPW-$C&DN_@[1_?\@"=5BJV^&[T-U(-Z.1^1X3+_6;/Q9/^-/ ME<6GTIL243OR%4*N1UWD-

*20V]RF"S@A.2VOK2++-D!TA73]HI&'->UT&EPE8 MOX3A10D+4?P44@VIH47P_>@LG_+(7"Z\EKRMK6IIQ."?A#9 MA#W.M.=R(+T5$U85>FJDD0[&=:UL=4L$B^I6FP#K5*AS+:C#5-ML]L+;O6Z: MRG^O!+'9HF66 8N&UQHK!;Q,"F+4"IG%*+!U^L*>B?% .C?;&.NED? *$1Q<.ACLL.4DE M6'S 9[KW!<]=]>VDUV%.KW(*K[=/\HR'6MX42F0,%))#[Y/,D#/S141A21H] MK<:[D)[H@P7T+,5.OYOP[+ M<;&@B<0[5$19N38YC]HB;>[,:V9!B0I"M4\]AJ"<0G2Q=8_N];M ZR9C\W.Y MU\-9U??ZO'KC-8E? WXY'F0#\8SRZ^+1#S[%M'M^F!=FC!]2J(]D'0T_5".*&/_F$]9H]^$'@E0&TWK1^!/-OL4__&WTXV@X&9T-*

*G&-6"*YY,AZ0*37AK6E=TW!WUWKJ5/0$&WS4:IJKSIW+? M\7Y*<-2>I4!<3DN-DLAS@[#.Z\R+= 70N0A*^%F'^40N.T8E).J.S8M*W ?H M4'<= ^R;'[4NW9DKJ43MTCF5QM+,)F%[=R:X#.(N M3UV#E 4CYY!=;4"F903ZI^1:E^2U3DX;OTF2^]H7""!C^/%""[666..K!]J2 MIN.0IE=)B^;BV!IF MH8YJ=F;//:WCNZCHT 9&(S+7N@+0&RGY$]=OH:=1>R!VBO7X<-MC6E;([_OUTO#_[)*039%$3!1ZD6 +QP"4QQ<:-*4'+YDTMG^+-VK[,P? 9;Z=%@[,8A MY29@OM6KM*T4=>_%RF.DW/T]+8MZBAP42*-]7GF*X)EF(N1VR;N2VG>#_2) M7Z6UT_@VPMW;55I"%H4MM7I,(E",5D_/&0-;UWP*6 2;6P72GM=5VE9"W^@J M;1N)[?\]37.6+3H+7M!&I2RKX>8Q@A-<.U>*"1NE\SS]JJ3'*K:Q#'N'[-?" M++-*

*U2!E43D<.+#LR/IB09%#28L0UD7&Q%3S\MHK@7PK!MON6N@=Q5U!+1V9 M#6!U,MG60'H""=^/4]I#--A!XOM8*Y:!!EYEEY."4ARMCCDR"-*

*Y&T$F0W9)R M$*9KXE]O(FR3X-V5!]L(NK%1=T(]$'=P7>YAB?9%4P-^' ?%)0-OE >O5>") MYV1%VL*

.N.\=!T[<>:P21ATDV.$@;U'_:>F;_%S_017NC,B8,O-8P(4L:DPO M@O.&3!5D5A;47E/KFD/WP/E6+()6&NG0YW<-M.5>M0&X3M;!O<.,8R,T4^-F M]-

A!!QWLA0=_TAZH"1L$SBVIH4)<\SL@/PMH=]V0I3>NTBP,0Y';X4#!V$+T MC>V(6=7!.;I%[<'%#LA9BB8Y!Q@U@A+D L>(%@Q7/,>2I.6;E-E<]_S]VP\-

M53!]+++\.%L1[/-???@'#G$ 2I"")3*=.ME*_Y[^J0N9TB%%<2Q^R,U:W+1]P!<4QTV$W"">X#++V,;YF.NX>6G+@K)/6;0 M]0J$?*

S:UD%2UX/IV'X81#/<%9+=7); M2L%B68&L:RU<)1/Y.M&3O^2T4(+<=O.G;@?T1'2HJ$*[A+$[$]07T?#T4W7 M9VG0*\VR;76YO!""$MV@C^+B-*

*LF\N)93)[M#=0:#"\(Y,)#'@TG+Y!DL6B-\UOX@I-77\@8IO=:W_S%(LWF/*NG5 1,?A'"$KGXKR[_+:]6YG M9B0300=1NWG51"%1^_8Z3NNR2-*

*)Z4RO%;V#S/LEV9EW-W!;"O:M[OU,1BIGP M)IC^]F'T^0=BV0\GM;!LK#[!\.5KS;>N*BMQ8PFZ_ISYZI/RU:)S\\E;59+8 M!F6KVA*

K3[M.QN/:57<6>__BZ]5W%C5U9[NL9T,Y:SAG'L]DS3#A[]?(NI.W(U[UE_VM'1Y;3Z09EAK;@07WAY(H(]=7;[0H-AM!HLYB[JR=Q,LO;:'TH3Q4?

_P_>H24-7O6J1!E"UFR326$,I60)5,D(5N2I3&3%-F3$&(J MA"R375G&OH1$=C%FQK].6,9AMCN?[^-WE\?CWC_NO>^9\YCES#GOU^OU?KV>

MK^=5Y@Q5G#D+'+,TLS #V-C8@'NL&\!< P2O!+EYAP)L < (:LMZ8 $^ 0 M&]M_]_\UV#G9_QN',3C8.;D.2_P_\[BG7G/<)UA/?_\V V

X)'@%=L%NQLIX!#@FSL@FS,=@_" M &R<;/\S@A!UV ZQ9IG$SI !'-B.3/1^0NE[>(WAHDR6NY/GEYE%M,_+B$I,)I1:4S9\]K MZ^CJ7=

*WN6))9G[5PM++FM]V=_1T'1[<'[@\]'GEZ!3X->A8<$AH6^>IU5/2; MF-AW*>]3T](_9&1^RV>7L@?N'_SG%QO SO;_C_]'OP19?AUBK0$'UW]^*

*ML1T*_N\#@AR<)S4."UVZR74_0/B49L01DFCPJK72P/D-UN-_U4Z>INL+&5/=/DH^7XII*V'0],1CZ5L_V1[E M\:586<^*W#0%_N_;56M.0%4D8NL"*

*(25<^<6*$M=YFSI.D9L7.45N:?E\XOSV MMX_)Z=@P"=_^FP_D$8U7X>2Q/=9#"C\0(2ETIHB18)V!<^VSO:%EI,;H*

MX8A"+U_1V\H34Q:/Z]D/JU1J^/]R4SH<++CDGN'S."C(+!,I!R; F=X$1I1-T^1!;8+4NISE8%G-:I/24-F.Q&;9

*M?:3J>I[+%:45GCK%OK/B&XO!R[HT865*7RW!!J8-RQTR Z_L(G#&477;[4CT M*1]K7GE0YIU)S(W_+SCC3/VK>.Q^IT23ELI?]SZ57Y9?*

*^D_^!S5PO#BT;+=^?,<\A-MHJIEG'VN;MT>^F4U';Z"U:)L:!Y_(+V0G>,55\IO^>]B*D^=+=^XYST 6,(BEX M?8#4V_5S(]TC#_Q<=F),G2\]O:@F(U@LJ>3?*

H953U<.R)SW]^]S"OYQQ0OZM M#$+:< =F-MBN(7/UA_'N.]D#;E\^)%K5!N25WRY7_&.6)#%C0\5Y]\XCV]KLSL<._N+IKX 7^&X4W1N>@R6=^, &"

*M,L$/U'>RW6:<0XB7_"H'=QU>IF[*:#YW)V#BMQ_^HSI/744WM!%QHR&!$:< MTZ,UY:A5>4KKWO[+0WTU,4EDC_PMGX5>N]*E/)#=C-BDFCB?*

*REPR#;4.9) MW"A&,TXUQ=*SF(G[@AC%,ZC:N@YZW/YNGU;[=]>/\[>9E*&K*(2$U!^X7]< M$.W%L/GH>[8^"X<.8R1#9V-SN&5YF,!+.$(^(485E=]4:*

*X#P4R+3K/QR)CA@]*Y%8/%&/YSCM_/^13*!-M3_:9])9N=%4_"*>*>>9P5W\LRR?+W7;RN#$,=:L]Y)!H(+)3FPE$V.//OC3G MB%@+*:TS?^F_G\9'*-*

=\5_^LNL:E^$>2&+D447O\>]VC@@=96'3?_X2&%?Q. M%-[H(Q/X=WJ1";S!^-!3H+Y^T9 ;2DSI"I0_*". H&")PM\LM7'FR!TBTC[_Z

*M33<"_3:RZUHLP^FJ0>BS9N-JJAL3./P3#+."3)@0K+_.OAHQ]'YE.+MO)U:> M,U.-$279<:GTSJB]RIO+=*P>F_-H=?:,[]=8Y7/4N%D9IOAW 9G=HS-*

*F*YV& M>1N$ =6YUGH_>8]-I;G4EH=?UP_MJ*D/#?-H^A?S+O?.R7GS1G+_W&,IO('F2 MXD9/8IP]]WO8,Z'2Z+*A:8" T_M^\^2?*

*U.XDBP9S@1^5ZFYX,!>#<-*60OC MN;G,[1#U5T4/_Q3;"TW&.UJ.XLJ8@-P@44VEZ/WO;$-]ZUOUP>M_=Z%?4""]J M8*T%O0\I8 (MUP>8@.!=\99-*

*4*5KC0F0MPF)<:,X;K!FTY8L\,:7LS3AFV*

*T6.78ZR.)WZ4M[K@HK%+&"08G=U#_.>"#]I0ZIY*5VR$RW[VB]E+V?#_442=3YKJ^RCF 0AX%A;5^CY)LH3HH:R0'1V MJ(\([M_S(<8?%TYW)I \T(I@*

L,N."80E\\$HB)(K+K)^-N!G5K666\NJ\K M:?KM$\0C+C)BB\W$4RRWY!@3P!W"VK/2S(_0S03>,$*,?0TZV6^_1.HQ]!X M&&QTKY#G!";P&N%0;.[V-*

23]XK"?0J^YGT]AFTH9T--:+.2O3U?^BF%-HJ,X M^U%6@5YI>))X1H6PU0#!8RJF>KXC4J:[X?QEZ] MVB!)JZFA"PS6!>H49=Q+4_.?

*KP]SP9N*V+]Z_OD&S)]=I-.:[XNG90$OEQ', M!)Z)(CDE@2HVR'Z*/?H(0QQGJMCN!%Y>S6SPE0YQX7+>]QR?[LZ[)RMG4T?K M, V3L'-XTZH.T3?#/>A"*

*@N!SFWIZ\/8G$^AJK/PV^NW6]EM@HQ/UAH9-SH31 MA)\3=R>[0# M?F_P K_JJRQR;8EZR'.MNZR ME71YM^^B/'6TL7;=3E*1'/K+@,_-*

*@T\.GI<=P0]GD/B!),O3_"*Q=5 M7Y,]16402=>(T,^98T'E7L^ 6'}I2$'?06=MR?3K1*NX M;(>&GD.OOITISCO+]KZ;'R(M])$]<6!'E'E]JC/,X^@0D%0?*

*MAGKY\//_'E#B"27R5;'>/,:^;P^"24,X%) MG06UOR%,P'E"\;IN6_>R_YC:KO%5C[L5&6JP2W2I[@M_?3GY?T:E'; Q_W*6,JF7S/F6UIBJVN!P'S-*

C,LW!D%$,?"'!B MVM 36OB;5\G[YM=(_:^,^MQX5?]"R[SWO4G(%P@GXG4!"R!M1%O*&UJ0H8G9 MQ;O$$\T[&A4I;B /

2J^RL<$A)+8ERJ]A#M+1+]>/=6=$-BY>.+L8CTWB!%1 M/$-W$N";"@M=2J8T';]T62]V:\(!ONF!3Z=)GZ2:J7=N@DHRF]$^'D++<-ZJ

*MG3^$&QO\V/U.$_Z$+3\M#=P=PN[U2;<30M,Q9=2>H+R: MX&23;,.1;B\DD7_BV=V-BS(OV*MO[.9TR2COQ*/9I<4.IXF8C?[&^7*

*M>'<2OQ%0&=CZ@MDS$MK4,58C^^?)94#.=9NOB7B9=:#(T+/X%GUMI?X8XV$]VP10!J9A4,J1**, Z MO,E&@%Z7!#0U/)=%12D@*

RO%PNDODXQT/_6,KS3#RNBV[R^>-/G3=UMDJ7/< MYG2MU7Z$L]G(P#5N2H@BVZ[SEW?/>V=04) KKK..'90^''&<-%[91]7(_?@A

M]O;JXMM8:RZ;Q%8L"ZM!!;ZU^M0#OW'[9A?Q'Y$]HQA5:;$U0SCGD5!!UF8T) M^(O$/S?3M>SD"")F&@ M(&;)AO-7D;CI(K35-,*

[(<>"NG?"52SFILP^]0056M^N:/$[MF!QA&/6'Y!_ MRZ9-GE%P6[$K-E?^'&HT"7]"=Z @I>[=-TMU_EU9,:$[X3MP(S366&>Q4>F'

*MO(>;;+8R*852S,KLM\;J"(?A@DK0,]^3"?]!=I-##]KRS@&K?U>,RR,8:PH MNWTECC:=!U]3[],*

*HG'F3U=B8 \1H24XW1_C$HKJAG:W:#ZSM&7)TTI5$J MZ[658+_SS9!$*E8FDA75/BM*"@9N.ZIWT9)6,KZR*(W*>"RL^N.AFR^,*

(DH7Z,29P!76#?'V!EP@9 MS6ZP7]2E"9DS>)ZB:PIBA?$#[4Y\T#;TL;[#=S4I?:GEY&.7,D1.+D@T<]8

M%:S3$ZH/E\ZO;C,4T^PJ*R4JZZ#^HVP9_6G^1PX$<(\LT(0X',91Z@/RL1V^>02 M"*23RTTKICV/W=Y?D1U9G4,H?G@8E_/*1V*

A3#T=E3RWZ.SPHM?HUU_#$TCU MVUY#74(_0D*?/=+EA\YG:--R0[I88B>!+$G?V,6]<;DPLHATV CJ31O 8R'Y M#R9I-

\GNKUJO&L()X_(RDD9>RU=I)F/C)]V_UKW?L/@#BX1#_^QS$7)D#,X M,(%#K-[DF]>)U\HV1L-B*I_T POWG\/RK <=:%_1GE0P0>#2,60R!O5D9 E*

M_7_8R6=/A=@3I.(!-K M]S_V>!9/O2SX(-T4M9 B"(DS29HWK/%=PQV>R"O&YQB MS[A]6Q2O6Q$>+D&A]KSNWFP^&)OWH\F<),=1#6;AK3BV]F;=-*

PV7C'\$U,"R M>BIJ-;ZE;I3LO=B>$71B B2X'ZBTV.XWOMB.XT/HD@::O?%T\SLO]VZ-G'8* M\96]>KM+6LG.I*09\>1 >!VF&S<93&D&XZCN8);5"$,.?

5&WQA4E>W\;>.M M(GO|&G7<51N8__XDT&61PS_M5-"CAY7>$U\G[S|HZ1BVGP.1)#^4S):<>"', M2;+:&<5]7BBOW1C^^&#[T@6NT51[/^(EJ2@N>?

OU+OR8/=2/A4/CV%?$5G2% M7SS"23XDJR/GU+E#,7]EB*/8#RP\1)-L_9(@E9#6.,B1$,5. M)C#>)#V89E=3=5=SYG+^>/?$PUOM:8I%F_ _FVLV16#!7?

*H[AK27K.[P@Y&& MN]]"PGY3[7Z&W!)]'O/%X8[(#:."3WH!ZAD6#BPKM>/*3+E<%J=LI%==QL'2W M X&(RA(=N:/2HD?J_\:R% YC>*

[@7\)3H_+OSU3#N6\T.UP6U<("\MDB) \[M\?PR0EP@X?$.)$9_/CW+0YVB\O-?E,BU9W%9;TZ]TZHK(TIJ)70\0=[P)OK?*

MT1__^>OUD1G8P0_*\3YW%55%Q_H>$8;*SEW&:-

*M"YLQ/**QA//KNYE0A/U"^&'^J$L_VT:H^0=:OU&/X*!.2A<3.(3D0/^78V:**"]"M9R#/MKD3WU/DR&O*

*M"9G$Y*9)R:P+VKQM+H*>TS,,G&EB*8"7+QECZ)JHSU29U0<"N5_I CI'+6X?98F-1XDC M&_!)16H^_ W M,LP|[K(Y78<+]#*

*[@WEK<@90BH1T9*A5]B")LE,M6S>3&S[4=J#/>>27'[44" MK%H&@EI&]Q?0Q)SL)<=HHN)$D5CA/--DA_Y%<^$)!+4KM[67E?;E^.Q,NP[RO& M;D+*

*[J)&,(^;$56@D5A:I2+LVG"MPGX1KULW,>C>%?)8L*EY@UR)*]HA!V(<3 ML4(K892"D^A;HQOSPV]X>BOE=+^1A+#@5FPLCE2"\[M+-*

*J:T^UERY047%1UOE=T*7V_QC.I@PF4WVCM M>C0#&\%N7:6.,?C&Z3E8O!]C1H"056=W'8JO23M(6^"("+IPK@4D]OF!?*$# M-*

*''QIL5V'.DV+*8AI.ZQE8'@_$2AZ@'#%)N-S&)QS#HF4%D'W]3RI]*H;YYY M086JI;&\|GR4JSPFP)Z$T'0LWF-*

*RD8J[%6*Y+FWJ3HSPI9!87S0OJM4#/=U7^P-X79(WI;F$8X^<=N1B?/BK-V]-?1:H4^QJ)?:]=KKYL2 M/O(7+P1-[/R[B,&RT&D6%*

<_>#I%I.DI3J7FO@R9A6FK(^DJ PC3A\!'TY,"& MSWJ4 "P+$C+6ACST=W84>0H,&YUOMQMS+"T)O+!4GO%6@U9Y-WT]CEP!G]2E M%

*(,11/N'&F"D4XY3P+L WQ*WUX%+;EOWY*SDLL"C7[E[Y %693A/>;&L_2*VK M'6F2ZYM1JG]2]Z!JHF8$5ONNOHL>9%Q-)*

(\^(F4XYW)MWMZS'T"U;1LA.7J- MJS,ZG[BL0T-I-318GP"HANG,):P RZL>"JZOW(^A7OI8J/-MIUIGB^Z/3<3"H[QVQFC9P@!U=[8ZM-

2Y=TK%T1WX&UH4!F^+/+DY"X2DQ>#@? MXEK34(,!OO{(^6F=WT;Z/6FC,\=;S2(RA;JX/SUX9ZT)TYZ'5L+6]LN0(W!9 MPPLD;IN?

*IVPEP2GJY5&U.)5CZV;/@L\>G3R4\V+LWW46Z/?0]_CR/8('6X8 MC3:-(F=N!S8@8=8W0?5%5P(LIK M-**

*(>PS@9\I+8/KGBF/]NVHK7/_4UC^C%\F^%0*5L]FH,MWTI,K:6)I5*[@EA M92$6CX'L[8Q@_,$/GGA#Y+"K=>!;/O]-@L/>_@^$/X4 M^0]%NHB-*

*@U;*S,\4S=Y10YX)T3\U9*[P"D+6JTAZ)^9]S^)M1"=8F5-OGX]0 M5?+V7EYWMSA97Q,H3;)\K1#Q'I_Z!_\^'X-8315S$O*{)+\>=] M:_<4 LGF*?*

F8)P.B6"FGX\%D]# M). "VK?BA#/E/5J4=8H-1]8-ZNSH(')S^[,D0:OBIS.NB.#3O]M7@'4"] M(I!6V\,XM_%QNXJ;?*

*J.BT:F=/U_B^&$[LW]E1][/[!WO6H1W5R47YSY@3^Z6 M.Y&T3S5]@+'*0BXOF.8S40K7MTE0R\]MKTY%"/W^05OI/JO3SU;N*RN].29UE*

M7_J"%2>6";7=.],E%>E<5^WL^5-2YH Q>,TCN_W]IQ%E]SH&1C"YK1+VZ\FT63.D._I M@1:S>G!(0R-9=(AKT<]JC["<',FGL;:8&?'8*]PDU*

QI&H(Y5%4OYQEY1_5CP5290]> M"RV[AXX'KIDB[US5_$111.USKE2'|ZQRXI7"Z@>NP:)Z;-LB2 M9IQ?

*Q[31$[D4ZM@&S92TAP],/,\$CIN(57Y909X:5/,MXZLHC"D-YOE4?]_? M3/0BG2#S*0<5+,-V67E.'51)7U,H0$[:*_(*:9TLR>(O\L-1%L,G__:OK<1)*

M\12[O'4BOFR]#GJ0:++{TG:\|=:DG|&K?P_&Q0V&AVKUSV^8DD"XR$%;/.B M$>\^K>NM5#72]G^_M?@D4$DM!CIFET+QI&?Y.5RZ]8"T_NN=@-

_N.B-<>8AV MAF7UNZ$&U3V4.VRB([WWMJSUN^XGC0)[F$X#9#6Q210\0S7R%NPX74"]!:U MG);JQ$55:O D03T&UH9-E>QAY/,*]QC'N":$$W\L)X61*

*ML+S(=MSW?@H?;MV&<.K.:ZF]")^_10MBLQ1&]1*2GY7$SY'-DLD)_3\38QM MY8GMW3N/[]3E(.?EI!F&]@.N_@@#RO==%$DR^L]|LO.E<*

*T1+.FL1[DGFO2T M*P+^J &T(:J<<2%F_WV?;Y][@L;MOPT";Q G.T?HR%!7<+=-ZI5R7X^:H>Y M#*V<3R>P7L%*

*(Q:>)YIX49T#QG1%YXB\H/=H30A,0I#X=\1GP8 MO"&RX3%5$J4)+5WR0@Y)BF,S#9;;^/;&7T%-.\]%SI!YD'1'5J]/34I&S>:A M27=QKQB*H-&792;.?*

UZ=$^&:LW=:\=90@U.^<_B[3OF87]:%OC>=E_&&/'8 M-\NR5.++]\LSZL)0FI;?VE^:/!8Y>]2@%?RX#S\IZ8?P!X_#2IH6_6TU:M+\ MUF 5!-

)+JF<(==S;CFE[?6.T+3UUZS MU' M\EN?(H,./OZM\L!3K5J?OT.87= 7]X%H$\TYEZU6+MA_!=+:Z&BQ@T=P-#UH(YP4

M/X$;^)W/!"+4&=K]R%YTQ=XKU(.D2'U8A*%4?E?!HX/;,L^_'WZ^WRWKWM=/-M>_)#0IY^&#C4R$75@6XHKL(_!!Q^5LEKNE3F&#"D;+\=_+QRIRJ.

*(41%/R&X M_^;&#EQ5W&3?E5X3]' ,Y8.)'[M>'PAN.UL[!1C?I9%97?R%0('EME8*I/$9 MNJIZ+:QV_1+9C'+JJ!2 -/AR7B+P9857K;4&*+O;J0ZS9"3VNA)?*

*Y8OGYT*Z M&4_[2WXU4Y!7>Q(BMV!SKH!IDXH_9B M(2VW[&].@6Z@;9)7[PGBJ:8-EA9]AO7P YV90"TAY.O"R=/II'K+%+OD#,VO M6[/5C=^HTN'Y7?3*

$]V2EQO=]_C]FR30BY%^0"M1LA*[KL5';@GN=_M"6-!|FN&),DW@|?C2XB-=>W0X_8/4[PWOG20P'$3@9K-/?(IV'F4XB8-S@6

MGY=I"/S6;6<2U"]3#RQZ.^=<0YUEE%L&%XD(!"B>*>)XV1%>0XQ^.OXA\4=-MS%S.S.ZNJ'>&O_N/TQXMC-*

,&22O>VQ">>_/VPHZ.V#P=70^^%FI,U$VWC8-_M^VF1(U$_J7GH3*OKQPL'A.0H9-ZN-I7;G#BV%":P5D UO,L8A50E12)E'+G8*

M.\+>/TNWSOW@/J'K':H$"*0[`L@Y$.#/LX_,Z2-":,V.,7H"J5 M8^A5F%'U20S^/8N2,0%WS!N&0(V!;X,]/L'JZANB7NCZ@QB4G2CH(;M0CLGZ MVP:?

*SO<^J,FBJ2!7FQVB|IGOH7^ZIWRLK7HH"1[Y<[>1R!U"6 M6;5_AG5L+ (Y_$Z=OR7".?@^*@$;;-?HLT@2[T07PA7+RY(O*5#2S2D6]6-1ST:4 MTTB#*

8H $P QUY)@C5&MMWQ.W1G)3^A+OM.'AQ6=NE=\(]%1F;F7E:B6^V78 MV2]ASQ+P,'5

S0MGO(/"V7K0/\$E7G/[H=%/3BF'QEN&(ZH';_KU1\KX1(NL__B[#W. M5O(4Z-/[+YS=<?0=\8?KU3N<%7_BY9K7/W07212Y+*0<>BP,(8J]_"9Q1*"?
MNLASPS!F%"T.\N'&MZ9F["A]\VJY@_/?_QOA13^)I>:)@SO!%7BUK$]J\Q6X MKUD#F>#M_J2"-_
DF6M^KALR,'PCBGO_"0$VV\0W6VH!YY8E\+Z&]T,';\,8 MD)S)@9(W4#/7_,;B'OP\=&QMI@VYF'=7?!Y4!]O;,Z?3LW[?RFIQO1(N$LT?
M'O'J^0U_P"OV,1'O^RESB^'X,PX0Q#Z)0&+DDY CZ/,$)%IM3&KLJ'MTH MI8E|NCYMT! '-74UHS0.U+#9L2J^GF$Y*3GXVI!6/)E7^%;:VR3U18AYH-
@A M.>"H&Q!E:5K;*087ML])_&=VO:-/S^+=5,6H[-?Z@_HGR+>%EA&Y[X\/Y|\ MN0B3,';\)
(&1%XOM$\,AQ!Z/8>HC&B#NN!@C%8MT,//$%JBE!1IB:CIW*/WX M&:JQ3'IF15$I1 2HGJ,<'F&U9OO [:?H^\|>\D'&?
MZY6\J%=;P@_9BDL_H5Q$A'//=2D,_11!1%@"$\12&"-*4N8&;A($.A$9%:)3 MAX\;%L"&:]!C GR5;-0N\)*#1_UY;4U>E@H2SI\@LBL6CLLZ+Z>
MCHS6TTQ.V>)RN6R[@LNBD)O_,B>]_?X4U&YLCHD53Y &G2_8)ZZF?J, #"N@ M3=GU5/"4V!85456X 0=93-%[65;Y1N=>!;U4Q6O4T#E\?
HJ>"7VK)>T6N/E M\EF>DO]9;NZ!,';#%%519;Z)55*RP%=EX^YUO-3'_^"L*5WQTI=1Y40&M=5 MV^!HAMA5<0%?K69%Z$INI-
!*!&93;!UQ^PJN]9R^HG_,5Q]YKKFX[CPTL>H* M6O@CVT\;J^>N2.,J:"R-GJYU@EA>#X]R;Z0ONS/-IAA'!>AKP/$!AA&B-M'N
M4_H6%RNQ:LH$R"_WN."O<9G1RQ5[DRW7\A!X-PV.8#>AOA?!$/D4(I8Z,"&I M#R/$?78]2A#B-M8)&9GO,'4?
JI2%V%T"S9G$0/ZDYDTDM+6O]Y4%P#VKV-0-, MAJ]#,>8T/OAU+6^@N6H3EV4L'\90IB6?"8RMF9P2G MI!_W#2P(KF+@D1G\3Y"8^JU>INO;IX=
<@P;M>7W3('U-M-%-75NV%=4 :2^OH,0]S+IL#(NZODD-#I52PN6Y&GO?_>?.W14A(1'$00(^Z M6!8Q.HD;^ZF*SO4GG5C)_L97:@JU(^BP!IFRKZH"
M# F@K"7'.!Y8E+KAC5IT_]JJQ,YTL^C ,0&ZC_[HI_0O' Q>5[W-7W-Y\',9 MBF]0%M-])UI;(O Q3EF20(Y("!&-4QB'"$/B!#P@**:(*&4QFI&?6'-N[WG!
ML22HGHAO@.&PJDV/C)Y2]EQKO\W!Z^Y:>\U64WU9,C8IDNKW'*9%U.SRPU3(M:EV1, =FX-Z$P:2S7:8P%[A_P^*,6OZ=5_>RXM 3;XL-
+P+]DWZ4^##& M+H/(:K"AAU.8]2F9!B3M:=Z(3):4\)256?5Q1-1]U1P;KA^#OL'/?\]8=GW10K"\#5RJAG@4 M9YEP!<#/X*G.JNC(I*OEB-
FL(:Q6)5YI\M**LA;#\ZJ_.8P4?+>?&^R->/ M=1NE^CCF/E^*9S]7]\N'2O7T9&2;J=TQ01W4Y$%-'_08)]YM2Y6X/(A7P]4 MU-
$&1D&3[6&B]<7GPZ&GQ6]"FFGPR-SS::^:D#N:J_B(?LRK2W?BK)^$WDMY M>?V\'=+V&ZI/>9ID:/&3?%T)FT+E=O^.+Z@?
XS"B(0P91L*)="E,.*]OPH<) MQ90Y5,F)G("WJ:-EN+CC%<"2 9E;]?H9],>U_(*;X8OV6@5H>*YS/%[\:F'ZU[P19G%\E[DA6D% ^B:"=" *
M;)OB:"'"B:#]QP^C(G%NMD&3ZX(1=GCD.1"S2,87PP3B!M;UT'H&--)ZK MJ]#VRS?\V!5YB ,GPCZ#Q*4)1#A%,"&)RYJ=8*?/N-(F)U>NJR,L2 M=D?
0H!1T-1-J#T%14[']S1-73LHX6D,0F*.IP6A9;2;"'!,9->3TIX$&"Z^F1 M1A=+S[QT7 MS_$'SBQ2UKM&T.ON2>(H(4D$&8\"F8?B01(Z+L0A21-*4B=-
/;W>"8/T=+YB MHPX*O4I>O;:RFJ?HPY"I*;(U&/24N2?_[K61*;Z *\EHN[#945HO4]]L2.R3 M9O$* QE!HU6IMD8Q:G/.UOZ0+X=4$H.(*FCL;0?M;T/-325?
QQ,-0-@ M%2(](+3DT/MQ):_-! M(_GFZ'/3?:DU.7G;43[@.PO6!]N9-H.2F=|S/)AQWBN.IP0ZN-UXMRQG9+O/HR]!DG(<1N@B%B?
@"Q\>01\QEW)&=S+2*'9TF-74@IRY0U%$V M*X,[@)/:,F)'>LT8SJ'@TY3$'1?.TI(Q0&C6M6)R4+9B]"/J1N$,0Q#ZD#D40IQZ#%(41SZE O_-
E'JEZ1":.H<@*:4 M5-F4DJK:I4@WY*O"V\U/S:OMG6(H]K>V\)%3^MW]VLUA(4-V)*>]*3620'M MEJ(ZU,3)*.I=OFM KO*R6O
T=J/()9#'3@*16*DA<82_0P+$ M$T:92Q.M_>LAB:D=YLV"M904 14D-?M'Z*BIK/GR:KI*>_?M[\:DE,_8?1)
M46SUBCXD,&^;Z),"'G2(/CW2L(ZV:=KLQ[7<^7Y*&S-P^82SI4SO>Y<7[\6S MU8)@QMPD<;,>C%$5)YD.@F%$?=PI'@,18Y6;:VI&)W8 C14 >[(
K&9!%E9 MKNL-Y7HEKT&)S1#P'#<$_^)1\X5^LE>I9G!^A!>D9[;4KAB0P2L&#>^R#'C[MHB]W7G0M@,5"WQ-#;*L2^%1LSELJ?
&*P#VJ)3TW/AENVJQU+VQ>5F^_M2RO%%WZ4X) R!AW?$[LTE\4P"<16S>=^&'#N:*'>*>, K8DUOZ7I:PJ/ MF"GX9_[$5VLN$V"N\E558%K]-
:ONK]9EE3_PXI*4]<]DR#5RD$M@2&5()@¥]\ M*=E.K/@M%TV65L<'^'88 1TGX&O'BV8>NBJR:E9@ M-KST+((EJ+0-
A*;@EHR%*M59#8(5^<;S_J1B]&<9KV"A80T$S;E*3% #41(&@VL@]FI6D M(;A&90L; !C6J# %0]_.Q)B 0Q4C3CX[7^V',?9WJCB,#C:,8LB$D\NRY%79
MVWXS$OL.11SR$$40I6X$$Q*DT,7$2ZD,8@1ZD8MC5&;)R5IMR %,5!R% M1S$Z<:[0FA&)6MZ&WD0QB"&!;,4=CM*8-]8P).9!?
&%PL)Y.,IXMW]X]6=89 M?[]F8](LS6AM>9M0YL)+PI@%,8,135U9$Y^)38;K0R>E04A8DHH]B(I>CE*: M6#<;VD 0![O4VW,#-24=QVM84:VBH*>LQ@
H*ZVR<.YE&*.1F?%7[:J.C[S M+.JJ+&"GLNH/F&9:RORNS;85H9A'//1KJ(_DS?.$P@1[''/I:2+W4PS0.M"H;
M[4X_L8)V:82&6_L]*.362W.!]71/73:.#!,EC(EA+B-R9?.8$R&."'28\'AUE M>GWGVR6E,IT\6]W=%/E*.)4V5Z4O5^SJ7[^E=>K_IAL1;/'9>_#"V/N^&D0
M0B=RQ:[.)3$D/G8@37@8I X+4:J5:V&!IXD55W (MN3!+H]UX^V62]G";V=@ MQZBQTMMX86J68N;7H&=>>J!^D0F ==?
$/QX9KG@/_U/P3V*6+,)EI,+3^1S- M?"O*&H2'UZ?L36UF:F^+ ^K,)E*:U[*N'_L=:,UN>-D)C:,-5'P4%,%J22K MI[PGL%'3V_,EUE/91MB&(*@I3G!!?
%@H2XIZ@LBL.CHLZ+YZCHP^,P_S"[^K MG::N^JWOIWXU1>)F_RN*@GLR5/##>\2L.7XK=W[_E* MS+X4>Y1+]I"M,KEUD=6OVSRM[LL4BNIXJ>-
L8#6#>@)Q#ATH)/$/HH'R.U M3 @CZI-G2-2\7("6FSH@L,M/ETE&HJ>=Z&*MI_V3(Z=D$'= FL!9&*-BZ,*)% M>]Y;
("-;P'%SM,)K$N!S4%2[O;XK*6.AP!:C@1&[8 M:U;D+:Y\L^;B#1_:%:14H54-\$X!F)[9D5A))L!-#ZM7DA&0K7[NE=RX'$?-
MI.J4)@#VJE"I$IZ[*I4F($>]5.G.8"&:VM0%:)==EWJ>[R0Z M%20U69A8Q^NE+UWFW]H2O<>\!/U"D[HPVW87IC_^-7 ;)CKS-<5D=D_BI4YT
M30$R]RPLG==^H?>6W?6$PX$3 M F.&HC!PO,2+E?)%=0E/'49IV9#E)=[E!<_N5F#31:N[NJ,:0%'%5#%V.@%2 MFF&3'DB]1GX|)MJF?F"26H&Z -
B*F*B2G3=8H@G&09Q$]_ES[N']1)7 MG-49[K+R1L'O^:JL*=/\@7_(R[+^?K:J01CS, E]F*0.A2B0=40YMZ"YEK'#+Y"LFEHGLS>C:
!0FQ]O"F:+%LHZ!DD:0#TC8N*8+9.QR"M>0V#BM@'.[_TT/D%?C;E@]HJ@_(E M|H(S+Z5>B"$/D-ACQ03#Q"&.V&BE8<0:814?>ULN /P\7H\3WSYQR
ML<\F\CX4ZXKZX#05'Y58:LX'2G2>XGH7;+1]P-6'M@*NI"P=#/#ELX$YF>QU:UBF'^$EFABY@7C112]4?@$Z_K?[/%GIL6$=O.J$$]A M*0?
H"5*_;B&*90,Z->(V;?%DO.YOUJ>&_>@*,3E1\XZMO_/]/F?:Z+)B7[X3 MCT]LLW?ZMS:DU;OQG9)XV$I:$E;/MAV1TW(;_6QSFI2NS_G[&UJ3PAUK%'M
MJ:%F'MR 4K\7[H;4>[$CR>]6V7_)S(*WN%B)MUPN?"],DB3V81@R>>"6UWYOZR5]WL'W[1B^VM[.F>A8\F-,N9C5 M0SD3]GW?
X]SI]+V*VP+++FF71?'Z^5]Z*&2IE 5]ZMF)K5%+LM\+1U@?\BQV M!BQ[RM@:+]7]BZ.RCSL7YXJM9QD4)&[/V2TY&4/B&7D81R>+Y.$:+4NQ,2R*YK8
XB?\>*)UX>L1/R?$V $49C*JO4"N.0C#(8NB['3 M(#\)M ZE1^A-K)H]U,&M&&YT+CT&FMH";Q$*/7751\&@&YKR2:9]S0YW#
MO)+HA[7EU1Y[T0CP:R[<:WX8$XP\BB)$4^C&,88H31B,,78@=@EAF',WB-P7 M" &?8'=B(_,.9P5XPLLU!_>DDMR'^+2.|
(YC)6]/<4L_\=8[TCP$\4[!VC;EJ*?+!+.@UC3&5Y M'Z1)<2TO>$X^8F-0<< MP T'PIMK66@;'HHY\"\"K9XX+W5]7FC"K.6K3@:=G,O82)3FSHC8;!)D)GJ_J?
H%N*Q#&1H) M$GU1QU725$H]W3LMX)A\>KD01X0Q2X#H3S1?UL,1]G=2'8[]7E\9>OZI/#@4 MR\6SIF]CNKKJZ%RO;JES]B9?
7JR_KAX=FXK):W9+EN[RX?%R2Y=^*MOJ6ZC*E
M.'4:]G=7<'O9&^5:.5^5&S%>VOX_ZR#]WI7QUWS%TZR2B43@\7+Y>E\)O+\N%3]T@=H@K^],0B+#/(.'B/[X3 M1 %'0>*I58\^,?!\(>B:),AHZ@:
<=P%1C3 ;BVD44E:4T"" .?%2.,R+&N_/-M'"(^*LQA3/CX,'VOX2K_PI>"<"@O\>UUHD6LXZ<>>G<$]QROQ,;6$04M9VU4_M*O?
X0GRNR'J:8R]MUF(X))+1>G=TPMF6M'"%O^JO6X#@]/2]+:EN/XCV7?:$> MIS.*EW7]&&,\T'[JR#:4"""(>RX:4R(.AZ_A.&CMBT5)J2C)(96*UZY/3R]\;
MAF98WZP)K*=T.K(J*YJ2+$.'$F*"WH&$^-=6YX;GGD7QE,3KM$]ML$%2.29B MRU%\R.IJKQ2::F;YJ0DFUJZ6+I"$+\W2WFZ>E'E_-K
BLIUU[62>IU*8DEUE& M^+"9})"3V4$QH2)FOE2!PFM;$2EF3 K[F.?\ -,/:%E@/:6L\UMKJC(-M4M*] *W\$Y2\5Q#QUO'\
*5YS^+'13XX>%=XQ+!FHBU[N_8#;:V:/J^? MMT/:.DKU'=@/FX/XB! 4,L^%01(Z$!&:P)C$"13J':E1_7,LG:&YI*QWZ3_6^U&S/O&]!ST0UP+Y6? &O35^
M?LU&:YC9*NQX/D/S5G^T!N!!B4A[,YL9VK>_O[UI%_\X"4+$&89NQ!*(7,S! M.*$AQ!ZF/D4X"9G6=9KMU%.'I]=%_BC<@M\SQH2K_A;++Q+,JZ:%
^\IV9(2>TGPK]WXMY[I6VN6*?=@6 M(_W Q0_YWB8W=JE+?$R@PT(7HE@H%@Z=6-8?)&E(<9R&2]7*S,A/[75T-=__MI6V9/B!X
CVFI)\NV5+314.,A_5U>N0T/05ET'3B#S9P9#FMFS?4Z] +XKG# MQYP?H[(A/0^#QMB*.6H#ZB2^4QM1PTEG,;3G"=P9XS-GT0^YOOUG]7SYK6"E
MO6PCC2EGRS-Z+US&"KR1?]V&2F2>2UL3OME@-(=R]A.*=>C_E.A*^>C9X6 M6LO90@:(&<67=>C,%GV+X?@S9YW#
JW30%ZWJ"=2W!:B.XB:6]R4JZS.5I M[R*-(H:CU(<^EWW22!1*QQ%#R@)*$EG(FVK54=.D/[MZE]DT:Y%&C5KD:.+ MJF*0>SJL- /?ISK)730NSD7?
*&T9LA@+-T/"5GQ$E 9PW;C>GJ*NE-H-+^I05+/.+7#,XH@3 M'Z:^3R%*(@23@/H0)\AS78Z\, UU:),5KJ;VMGH\@OQ14!1%&*
(<$)AZ$:N0@[//13!:HP/$%C\F2\ MAJIZK.H4%N.!/0I.2ZMFN*'68<04Q(M),P-\6G". ^=:+&]PR#LUJQFRB@32A]LTGRP!ZQHY$]5Y6\@D^9<> 5-L91,
ML"(>44S)-T-8<;=I'3#+_>3ZO("&&>LNDQ$(4S:,.TG[Y3O/C<&BU(9N=!(S M$]1UMQ/:V!WZH@N>IE$<^P@RY(H](W6%W4DC7]@=+U_?
$UC@!P;6Y4Z]>0S+ M%2[O-STH]2S)2:#4C.99$W92C4?' MFVGL5<95KW#M#8+;W)9-&GA<.?CC%$8I8@+:;64+3W@IU;W6]4Q>!)2_:&IT]W!0&
]D($$])R .(DUAH+?)# MX=&'$8P2%#HX8C2-\.)1;#QR]]7"1:6HN^?PI//![W.FM0Q?R!CK9:)@"N
.%WV:JN\I>GH*&D:0G.>C5Q&@2^%WN0A;'L0TLC&#.L'*&01H&? M.N]BH'TU:U?LAWPQ'5]67PM?L9=Y(8HV?"Z(-8U]C6SM??;H78 M*Z 9(BO[M[?
VP_X3%Q<$&4+96D;-XF7>YL0';P;ID95+# \9^$^%+4M:'F0L4X!!Q#\'0 MI[(!-Q'NI+QH3@/B$B^)&:61UH'A,2I3^Y,[/N[T'7
M5UQ\3:_Q=__FE7W]_E2[@O?Y<7Q MJY +2@,W2ASA)Y) ;)4=UQ%NH\>A2QS.<(@=YB5GG!GH\C//F4+;S*3@CV+ M?7U16$;<^@=2TP"[3G'%K)NS7?
08^7B^%7L M[>U:^Z<:IJ!8/O709N-%3D5.P3IU:F(G_WVAQ]Y]2D5:-S40:_]KEE:W2%' M2>12'$'I\0B5YC) F(<-P9PMR:-9!J-
4(]GZ6)G9FF0Q[=Z9#7)LXV_0LO MZES:/)4V4',#;N%]J%G >5'6LX4*+0@_-@!+8SG%QM\>.C,T"U1DZ(=I"*@'-MH$[3/\V9S4SF]>D&.J\>-
[>=MC>328AB\+$$YLTAPECF% '$L(*+9HC"'F M18Y/%T^\(+FJ.1PBIZ."?:+*FM@1S[BF_S8(DI]%LB6XGNW94.W=4P)?K9;6 MTQ'0DOD8)#6K85
1>E_EE9XQ4^;;HJY:^UQW!6P;!-8;FX6?H'1-@AA&;BHV M=9'P: A+&70PIT[H1*X7:IT%G*0TL;?2T05ETX025\)U*2OSFSVG(4N0$Y*(M^)"XT@+&*
(*Q&P20XY@P]D>F3A)Z88JBA'BZI^MZIO*=8=,^47_;M,*9$#&U)<0*!GKKQT:= MVIZO#=6N]ZN|Q6$-4-$LKQVDZLRX;H^+NKQGC#QAF/M7=6JY7?
ZP$@:5L4?\> M9ROI?'Y;,>[!_H4S837NKEUKL+&HP)@GPDRR,"!, M& N'T34($IKR,T^0<-O;9KWA#]P)!MN=,LA7()57PY_JJ^'W#9]B_(91S5P;
MT[>C9D\F!=OLK&$#\)8G\+X& ^$,'<,_N?MJTJ-GB@F MKB4AUG^IU!C8 =MF!S8*IGN2:#4ZLHT3F8&%4G M,B(X6YFB<^#HURLZ:Q[]M(F;
(F=K6A=I^*+IXSRLKT"@9T(IY0FD,=,[.*] MB(E=/'=@G+ H"", <^8Y2"9\!?*A,,GI9NG23;$M:\)3*,T;#EL";YYGFHB=!; M;12C0IV127%Z[MF2*4;%Z^=3C
\V+-W<9@/4N[!/=34:]3*&HY-,K'<=W68K M#QK*FM6;3\JOMN&P(KJ>XHVD&URT.$Q1[GE,6%O5GT_2F;<8])BX!{6A1Q\P M;621%Y78W#_4-
Z^O\K):!&'(W2CT8@I&5)[I^S#*Q$BS^F201\UP_9DK-UDZ3 MF%AW:X)0//C0UE&0.6_=2 ^<+Y*L*@[7G"ZF]KE%,2ZPHB7 T):M'7X00LUOHL
M'!"8N6_"*0$/^R"<'!E6J?^Y!.K;Y^4GJ;N(*"FE:9RZ6FBDDC:2G>,=TM*MC/UK$IU3*A])3HZ MQDQIFG89GQYY(69;W>U6^.HRW]^L^4?
^O;KJQI=/_/=\5=V7"^XZ$<4HA6>,8J6FX%63"M<6#)6'\DW]PL^K:NRPO4%F 7A,?%#DD+*.MB0M1$E"Q1< <)C'S$TI:8EN3VR
MED35]/DD)L,*;$-2/8W5%%)92<QES*BM>3J,O##G11H(ZCOSK_L MR<#IAD#3G@>8(C!E-Z ?)OYO"HY23Z#IXOUUF_1;\6Q3=C,)$D*2 #).Q#+.
M_1@FG#@0!=1-L!]%4:(7^^O//K&A:']^2V):A3;/ Z$8X#,53S.HIRR9?B#O MF 2V@G<[<\;L#LFUD&0[N@@,S7ZS.D2E^7VJM>Z^I1>4KI^6-?
5]4[5<&]S M.8.0>3AQ.?0I%VLX#E)(& F@0T(//2CR,"4Z>G<>.Q.KZCYSX?7-G:=8S M2\K]-2_^<;VZ*7+9Z+
^V_S,2UX\\7(1N;YP.X@LC>^G$*'$@TGD$>@D/&5. MRE)$M9P1!9I3'UD(PK)RQ6-#VK# W !D:A;+,A!Z9FE#_)T<+0,;!(0.B8F
M*#PW+K'M^G,#%%^F# TX!">KT2D\;GJLD#_R0NQSQ*=27:Z8;'OS*'<\@L@B M#&CD^0&!:>3*"I-I"A.$8ICZ41*%#G$QBW72CH:(39QWU)&^
(^2>'W7FW?D MZR*ZNF<([BI'B#804/W]* #XF8#Q-LM$!\'@# X/!B7T-K)P0"IF8\-QH4^ M/#-0>,8P'[J-9&1BD0J3A"*',NAX'H,H#5,8!QZ'
4<^3KV8Q(CKZ'-O[HG5 M]U8^ GKT-%.8>R"H*:>A:'JZJ"*?!?N[P(>>VTH%[,\^;X7LHTD'2[I$A9UV5 M;=*&Z/-5QJKO\I2;D."1&S\+S_<#7\8-
6(!#B'S/A=A/&(R1XWIIBADG6I<'M3)B8V(7N[I;2EB= .Z;,+M?IX:MX4# Q:IJ'!2U@'3M@P\ .R<'12WW6[^D: M86+W_JX>"R]QK]<(I!/W?
RT[I1\O0(\M&?+:.9\RX=*8BEL-68Q88M=T8/00MM[X&Q(;M3,5*;Y4\4P] M0 :J9VI.9'ID6W+QD.RY_88_\65>ASH$:;XJ^8)@3C!*0WG[6FRE/!]#$B8$
M.L^-4B;^SXNTKDX,4IO\P+6A74?9V):Z[F']$%Z]9Z664-]"NT!T",.6LHV MS5@5!+1VA#E$:^832@6Q#P\@51XRK/!'ISE,+_FG]'@3P5Y]Q_+U\W9,FVC5
MI(:(&X,+G&"?!;$+DYASB&(;P)C)CG\\H7Y,4.RD6EUQK'$VL='H^)1K:U,A MDJ05,ON\]LMDEH \[PSC9XI.WPMKU5?RVN#
MUZ)?/M$VA+:J+EXC:]YBC;;A/*CQ:)V J3?VE"^?LM7=5<%95KW#M';VVDPL MUPD#AEQ9>2)!PAOS?(A=SX$[\P.WBEW/PYK>V
"UR;VQEC9HB(..NJX[-@28 MJCMF"09==^P$ I,DG2F(;TA&Z(ULT.F(/:A0Z;RD'ZXY[9@PHP(QRXK;IOR M!E=*-1]//3NQ@FZ)@3?*-
\E/RCD>:3E71#WENRUP?6^U9]B'JL1:T9(AL8R" M(4QGS,N[*? M"]?!JG_VA&96]2.OKG!Y?U/D3QGC[/6SX$!0E>3[G>-1E]%J8^3!;<@'29?RN!?/-"&5M.
M -ZP\IN>>3. 6GD&3B>,U=ATW,NKQ2C(D(/P9;'@"6Z8FJ5=MCHDE M(V; P*S6RQR@?;-UQDSS7O%K 1 <$481(C!,&(>()3'$-&0P\E,2,V'6J%IB

MRUG<3&S%%&^8M?U:C2+#¥|T,U>C(3!#K1D_N]=G.^)K!:87OM7W I%=[#9 MNM-G(X)[HE1Q5S(SC5.4D"@5ML\1_\&I#Q.?A-##-(GBR/4QT3* P^0FMG#; MFMQ-KZVEZ96 $=#4#)4]*/0LT5!E?GEA;FVL[/:K@,Z_6Q4J[3?4)V15"O&>+K1GD M-918+\ [*)19B/? XE/,%>0=%V@GS#H\\.X.^J=AW799KSA;(Q03%<0@CDKAB M<4$QI&'($U#-_2\R(F85M>=$W2F#F[L9,JWI32SFK)Y%S_;NW+1J:%Z"A.LGUBF-BV;]2L4/EI:Y1'|-UX.K$T>'Z+M?;M?U;/E]*5EZRO[];:5^(,/'XU*?H_US+C(XZ0:@$@O2ZK.HLH@OP+L^K5:YS MLGX*@7'/RX+P>N]G((<$5Q-&Q#1RQD[-.9LW-B)4WQT;&VKJCZUDS?3F(/]S M5OZC+:*.[[B]H B3-/4<&&)7+);4X3#A$8.QA[D3^E$4Z#57&"(VN6?6(PT*_M0? M"WEEL]>NNE@.8J2Z9=I#0?3?{('RN0;@9!\%@Y1R7SMKR.4!]YC5T7.C# MA53A&?W5]!59F+D;<%\N\F5&.U[*@D:7+'^L.'NWQ>]JZ^KH1!-K;4L? =!E=_M'1?U+9>Z2!.K&_.V*FOMN,(C:^[5L'14V1-7,!7R8ZE=5A9;*,5>7SVV=9F M94'[JI3Z0\9-S;J3CGXO5_'W):^3V5?L\B$QJNR_ZI^? K'>T",1"H>80C=T M'8B(V_,+@A@Z8>K&7HQ\'"/-'FA6&)O8HLB>D{\!W#M(9#UN;_W!/3:UNZG9 M>3EJ3L1+0*YGI_H'MGT6+|"&R1KR/IL78*]RVL5NZ32K+=ZLXF>O(YP=MN9N M(&<5S"/]YNS.;[F,X_LB+\N%V">YG <^I! {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`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l,.WRT.V;+8:UM(2V%>I2(SIO^$L+B(.0F-[3]@M? M=*>:-[+:3KXZ=O"Y""B-62IK6WBIV'S'(8:$!S'T(IQZ)*382XG."L&K.]JN!.@F3O @WBEQ":003UQ=6'KD>)*{CPY3Q MD/A)@JFO5>9MSA=A<'/OQWT1:@O#C/#JK1@*U4.VZ2OR,D/-X^1')9;PFJ$X MB HW/TPY$ WH=_J Z$QK7!Y37LDH/W/*LR7E'(TZ3F+O0X*O21XHWC MSYB&DDMA5+[@)2_;>_<,)4Y((0RI%IZ SZ&."$1]!FA08R=B+I<+X"\1V'R ML"9E$7+ <]94="YY\9117H(RUZU(<_B/:JSX#*%U(\2-O#6Q"8H3G!3%6C1X M?_Z98\ GQ#N,_)X::+C6RE[JUP^/."MD^.KJ'A=WO%R(#0<-?!3)/'$UH_$ M0OV\Q(>.$U_9K*W]6L?)3+V^2{@VU#5#!;=@$9Q23U;8,W%M)9U2Q^T M%"VNDX,2V5QS=VT<%/1@51P>;9XA? MMFN"YBH6^)XS$8H@1!Y&-YC"I\ MWU3\%'N$HB#U=<(P_X?"B1] MS.*8$^KC**"ZF?%&\IL43"V*9YG]@#4Z>!X%0R)[?M"'4MH/QBC? P/U9E6N+MG?RYNB^/)$K\JJ=185;Y^>>>'QB%;F1 M\0499-IV(,W12:V?5\;AQE(ET?]SNDI$(85R)+|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|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`G86H?I24>ZD=E4Y*'67 )+Z(.1JP99T;-NB:U=S=,_?$5'95I(J0Q& MVRF[8>>>B*:Q97APOL+E=;BX 3L6K_^_R(N69[`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{<.([LB7X5Q.Z] MNST1QKE\@"0X^Y?KU5- {N\N^5>Z>F)@_"C:.B-+'DJN;I]/?P$^).I%(2&0 MKMV8[5/=12(S?U0F,A.)S 0^+7D;.G:/.5-V^((;5BPMS L$ZCF(F'|HY.T MH0H7AXE- 6Y'H)/A!J:';6W[._MZF+6]TO=0OFWM^3*NO]MY_W*=15G">$YS+4F&2DP*S.(FPYDE6 M%"6-'+M'}1<=6?$,!3<%VQ%T6)]\V8>ISS<3'|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

*ITG33L!*Q@A6,0JH@50'G:.E8X M) >EK!Y+>#9NJ-I$2'T+M1FUV]P=NZ=2E[1DRI@66N=[<\Q*VR0F(UJS-#.V MAX&&8YTD-;)CLB'-; \;.U.V M_1K.RA;J5\-I0M/V:3@K\$&/AO-OP)1Z5:WO?V7_N:PV\4K=7{1(TCR7,L{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j%P4M(U)B%0O;PL;$_%PJ8Q.R9RR86ZKU2,N.+# B/XZ0D-SVM]8X-9LR)H72N&0ZPXG2460;&J0D]BC* MN "HB^LO3N&%5E49-C.0ANCL;RXM\+T#Q:>K@FB-K^4>BZ]FP5BOUS,Y;*K1{1 MQS-0P(WDH*2AS.)O(M.;PD\|%#*TS?\-- ^ONY:B)>GE|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{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{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|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{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|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

*9:DY*VG!,"MM+QH9%;A4B7%W4YZ3+$VB,LK]VU9,51W[<;6>/=678[;% ML9% :M&*MF\A25-^Q6<;+>|-SCOG=]*

M3:3[A3T!QRFV+XVL;98$]&9O)\YYC]);$F"X>'@,<=5+V:!!(3WN]^X)=,'U MWFZEB6_W[@EP>+EW_P'/L4ZVJO;+V(W 9=E0C&1,EQ26\]3"HIY M5'

*L2J43%BFA2WZ_4]V,W#;L88).OT R^8'V"?K_#ML]O(7/?I(-:3M[0[+ M"? ^QQD W3:T *#XC7>]T>@3[AIY_-32/HT&?+R3DY"AYCL-$YMVP).3X <3*

MGMS>\@TZU^9W../S9F#4ZHM:?_Q3S%^LC?YYN91_S.;F5YMD).$YQ]RP[\(5 MYYBE*L9*$LT34I(\!Y75NA =/0SM6&@GN5VAQ< (,W_L7%/0L(A P]$-*

&-U6EL7[F]/JANFLT[!9>5^]K$W*C63,]$<]5G(4V ?4]I(E7) M*!.;2)K8F.,QXADF62XQIRK#I#^M7FH+]]M#GM3\VC\7]0U#X%C"1/?@4WVWL1J)XYG1;*

(;PV0 M#=&KT%?6SPD6R'Z=)#.I%3HG[+XM.?O\)8>27;^CYB[VKVK]N)1;Z[2Z5R0)-MHU0(G.?&,A!9&// "<%)&:),@Z:^4_/.:

*$N6'5#&'*8&0*P2XXU^]W46MP:)GH^5,#>WB"A@QYVGJ/Y M!L>>CC _>WV<-C;8ZLM[--8"GQ7:O PPBOE\MH"<,H+K L^(-U :>?G>R^L"S[/=K*

*M!,_',*C>;]+E]GBH6WQN%RT =:F)D2M?ITMEE7=A,88!V.-3;SEMFL3 MEL<)9066-%:8L*(P85.:XD3%)(TURQ25]VM|[<7'(1J5=Y#)W$@ =17:K$GK*

M3ZTMPW7&1$WD;HW[^7VG$HV$H_E/DX",RA.Z+BY5(GB19P13E7-,5!SC4@ME?EPD3KF,9,'8)E)WWYA 3/A${/ = MICS8',K!-!?8-W+:%\)!Z&?;>(0=:

[DQ';KA!7W< [1@ M9Y^]< AD86&T)[617K#L6SF_13S'?ZW>&PU4=|M?%||S6RN[UUX%,A-L>*F1 MH_UVVG?-@OW)W\VLZ[I$OWZY_=PK*

C;^2\T6<)+8&92&<-<(,&A2LVH]2< M 4KO/Z_LS/K3#C%S$_9@LIGC;WX^25.0LK$I1R[GT#Q2C++<^"%)ADG$"Z:^4_/.:

M<4M+FB9B4@F!:@UW%F*8QN%FOY?86[#>9C<7(6@P@,5OJT7.WH/8I0;3<[" M!O(!SM.;=-]W%G]_KW=_,7RMV'NV>OPT7_Y1.Q?[E0N?*

*EI5EI@FQ;&N.)K*R MQ49E4I8\+F*D;.PG M&^7\!=DHQP8Y+=_V:I9-QC A7IY>YG7F[.;]9[.WFUVYB7["E93Y?F8W*_=6*

M7VVLHK+Z8UJFNWJR@]HQPR7:Y7Q39S992=F%R$Y04^;+X0]35'8AQ)"JLDM) MP4]^;Q]9]

<3>OZS6AH6J.]$K%6<\S3DNF&28)+S$I4PUC@D1TGB$3'"G<30G M*8SL[C4TW<\VCZ-P_CCW8ME@5JLAAS;T/$YQCTOJ?H)[L<1^I[=PR4$'MX-2

M#1S;'G]OL@/;0,:[A[7##(\31I^LDWJ]NM&W5?6/ZN-"WNB/_UZ_7O]A M>? M]\5:?EI4?[/Z-)>_Kl:+A_?+A5Q]J.P?OE?R'Q6L&TP8:F.;G&IFW(%_%8A*

MPV$_X#+.7WNO&>F^N']G:OCJODS)*K='U_/J;?U:Z67-:]Z'IR:]^^5U59D&[AGL^*]!'/) RFQ[[S"0M9/Z@5>V7W]=+M0K>F+5O\R&*

*MJ5^_R8/IK#N":JH\"BXP#;_S3E:IZS_TN!B]FQ%8^$ 6P)WNI(8!#,>^O8 O M ,_?U-5,3:WE]VW9V47TG*5)(G-N^Q#&F$1484Z(QIE.:5;F(BL*X9K!.4%C*

*M9-/0IUHW<064Z)]"Y7Q&)X"L,'4_%-,C]W-*7O>\3@"Y_3([@,\,2NF<$6@@ MJ7/]SW-@ZY/W0"5/;LRG\]H^(L+,PZ72@JKS3DJE%\9SNY2TU7<'!5AI[CF*

*M^!,!IR^7]8UQ>;_J>][^F6V4)_7ZFEUK]*XE(7,<4&8-CMQGN-21 QG1(DT MX?:2B=-.,#"$Z>LS=GPA[>:@=U!8+|$_+!ZH9N60JZBE*

*78/RL#!!P_3+$;IL MBNH9D<<8JG]*Y-O-6#T#PN#(U7/OPDR&5+/[7\P7G-|^&CO^Y:5VSQ)!8AK1 M"!-K04DD4EQR2C*

M::%5GG,G(Y9CRT^L@FHR:&:'FH(NFGZ41R&-?I2Z6": M"Q#,64&')!C87\UKC0Z;/VQ5[^ABDZC8D!B=*@T^ U.95;6^K]ME?%7/YF,]*

*MLI6ZK98/%7MJEKW1WQZ9^9+7+^O'966+X>^6[[3V87D?I33)\B3&/(M-$)SD M&>;Y+G'&2)(*HA1ED8M^7DX(+LP4U8:0EA6X[7+?,7+56PIX5-*

*HQ>;B^"03*TRQLBO1W>_-O6 MQ%Q.?Q)[% RFSGB%6]!S=F27&GSWNAE]]]{6@-G1[_>EUH(F6F&1&1^!&",& M>6H'$^11IF*,Y\9M ,V0'*

*(VMOO$40U1?1/2Q,8+ RCY18E!,, Z&3 Q(#2W-YI F^1\3LK[HD\XG/W M?&<+:5552FYZ$/RR'9K\1:WO.>$B*WF$I4Q2:**1 G.9YSC.TR3)"2VT9K 9*

M0X/T1K8/'?6=9C'084/#@+EMZ0%A@.G_!H'>^+ >[,I-<^V"^W4=B,[9[TW26>TZ&/7]+]M Y\6\LUC?RTQ(KG."RRC3 MF BM<1DKA4F9%C(OXX)&\-

*[K%[$TE[9\@$_@9F*F!19FA9J;,1MD M=T\+>^SU!MI?H2V+34>GALG _]B" !;RPMIE#$U_/RT(@$>OHX59V<]P?A,/ M2K[,E2V(/MJ J6Y]*

*<%]DBLB$&+M(DQ*3G"O,!,]PFA6VQ"DGG(,.4=W(CIVX M;9GH730X;+G6-N, 9D<<8745>,'!@AFU4]BY*?/USQEP>8_VC!+S&=)K]"TXV]A:*

*<[*CBN"#]LX<33WCNJ_:H MXIT]E3BQJ[|W3YRRU[M?ZION6T2HM>KU7R>)SF*_;XA69^W/KXL MI/&NUH^N9ZY3?D-*

'#^#'^C(>Y]BX9NUD3(3X^H_U\K07/S4):!1@\?O0(+(F]6F]I8?$0Q(VA+ M+Z*

'YR11N/FA1VA,/3#TM)A')H0./!RVS=NG9:5F#XOW=4MJW.CA:1YD48:"Y9$F-@)PR4M*8YS M\V=-\CA.LQ"C02]G=62[T#*(1,LA6F]91&S#H_$.U@-

MP;^?(#4]IM_%)^4 M]V SM^Z3=?RCG@!H'X'M"?SG%6JE0'TQ;%N/11#Q&[N% WOD_FX!&/TAVKR% M]RUVUM BO#21%NUK#OV*

*R_Y[;TVLI6]_7B#:G*7W>W;EW78#%XH)LQN^4D(MJ@8Z(8M7X<_^6I/5^)P0HE_.<^J12V90?5N;X,CJH:W/4&NAK2L56J1Y(@J< MR2S'A&*

*<9+K.TP$F<4YUE*LMA53L#M$8/;^HMH(@ 4P-M,:1?ZLYIZ"A?H7=L;AMM!J_/=1 UZ!"BXY3>8&C0H,C'A_P,OP+OF&&'!=E^ MVG^?*

K1^[CHAU\>CV_G<;,LV>7?I;+(2ZEQ1E.:B>(E9H6*<*05H:CB6<2< MTA>N!$=6]8X%9'G8=-&\0C4;Z)^6$=1R N@ZX83DL.Z/@0_ ,+PA-.[=.4)# MY-*

*>J(PA4H"8>$+]D':GHX+3-9>P^(4/U>'Z#W/!N2+9^>9DWRPC8NJEM-/YCX M9*96VVY%VXK\K(AUJ:)Z6IEM;5 JS,N,XU2IM"2",,KC^^^]XDOGOF0@!B*

_M^3X;@%_\AIVF)5>?(6"G,ABT;B[3>'!!C>@ 3CL31X+>=[@,AE#=RV#$IVUA MY@7.01\SOU5\;TWP]9%).XDNC4E7&DN6IIBPS%8;))'-

*(DS)819"U3^=YS, MR&Z8)0J!I_V]Q&6 MB[K.I3W3S'BB8DTCS)@J,9&48WL9&;.R4(5Q$2*J0"F1 PJC1T>6'JH)PC?U*

M72S<]VUO">%;Z)R4)N+ONKC_Y\GI4O&-[V/$'X>GY7Q6K]=6FSAQ3 M\[U71E:6EI+C+U]<.V:J^:U*]RWTI[Q/2VH2+B)**

*N:QIAPP>PMCP2G.M,DD3HJ$@[92H;)C7V" MU1%*TL]2#<>1QS=MJ%PZ,#4;PO,MP:8AG2OJTZX#/+ZX47=+=O"IQO]*

<:&7YJ=2%R^ZGT<#EAR_(LAR M@CI6D'RI"T:Z>CI[O6O+SQ7X$!L"WODM=B3<8#8@,&2PR3AP /S&WP#H3#?C M!B[\SB ;C]?

*#3ZS]HM;;RV3UM,2?V6QA_V9_:N)VC*E@G!CW(L64E+9_5DHP MUSG%21E+PE5!"$\#3ZOU8--)XRZ>5&L80[/M-XI.-5=EH*

MOV3O0FP[]];RO'EDG_'II]1>.H$$VI]N/LARA8OA!8RF?82,A/?7[QI+KO4

MH_I6GQ>WJHMV3W56C,9$RP*8_A)*@JS#T049Q$I&-4RB6)0I7I8]D;V3YOL MW[[M/;03C'TCCX#?QLWJ_UVB,,,=H#;AC?*

=EVIXMN,F&ZX;>V_V9^.&:35; MOP3I-SLNPF!]J_ X<_]G7" .3]AYFBX>?J^4? MZ\?WS9":>RHSE66)QFG&2DRB5&!.'HX),VYYD22"QTZ3[,]0&=F@-

*I111QHU MM%%+W+T5_A!2PU8QH/PP\^8I.JA9OH-@7GWSA]:=K(6^@W#];OHNC_MY6!^U M5F)]L_CT8O>1CZQ:& -*K)M%RS^)4)[Q0MNZ585**

($M.TE#@A422R-.8]D1'_M;8C8V,I:DT9F!]8U<;1:ZEW' "W-^!F%S1>A]_=LIW6YVY+-@F*8I M(TQ*6#TGF ?(K]^KI/-XSTFN%DK/UIX-*

:]T1=C,/HZ(&LQG'&TE.V#K2&XO MG6_=Z;])+UPP/>ZX\(7\K-.O>:[Q\8UEY2Q6*0Q3F4B,:&YQ#PA!28)D3R-*

*M:'%3XW]8*WINAFB8',@!V1\U5]+FDF>OKRUB;Z1M1Z'OE@^8T3D#G)N%"0<' MS)SLI,,>>9RUFXR!S,098I/:!#?!]PV XUL7%(U*8TF:5$-*

*-++)FG&2T)C;!, M(]/DA='T,HL5UEDL!,GB3)2@B39'J8P<7&QH(L'F\R['ZE%&>H".FR9?+#-, M@;?B-O3&*BD[)5'(LM(#&M.7EIX2\VAYZ4Q[#)*

]NU1]\!YW/HP?Y6;L?-S4\;X'YFB8S@ M:AYA/MA[]7;EB8^;#T0Z/"'<^?.32V1VV.&AAP'YM.I]MZ_[^V^OL$2=T +A=S-\HP()-#3#HPA_/C;#XE0)^)

*ZM,>DOM!F*Q-VG%&^PW13CP!OYOZ9;GXV1B5]I;[!]42U:S.LX,'M9]?:6PM7R[P MS]?7MZAK<=#CP?V^J0,@P\8@/!9 S$ PPA#U]U%],1'ZK#\9-*

*='W47MWQH% MO.471%QO;R0>[,7>[=XETTFN8QP):EL5E1FFB1*8%7%99@7/:1E!8@C1/YS_L&7CQ)2'$;*.,$ "!0..1">- 6! [+O^ MP+>]W(%;M?*

RBEM??^]&\+]PN;SUULVDX#V%&>6F< 1L ,&OIC_?U=5>Q! M[=U&:]E!EA]P1XIS&#FY!Z'@=@?L&X9"!^@DN,OLZ"8-K3^DAN BYYQXXO0+3

MY6X_O/_MVX=[D>J(Q(3C7)M_D#16F&8JQKPHLE27@J91XJ+9_45'5F%#P4TA M=P0=UCQ?]F$]]MMBMJZ[.QDCO;+' .UDVROT83F?LRK

G=5C@@SH3?=XHSS=_MOVTU:&>Y253EF_"=3ASI.S_'^--L84=8_&(\;_5U]O"XOM&_K53=-_R>"E[& M1:QOD2AI&W=2XPU3C5/&1]QU7EU<\S^%M?

X?'Y=R\L6HRXU^6:W6LKWR;_HR, O1 MGH.-TW0?+%^HLW9GNM,>MD/A.#AM!R\ CVSK;@]W3P]_6_[QZ^)Y]GZQDN;?

MH4GNX55&5O2:.+J;,K%Z1ZYFE)PM5"+=8?ED]LMWC/RL+XZ"+& M6N<9)CG-.(W,OPJ,O-W49H2#:]^V:,R38W+AEZ09T/6]XIE'R"WW?EBL;UV

M8H#$GC4G)R0*6EFR3^,-ZD=.B'F\2N34PY<$U#-,:KY:5_6Y?MW:7J5)5D8B MPRPJ;5F:XIBF2N!4Z"1+F3+_ QTMG: S]EE21Q5MR7K-

ST%$R2@ODAXGV+M)K=GF'Q2]J A\B&5-PB/3XIZ/#0^_:AGCX'EXN%.54]V#DY;N7HO2B;+.!*8 MQ%F!21GGF$4RPK0LTCS+"Y'&.41-C]

*8645_4:O57]O#WC5Z;F?5+S6:&U:P M6?)2<,,L*O $:C<5/5" &!J:HEA2PU97_C8><#AD MJ$(B 4Q2#8 P1G[*55*_%-79U:?+4KD*NI.H-"4V-*

*_K$*YLV9/&]S:DI2FV\=ZZH]=Y+XP]0 MAD4>184N$RI*T-VOB?@>V=YLZ2/19P#F5$SU#=TC?*

G/XE7FLEL/V?;_>C&0Y]>K5MAUC.#]I80@#^5I3<3VIOS;Q!CW^.8F M[UG_ORG_7=TMM[N=+2#\O'C/GF=K-J]K!/A^?_ROZM\OL]5LK;ZIZOM,J;[*

MO9UO];"H5ZD[X=W'"8DXR\U6$R<9)IJ7F(DHP;2@FA4LX2P&G;N,S?#8+]Y8 MS[];(XU-85%ZV4SY1+7_.YTUP7>01C[2[KM/S_2]P$ZWK>?*

*WU\=GRZR5=_K M.T>JLI5(2"_MB*G5&O58#'CI82(<0UV7&)O=;2];3 3^P16-J>CZ;19?U!_7 M0MB-R6Q)M]5R8?[83"VT%\B;K6ME]JI>,*

*[.%F#*W/U6H;?!=<)#I*J#W@XYC0 MTNX%48JS/(YS3B,2Y2DL-1F"K=%SEX9)M.7 EG@O)*LDL.=-D"_@9LBG1A5H MK(] B7Y[EF9/K9M5] _*!*

*[9,;#D=*DH:$+)!=#L+2I+8W)(C[]C7HVKZ-*+\] MJOF\&U84I4S36.4X34J*25HP3%.:XJ+(J8Q9DI!2P;I0]I?1=/*8%!=TG-Q9;N)VD\=$,>PU>?*

0I7S6R.S:KYV43 M#]WR^ENA-(JV MP)5ZCK M;J_!VTH]5=^?\^]F:S91N(F/-!-U'DR^*MDVV@AH,B>=6$[2TU60'8<1'ZU5XG

MGH#ORN_9ZM$>VGQ:5LU!_LJ$0_,7J>3GQ=VC:MOYV>]UH^NV!KTA#']WJV7J[^#GYH3YTF&\HI"(#7A/0B&OY7?;=\>6(FAM2-FF9-M39$4R%?-

(X#BG M&L,D3C!/,<64D92+(B)E#IIV"(^\EZT/XFE&X-@CY,[9F1[) 2>6P,#>7B#*

*M&1T\V&ZRAY4]B.\XL85N6UY&'6;C:4;@\W88[4D/UKU@V3]![UO$\Z+C[&$Q MTS/!%NO>B?QR/A.SOH:D*M%YDJ984I)C4N0"TUPG6$8QUY%2*5'*

@B(WPJ.7 M#+UC]UG=!?+6/-1Y$L +CVX0NAF9\+# K&N/_DY53\O6#]K,8/ZOE0\6>'V?BO97)3K;LBR-GJW^UZ\+?QX]W^\^XLP.

*[^J3""U7*R,69'UBI_7ZFG5-KC2:4E* MGL0XHGF,B: 4ER82-2C31"912GC]=!HV1&3L'%F?+*KI GN #2(TK-^AY 8F MJ'Q$=E9D%YF&=->\W]-*

-:\V];G1U<>A(U=1&NTTRG9_TVY=OEJKZ!T/[(HC+) M%2\%+B0W:IBF O,T9E@0'K,HC>,XE9 =>'?YD16P(^;9>6\/"K?]U%]F:Y*

MRP;>)X^+$&A3W%M\TAWPN&#[V!V)I^^'5K^]GZ]?K2K&VQ%7DM%0'"\6Y<659 MBQ63[BPT6=7H.?:*

[Y:%'_]ZS3]TV!=ZVUMJ<'S')5%XD.5:),+L,TQR7/&=U M+2B/LSR2,:BKY&E28ZM+VZD-?L;I@)+;!A1&=IAB]6CV)J"/,'+XO'"AFM:= M)C1M[[JS

*A^TL#Q_AF>"=S,H_6:J]*H/JII\!G=[7ZLEQ_4'O9P\(>=%MRO M_J:DPVSQL&URN:HKRNL_W>A-$\Q:5=6-X0P.UPNY_<_M]ON+_3'8V8D[4]CO*

M%6,QR:/$& B;$HKR%)=IF>_(<9V3"Z2$M39\H>0:L(#LJV O1ZP*V2$15MI M$5LA*R_TL.R' ,_U/_XC\#J>2>[)<^+CVFQ_R?(''*

M'L9/I$[.^6V+K=M6,C)B,,,/Z\CVQFW5#O"8O$7:EH,?M-W9 43^KXX^+9:"F-AK^7RV0XKAK:Q=5YP9"/3\H&Z,OU-

*H8*MB[(LFO6+^]IF<5N:0+)8QVF1V?%.W+@L&<<\+5),\B*2(J8]8Z[J MU %:(UN-FA2*@5-C:[!Q\S@""0S3>DL4U53MO25+UW@/C?PC5&LXB!AJE,P*

MI6G'R9P7^6"DC,,K?OI[4.OQ[O6=6HC')U;]JYYQ)$NELBA2."%QV 2)@=7<5,Y#. .MGR4WJ>[^K^O_<[O>;8;KF>-=X.2LM+LS%0JS*+2;-*

I&GV/DA0S*DE1L+(D MMC_!C# D.+F_3BS?:7AS[-%_^L;T3&1=I(B)2 M8,Y*9K;1),)R^]XZ^^N&Z[78?I$G QYH!^;1-B;]G+[>)O$*C#6R"D*

MAKJ_74IBNLYP@<+8Z1H7:DW?PLJ%.GM:W;'N4]NQ[JNRQ,^>S=^M7^_CC/$I3D6248P*;2)X^*<8)UREG*5EZD&31>#D1\['VN8L4[7 M0??$E\5+.*

*['E:5;?B#9[RWH M8R=D::F#UD93[_:*SE)T4 MJ&P4Z("^>P1HY[ZL4,>!-/;"IBN['J&U88S]%S9NY5/P&24 [YNMB<07'XW MF%K:M:._I=X.*

;3T4<@+H&^N&XOF@-CPVP'1V"\NW#2PU"U,)63Z.W% 'B(<0\S-.;H0!^"1P3X$=UX0@)VB 2$#=>4'"$SJ]@R(*

*MN._G##WJVZ:Q&4#Z037_]_/BYKDNQZV#+3LB\CX6.4M2G6*9:N/8I"8**HLD MPP7C,96)R JJNU#(38//$_6(@F JW8YG]QL+-JE/NQO-*

'7;OC"Z*74@:#*S+ M9MMAM#]UU/]B\=DP@%H.0C*?%.^L;T3&1=I(B)2 M8,Y*9K;1),)R^]XZ^^N&Z[78?I$G QYH!^;1-B;]G+[>)O$*C#6R"D*

O;9_V3C@J4]+7!0Y9BRSRJR-M,C-"NV.WOP"MZL2_T>+_.-^7:-U MMUSBFDW4%Z4_'JNVX[WG6GE0+=5NNE^%8U0-I1NQ+1"G6"HE:QY!%G9T/8:

M6\!-X6T^2Z@-96+NI]V,WN;3'&QD;\2&Y\T?(5Z>7N8V[54T0CKN$PP;(8TSC)<9;Q(B]EIO+"]8#9A_CX1[0= M*ZCF!>TP@QINT$^6G[_X>>\@J-TVB;$*

!)_C!L0.?GG) X10=YL@I>]^N0! MRL'-*)\U_,S0QW^_S-;&N1=M@NCOL_7C\L7$ $S.Y]\?E,VBS1:6T,;P->.X M[H62-*

*$]UCE,A[#!EVU$T3[BM>=6)2'3*T),R+!G/ M>#/9\Y;`+%V.TJ3(BS4 U+:,L3^J-A"K5?FVT^B K, ET$ M"-C(.(H9R)2V1+?YU-WM2'|2S;2JY:EL 2:FH5A'%*

*M<5003*34F(I2XHCS4L1JKV%QU9X0P%-S7;$718J7S9![KA+]42-=\. MO;<^55/$;/_SY2IT3(2!/H#=XXW"=/^V59:=Y291C6,"=(IP]. ^\ZQ1-X'[']*

M_OPP6XGYTHZO[@UM931C@@LL!%?I(B>'Y=SR+ M"]5JI=2F8G'GYOEK=YOKPXOZAV+5)_.CN>=9F1H=SW"]<2$Z@3S6 O,E%:<

*MTBSEA=.\15\&1MX=S2^'`JOLH BZJ?^8N.!,0L/)5;_\N&:FUQ\RHZ!YPK= MLIF\0I8C9%D*6*;G"4;H CXH^6E+^SS!.2CZ\UW',V?/*GNE?'6KJOI <]/:*

*M)I6(7]5WM7A1GPS[`_\T6K-@_MMM90O8FUOA7Y3U?>94*MM M])"3/,J5)#A1M@XP$@EF253@LDQ52F-=9# ';#1.QZ[XZY?YLKE:U55@LX2%*

M3,^$+>)]>4,_5\N79]]*Z=!?S\T4_1#?!'I"4?.K:BCBNT8K*><80=4Z*D+0FHLW MD70$X$$L[O^E;]=0T2I,V"M%Y)

MZ0=EW/S9^CY/>2E99K958GM\J8+ATL1!F,M(YGFI%"LX+%MTGNCH>:,.!:1: M'J#%3F=A]55OE3IRYN96.

MO8E[;LWV!Q6>CF9DT9>DT_']J0OP(5&61 (0R/1^F&G;(7$>TCDX[V/K4'0

*MV$5)W@PKQ3OXYYNU"*J>3(GU5O@T"7#AVB=3!AR7/QF_Z;@DKMF]*YJ8]*LI MRH-Q_4>[=[75OZW6RK_\N*[JE9"""9#RB,,\(@3A6-@.)0PF5]DCS+*

*486O];P,ZOYYV?@S%Z8,X *-%CP>PO8,A=X MCDUF6M,#\7::SX5NAZJ;4:]\%=FU.#,&^F/T/@N*S¥HGC9#EUF¥\Y]Z^2ST)E UD;?*

*6U^VW4;=K$'=7GVZ1#_^=_1TGPKU%P!?3SEMF["SX&LXMW M&>;;*8T6IZO!+L7QOKH=>IKO@[I8CZTQ%W/)5[N,.R++MM!YM/>T6C9LM?*

T=JL8KS,@DBF"09TAW M%7"8!0C#B*8XSU$:,A39-O4<0)A9P^QZ7%J@0$$%&JQ]0\\A7\:UA1=J[=2! M-:%.K3PGB;FHD>?*

PQ.7;>$X2=*])Y_2#_N9^]'.N5X+(+*9I"+,,ID'JJLX!Y MIBY_CJ.L(91&B=VX^S%@,PM?>^UL]DW,X$TWV-[R,A]EF-G%[8L-EC&+L\,|

M,M#S#NIX3>",HSEVH'[X,([71)N,WSAZQ[4W[YLZI"A:%(QU]57POQ8%KSZ) M^E9^%I4HOXEJE8@0!8PQB-3M"7%(8TA($L L2P,1IB)04F[7IS<)?

W7S&!'OK()N&N'"7 MGS$+CCO^S%]U=/;UL-5/BA!2?6WI"[ME]ZLL#>,XS"AD+&40QX1!2K& 6+(P M5H9V$%#B4")_%]#1]_[BNOAV"NVVV$-*

%CKLK9F0;>EXWZ6;88> ^D5<<'/% M&\H[F+NE'+&S."[9[$*\A 1Q *8 M2\S5/4GUOF\](IC3#.,,9$F-C4RIH!G+IG9QW";<'=UX"L_=6@ ;EM!8\Q6

*MCWD]2V;-F<5;.%?9RX>MNC]% M5>M2W7X>5M>R+K,,4"Q#R)E.K;FS(,$RA;E(<1Z'/,>9T;@J2[@SW_T-%]!'' M_1XM*7S/2:6 [0-*

&6JF3&9@DYTN,>+0#',!+ GW-77;$,JR([CM6'$TC]OR M=7NC_T-K/]Z71'=L79?EQ_6V[=,RL'_/OSQG_*F!"3J@PQ6 %?A=(P :##Q9 MPM,Ð.EG#

(\=KS%3@QO;,I;/XEZ164H4$YRF,_ ?6^ MKOPQ4,O>\P9$'UWN)N]+&\?B^>1 M,A$+KDQ[+EX88IDZ\\@+!*Q=FDE8G#^;\]8LY,).$#?V7Z8?*

G#>$KFOI[QG6FQ MR@5-"(DXC))(0BPE@20EB6)O)FBLC'16EW UAC,+/3]:Y+.,$\72\]!O.-^) M,W/&]: ;"24-3LO'^(.(8L7"P?P _3QGU/%; C ^"'![T^!.%-*

*>L?B:,S8O^ MXEC:!.??GED_W-W<@AYJN\'Y(C/@# >F;8#+B;=3 9?1;77ECY/F=-^?.7*Q MRWZ1@BQE 2);'=8!H[!.86XMVCALKO W*L02_\ 0=-^8<*

MC]9Q/;=-/;T3Q53_4>I1/4R&H)]E6JS!D2(8R@3D+E<.1YQAF$8\@ MBK*$Q1G/8^92A#L&TTA_-3AVJF744:9J9+Z7;K>FNA@@YL,RQ+N1--/6XS*

*M8/I-&\WW6(1K0]@GI3 *:E$%8$+T:V$W>L=?=G3G2W0K\/0,DX?M^K\$7T68 M8)+$ 224*U77":!2&D#.7*!A$\BXR:6-W SVQS](L;RQU 4'\E-?*

B#5&"] M99MGKOZRWJH_"L"%%&79_-[4]%.RT6FORW.!(QWSP[Z8:F??.$@(-$S?(_ MO&G":3;,F#@< ?[#4XG3C#%)+AJ2\PS".6!S3) M4I39+

*<'PQCFGW19'O)n%;V8FBJ=-V&FXQ@6[J>AK,_HK&6G!B0 M?30VP,@E]ID[33QDW:P_$T]%6:\CEF>!|R2F*40ZWI/PG@.4X1"+*,H"4*C*

MC.@8D)E5X6XHS1XN:_';S]\YXL^X%/NBVC(>84^PTQR>NF^8"#"]2H[$LI<624\A5D6_"TAVE#YC:IV$[PP]%\G>ZS,7%[TS1)V2O'./ M7C F0SL9I?*

*BJ_+3U-]&V[A^'#ZNJ8]?,Z;@GW^\4?*4!KNNZ7-/GFM"_N"_N M2#,7BB6"1WJD?LZ3#&(>$:C$F4#E8: XHDQD-.@#_&:V\5RH.N0%+-5 %R:G*

M79A<,\3Z:M+YR:()EC\555V>EVVV^>?]-()LJ.AG>.AQ]C4Y+O^SU_>!#^' M/UV!OP0_!U?-.;]%/[;H=_7.L?E;8/ E6*QYMSF?IEOU"F)G]/_1#OF#\R '*

MX$V+]$]-&V-FF51)VF['Q3:W:(DMB%5M99KUM5>[,B] D.=%2EIVpc,LH<:"X_6&5&9I^05+\HHMT;<;WE' ?C%WYM]' *?JO.2OV-*

MT!6R6_ZIV);]K[^0:EW=:WQ6+(N0U'.96:#^#R,(&W9H^+O8S2,"_V(M#\<8FPV>WH4RLP:L@=FN;EN MG#'C>LH;N78ZQYQ28[5B1,F8BE

*'#-2#^FVO&L;/7D3,C9;0E]VBY\::H]UZCL?81^-OMO5^('<;8E2VQI>:U_5*E4:1G*,H!) MASA4JB+&YO0MXP>&_TO&L74$UT'.>&E'H;3=556?\"@5.*

M8TB8S"#&G$$:\0"BC"L#(<$Q3D[7J38&86U!XH$!U4V[Z=DZPQN^ O)]A. M+'>T]@!GJ#@9I\E:,\U)(NWS(P1>MP8,_JT0P?*

*LMMI>\W]47[ZQMU5?]V3: M_WKBW9G%[*Y+2.W#OQ7X(LIO:R::/@Z+QM=3A(_+FP^:[21MBER/@C=%G%O; MZZD#EVMZ'2'GH.5U[#FO#:_5+R_#?*

*VG*H1'F<1B@& ;ZA@N'C,%,4:I\Y@QS M'O"<(EI.0>';_0ECF[6/N>5SH;XJO^ MW)WD>?M53P"^,W2]CC@*L=U[*

0W7?)JF^.G9ZV?;N67KT1]OP:#>724G:V2 MG-%09@F4<2H@SF+E^.,J_P1#DJ&$T)"&=I7>5O!M),.I\KN! MZLMZ!J$+!#< M$&?'3!2'41BE >08,8@1%$+"(%))F4JPCB@6-KHYME8Z6.G+BL>'XN>K: 8 M#-Q:B-MFVGLV'MH[!,MNBTBS1KVEH,#7*Z;O#7S[\^=F.!)I=O!7E2K.['E MM6)W.\3>]?I2__,N9+?*

E?57>5/7ZL2FF^E747PM^+[[7ORC"_FGJBIF<-;_^ M^5(K&.'NU+Y)48+[+Y_!'A70XF+NGADQ9]I=\\T7.QUAPA+PNT8$-

*)AXO7+NM@4#VM6]2G8/JB7TUQ9$LK7"^,X M@3C5G3LLC"#-".4)YXB831D8 S*SK,_F@GT*#O&A=@7D7:"NX.XZ^PWB'&: MD\R[OGF&S<[Z0?*

*0YF6!L9HRH:U53>)VF[']

*PH0<&53RZ#C]YDA]Y8.TBO], -WX5/$L0/:O3;JZ,#@;3 Q"3P5 MP9P"$VR]/)\9!%,H,!?;*2F+Y:YUPYV-UX};UGOJO(MO7E+ F@(NHP0HFDS)H&+8^^-E"QK@55,=H]=[%WN-$ MW %*]HF1V6U<*VO5]ZE8=Q,?4-|'"7< M#L#Q+.=UF7,X>QNF^=7L>?@R)4=I$]RLFZ>HUQ\T_1$=1$M;.5#DPI<@59'-M.TYN)V7(>8>K4%.K+|-B1K{6\E:?C3)-T]5$>$,[;Q84^.4Z M;H+DY8HE[\LJ7:QC% FVOM[V-%7C9L0;XJBQ KI(Z&SPL,OTM(GFS"(Y?<"M M-K6EAH:(/J'1C4;S.:BSK;Y83.NRSH=H&3=[W1!+381]!(#F#\VP M5+UGZG3*8$217")'B:V#L:=H&OE"[ZGSS\?KY0>;DKE]IL<@ M.S%W>=7!1YR<=-[EPS>*A4S2NQ2A))-!!53@==$UK11#8)*,6^L^QZ>8=W([M9?:>U$1K['SU:,Z8_A?FB1!*BGK&DWB@K=ZG M'Q"&2X6? ^%!=;!X>/4_0# MS$/9!RF/9S"/4D<'[OHV:EXME^?$2=&9:QD8,&X=!;Vu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|)2//+.T-=PW4U0'H_A*FLRJ[-[/WX0S?E%LC-F^FLS*7 MR"$X+\",N)T[Z)*-U8"EJ(Z&1Y&(@3\-'IGW$0BNN=2_-[92,/"2U-RPV M4%*

<'!G)]&Z>V6R')74CRY;=J[7%BH[!*%0,V>T6RL20;6<9+%@BA)@E)*4ZR?/1B. M/C&NT;KQCDW&=1-/G^<>0FD=W/-Z@+.+@=K;!>ELB8SE#-$'#HI[5%S\GR9 M<$$EGWCS@8W[4]E-'2M)3O-.J;L1.#[_!M^'I]ICQ+%%TM\%;)6R6;V(NK06Q M1JL,58B@I&*TMAF'$K)P60L39/,2]YVIZ_(C$@"}L%Y.4 6]+!LTM2R(;@:IU8GM/$KL\W!L: MFD.HKPM\[BI/B58NA<0%)%X$*'02(J?(#5GPIJOF9R^[4=1G9#(7*@936 MKT-Y6<"Y59 D1:Y83*;FZOG<2A;*6N M'AS*#:M?KR 07_BF:,ZCF,"2-?):N.3]A4^?B2.9 FAAC8K)L,1:YQV?IJ[+ M!{(9+NY=GFRJI Y@]PZ_7'H>;\I%K_%-9NJ$1X(s[^9M'2)*B]=992%S+,R1 MBV&Q=0S]*$%=NH1#@:V=:KIP "_$A.OY'6\74Y+8E!JJ\8+#248KD\0(06M5 M^R0DB 81:*M(V;"G;UI7GS]*4)=NWE!(:Z>:?DY.WEZOG1? 3*L197FY2}',B)$*N-2U*SXRUW[PU*,4=9FH'FP2;=:FS;IE^P9N'_MEZ]YY.6+8SH MNAVOH@X\M^Y^Z,7%P+_ ->X[M\8?XA M?/O[=/6IMK,D,1* #]0#2Z.G0^E==S[M\R,A=5"%]H/?W:4[D5P&5^}1!XD*"XIT-.,O'##9(DI!!+[: GN<8=MG1BC M RFM@W.7EZ5@6KTI+[_1#C'[B.| {[6]FE=GZOWK^_C6<72Q/DN,TT5JH_T > MS>T?;'QRPI5![W*&Q),'I1(M3!\2|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|=5Y]J M-5)M$W*58OV/^72V^AM]<{[8P%7R%.OH%,))T!%PD L20.G^* M_4@\.A#>_KJM[E4DHQF-.1,@\)4>Y2& AAEC)R+$)K/:=R=NI%#Y0%Q=2^" M'D9C_5]O=6N%_&X^W3?1(;&:3ZX"TA4N1>T9Z5P MI*CXX^2UUVBOM M:LQDGC5K? 3MG.R7'3\39?.H-,D5&)R3A442IZVVKRW*G%+1)@DD17&N/_P%2 MQC4<#?1_?]+-\2+O.3I^@8OIUU ODE[/,WTU{[F=7W3&.,10//K 9B9D=[*; M&9>K5VZ\B?:D?\?\!=8UG6T(=,6DR -$5@B!S"D(R=%7+KNLK"@JM>YX<@2Y MQYNIO5 ^]<>PN"M,F%Z XPX.2N@:MX@[0,BVL9/VF&YTO-|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`6U"2)R2]X 9<-(%TSNNT5DTZ9[YD MJ3F&U#I@&JH5Z?OT"2/Y&;XI=]!0G9>IV[>AGT(PI$/RD &SB@<`M"0%B(:^4,<>51Q=R:&VR#B2UTS:E^V#H7B+_!$H: <2LEF[+!XL:8Y)OIR,N[_XSVO7,'W.8>ZY:.M#2920M G< "N@05=1": MB_9=:=MVW:6GU5LV=Q#J4]!.! Y6"D/[8F:T$8=$6+7)N,A\CJTOP3Y 2E]] M=O?0]_TFJ<>+NAM_=IU06&YD%&AWO^@">X>[!)47-@I{G$RIDKEF%EB=2X#"_M25%08-[++]WUS7TUUST -R<0> >9QFW=IZ^S5+.^'U?GB?K8JA\!]" I$K;Y7 M)7KPVCCPEC/C4[&"MV[M> "9XY[W-C5Y W[F%O0]0-I9)^_>DM';P/=]X??M9P[<;'3&+O MV1Q;&15\0 ',\@{UC/_>A%3Q.RY0,48:UU\?N*FXQNO>#6CESS+7^MR67Z8 M7VMFAD'7MND[P^BM M7\-6VRD?;,DV?KEA)_(!;=4#_:BUX2&R%"#:];5.5."=%6'TEL$F'9-MWPUX MB'[D-S')M2W@UEO7/&BSK4+Y/=I \|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|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}(6B2.6 MU2D17L1=O,\'C]> -(>!BTD.#((7N#9]"LNOK_ M4 N&AP'(E9BN+)HMS.MH@:AF%$XI M-%WZT!T9CN8[L6E[PYR0EG:U_*)VE1LUQO M_K-Z+<-$&C!,BVD]$*FW=H[/>%:/DC 3IC1K3$S:!S21MAC(^;B+LTF"U>;Q U7 M9K%PDUD6";

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|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|CWZ$MKHWR;@F/-PILO6]?9Q^OI3<161H>F(<'WZ=B7.?X""W?

M0I'"KB#G8/VP#!+N;_72VW>%/^NL3UW=]GG^>+U?2_ MUGJ92%6<%Z!+>

*XX(BEQZ\,$AA"+7MZ),3*U/TGT+SI8XB=HI%4($+6SMP5TH6.22@Y.Y!IY#XKNUF3T057?(&=?='0A) MQXB_2_T3(_X"+SS<6EF=R/+AVP(/QH+2RX N9V9#1FNRY,.7UW>O[5(SK MY3;RI"[@_B?PN+;2U1O6$@.DLL: 173*F5U 6"LAQ\0EUL*D')UF;E'A'C M[CQO")#CQ-L!/FX(M[G8+%R-VX2H<5L I[.% ($2B;R*S>]<^^/LZ]#OC8;#. MH@WQ<)@X>P^#UVY6'2VQT1CQ-Z0'E%UN^N3FP;*>S(R3.1,]D'G9!"BJ$?; M@2OR+VKG*C(.T3"F V\=9;;-G!_QQ2=<6%3&D!]4E&$1[Y4Q-H'HFBE'=/D M8+4 ^;W]$G*YBZ7WTOD?XLY?-EJ0D6X>SM?3]O"7M;UN)S6 MO79*YM7SY$Q $F&]GKIQ F+{'#!Q%+:@E[+UG9,FA(^+R&8PVAV> ^FT,R!? MW]Q_?KZHBI@PQ[@0P@)?9\%%CA ,"G"9)9&RSBH/F1*Z2T]7>:!6AO HH7<. MH#V6#;.A*!4-),TH(LVEU!-?7QW/(C3YFN:D4/L1;>%Q2-H#H@.IM5*/K^D;3'$K(Q MD=^@.23F2:A.)7#%!2C!>T?_&'(>,H-^%/$=&L=#(;4?7 ?2: [}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

MQK!\$\]DGF54YOOR6/M7>KB3CU_C'@U(4M@CIN0,O"H7C45(XCA0;Y2",EK$H M%?(_^^]Q=':25#3ET3SVI,CHP=W?
XWP2YX^W,I\74?!P%_R!8WGHD.&$!;_6U)AXE@K(R7-P6%"YP M*S$;AJTSS0<3.]Z6WSV.CU=N[YF;!DVH'WA0T^S+2=I-W]GQ=5:&RWI$+W(" M19:+
I)0FUU+4<$,5YI-_LZ/9%+CVC"FP3M:AP)C!194@D6G.DF.*L?4-O!_Z M:'8?A!Q]-+N/S+8 W MH&(Z@-W>IW_H6) Y(<2@*:[GUH
3O$K6.&ZD]SRV3L#\T$>S@]F\8Y73 ?CV M/ %D49/5E@XPND"BI/7E+6I(.L8B3#()6T^!_H&/9@>R><PNAQ!
M.2_7ZR_,\K;0Y]CF]T>]KFFPT(+E@:H]%5+@6%/'/),/XX($%TP RXM7@FE& MN^D/%%)L"/$J3_]B_*8OF[7.(',>7"$3KK2HV9Y\BN9\W#VOS L)N0C:"]2
F3,_M5BM>!Z50_$0VW06>,T^\=4AQ.+7C@G$X!-UK,G$2=?XHP'6QOJ:=YL,?>/85 M?Y_/5I^6$Q68S:@,$+C(^2#/EUP<+<"$+
M]RXT>!,;9;.!TW)NX+M,>]\@>" M;%V.'_Z8TXHL(M;%Z&K?,<4L>>2%19 HM,WU-$>VOA>Y)XGC1L[= ?00Q?UH MN"2@(<6*CFMO(@$H,U!
(+I7GX]CMDHK)%C,N,BN1XP;7?6)S;^7]8.C\=7Z^ MF'!?,'M3@#Q^ TIQ"]Z(VFV+?'T6"LK<.BS:E\9QF]QUB%V M
G7\0'9P8D*B.YXD76BR],0XQ*@4Z%"2,;' E>=FEAU4YYO<-S6Y]^I,*-1@Y>.0M*F)H8S1PD<9UK(8B.K;M: M[TOCN%:Q!V@>J[@?)A7Z?DB8J(=)H%
(OE8Z$6_1.P&>*^=U5%PTSU[O2-]X MYRF=P/ 0-?THZ%LGX.N19<(BP48E:%DQ W7F Q0N$Z:"4J;3;M;]G)KTA,"]-M5?6#8'"=^\S>^B2S)%-G=/[-
(1H4NTNRV-Q+)OFM3N]TC;NV4A'"-Q;42.? BMS#:7OJ?3FMHPTBG6(K5M.[D?@N*<98T*PBXOI62G$ M3H?I\,GG+V%VU!VE1Q[6Z
;2KN0VNE_T\C_/2=6_X^K3/+^:?26"UL!Z-LQ_ M,9_.5G^C;\X7&P<:ADR)T890YCQY5$&0NYYB O+34Z3-$)5H'=KO2>+1@X73
M)\SG9_BF//#B#W7HZA09Z8M)!4+69&NSJ:8V6U"*R:R#5MRT;C6T&V7C'D(_MB:=[$XK;:ZJ#<._=GM75_S8L*+Y9A-F2Q$3*6_[R??-?
GGV;+B<^6V6M8Y!= M(O_3Q#}I%@PK)22(]H46Q_U[T[=N#@< AMW^_\,HZC.(/AB7D_T)B@*#YD9 MH.5*XG$RK^]- T,KM"%?P#4?W']?BG$A-
92^'X'5 <(?$3[+Q6IRX[Z\G*W6 MZ^Y$Q,4D>.MUUAFB(@=2(04ESGL-3DL1K.8R\ITJ1N@5&]"A[VY@_#;^X'- M(?J<-Q5N!];E2=-
,+C. ^6N'GY<3ZG+41"BL)V2*O(-(H0S$E"S3F:STH>C%UAW* M=Z=NW"/U$VQP RFJ P@^P,]$V7HC..!*%!)C5S75$B 7LA,,.226B<='B"F
M<^_I0,W/VZNA&S2]QW39-.3O4V+H?/4.0YZ>?:?H'1>?![.Z"\-T\?PMDY
M7B;LF*]CL@R#A)515QP$'G,D;H075@NRY8/@[0!B.S=W+1$YM"HJP.R&Y%[_MKOV*Y?OSN)SF:5C4)JG+Y3RM?
WHW>I\X%HN)CKC3M:R5(GCPVG$03KG():K" M6F>!CB)XW+*C$V'W="KM +]O5I]PL9$1OQI>'83DNBX^Q>H12& ,@F0:D F* MO:P,VK8N?7N
E'$+C4Z$N19].!A-7W$1YERWO=-%$^HH'$;317AH@&2A0,7ER MHD.$"JHX!HL2>>O@XSX5XQ8+G1)%APN_"P]D!UZ>[Y(G^]5D%{))NN)N?F11' MP;G2
9A)%(_I)"E@1PO,92:1N$;6NCOTOC2.6U1T(O _JK@.=LIW^!5GYUC9 M>#Z?K4]=JE?[_'RYFG_&Q"0 ZI4F$]HVV=[!R9SW""*DD\%S6/4U-)[-C^Y?8%S]-
I]]K%%7_?KP<_N' MGM3HT'XG0AN=V*^?/UVFLWD=9W5]D*I8]B:*!";P6LA=M6\)CLEQ]JK^M17,WK6>5U%%UE,G]'R:FA1A%(OD&4(I7C0)ADN5
Z^N2NVA8QQ M1X7I%&%(E4@FHD+B11V>,W!N1"\+=-JZV'P0 M!E9*1NXH?+2&GX#, >(>^'KA*8:S1R=6QH?6"0;9D M><$@>?'A2
$#A$8_.6XNM*_^J2-7+C?72,0CZ,!A2*"$%Z M"@@=\<5M$69+6QRT$6,76'B^P<2508L2I4.M@,L< MR:WB&1P:
63.M,B:"YG$EC8U#*1QZ@,@85CQ=B!.WG;P:I)D2.*ENGP2M3 M:D2&$"+)R?'-],,'2!EW+VD=@+20=W>P>36C)^-R/3WH_6J=9+Z8 M(10^XB3%
(?R.%C!21%]+N2 8KD!0]$^4!4RFl6'F[M3U%-T>"(9' =9,,]UA M[GE8++[7E/%%Y4I*A44F$*S :L@]F5WE"TA)XD)%&5>&M5>WZ>G): V!JR.D
MWP&2_CH+G^>+U?2_,*_96B[/Z\W!E]^^X&R)$^&3,(1^<*D.>PPA@S<4VD6G MG#.:162M,RF/4S2N&ST$FA!JH ,\5>?RPZ5S.?$F2B-C@,P8655E
G$1,PBM MN&3T>IV;3Z[9>/^X;O806#E8NAUT*]BD ;HJ)*:24#(&,2N*$$20$)*/]>($ M-
RBU=Z9UX]$M9(Q;DS,T3@Z1=6>&Y/5\EJZXB$+SI#3%&D2["O4FEBL&LI-) M&\,E5\!T')FZE9-Q:FJ%!R\^>$V^&CWJ*QY7>7#O,0W++#AXG<=B: XM"
M,N0"M&.D;Y<+:-]"0R'D:%^8U*IU"=OI:@ZXUIX+KL&0N2/F:*>D56B,A^&"2 M4J$8VJR_"@U!_OH?9>:@WU$W8]@'^,FH.]E+M+S<$^DNX0+9?
I\VP3%EXX6%='Z.6D(!9H&0>N;(YZ]"Z MO=8/4W.PEX9WJSG81]R=G#DO+X]%F',;,=KJ?I.US39 5,*"%26@]B(GKM%:^/_:^[+FMG(DW??[M7S"#?
7FY$?)6XQLNVV&I:J*2%%AE3E$\:I)R6?/K;^*0U$I27' (J*HB.MRV MY<+)Y4,B$\A%IWS=K @1T7AJ=WE=;BC#Y&@U/9M6LH ,FE+ZZBW<4FQLR*UP
ME2(@#G"PK& 8?"LG,01J),I]-GH#:27#*?T0F361/[N"2)J1["E!$7)P.S) M ")Q<.B%(+7U@3(7Q0Z*/RZ7Y-0Y18?:^C)BK(R%+_%'-_XQFEQX^.YHGJSO
M6RZ&AWE2W+CDC03/.0^E2L(CAV'C",EM[NA)&+8[P&*7;S69;70H0HH+MX$H MXG7/RKLE*[V73(F5S$/L+7C4B L,'"A&D=-
!1H.E4<4'O3VEHJ77VN/CS2.E MW!Q.5OVFG,4VL8B(91[*.CKHAQ[&ZW0]5 P3= %AN M# >5#9I864C"/36XDS6@NP=;0]_+$($*&_H>+^F
MA+R;@PWLJ57SK8@CQ@I;)'Q.HI-.(BTI0PQ+[G"(B1=/.]M$2TL/, BMX M#I1Z ^CY$]^68Q,^I47?HOO94993D7Q0B%G&^2*,R:Y-
PXXHSDKA@>-7*YSXD+ +I 7(39?VHPMG\9\\ M/I;N=6.\90<4L[FV1<8D1;8H< L M)C1]0Q_4Q5%5IO9MZ60LY=T&T/&"O6+(?]Z>XE]KH9"4!=H
QGMMA&9;G M)&!CK> "&U.Z<>Q^%+:9IEO:+A724 /XVUY;%;06S"M$8NY=$]5&EN](''+-" M\T"\L&I0S^N RK:!^M4-[VL=(?
UVQ\>]B=/1CS[!>C$D;V3'=QS/WG73.+]8 MO/W!QO]1"IIWDR6V77"\OO%$L\$TJQC/45A?<(
M.YN$_XKA(D/4PX_ZCL5KTINU=,$QXR#VS(52VH)S%I)!. *@L?:!)5'<;!Q, M[O$6=/7IQ3VC5-0KQA6"Z!OL@<+YU=T(E*05GDLV M]']-
'$0/Q5;WN3]0VO $$HG11#-C7+A*' H_.M CD3AL,&6:'Z"';6BIQ6.M':#HC: Y4NI-
(6C5Z/9>+A")U%'"3)YQE8M7&4$N@6]JA1/!GCNN[!+IE9YIM[FQMT6B809 N+S< N5L\TU M%]R8 -%4>0AMI*?V2]%P0"JC@@;@]'K:S9:C+?S-
_2>)E\1Q)$CG;EDRD&@). K6ES[E=B2M]CO10" ,0C$-X.W35=;,BG85,6&:HJAE M+KC(/?
IBB"A%PSDEE/#B5=KWOU_[I6<@Y!PLX@;@L3;$_04D\@%VPZN;9.3; M#SW) XZ_CZYZSY((\U:74.1,E%E<#%GM$]+.4LLX9I&7OTX]A-)63L1AXKO"
MFFH CVO86.Y03YBGUA&4L *[&TR$'0H6V#DOM226>UNZQF$C,.TXI,,AH1M" M+0W@ZV.%
HL_=;-3K(N\K"%Z]U\0A9K+KX,"H:PAA$68B4A(P=X)Z123$OY0.MNE.^,P.4;' M;SJZ'"#0!J#P]7LW7=T@:!*9Q; 7/(;HD'L)AYTR$">]8#F1,EI3.@[_]_FZ
M$5%!,!PJT@;0L'1^WL39Z&)B;RUEI, QQP8QP<&Y(N!A&4H8BBPQQ53@SI2. M]M=3TLI%S?$^10%)-XF7Y?
]11";#\N@D2L6R^3QU&AF3*..1&QU+IW9OHJ6) MB.4H/3\+G0.$W@!X5@S$<#9;\G1W;[":MY*(<=$DQ&TT8(=%1"81CVR,2BH% M@J*X,
(YV(*LU2!VB_R>W>&6541%2L^G\?/5>TF^V%+#5)K M)9&G-PE%TVY!#RQ\I#T#PISOP//[YF]Q XP^JHZ184M^2?/YV7B\I#\GPBUO
MB9Q2)N$$,5Y&,-<"G'/-D&0B446PM%OKW&;1_\=%]^,_5!]8H&'UISLT;*.A MCNTX3IM=8=&V (^WOWTYAX LFNB ?^4IRNW8$$3]%'DB2$P.>
]RU3&AO,. W MZZB G.8>0V%?,;:@^O_W^5_GFG& N.=($0:!F4W M-)P5G(?4TK<6[4MW7-O MU<,WZP2XPZE^7S&VH/JOO[PY3V#R=%
1X7XP5@HT9T!+)))7@\#<>$U14]?#- M.G?APZE^7S&VH/K?OKXY#\H!<\(AX_+1%QA&1H WY)T4C%D6*2E]\.&;=:XL MAE/]OF)L(-!\9T?
3W^WX.KZZ^3"R;E'V/+:SV;*3-^$N18N"9SI[0@19R2AB M+D8M:(K*EBXFV4I0[?+.3>$HA6K,!^^C7:7%L3/DV^Q+Q!5'Z^GUPINK>E!0$X"9H-
X&&RIV"^Z14WUU>VL'PCT&H# %U9:30$]#?QTDY"WTI[R8AT M(0F=)S*:",:D(ECW""%G&6$]N3U+CWHMWZD[F/DRP#7<9IX$B_\W4^W+8: MX-
8PEP0!%G(>F:,8?&/CD58:+YINA_(CM9Z04;L-PQ#9P8?)N"F8 -9!!7:\ M[!Z!K3.>,K"HFD$<131! /D,?"%#2)@H6?YQ:CTMK23^]CDC: Y0N)-(2?W
M$/R45O4=YTP)G@C1")O(I86UAM-0NMOY)EI:*40HC9PC)-X4 MO-P,_S>C:\OP3@'3*@A!,$L,FXCRUM"_8L"3G41A*?E^\KN M2%PK*
<#EK5(YG30%MK.?<6HOXFW[FT4%V=?Y=/3'XB_/!0G 1+[A9TGF?>3 M%W 4!6J=3U$DRX>#V[/DM9(?5AIP9?7R4CM9O4TI^OFL2VL+C;K)I]?O(2!Y
M;Z>$Y:=QL['Y6AU%9QDJY6!0340&\K3ED0QA>&6(TYB/:H R1!]*.4MIT,-U M=ZK8VVK7HKE7-^\G
(A%K^"^45[^2!_K;^]ZLHCCH@G:19TGS]F<)):'+V#" MP!91[(/W7NN3- T;A+M6(J!A\7Y\>U)T-. 4[.!R\50)15=H 0CQ8B#,#((_MY)2%LU-%%9AE3-
#2VTBHKRLLR\IX^!CG7^WX]D4&<^H# MYQ))G;M],L&1<2 /9B+A-E)%'@_(6XN"AZO6O3(<1O='R*V!(^5U-YM_2O<9 MD,1;S7Q"0G"#N/,&V1
8,A(.VB"M(K%TR=X3(NI>_Y7'21EI-P"751>QI;U; M,N$=M0 M+!Z!D1<"3E#C'=(B)!14P$))9;CZIR_7BPG&3@""'J"^N=F08T$QK6"G)@Z,
M"$61]ARDJ!CSW"EA0ND>F^^MEE]!(6'GEE_[J*4!?-UF>3UL.<6T$";IA+!S MF?;HD$M"(Q+!RW 0< A9.@-I/25-5#D:]^9-
>;N'R[P!Y&QMKBYC())%#,YG M[@-+.$76VX"PP(109ED@PV4E'3C% 0Y "_N0#U(H4V!MA+4"]"_U?OV1O='*%$!1'V;]GT-V#8_UARP(D0
M(D6#L,EYI9@3Y +/14$AZ[^IY+)TZ=53*EH)/0MCYTAQ-P"85>.,KW_;JR4`MROI A++(&!\0!W<4?J<-&,T80E> V0&H/NZ/^#? M3WZ;@-
D>C_XWAA5+GR99\C%DMMY/"@32D9QSX0D!5I$#XXUX9 I9&TB_3;4Q MW M>NMGT@:2VXJ*50\UC^WD"%>Z/5+- ZB1>Y"9SWTX"V,>W/?
=$3LYM(HDE MS1#!(%TNA(#N4K2WXH3.QBVJRF[6]BPRZ.LURD?C')&_W]9%6/<X MS[?P%"F?TZP<2;DOD44D6$>]CM05;Q[\%X$-
N\5EH5]>74?;WFYNQX5CL]46 MO-V4*_;73^M(F+B1>(2EWXG'):C5AJG#8;[A@#QU]D>]^2P M$$P6!4O$8D=R1]O)&J71LLYF81F$R!-B#8?8&DO$?
9]0F"A& M5&M*$@>&6I4=*^3U$&=MH ^B^Z 895=^,'P0/F'|/[KIOF#E.=BM]<>_!?=R?0?,,'P&8) M/.;.]S@)8PID.E"%.+,\76QH]& TR5"6J/-
.V^+B[PBSLAQJ7_,A94^?M6/V[M"]NU(@=!?)[&.;"GJ9?:,HD4SLU_C; YF]2AY+7$P@1%4^G+GEUIVPVK+_EU
M"+18:@&7OM3<)+F74<*IH'&?9(D38/@*)"<[.=8 M0MHXC+QT>=B83B&4S]+]>S3NRDUO"7<>1>[@<(I>(([!',3T'"RV\"))OFUCT
M3^.N/"CBMH:*;T^#H7V*V_91:%/@7)/T;J,TEEB/# D6<:SA=U9EU@3Q*42I^'#@ M?%'%;7MI?9_BMGU4T "<((")[.)H?K-
HZ+NJ=A+8"><$EBA8XX5]+S$1)B2= M(152;U,81VL):05 Q^KY2?N>8X7> '+>==,_[32L1+-J1$182"%/]5$^Y\," MV4;&\H2H\\HH3CCVQ8?
9K:6DE93EPM@I(/8&P/-T@GQOE5ETW"4ID7<$(RY2 M;E-N)1+<1,62]326#C/64](*>)IVJPHHL4DH+GGX7. 4)O #P?NTFXO1U;EN)(+8D^>L18RIT;
MB47@4%IDF">>X@5C3(&())I0L8C^T)_E?HFG/,"5A*G>TB\[;C591:48$D"WF*D O(2MC%
MGG&=8"='ITNW!'NA/<'W4OM>/<'WT4&S/<$U5C&!J78D#WX7*2&+@T,>.Y"9 MD(3AYY[67FI/\+W4MU-/\#UDV8"!V?&96WFL1.YO#J)71&F0=
[!]JA640 MR4IA2U\]_=.28M";]B.5W"IT'SR,G\V>UH:OV,Y5LU&SI$4"7GV^V\NIS88(M@1*A0GK*,N.G0/4^1+=R^5H.2;N
=3"UMILN(E/RB3ZHH+H%_JS-U':]_ ^9[=Q_R- 7VF9R$.[& #0 M@S^AE4"")]:IE%'QTM=3V^@IUHMX(?>S!W)?.WK^+]^GTP?3*)?G%_662$9
M5H@QGA '/QRYP"R*T3&O^&,ZENZ,5HSXNC:W&-XV-CT^J7(;\!QN&7]U<]?0 M8!2G0-3WFP_Q1QSW0:-/#@((U!DEN09K>#4NQ@0QPD.,TR)Y8-
!=BMEC>#Q MM++#9!-YR.FP)F??/O*?]K8+7Y&Q(#(++//&>*Z60IEH@1Z,-$;:^CJ7O)OSWJ]D>4MAXC"!G#Q$640B'+E\RN3C$@E0FPR MRN#B_;JWD-
,(SL]#8!/4;2&G;M)!77 -=HI%&P<66K!@OM*2,(:&X13RQ@+0/!%D2=;!$"9,&&Z/R ME)RZ[WEUP76(1EH
U],:G47BA=288R(15GG\C$L*.0O.A)0N1LNLC*)TER^U ZPC%M(K,_L.(LS_]_;? MUZ,?=MR_2^6S0'MG.7'@%SNNX"S(M001?&7M"6&"89I4Z<>?
S=0T$EI4]0(+ MZ;H!U'V)L 5'?A[#>]I6_^URASDC8I36@8[+?2M80A,.84_]8>\I$:5P> MO_#=((@49KI*"FP K+]VDWCS]YW^>?OKB?AE@MI#DKJ
NQT2.B*JZ4!<+VRDS^^C2[CFWC5S4:W@LGC> 7C$7G! M([SX$"X &=% %9<9$(H6:H7Z7I*ZGIYUO=HC6R. ^<"MISD%IE\9<4ER^E"#L,OX"GY*
(FVQ<<#[DI<7==S6+P- MHZ$&H+>481BU0B#O$;TC02I U63&A)1"H]#6U/ M$NO>/ X+PR&UU0 8[XIOEG;YD$'FZ\V1ZG MZ&!1R-"GZ|'R;@
O&Z5SKF445H'C2KCRB*N01^,8@A)QCCI&BY*VR4J$9)5(!!'*OEK(N838#O/=GY>=!,2>(8"|=B=6XH"-=*CB+'1'@; M@F.E:XF.I[JNS3T!=D^LV :@O"'
NF-RG:N#*38D1(5RQCCP*'-['T\1UH1; M;@S6JGC%R %TU@V.3P#7P977 $"WB_$\<2E9D+D["X.3PTJ,K*<.)4Y-(I8S
MBTLW^]Y.4=WP^02@*ZB08F'0:,J!]*2# ^IDQ1?M_//N=(3M^[.?D27I*.:I M50IASR,@BFID.4W(<' 9&9?&^9?4X^~-=/,!L=Y^Z=R0*#65#/61(&?
<+++= ME.1)$4JEMJ4OFC>0TLB#[K%8>'KY=[S@6S@0N\G%MSB]S.R<>VZMMMO8B&8A M'*N(#+80.'DPM,EX9D-I3^S^]QNYA"F-E(-
%W&Y[]S/OKR^OQ[F?U].9C?V<
MWM4X]EF7MO[C14.]PX^\H2@I=''B>1%"%CLW\,CN_N;O7UM9)2RPRUN)%7%F#2RRS#3%A#A#D!$8HNUH*+)4,40$(4Q% M:DWQ:6S[T%?
W$#T"&4]>/922@-GZ6U;T(6\[K9V7W^_E2$2)XM/(CTXT2 U-MCA/B26-9HU4QIA6PFJG-\T& ZZH932 ,(>\;"LYV,"6QL)1R*(W!];4^0<-M
0^%">8B3A2BZ$$L]2-"ZB*JH**[TE)O #H];+A5UK\!1S?BB 36,5\8Z2C MT/ L+ ^Q^$!6CD8;C_BU'7E 7>OOV]. 7PW[O[L
MAQY_[J5^6Z'N+/7,HR140)S;@!RE#!EO[-S&-)C&\BA/XS3SGW<_.PO]<+WA<5?,1 M;0@+ D7M,XC_/:(2P\XRGD'T%AUR0BE])$_$E7[-VI?
&YD_E,MOW^ M;#Z?CMSU/ OK6[=P.L) J2^V9]?NO%X.2_X/ IM%3=Y+AD3"%O?A1RA#@6O M,3>2)E.\FFP/\I]/5H[R6-
0#J2T)N+HK_/,__&]&X.^9@NW."?<$"SRG$_] MP-Q;+)$AG")MA0PZ0M2E2[_3/J6B,KZ&4OF3Z^.CI'\P@J[B=-2%KW,[G9=)
M,O:C5S%UT_@E^F6BZ6)TV6PEL772/%>2\&09RTU!0VXJDFL)G&4D"L<4YDJ9-MTF'(8916/GY/A,83:+&!_,@Q<^]
WOE28)&9.O_<;XVM##L59(HL(I6G(7-P M,):!A3B,AE%=1$F=)Z2OLHXFN'%"?",&GU>W^8#8+,$_B179=RM5W;/!_5IQ^_M[J.]IMH,A#X-
(&KFCI249'DEPY,C^5,3ZA7ALH M\5SC"7$20[">(&%\;BKL&'(AW\-J P+4B3I9^FKH0#]TN/K@>G[H/M(_T@]] M.[EO"D^?
3KC^,Y\X00.F$>Y)P;G2!%X\1S#!I@]@&&XR.EB+)<#F\$^)I<.^2# MU39Z)V3Q=K5ETP8?"^_3->5D';X5%G=KB6GD)3=@RIE"7!B#G%0<61&#$9F!1;%-

F$:*G#(4Q*PC%3,G3(:L0I]0\PL&|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`D1GJ$!/42LDBL:IT M-1/&?(,XLT!P 3DHBWV!M2C_'#GN/=E>__<#-@R_=;WNY'(5. MG;8V! 122+ IX'>.Y(Z%L\"V9V\IN_1]L'-YN:@95740EN>OCU- MT#I1F2S",]"TI,$"4ZM.S7Q>D$;3X+JW-MGZ9]9-L"():] M1VA0PO- D$Q1(Y[;SYA@#%*4)>UD(I&6Z-W26)^FO92UH4_3/I*KW:[G09\A M{(BPU9 ^W\(\,NB57:GR/OE]6G;2V4;^S3M(L_;BG_09\CZ MZ#"WV8%W#E!/'+*;&D0DEV#W-MAIU+QE]>GZ6#%'RR_YNYPX:SK3[Y9G/Z(M'V[3+ 0&D1CJ03(8P Q2099+#1IEU%)'34JE7@LG1?!1GBT3(3^E]CH O5RH]#\E;.'(%2GT;-<,]',<>-FJ4SEBLDW>/ M"AC7W]<<^/FZ7FIV#'2G54@#ENYM2M'//TW>70.G\;V=3H#=V>)M]UQ%'I64 M&@3) GC*I283?J8B$MU8)EV3BI7/TMM%3U[(-AK;BJF@ 5CL^F# CDXM"@]VW M6(IB@,W^VHW#.7%8AT3R@$N2X];DD-8&_FB%5#9;B>US5\PF?JKN<_N@QV-I M0;_).$'(E[*=I@TX6U?.D&B\,Z,GN:) \)%R@.7*#H)}J6"(\T<_!%3JX45 M3.[6(OU%/G'X1!@S(@\I%,"\PP2Y0 GR46-/A7(^E$[_^*L\<>R#FV.>./91 M40/>VI:38G'G&YDS6"E$.?S")=AP&Q5%C'#+N:.5!VM+]=I\AZ>4\C^P%A=TO M.?;62P,PR^_B'HEL.3)&!1455AAA)TGNVI^089XCYP2/6$5'8^GTR(W$-'NG ML;_*'\]6+B+_!H#T%IRI[B;&KS'7 T_\ZJY:<"QBG@' 533 !F7(2DW@%T:D M3MI[5_I&=@,I=4%42-&/[R<*2+WR+6N?8;ZRT8LLX2432;)H=&^<|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|%WDYP4 MV@OX4[KM;@)"!E\PYR"_@RVZVBW? NMQ#KAN/0G^/T#\=V3Q4W06,;(A]X$F1 MQ9HC0ZSG"<)2)4N]Z<=3W:B-VP=93V\%3]K*!CS_KZ"Q1 BQOW-#*28LC;9.E)_O>9^ RJ:LG&(? 0^9@*5=.8LK%.M,1 M."3E:NR2KVQC*7H"$%!$Q"'8 [!?\]02]X(X;609I=)$!L_T,2I=HC"NM+2 M]PR!?+^1#_2[ZIL8'G$#1 =A' C$.PAG(M5PU">)C-7>|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|#*)8:.KCA9OV*I]__#]+55+K73RX"4<)N+]2FED8=UWTW* [+7G5Z]G M @_3Y<[RJFTS8YS^,NVNK]/9M<%-;IMW6J^[Z%V]'D9U;.HWW/O_G!+:"DM M;ENWFL=YJ'5]7D;5]V+WK9O; <8GRO<=K5>N26RN+^AHZ_-K.Q[??+:C M4$A1ZY:LU@_E<'UMD4SMG^K\Y X4]E%C(=.X:AY% O\QGQ-*2]GK)[%]*D$M>M7:^]2 %=;A%6"Z;TEM3B!G7C MRO4:@QQC5Y\35/4\G^O1_";-EF($L*;RWZ$VYM1 F(B<%M*NWM^JEZ?D /5 M?9@H:X>-C\S, [I/^$.F'OWWOQB#F+_-2D>1^GZK78N3@N[M#1-F<_C_&^?N) M[RX+W:'O](%ZG4:*Z7JSV)K3\)-+YJ$TO>5#.VF\J;NC \186?-KS$_F?'GY M54;INWYC)WVW=/NTI_":V^2?YM_C=.#]O?X,.QZf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{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

wst-20240930_htm.xml IDEA: XBRL DOCUMENT 0000105770 2024-01-012024-09-30 0000105770 2024-10-22 0000105770 2024-07-012024-09-30 0000105770 2023-07-012023-09-30 0000105770 2023-01-012023-09-30 0000105770 2024-09-30 0000105770 2023-12-31 0000105770 2022-12-31 0000105770 2023-09-30 0000105770 wst:BiologicsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:BiologicsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:BiologicsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:BiologicsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:GenericsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:GenericsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:GenericsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:GenericsCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:PharmaCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:PharmaCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:PharmaCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:PharmaCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:ContractManufacturedCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:ContractManufacturedCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:ContractManufacturedCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:ContractManufacturedCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:HighValueComponentsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:DeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-01-012023-09-30 0000105770 wst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-07-012024-09-30 0000105770 wst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-07-012023-09-30 0000105770 wst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-01-012024-09-30 0000105770 wst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-01-012023-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-07-012024-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-07-012023-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2024-01-012024-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember 2023-01-012023-09-30 0000105770 srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-07-012024-09-30 0000105770 srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-07-012023-09-30 0000105770 srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-01-012024-09-30 0000105770 srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0000105770 us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-07-012024-09-30 0000105770 us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-07-012023-09-30 0000105770 us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-01-012024-09-30 0000105770 us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0000105770 srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-07-012024-09-30 0000105770 srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-07-012023-09-30 0000105770 srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-01-012024-09-30 0000105770 srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-07-012024-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-07-012023-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2024-01-012024-09-30 0000105770 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0000105770 2023-02-28 0000105770 srt:AffiliatedEntityMember 2024-09-30 0000105770 srt:AffiliatedEntityMember 2023-12-31 0000105770 srt:AffiliatedEntityMember 2024-07-012024-09-30 0000105770 srt:AffiliatedEntityMember 2023-07-012023-09-30 0000105770 srt:AffiliatedEntityMember 2024-01-012024-09-30 0000105770 srt:AffiliatedEntityMember 2023-01-012023-09-30 0000105770 wst:TermLoanDue2027Member 2024-09-30 0000105770 wst:TermLoanDue2027Member 2023-12-31 0000105770 wst:TermLoanDue2024Member 2024-09-30 0000105770 wst:TermLoanDue2024Member 2023-12-31 0000105770 wst:SeniorBNotesDue2024Member 2024-09-30 0000105770 wst:SeniorBNotesDue2024Member 2023-12-31 0000105770 wst:SeniorCNotesDue2027Member 2024-09-30 0000105770 wst:SeniorCNotesDue2027Member 2023-12-31 0000105770 wst:TermLoanDue2027Member 2024-07-02 0000105770 wst:TermLoanDue2024Member 2024-07-022024-07-02 0000105770 wst:SeniorBNotesDue2024Member 2024-07-022024-07-02 0000105770 wst:SeniorBNotesDue2024Member 2012-07-05 0000105770 us-gaap:RevolvingCreditFacilityMemberwst:Revolvingcreditfacilitydue2024Member 2024-09-30 0000105770 us-gaap:LetterOfCreditMemberwst:Revolvingcreditfacilitydue2024Member 2024-09-30 0000105770 wst:TermLoansMember 2024-09-30 0000105770 currency:SGDus-gaap:ForwardContractsMemberwst:IntercompanyLoansMember 2024-09-30 0000105770 currency:USDus-gaap:ForwardContractsMemberwst:IntercompanyLoansMember 2024-09-30 0000105770 currency:SGDus-gaap:ForwardContractsMemberwst:IntercompanyLoansMember 2023-12-31 0000105770 currency:USDus-gaap:ForwardContractsMemberwst:IntercompanyLoansMember 2023-12-31 0000105770 currency:EURus-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMember 2024-09-30 0000105770 currency:USDus-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMember 2024-09-30 0000105770 currency:EURus-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMember 2023-12-31 0000105770 currency:SGDus-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMember 2023-12-31 0000105770 us-gaap:ForeignExchangeForwardMember 2024-01-012024-09-30 0000105770 currency:EURus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember 2024-09-30 0000105770 currency:EURus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember 2024-09-30 0000105770 currency:JPYus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember 2024-09-30 0000105770 currency:JPYus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember 2024-09-30 0000105770 currency:SGDus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember 2024-09-30 0000105770 currency:SGDus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember 2024-09-30 0000105770 currency:USDus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:USDus-gaap:CrossCurrencyInterestRateContractMemberus-

gaap:NetInvestmentHedgingMember 2024-07-31 0000105770 currency:JPYus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember 2024-09-30 0000105770 currency:USDus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember 2024-09-30 0000105770 us-gaap:OptionMember 2017-11-012024-09-30 0000105770 us-gaap:OptionMember 2024-01-012024-09-30 0000105770 us-gaap:OptionMember 2024-09-30 0000105770 wst:OtherExpenseIncomeMember 2024-07-012024-09-30 0000105770 wst:OtherExpenseIncomeMember 2023-07-012023-09-30 0000105770 wst:OtherExpenseIncomeMember 2024-01-012024-09-30 0000105770 wst:OtherExpenseIncomeMember 2023-01-012023-09-30 0000105770 us-gaap:FairValueHedgingMember 2024-07-012024-09-30 0000105770 us-gaap:FairValueHedgingMember 2024-01-012024-09-30 0000105770 us-gaap:FairValueHedgingMember 2023-07-012023-09-30 0000105770 us-gaap:FairValueHedgingMember 2023-01-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember 2024-07-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember 2023-07-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberwst:NetSalesMember 2024-07-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberwst:NetSalesMember 2023-07-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2024-07-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2023-07-012023-09-30 0000105770 us-gaap:TreasuryLockMember 2024-07-012024-09-30 0000105770 us-gaap:TreasuryLockMember 2023-07-012023-09-30 0000105770 us-gaap:CurrencySwapMember 2024-07-012024-09-30 0000105770 us-gaap:CurrencySwapMember 2023-07-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember 2024-01-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember 2023-01-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberwst:NetSalesMember 2024-01-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberwst:NetSalesMember 2023-01-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2024-01-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2023-01-012023-09-30 0000105770 us-gaap:TreasuryLockMember 2024-01-012024-09-30 0000105770 us-gaap:TreasuryLockMember 2023-01-012023-09-30 0000105770 us-gaap:CurrencySwapMember 2024-01-012024-09-30 0000105770 us-gaap:CurrencySwapMember 2023-01-012023-09-30 0000105770 wst:NetSalesMember 2024-07-012024-09-30 0000105770 wst:NetSalesMember 2023-07-012023-09-30 0000105770 wst:NetSalesMember 2024-01-012024-09-30 0000105770 wst:NetSalesMember 2023-01-012023-09-30 0000105770 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0000105770 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0000105770 us-gaap:CostOfSalesMember 2024-01-012024-09-30 0000105770 us-gaap:CostOfSalesMember 2023-01-012023-09-30 0000105770 us-gaap:InterestExpenseMember 2024-07-012024-09-30 0000105770 us-gaap:InterestExpenseMember 2023-07-012023-09-30 0000105770 us-gaap:InterestExpenseMember 2024-01-012024-09-30 0000105770 us-gaap:InterestExpenseMember 2023-01-012023-09-30 0000105770 us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2024-07-012024-09-30 0000105770 us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2023-07-012023-09-30 0000105770 us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2024-01-012024-09-30 0000105770 us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2023-01-012023-09-30 0000105770 us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2024-07-012024-09-30 0000105770 us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2023-07-012023-09-30 0000105770 us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2024-01-012024-09-30 0000105770 us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberwst:OtherExpenseIncomeMember 2023-01-012023-09-30 0000105770 us-gaap:NondesignatedMember 2024-07-012024-09-30 0000105770 us-gaap:NondesignatedMember 2023-07-012023-09-30 0000105770 us-gaap:NondesignatedMember 2024-01-012024-09-30 0000105770 us-gaap:NondesignatedMember 2023-01-012023-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000105770 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000105770 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000105770 us-gaap:MoneyMarketFundsMember 2024-09-30 0000105770 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000105770 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000105770 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000105770 us-gaap:BankTimeDepositsMember 2024-09-30 0000105770 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000105770 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000105770 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000105770 us-gaap:CurrencySwapMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember 2024-09-30 0000105770 us-gaap:CommodityMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember 2024-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMember 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:BankTimeDepositsMember 2023-12-31 0000105770 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2023-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2024-01-012024-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-012024-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2024-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2022-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2023-01-012023-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-012023-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-012023-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2023-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000105770 us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000105770 us-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000105770 us-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000105770 us-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000105770 us-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember

2023-07-012023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-07-012024-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-012023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-012024-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-012023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000105770 us-gaap:CommonStockMember 2023-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-12-31 0000105770 us-gaap:RetainedEarningsMember 2023-12-31 0000105770 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000105770 2024-01-012024-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2024-01-012024-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0000105770 us-gaap:CommonStockMember 2024-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2024-03-31 0000105770 us-gaap:RetainedEarningsMember 2024-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000105770 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000105770 2024-04-012024-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2024-04-012024-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0000105770 us-gaap:CommonStockMember 2024-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2024-06-30 0000105770 us-gaap:RetainedEarningsMember 2024-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000105770 2024-06-30 0000105770 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000105770 us-gaap:CommonStockMember 2024-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2024-09-30 0000105770 us-gaap:RetainedEarningsMember 2024-09-30 0000105770 us-gaap:CommonStockMember 2022-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-12-31 0000105770 us-gaap:RetainedEarningsMember 2022-12-31 0000105770 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000105770 2023-01-012023-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-01-012023-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0000105770 us-gaap:CommonStockMember 2023-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-03-31 0000105770 us-gaap:RetainedEarningsMember 2023-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000105770 2023-03-31 0000105770 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000105770 2023-04-012023-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-04-012023-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0000105770 us-gaap:CommonStockMember 2023-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-06-30 0000105770 us-gaap:RetainedEarningsMember 2023-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000105770 2023-06-30 0000105770 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000105770 us-gaap:CommonStockMember 2023-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-09-30 0000105770 us-gaap:RetainedEarningsMember 2023-09-30 0000105770 us-gaap:PerformanceSharesMember 2024-01-012024-09-30 0000105770 srt:MinimumMemberus-gaap:PerformanceSharesMember 2024-01-012024-09-30 0000105770 srt:MaximumMemberus-gaap:PerformanceSharesMember 2024-01-012024-09-30 0000105770 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000105770 2022-12-012022-12-31 0000105770 srt:MinimumMember 2022-12-012022-12-31 0000105770 srt:MaximumMember 2022-12-012022-12-31 0000105770 us-gaap:EmployeeSeveranceMember 2023-12-31 0000105770 wst:AssetRelatedChargesMember 2023-12-31 0000105770 us-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0000105770 wst:AssetRelatedChargesMember 2024-01-012024-09-30 0000105770 us-gaap:EmployeeSeveranceMember 2024-09-30 0000105770 wst:AssetRelatedChargesMember 2024-09-30 0000105770 wst:ProprietaryProductsMember 2024-07-012024-09-30 0000105770 wst:ProprietaryProductsMember 2023-07-012023-09-30 0000105770 wst:ProprietaryProductsMember 2024-01-012024-09-30 0000105770 wst:ProprietaryProductsMember 2023-01-012023-09-30 0000105770 wst:ContractManufacturedProductsMember 2024-07-012024-09-30 0000105770 wst:ContractManufacturedProductsMember 2023-07-012023-09-30 0000105770 wst:ContractManufacturedProductsMember 2024-01-012024-09-30 0000105770 wst:ContractManufacturedProductsMember 2023-01-012023-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember 2024-07-012024-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember 2023-07-012023-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember 2024-01-012024-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember 2023-01-012023-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember 2024-07-012024-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember 2023-07-012023-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember 2024-01-012024-09-30 0000105770 us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember 2023-01-012023-09-30 0000105770 us-gaap:OperatingSegmentsMember 2024-07-012024-09-30 0000105770 us-gaap:OperatingSegmentsMember 2023-07-012023-09-30 0000105770 us-gaap:OperatingSegmentsMember 2024-01-012024-09-30 0000105770 us-gaap:OperatingSegmentsMember 2023-01-012023-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2024-07-012024-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2023-07-012023-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2024-01-012024-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2023-01-012023-09-30 0000105770 us-gaap:CorporateNonSegmentMemberwst:OtherIncomeExpenseMemberwst:A2022RestructuringPlanMember 2024-01-012024-09-30 0000105770 us-gaap:CorporateNonSegmentMemberwst:OtherIncomeExpenseMemberwst:A2022RestructuringPlanMember 2024-07-012024-09-30 0000105770 us-gaap:CorporateNonSegmentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberwst:A2022RestructuringPlanMember 2024-01-012024-09-30 0000105770 us-gaap:CorporateNonSegmentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberwst:A2022RestructuringPlanMember 2024-07-012024-09-30 0000105770 us-gaap:CorporateNonSegmentMemberus-gaap:CostOfSalesMemberwst:A2022RestructuringPlanMember 2023-01-012023-09-30 0000105770 us-gaap:CorporateNonSegmentMemberwst:OtherIncomeExpenseMemberwst:A2022RestructuringPlanMember 2023-01-012023-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:facility wst:segment0000105770--12-312024Q3falsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent10-Qtrue2024-09-30false1-8036WEST PHARMACEUTICAL SERVICES, INC.PA23-1210010530 Herman O. West DriveExtonPA19341-1147610594-2900Common Stock, par value $0.25 per shareWSTNYSEYesYesLarge Accelerated Filerfalsefalsefalse7242234974690000074740000021444000002217800000482200000459100000141950000013668000002647000002883000007244400000-5600000-10800000-22500000161300000177300000410300000515100000700000290000038000007800000460000088000001480000018600000-70000038000000-70000039000001645000001870000000.042060000052980000032400000294000007070000087800000390000037000001270000014400000136000002500000400000-80000019000007470000-40900000670000-36900000-2000000.0-300000-500000800000-20000012000001200000.00.00.00.020000000-10000011000008000007000000-30000065000001200000200000.0-1800000806000000-39500000750000040000000.021660000012180000037010000041640000049090000085390000052430000051200000.040120000043470000013420000013580000013000000300000000000000.250.252000000000.020000000.07530000075300000725000007350000018800000188000002330000012020000038569001363000001438000002800000180000010106000000637600000275210000028810000003675100000382950000036260000045640000011200000.0991000002311600000190000069000009700000135000002060000047300000463300000537400000272100000253300000180000066000000-273900000-259900000164700000016900000.017000002320000004380000042200000240000000.042600000560000053000005065000002613000005500000125537000000-270100000130000-3100000-363000000.043000008539000008943000004909000008986000000Basis of Presentation Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("U.S. GAAP") for interim financial reporting and U.S. Securities and Exchange Commission ("SEC") regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all

disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2024, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as "West", the "Company", "we", "us" or "our") appearing in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"). The results of operations for any interim period are not necessarily indicative of results for the full year. Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("U.S. GAAP") for interim financial reporting and U.S. Securities and Exchange Commission ("SEC") regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2024, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as "West", the "Company", "we", "us" or "our") appearing in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report"). The results of operations for any interim period are not necessarily indicative of results for the full year. New Accounting Standards Standards Issued Not Yet Adopted
 In November 2023, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company does not expect the adoption to have a material impact on the consolidated financial statements and disclosures.
 In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure. Standards Issued Not Yet Adopted
 In November 2023, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company does not expect the adoption to have a material impact on the consolidated financial statements and disclosures.
 In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure. Revenue Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification ("ASC") 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. Revenue Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification ("ASC") 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
 The following table presents the approximate percentage of our net sales by market group:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-

*align:bottom">Biologics</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 40 % </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 40 % </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 38 % </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 37 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Generics</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 18 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 17 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharma</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 23 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 22 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 25 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 24 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td></tr></table>
 The following table presents the approximate percentage of our net sales by product category: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">High-Value Product ("HVP") Components</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 45 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 50 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 50 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">High-Value Product ("HVP") Delivery Devices</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 16 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 11 % </td><td*

colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 12 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 10 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Standard Packaging</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 22 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 21 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td></tr></table>
 Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from HVP Components to HVP Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.
 The following table presents the approximate percentage of our net sales by geographic location: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Americas</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 48 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 44 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 45 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Europe, Middle East, Africa</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 44 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 47 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asia Pacific</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 8 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 8 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 9 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-

align:left;vertical-align:bottom"> 9 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td></tr></table> Contract Assets and Liabilities
 The following table summarizes our contract assets and liabilities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">($ in millions)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Contract assets, December 31, 2023 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Contract assets, September 30, 2024</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in contract assets - increase (decrease)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">20.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Deferred income, December 31, 2023 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(53.9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred income, September 30, 2024</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53.8)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in deferred income - decrease (increase)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2024, $32.8 million of revenue was recognized that was included in deferred income at the beginning of the year.
 The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year are not material as of September 30, 2024. The following table presents the approximate percentage of our net sales by market group:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Biologics</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 40 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 40 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 38 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 37 % </td></tr><tr><td colspan="3" style="background-

color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Generics</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 18 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 17 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharma</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 23 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 22 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 25 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 24 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td></tr></table>
 The following table presents the approximate percentage of our net sales by product category: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">High-Value Product ("HVP") Components</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 45 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 50 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 50 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">High-Value Product ("HVP") Delivery Devices</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 16 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 11 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 12 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 10 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Standard Packaging</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 22 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 21 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 20 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 19 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td></tr></table> The following table presents the approximate percentage of our net sales by geographic location: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Americas</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 48 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 44 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 45 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Europe, Middle East, Africa</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 44 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 47 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 46 % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asia Pacific</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 8 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 8 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 9 % </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 9 % </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 100 % </td></tr></table> 0.400.400.380.370.180.190.170.200.230.220.250.240.190.190.200.1911110.450.500.460.500.160.110.120.100.200.200.220.210.190.190.200.1

The following table summarizes our contract assets and liabilities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">($ in millions)</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Contract assets, December 31, 2023 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21.5 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Contract assets, September 30, 2024</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in contract assets - increase (decrease)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">20.8 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Deferred income, December 31, 2023 </td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">(53.9)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred income, September 30, 2024</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53.8)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in deferred income - decrease (increase)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
215000004230000020800000053900000053800000-10000032800000Net Income Per Share The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136.0 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">362.6 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">456.4 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average common shares outstanding</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.8 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74.3 </td><td style="background-color:#ffffff;border-top:3pt double

#000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.1 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74.4 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dilutive effect of equity awards, based on the treasury stock method </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average shares assuming dilution</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 During the three months ended September 30, 2024 and 2023, there were 0.3 million and less than 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.3 million and 0.1 million antidilutive shares excluded during the nine months ended September 30, 2024 and 2023, respectively. In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The below table summarizes the details of the Company's repurchases of common stock under this program: </div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares repurchased</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,771 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,329 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,409,786 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">753,399 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total cost of repurchases ($ in millions)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">52.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">261.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Average price per repurchased share</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">306.34 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">360.25 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">359.24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">346.86 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">362.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">456.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average common shares outstanding</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.8 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.1 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74.4 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dilutive effect of equity awards, based on the treasury stock method </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">0.7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average shares assuming dilution</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
136000000.0161300000362600000456400000728000007430000073100000744000006000001000000.0700000110000073400000753000007
below table summarizes the details of the Company's repurchases of common stock under this program: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares repurchased</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">170,771 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,329 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,409,786 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">753,399 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total cost of repurchases ($ in millions)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">52.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">506.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">261.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Average price per repurchased share</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">306.34 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">360.25 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">359.24 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">346.86 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1707717732914097867533995240000027800000506500000261300000306.34360.25359.24346.86Inventories Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">170.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">172.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Work in process</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">175.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">401.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">434.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">170.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">172.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Work in process</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">175.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">401.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid

#000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">434.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
1703000001723000008000000.0873000001509000001751000004012000004347000001Leases A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.
 The components of lease expense were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.3 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18.1 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease - amortization of right-of-use (ROU) assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease - interest on lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of September 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">ROU assets, net</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities (current)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities (noncurrent)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other long-term liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td>

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Supplemental cash flow information related to leases were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating cash flows from operating leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">26.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">14.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Financing cash flows from finance leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for new lease liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">36.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.5 years and 9.8 years, respectively. As of September 30, 2024, the weighted average remaining lease term for finance leases was 7.0 years. As of December 31, 2023, finance leases were not material.
 As of September 30, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.84% and 3.55%, respectively. As of September 30, 2024, the weighted average discount rate for finance leases was 4.92%. As of December 31, 2023, finance leases were not material. Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none

style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Leases</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 (remaining period as of September 30, 2024) </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116.4 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: imputed lease interest</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"

style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">102.2 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Leases A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.
 The components of lease expense were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.3 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18.1 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease - amortization of right-of-use (ROU) assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease - interest on lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of September 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">ROU assets, net</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities (current)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities (noncurrent)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other long-term liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-

align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Supplemental cash flow information related to leases were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating cash flows from operating leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">26.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">14.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Financing cash flows from finance leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for new lease liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">36.8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.5 years and 9.8 years, respectively. As of September 30, 2024, the weighted average remaining lease term for finance leases was 7.0 years. As of December 31, 2023, finance leases were not material.
 As of September 30, 2024 and December 31, 2023, the weighted average discount rate for operating leases was

3.84% and 3.55%, respectively. As of September 30, 2024, the weighted average discount rate for finance leases was 4.92%. As of December 31, 2023, finance leases were not material. Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Leases</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 (remaining period as of September 30, 2024) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: imputed lease interest</td><td colspan="2" style="background-

color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">102.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The components of lease expense were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease - amortization of right-of-use (ROU) assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease - interest on lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Short-term lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Supplemental cash flow information related to leases were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating cash flows from operating leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">26.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">14.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Financing cash flows from finance leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">36.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6400000430000018100000150000000.03000000600000010000001000000800000190000019000004400000250000014000006300000044000000 following table summarizes the finance lease amounts in the condensed consolidated balance sheets as of September 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">ROU assets, net</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities (current)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liabilities (noncurrent)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other long-term liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>3190000009000002200000026300000144000002320000003680000066000002430000008P8Y6MP9Y9M18DP7Y0.03840.03550.0492 Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-

bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Leases</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 (remaining period as of September 30, 2024) </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: imputed lease interest</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">102.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Maturities of the Company's lease liabilities as of September 30, 2024 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Leases</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 (remaining period as of September 30, 2024) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116.4 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: imputed lease interest</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">102.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
62000002000002320000090000020200000900000155000008000001410000050000037200000100000116400000340000014200000300000161
Companies The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">December 31,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Aggregate carrying value of investments in affiliated companies:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Equity method affiliates</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">210.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">203.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Non-equity method affiliates</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total investments in affiliated companies</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">217.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">210.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> We have elected to

record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.
 The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">December 31,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payables due to affiliates</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Receivables due from affiliates</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table summarizes the Company's affiliate transactions: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Purchases from (and payments to) affiliates</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">34.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">83.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">118.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales to affiliates</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td

style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">3.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">10.7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">8.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products.<div>The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">December 31,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Aggregate carrying value of investments in affiliated companies:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Equity method affiliates</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">210.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">203.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Non-equity method affiliates</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total investments in affiliated companies</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">217.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">210.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">December 31,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payables due to affiliates</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Receivables due from affiliates</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table summarizes the Company's affiliate transactions: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Purchases from (and payments to) affiliates</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">34,4 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">83,6 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">118,5 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales to affiliates</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
2103000002032000007200000680000021750000021000000.0248000002590000002700000160000030100000034400000836000001185000000.The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Term Loan, due July 2, 2027 (6.67%) </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">130.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Term Loan, due December 31, 2024 (6.32%) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Series B notes, due July 5, 2024 (3.82%) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.0 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Series C notes, due July 5, 2027 (4.02%) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">203.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: unamortized debt issuance costs</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">202.6 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">206.8 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current portion of long-term debt</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt, net</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">202.6 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">72.8 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Credit Facility
 On July 2, 2024, the Company entered into the Third Amendment to the Credit Facility Agreement, which amended the Existing Credit Facility Agreement. Among other changes to the existing credit agreement, the Third Amendment established an incremental term loan in the stated principal amount of $130.0 million (the “New Term Loan”), which was fully drawn at closing and matures on July 2, 2027. The entire stated principal amount of the New Term Loan is due at maturity and there is no scheduled amortization prior to such date. Together with cash on hand, proceeds from the New Term Loan were used to repay an outstanding term loan under the Existing Credit Facility Agreement in the principal amount of $79.9 million prior to its December 31, 2024 maturity date and to repay an aggregate principal amount of $53.0 million of the Company’s 3.82% Series B Senior Notes due July 5, 2024 issued under that certain Note Purchase Agreement dated as of July 5, 2012.
 At September 30, 2024, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million.
 Term Loan
 At September 30, 2024, we had $130.0 million in

borrowings under the New Term Loan which were classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the New Term Loan.
 Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2024, we were in compliance with all of our debt covenants. The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Term Loan, due July 2, 2027 (6.67%) </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">130.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Term Loan, due December 31, 2024 (6.32%) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Series B notes, due July 5, 2024 (3.82%) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Series C notes, due July 5, 2027 (4.02%) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">203.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: unamortized debt issuance costs</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">202.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">206.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current portion of long-term debt</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">202.6 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">72.8 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
0.0667130000000.000.0632081000000.00.0382053000000.00.0402730000000.0730000000.0203000000.0207000000.040000020000020260000
Financial Instruments Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value. Foreign Exchange Rate Risk
 We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of September 30, 2024 the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 421.9 million and $13.4 million. As of December 31, 2023 the notional amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of September 30, 2024, the total notional amounts of these forward exchange contracts were Euro ("EUR") 143.9 million and $47.1 million. As of December 31, 2023, the total notional amounts of these forward exchange contracts were EUR 278.6 million and SGD 94.0 million.
 In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Sell</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Currency</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Purchase</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">USD</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Euro</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">SGD</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">EUR</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24.1 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.5 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Yen</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,102.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">SGD</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.0 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2024, the notional amount of the cross-currency swap is ¥17.0 billion ($130.0 million) and the swap termination date is July 2, 2027. Under the cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.
 Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange

rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.
 Commodity Price Risk
 Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.
 From November 2017 through September 2024, we purchased several series of call options for a total of 1,106,908 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.
 As of September 30, 2024, we had outstanding contracts to purchase 187,861 barrels of crude oil from September 2024 to March 2026, at a weighted-average strike price of $85.66 per barrel.</div><div>Effects of Derivative Instruments on Financial Position and Results of Operations</div><div>
</div><div>Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2024 and December 31, 2023.</div><div>
</div><div>The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location on Statement of Income</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair Value Hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Hedged item (intercompany loan) </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(16.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(6.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">8.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivative designated as hedging instrument </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amount excluded from effectiveness testing </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table>
 We recognize in earnings the initial value of forward point components for hedges of intercompany loans on a straight-line basis over the life of the fair value hedge. The value of forward point components for hedges of intercompany demand notes is recognized currently in earnings using a market approach. The expense recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2024 was $1.8 million and $5.3 million, respectively. The income recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2023 was $0.2 million and $1.6 million, respectively.</div><div>The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income ("OCI") and earnings, net of tax:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in OCI for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair Value Hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash Flow Hedges:</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of goods and services sold</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward treasury

locks</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net Investment Hedges:</td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(8.1) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(8.1)</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in OCI for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair Value Hedges:</td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(2.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.3)</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash Flow Hedges:</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(0.4) </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.3) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of goods and services sold</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward treasury locks</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(6.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net Investment Hedges:</td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3"

style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr></table> Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2024 and September 30, 2023. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Net sales</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px

0;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Cost of goods and services sold</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div>
</div><div>
</div><div>The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of (Loss) Gain Recognized in Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in Income for the </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location on Statement of Income</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity call options</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Currency Forwards</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">(3.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.7)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table>
 For the three and nine months ended September 30, 2024 and 2023, there was no material ineffectiveness related to our hedges. 421900000134000006015000001340000014390000047100000278600000940000000.0P18MAs of September 30, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Sell</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Currency</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Purchase</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">USD</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Euro</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">SGD</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">EUR</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Yen</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,102.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">SGD</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 241000002650000000610290000028700000114000001700000434000001900000.012500000090000000013000000017000000000130000000The following table

summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td
style="width:1.0%"></td><td style="width:27.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td
style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%">
</td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td
style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%">
</td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td
style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%">
</td><td style="width:1.0%"></td><td style="width:24.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0
1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss)
Recognized in Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr>
<td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months
Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:100%">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</td></tr><tr><td colspan="3" style="padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:100%">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-
top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-
serif;font-size:10pt;font-weight:700;line-height:100%">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</td><td colspan="3" style="border-top:1pt solid
#000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
2023</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</td><td colspan="3" style="background-
color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid
#000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-
align:bottom"> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:100%">Hedged item (intercompany loan) </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td
style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom">(6.2)
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom">$
</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </td><td style="background-color:#ffffff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </td><td
colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </td><td style="background-
color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0
1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-
height:100%">6.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-
height:100%">(10.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-
height:100%">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:bottom"> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:100%">Amount excluded from effectiveness testing </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-
weight:400;line-height:100%">(1.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-
serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</td><td style="background-color:#cceeff;border-bottom:3pt
double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-

color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div>The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in OCI for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair Value Hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;border-top:1pt

solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash Flow Hedges:</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of goods and services sold</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward treasury locks</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid

*#000000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net Investment Hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(8.1) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(8.1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in OCI for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-*

size:10pt;font-weight:400;line-height:100%">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair Value Hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(2.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.7) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.3)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash Flow Hedges:</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.4) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Net sales</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency hedge contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.3) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of goods and services sold</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward treasury locks</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(6.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net Investment Hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"

*style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">— </td></tr></table> Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2024 and September 30, 2023. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Net sales</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Cost of goods and services sold</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"*

style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 16600000120000062000008700000-16600000-700000-620000010000000.0-1800000-1500000-5300000-4000001800000200000.0530000017000001800000-530000020000016000005000003000000-2300000200000500000-1000005300000-2500000-500000-11000000000550000-2000000.0-500000-1200000-8100000290000000-810000029000000070000-2300000700000-4200000700000-2300000700000-4200000300000-4000002000001200000-1300000-6100000-3100000-150000000-100000-100000-1000000.0-6500000-3000000.0-280000030000010100000003000001010000000001000002000001200000500000110000031000001500000001000001000000 The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of (Loss) Gain Recognized in Income for the</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of Gain (Loss) Recognized in Income for the </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location on Statement of Income</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity call options</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Currency Forwards</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.7)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt

*solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> -500000500000-600000-500000-32000000-2700000-200000-3700000500000-3300000-700000Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
 •Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. •Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. •Level 3: Unobservable inputs that reflect the reporting entity's own assumptions. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
 •Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. •Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. •Level 3: Unobservable inputs that reflect the reporting entity's own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance at</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of Fair Value Measurements</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px*

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity call options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">248.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">139.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">108.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3"

style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liabilities</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25.0 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance at</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of Fair Value Measurements</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404.4 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404.4 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.0 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.0 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity call options</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">486.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">414.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">71.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liabilities</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.4 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.2 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.4 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;

height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.6 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.
 Other Financial Instruments
 We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.
 The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2024, the estimated fair value of long-term debt was $201.6 million compared to a carrying amount of $202.6 million. At December 31, 2023, the estimated fair value of short-term and long-term debt was $204.4 million and the carrying amount was $206.8 million. As of September 30, 2024, all debt is long-term.</div><div>The following tables present the assets and liabilities recorded at fair value on a recurring basis:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance at</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of Fair Value Measurements</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity call options</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">248.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">139.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">108.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt

2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance at</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Basis of Fair Value Measurements</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid

#000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity call options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">486.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">414.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">71.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
1130000011300000001285000001285000000073500000073500000019700000019700000015100000015100000020000002000000024830000

Other Comprehensive Loss The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax,

*for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Change in equity affiliate investment AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Defined benefit
pension and other
postretirement plans</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign
currency
translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10.1)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(136.0)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(143.8)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified out from accumulated other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss), net of tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td*

style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(11.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(129.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(136.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Change in equity affiliate investment AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Defined benefit
pension and other
postretirement plans</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign
currency
translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance, December 31, 2022 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(9.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(175.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183.0)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive (loss) income before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8.8)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(45.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified out from accumulated other comprehensive (loss) income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive (loss) income, net of tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(40.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance, September 30, 2023 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.6)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10.6)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(212.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(223.0)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>
</div><div>A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table: </div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.269%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location on Statement of Income</td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Detail of components</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Gains (losses) on derivatives:</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.4)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4.1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of goods and services sold</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Forward treasury locks</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total before tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0

2px 1pt;text-align:right;vertical-align:bottom">(9.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Tax benefit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net of tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(7.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of defined benefit pension and other postretirement plans:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Actuarial gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(a)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"

style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total before tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Tax expense</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net of tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total reclassifications for the period, net of tax</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table>
 (a) This component is included in the computation of net periodic benefit cost. The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives</td><td colspan="3" style="padding:0

1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Change in equity affiliate investment AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Defined benefit
pension and other
postretirement plans</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign
currency
translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10.1)</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(136.0)</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(143.8)</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified out from accumulated other comprehensive income (loss)</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.7 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss), net of tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(11.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(129.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(136.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivatives</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Change in equity affiliate investment AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Defined benefit
pension and other
postretirement plans</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign
currency
translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance, December 31, 2022 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(9.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(175.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183.0)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive (loss) income before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8.8)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(45.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified out from accumulated other comprehensive (loss) income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.1)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive (loss) income, net of tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(40.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance, September 30, 2023 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.6)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10.6)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(212.3)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(223.0)</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>02300000-10100000-136000000.0-143800000-3000000-6000006700000580000-230000006000000-170000020000000.00-120000067000007500000200000.02300000-11300000-129300000-136300000020000001600000-9400000-175400000-183000000.0-8800000-100000-100000-36900000-45900000-7000000.0011000000-5900000-1800000-100000-1200000-36900000-40000000.0-160000001500000-10600000-212300000-223000000.0<div>A summary of the reclassifications out from accumulated other comprehensive loss is presented in the following table: </div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.269%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location on Statement of Income</td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Detail of components</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Gains (losses) on derivatives:</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of goods and services sold</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Forward treasury locks</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total before tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9.9)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Tax benefit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net of tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.3)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(7.0)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of defined benefit pension and other postretirement plans:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Actuarial gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(a)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total before tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Tax expense</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net of tax</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total reclassifications for the period, net of tax</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1.7)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table>
 (a) This component is included in the computation of net periodic benefit cost. 0-2000002000000-15000007000001400000410000020000000.00-340000010000000.0-62000000100000100000200000-700000-5100000-3000000.0-9900000-2000000-1600000-700000-2900000-500000-3500000-2300000-7000000.03000003000008000001100000000-40000030000030000080000015000001000001000002000004000002000002000006000001100000-300000-3300000-1700000-5900000Shareholders’ Equity The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.431%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Shares Issued</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Common Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Capital in Excess of Par Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Treasury Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Treasury Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained earnings</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated other comprehensive loss</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">120.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(637.6)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,523.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(143.8)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,881.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(65.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(267.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(267.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dividends declared ($0.20 per share) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive loss, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(48.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(48.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2024</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">55.2 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(825.2)</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,624.1 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(192.3)</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,680.6 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(21.7)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32.8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(187.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dividends declared ($0.20 per share)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive loss, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33.5 </td><td style="background-color:#cceeff;border-top:1pt

solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(979.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,720.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(216.9)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,576.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136.0 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136.0 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income, net of tax</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,010.6)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,856.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(136.3)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,752.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents the changes in shareholders' equity for the nine months ended September 30, 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"></td><td style="width:32.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.473%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2"

style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Shares Issued</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Capital in Excess of Par Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Treasury Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Treasury Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained earnings</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated other comprehensive loss</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2022</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">232.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(370.9)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,987.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183.0)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,684.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(50.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dividends declared ($0.19 per share) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td

style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">181.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(369.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,113.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(168.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,776.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">155.1 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">155.1 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">158.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(501.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,254.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,746.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(35.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive loss, net of tax</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39.5)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2023</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">122.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(466.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,415.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(223.0)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double

#000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,868.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>The following table presents the changes in shareholders' equity for the nine months ended September 30, 2024:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.431%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Shares Issued</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Capital in Excess of Par Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Treasury Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Treasury Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained earnings</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated other comprehensive loss</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="2" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">120.2 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(637.6)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,523.4 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(143.8)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,881.0 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">115.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">115.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(65.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(267.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(267.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dividends declared ($0.20 per share) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive loss, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(48.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(48.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">55.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(825.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,624.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(192.3) </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,680.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(21.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(187.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(187.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dividends declared ($0.20 per share) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive loss, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(979.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,720.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(216.9)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,576.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136.0 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136.0 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income, net of tax</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,010.6)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,856.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px

0;text-align:right;vertical-align:bottom">(136.3)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,752.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>The following table presents the changes in shareholders' equity for the nine months ended September 30, 2023:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"></td><td style="width:32.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.473%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Shares Issued</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Capital in Excess of Par Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Treasury Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Treasury Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained earnings</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated other comprehensive loss</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2022</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">232.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(370.9)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,987.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183.0)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,684.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(50.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Dividends declared ($0.19 per share) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">181.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(369.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,113.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(168.4) </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,776.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">155.1 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">155.1 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"

height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">158.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(501.4)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,254.6 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183.5)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,746.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Activity related to stock-based compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

*New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(35.6)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63.1 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares purchased under share repurchase program</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(466.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,415.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(223.0)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,868.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 753000001880000012020000001800000-637600000035234000000-1438000002881000000115300000115300000-65000000.0-2000007940000014400000700000267000000.0267000000.00.2014600001460000-48500000-485000007530000018800000552000002300000-8252000003624100000-1923000002680600000111300000111300000-21700000-1000003280000011100000500000187100000187100000.2014500000145000000-24600000-24600000753000001880000033500000270000097950000003720900000-21690000025768000001360000000.0136000000.0-10200000-1000002130000011100000200000524000005240000080600000806000007530000018800000233000002800000-1010600000385690000013630000027521000007530000018800000232200000120000037090000002987800000-183000000.026849000001400000000.01400000000.0-50800000-3000006180000011000000.020000060100000601000000.191420000014200000146000001460000075300000188000001814000001100000-369200000031136000000-168400000277620000015510000015510000-23200000-2000004120000018000000.0500000173400000173400000.191410000014100000-15100000-15100000753000001880000015820000001400000-501400000032546000000-183500000027467000001613000001613000000-35600000-200000631000002750000010000027800000278000000-39500000-395000007530000018800000122600000130000046610000003415900000-223000000.02868200000Stock-Based Compensation The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2024, there were 1,338,673 shares remaining in the 2016 Plan for future grants.
 During the nine months ended September 30, 2024, we granted 88,588 stock options at a weighted average exercise price of $348.50 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $134.33 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.3%; expected life of 6.0 years based on prior experience; stock volatility of 32.0% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.
 During the nine months ended September 30, 2024, we granted 34,188 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $348.46 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.
 During the nine months ended September 30, 2024, we granted 8,302 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $342.74 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. Stock-based compensation expense was $5.1 million and $14.4 million for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, stock-based compensation expense was $5.9 million and $21.9 million, respectively.1338673885883 48.50134.330.043P6Y0.3200.00334188348.46028302342.7451000001440000059000002190000 0Other Expense (Income) <div>Other expense (income) consists of:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign exchange transaction losses</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.3 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset impairments</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restructuring and related charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on disposal of plant</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.6 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other items</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total other expense (income)</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$

</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">22.5 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Contingent Consideration
 Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.
 Restructuring and Related Charges
 In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were implemented over a period of approximately twenty-four months from the date of approval. The plan is expected to have annualized savings in the range of $17 million to $19 million. As of September 30, 2024, the Company does not expect additional expenses or payments associated with our 2022 restructuring plan. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Severance
and benefits</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other charges</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(Credits) Charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Loss on Disposal of Plant
 During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million, within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment during the second quarter of 2023.</div><div>Other expense (income) consists of:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign exchange transaction losses</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset impairments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restructuring and related charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on disposal of plant</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px

1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other items</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total other expense (income)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">22.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -4100000-1800000-7300000-3000000.012000007000003200000150000010000000.035000001900000069000000-25000000-2500000-800000000-11600000-6000004000000-900000-300000-4400000-5600000-10800000-22500000P24M17000000190000000The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Severance
and benefits</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other charges</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(Credits) Charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

*style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3000000.003000000.0-25000000-250000050000000500000000-116000001Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.
 The provision for income taxes was $32.4 million and $29.4 million for the three months ended September 30, 2024 and 2023, respectively, and the effective tax rate was 19.7% and 15.7%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the three months ended September 30, 2024 as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.
 The provision for income taxes was $70.7 million and $87.8 million for the nine months ended September 30, 2024 and 2023, respectively, and the effective tax rate was 16.8% and 16.6%, respectively. The increase in the effective tax rate is primarily due to a decrease in the tax benefit related to stock-based compensation in the nine months ended September 30, 2024, as compared to the same period in 2023, partially offset by a shift in the forecasted geographic earnings mix.</div><div>
</div><div>The Company continues to address the change in tax laws enacted pursuant to the Organization for Economic Cooperation and Development (OECD)'s 15% global minimum tax initiative (Pillar 2). The 2024 forecasted impact of Pillar 2 is not expected to be material to the Company.</div>32400000294000000.1970.157707000008780000000.1680.166Commitments and Contingencies<div>From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</div><div>
</div><div>There have been no significant changes to commitments and contingencies since December 31, 2023.</div>Segment Information<div>Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.</div><div>
</div><div>The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.</div><div>
</div><div>The following table presents information about our reportable segments, reconciled to consolidated totals:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-*

size:10pt;font-weight:400;line-height:100%"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Proprietary Products</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">601.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">602.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,720.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,803.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">144.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">423.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Consolidated net sales</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">746.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">747.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,144.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,217.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table provides summarized financial information for our segments: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating profit (loss):</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Proprietary Products</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">158.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">181.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">415.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">546.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total business segment operating profit</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">180.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">202.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">471.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">599.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate and Unallocated</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Stock-based compensation expense</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(5.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(5.9) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(14.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(21.9) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate general costs (1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unallocated Items:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Loss on disposal of plant

(2) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11.6)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost investment impairment (3) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Restructuring and other charges (4) </td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of acquisition-related intangible assets (5) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Corporate and Unallocated</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18.7)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25.3)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(61.3)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84.7)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total consolidated operating profit</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">161.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">177.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">410.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">515.1 </td><td

style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest (income) expense and other nonoperating expense (income), net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9.7)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.3)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.7)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Income before income taxes and equity in net income of affiliated companies</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">164.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">187.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">420.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">529.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.
 (2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.
 (3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.
 (4) Restructuring and other charges were a benefit of $0.9 million in the three and nine months ended September 30, 2024. The net benefit represents the impact of two items, the first of which is a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represent the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan.
 (5) During the three and nine months ended September 30, 2024 and September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</div><div>
</div><div>Please refer to Note 14, Other Expense (Income), for further discussion of these items.</div>2<div>The following table presents information about our reportable segments, reconciled to consolidated totals:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt

solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net sales:</td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Proprietary Products</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">601.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">602.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,720.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,803.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">144.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">423.8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">414.2 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Consolidated net sales</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">746.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">747.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,144.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,217.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
6014000006025000001720600000180360000014550000014490000042380000041420000074690000074740000021444000002217800000<di
The following table provides summarized financial information for our segments: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">($ in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating profit (loss):</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Proprietary Products</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">158.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">181.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">415.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">546.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Contract-Manufactured Products</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total business segment operating profit</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">180.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">202.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">471.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">599.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate and Unallocated</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Stock-based compensation expense</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(5.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(5.9) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(14.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(21.9) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate general costs (1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.9)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unallocated Items:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Loss on disposal of plant (2) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11.6)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost investment impairment (3) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Restructuring and other charges (4) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of acquisition-related intangible assets (5) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Corporate and Unallocated</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18.7)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25.3)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(61.3)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84.7)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total consolidated operating profit</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">177.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">410.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">515.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest (income) expense and other nonoperating expense (income), net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.2)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9.7)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.3)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14.7) </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Income before income taxes and equity in net income of affiliated companies</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">164.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">187.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">420.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">529.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 (1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.
 (2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.
 (3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.
 (4) Restructuring and other charges were a benefit of $0.9 million in the three and nine months ended September 30, 2024. The net benefit represents the impact of two items, the first of which is a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. This benefit was partially offset by $1.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represent the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan.
 (5) During the three and nine months ended September 30, 2024 and September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. 1582000001816000004155000005465000002180000021000000.056100000533000001800000000.020260000047160000059980000051000005116000000330000003300000-9000000-900000010000020000020000060000060000-18700000-25300000-61300000-84700000161300000177300000410300000515100000320000097000001030000014700000164500000187000000.042060000052980000011600000133000003300000-900000-900000-2500000-250000016000001600000100000900000-800000200000200000600000600000falsefalsefalsefalse